US20070099894A1 - Thienopyridone derivatives as kinase inhibitors - Google Patents
Thienopyridone derivatives as kinase inhibitors Download PDFInfo
- Publication number
- US20070099894A1 US20070099894A1 US10/561,052 US56105204A US2007099894A1 US 20070099894 A1 US20070099894 A1 US 20070099894A1 US 56105204 A US56105204 A US 56105204A US 2007099894 A1 US2007099894 A1 US 2007099894A1
- Authority
- US
- United States
- Prior art keywords
- pyridin
- carbonyl
- amino
- phenylthieno
- pyrrolidin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229940043355 kinase inhibitor Drugs 0.000 title description 2
- 239000003757 phosphotransferase inhibitor Substances 0.000 title description 2
- 102000002574 p38 Mitogen-Activated Protein Kinases Human genes 0.000 claims abstract description 28
- 108010068338 p38 Mitogen-Activated Protein Kinases Proteins 0.000 claims abstract description 28
- 239000003112 inhibitor Substances 0.000 claims abstract description 24
- 238000011282 treatment Methods 0.000 claims abstract description 14
- 208000027866 inflammatory disease Diseases 0.000 claims abstract description 9
- 230000002265 prevention Effects 0.000 claims abstract description 3
- 125000004214 1-pyrrolidinyl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 claims abstract 3
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims abstract 2
- 150000001875 compounds Chemical class 0.000 claims description 310
- -1 hydrate Chemical class 0.000 claims description 181
- 238000000034 method Methods 0.000 claims description 144
- 238000006243 chemical reaction Methods 0.000 claims description 109
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 52
- 125000001072 heteroaryl group Chemical group 0.000 claims description 37
- 201000010099 disease Diseases 0.000 claims description 32
- 125000003118 aryl group Chemical group 0.000 claims description 27
- 208000035475 disorder Diseases 0.000 claims description 20
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 20
- 150000003839 salts Chemical class 0.000 claims description 20
- 208000015181 infectious disease Diseases 0.000 claims description 17
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 15
- 108010002352 Interleukin-1 Proteins 0.000 claims description 15
- 239000002158 endotoxin Substances 0.000 claims description 15
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 15
- 108090001007 Interleukin-8 Proteins 0.000 claims description 14
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 14
- 108090001005 Interleukin-6 Proteins 0.000 claims description 12
- 241000700605 Viruses Species 0.000 claims description 12
- 229910052739 hydrogen Inorganic materials 0.000 claims description 11
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 11
- 238000004519 manufacturing process Methods 0.000 claims description 11
- 208000002193 Pain Diseases 0.000 claims description 10
- 206010040070 Septic Shock Diseases 0.000 claims description 10
- 230000036407 pain Effects 0.000 claims description 10
- 239000001257 hydrogen Substances 0.000 claims description 9
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 9
- 206010003246 arthritis Diseases 0.000 claims description 8
- 201000008482 osteoarthritis Diseases 0.000 claims description 8
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims description 7
- 206010006895 Cachexia Diseases 0.000 claims description 7
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 7
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 claims description 7
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 7
- 208000020084 Bone disease Diseases 0.000 claims description 6
- 150000001204 N-oxides Chemical class 0.000 claims description 6
- 206010040047 Sepsis Diseases 0.000 claims description 6
- 125000002947 alkylene group Chemical group 0.000 claims description 6
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 6
- 125000004215 2,4-difluorophenyl group Chemical group [H]C1=C([H])C(*)=C(F)C([H])=C1F 0.000 claims description 5
- 208000030507 AIDS Diseases 0.000 claims description 5
- 208000023275 Autoimmune disease Diseases 0.000 claims description 5
- 206010009900 Colitis ulcerative Diseases 0.000 claims description 5
- 208000011231 Crohn disease Diseases 0.000 claims description 5
- 206010028980 Neoplasm Diseases 0.000 claims description 5
- 206010063837 Reperfusion injury Diseases 0.000 claims description 5
- 201000006704 Ulcerative Colitis Diseases 0.000 claims description 5
- 230000001154 acute effect Effects 0.000 claims description 5
- 208000011341 adult acute respiratory distress syndrome Diseases 0.000 claims description 5
- 201000000028 adult respiratory distress syndrome Diseases 0.000 claims description 5
- 208000006673 asthma Diseases 0.000 claims description 5
- 201000011510 cancer Diseases 0.000 claims description 5
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 5
- 230000001066 destructive effect Effects 0.000 claims description 5
- 206010012601 diabetes mellitus Diseases 0.000 claims description 5
- 239000008194 pharmaceutical composition Substances 0.000 claims description 5
- 150000003180 prostaglandins Chemical class 0.000 claims description 5
- 230000036303 septic shock Effects 0.000 claims description 5
- 239000012453 solvate Substances 0.000 claims description 5
- 208000024827 Alzheimer disease Diseases 0.000 claims description 4
- 208000035473 Communicable disease Diseases 0.000 claims description 4
- 206010018364 Glomerulonephritis Diseases 0.000 claims description 4
- 206010020751 Hypersensitivity Diseases 0.000 claims description 4
- 208000034578 Multiple myelomas Diseases 0.000 claims description 4
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 4
- 201000004681 Psoriasis Diseases 0.000 claims description 4
- 206010037660 Pyrexia Diseases 0.000 claims description 4
- 208000006011 Stroke Diseases 0.000 claims description 4
- 206010044248 Toxic shock syndrome Diseases 0.000 claims description 4
- 231100000650 Toxic shock syndrome Toxicity 0.000 claims description 4
- 230000007815 allergy Effects 0.000 claims description 4
- 125000000068 chlorophenyl group Chemical group 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 4
- 206010022000 influenza Diseases 0.000 claims description 4
- 230000002062 proliferating effect Effects 0.000 claims description 4
- 230000002685 pulmonary effect Effects 0.000 claims description 4
- 125000003944 tolyl group Chemical group 0.000 claims description 4
- 230000003612 virological effect Effects 0.000 claims description 4
- 206010002556 Ankylosing Spondylitis Diseases 0.000 claims description 3
- 201000001320 Atherosclerosis Diseases 0.000 claims description 3
- 210000002237 B-cell of pancreatic islet Anatomy 0.000 claims description 3
- 206010063094 Cerebral malaria Diseases 0.000 claims description 3
- 208000037487 Endotoxemia Diseases 0.000 claims description 3
- 241000709661 Enterovirus Species 0.000 claims description 3
- 201000005569 Gout Diseases 0.000 claims description 3
- 206010018634 Gouty Arthritis Diseases 0.000 claims description 3
- 208000031886 HIV Infections Diseases 0.000 claims description 3
- 241000430519 Human rhinovirus sp. Species 0.000 claims description 3
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 claims description 3
- 206010061218 Inflammation Diseases 0.000 claims description 3
- 206010028289 Muscle atrophy Diseases 0.000 claims description 3
- 208000000112 Myalgia Diseases 0.000 claims description 3
- 206010030113 Oedema Diseases 0.000 claims description 3
- 201000001263 Psoriatic Arthritis Diseases 0.000 claims description 3
- 208000036824 Psoriatic arthropathy Diseases 0.000 claims description 3
- 201000010001 Silicosis Diseases 0.000 claims description 3
- 206010048873 Traumatic arthritis Diseases 0.000 claims description 3
- 208000019664 bone resorption disease Diseases 0.000 claims description 3
- 230000001684 chronic effect Effects 0.000 claims description 3
- 230000004054 inflammatory process Effects 0.000 claims description 3
- 208000011379 keloid formation Diseases 0.000 claims description 3
- 230000036210 malignancy Effects 0.000 claims description 3
- 230000004770 neurodegeneration Effects 0.000 claims description 3
- 201000003651 pulmonary sarcoidosis Diseases 0.000 claims description 3
- 201000005404 rubella Diseases 0.000 claims description 3
- 231100000241 scar Toxicity 0.000 claims description 3
- 208000011580 syndromic disease Diseases 0.000 claims description 3
- 230000009772 tissue formation Effects 0.000 claims description 3
- 201000008827 tuberculosis Diseases 0.000 claims description 3
- FPJIRCQLPFLOBH-UHFFFAOYSA-N 2-(3-aminoazetidine-1-carbonyl)-3-(2,4-difluoroanilino)-7-phenylthieno[2,3-b]pyridin-6-one Chemical compound C1C(N)CN1C(=O)C1=C(NC=2C(=CC(F)=CC=2)F)C(C=CC(=O)N2C=3C=CC=CC=3)=C2S1 FPJIRCQLPFLOBH-UHFFFAOYSA-N 0.000 claims description 2
- YIAAMVXYBZQEIV-UHFFFAOYSA-N 2-(3-aminopyrrolidine-1-carbonyl)-3-(2,4-difluoroanilino)-7-phenylthieno[2,3-b]pyridin-6-one Chemical compound C1C(N)CCN1C(=O)C1=C(NC=2C(=CC(F)=CC=2)F)C(C=CC(=O)N2C=3C=CC=CC=3)=C2S1 YIAAMVXYBZQEIV-UHFFFAOYSA-N 0.000 claims description 2
- APUGORVARZNZCB-UHFFFAOYSA-N 2-(4-aminopiperidine-1-carbonyl)-3-(2,4-difluoroanilino)-7-phenylthieno[2,3-b]pyridin-6-one Chemical compound C1CC(N)CCN1C(=O)C1=C(NC=2C(=CC(F)=CC=2)F)C(C=CC(=O)N2C=3C=CC=CC=3)=C2S1 APUGORVARZNZCB-UHFFFAOYSA-N 0.000 claims description 2
- NXHDDVVDDWCGMN-QGZVFWFLSA-N 2-[(2r)-2-(aminomethyl)pyrrolidine-1-carbonyl]-3-(2,4-difluoroanilino)-7-phenylthieno[2,3-b]pyridin-6-one Chemical compound NC[C@H]1CCCN1C(=O)C1=C(NC=2C(=CC(F)=CC=2)F)C(C=CC(=O)N2C=3C=CC=CC=3)=C2S1 NXHDDVVDDWCGMN-QGZVFWFLSA-N 0.000 claims description 2
- PFAUYNSIJFKANL-OAQYLSRUSA-N 2-[(2r)-2-(hydroxymethyl)pyrrolidine-1-carbonyl]-3-(3-methylanilino)-7-(3-methylphenyl)thieno[2,3-b]pyridin-6-one Chemical compound CC1=CC=CC(NC=2C=3C=CC(=O)N(C=4C=C(C)C=CC=4)C=3SC=2C(=O)N2[C@H](CCC2)CO)=C1 PFAUYNSIJFKANL-OAQYLSRUSA-N 0.000 claims description 2
- GJOCRLLOEDDDDN-OAQYLSRUSA-N 2-[(2r)-2-(hydroxymethyl)pyrrolidine-1-carbonyl]-3-(3-methylanilino)-7-(4-methylphenyl)thieno[2,3-b]pyridin-6-one Chemical compound C1=CC(C)=CC=C1N1C(=O)C=CC2=C1SC(C(=O)N1[C@H](CCC1)CO)=C2NC1=CC=CC(C)=C1 GJOCRLLOEDDDDN-OAQYLSRUSA-N 0.000 claims description 2
- FXFYLZCXPQLCBD-HXUWFJFHSA-N 2-[(2r)-2-(hydroxymethyl)pyrrolidine-1-carbonyl]-3-(3-methylanilino)-7-phenylthieno[2,3-b]pyridin-6-one Chemical compound CC1=CC=CC(NC=2C=3C=CC(=O)N(C=4C=CC=CC=4)C=3SC=2C(=O)N2[C@H](CCC2)CO)=C1 FXFYLZCXPQLCBD-HXUWFJFHSA-N 0.000 claims description 2
- NXHDDVVDDWCGMN-KRWDZBQOSA-N 2-[(2s)-2-(aminomethyl)pyrrolidine-1-carbonyl]-3-(2,4-difluoroanilino)-7-phenylthieno[2,3-b]pyridin-6-one Chemical compound NC[C@@H]1CCCN1C(=O)C1=C(NC=2C(=CC(F)=CC=2)F)C(C=CC(=O)N2C=3C=CC=CC=3)=C2S1 NXHDDVVDDWCGMN-KRWDZBQOSA-N 0.000 claims description 2
- UEGOQWHZEHABCU-IBGZPJMESA-N 2-[(2s)-2-(aminomethyl)pyrrolidine-1-carbonyl]-3-(4-fluoro-3-methylanilino)-7-phenylthieno[2,3-b]pyridin-6-one Chemical compound C1=C(F)C(C)=CC(NC=2C=3C=CC(=O)N(C=4C=CC=CC=4)C=3SC=2C(=O)N2[C@@H](CCC2)CN)=C1 UEGOQWHZEHABCU-IBGZPJMESA-N 0.000 claims description 2
- CBJVNMCCIYIPBW-HXUWFJFHSA-N 2-[(3r)-3-(dimethylamino)pyrrolidine-1-carbonyl]-3-(4-fluoro-3-methylanilino)-7-phenylthieno[2,3-b]pyridin-6-one Chemical compound C1[C@H](N(C)C)CCN1C(=O)C1=C(NC=2C=C(C)C(F)=CC=2)C(C=CC(=O)N2C=3C=CC=CC=3)=C2S1 CBJVNMCCIYIPBW-HXUWFJFHSA-N 0.000 claims description 2
- YIAAMVXYBZQEIV-OAHLLOKOSA-N 2-[(3r)-3-aminopyrrolidine-1-carbonyl]-3-(2,4-difluoroanilino)-7-phenylthieno[2,3-b]pyridin-6-one Chemical compound C1[C@H](N)CCN1C(=O)C1=C(NC=2C(=CC(F)=CC=2)F)C(C=CC(=O)N2C=3C=CC=CC=3)=C2S1 YIAAMVXYBZQEIV-OAHLLOKOSA-N 0.000 claims description 2
- PJCHBVNLSXEZJC-MRXNPFEDSA-N 2-[(3r)-3-aminopyrrolidine-1-carbonyl]-3-(4-fluoro-3-methylanilino)-7-phenylthieno[2,3-b]pyridin-6-one Chemical compound C1=C(F)C(C)=CC(NC=2C=3C=CC(=O)N(C=4C=CC=CC=4)C=3SC=2C(=O)N2C[C@H](N)CC2)=C1 PJCHBVNLSXEZJC-MRXNPFEDSA-N 0.000 claims description 2
- CBJVNMCCIYIPBW-FQEVSTJZSA-N 2-[(3s)-3-(dimethylamino)pyrrolidine-1-carbonyl]-3-(4-fluoro-3-methylanilino)-7-phenylthieno[2,3-b]pyridin-6-one Chemical compound C1[C@@H](N(C)C)CCN1C(=O)C1=C(NC=2C=C(C)C(F)=CC=2)C(C=CC(=O)N2C=3C=CC=CC=3)=C2S1 CBJVNMCCIYIPBW-FQEVSTJZSA-N 0.000 claims description 2
- YIAAMVXYBZQEIV-HNNXBMFYSA-N 2-[(3s)-3-aminopyrrolidine-1-carbonyl]-3-(2,4-difluoroanilino)-7-phenylthieno[2,3-b]pyridin-6-one Chemical compound C1[C@@H](N)CCN1C(=O)C1=C(NC=2C(=CC(F)=CC=2)F)C(C=CC(=O)N2C=3C=CC=CC=3)=C2S1 YIAAMVXYBZQEIV-HNNXBMFYSA-N 0.000 claims description 2
- PJCHBVNLSXEZJC-INIZCTEOSA-N 2-[(3s)-3-aminopyrrolidine-1-carbonyl]-3-(4-fluoro-3-methylanilino)-7-phenylthieno[2,3-b]pyridin-6-one Chemical compound C1=C(F)C(C)=CC(NC=2C=3C=CC(=O)N(C=4C=CC=CC=4)C=3SC=2C(=O)N2C[C@@H](N)CC2)=C1 PJCHBVNLSXEZJC-INIZCTEOSA-N 0.000 claims description 2
- GQSDFHBVBLNEPI-LJQANCHMSA-N 2-[[2-[(2r)-2-(hydroxymethyl)pyrrolidine-1-carbonyl]-6-oxo-7-phenylthieno[2,3-b]pyridin-3-yl]amino]benzonitrile Chemical compound OC[C@H]1CCCN1C(=O)C1=C(NC=2C(=CC=CC=2)C#N)C(C=CC(=O)N2C=3C=CC=CC=3)=C2S1 GQSDFHBVBLNEPI-LJQANCHMSA-N 0.000 claims description 2
- GQSDFHBVBLNEPI-IBGZPJMESA-N 2-[[2-[(2s)-2-(hydroxymethyl)pyrrolidine-1-carbonyl]-6-oxo-7-phenylthieno[2,3-b]pyridin-3-yl]amino]benzonitrile Chemical compound OC[C@@H]1CCCN1C(=O)C1=C(NC=2C(=CC=CC=2)C#N)C(C=CC(=O)N2C=3C=CC=CC=3)=C2S1 GQSDFHBVBLNEPI-IBGZPJMESA-N 0.000 claims description 2
- PHSAUCGEGXBTJY-GOSISDBHSA-N 2-[[2-[(3r)-3-hydroxypyrrolidine-1-carbonyl]-6-oxo-7-phenylthieno[2,3-b]pyridin-3-yl]amino]benzonitrile Chemical compound C1[C@H](O)CCN1C(=O)C1=C(NC=2C(=CC=CC=2)C#N)C(C=CC(=O)N2C=3C=CC=CC=3)=C2S1 PHSAUCGEGXBTJY-GOSISDBHSA-N 0.000 claims description 2
- PHSAUCGEGXBTJY-SFHVURJKSA-N 2-[[2-[(3s)-3-hydroxypyrrolidine-1-carbonyl]-6-oxo-7-phenylthieno[2,3-b]pyridin-3-yl]amino]benzonitrile Chemical compound C1[C@@H](O)CCN1C(=O)C1=C(NC=2C(=CC=CC=2)C#N)C(C=CC(=O)N2C=3C=CC=CC=3)=C2S1 PHSAUCGEGXBTJY-SFHVURJKSA-N 0.000 claims description 2
- PBDWECGFDIPGDS-UHFFFAOYSA-N 3-(2,4-difluoroanilino)-2-(3-hydroxyazetidine-1-carbonyl)-7-phenylthieno[2,3-b]pyridin-6-one Chemical compound C1C(O)CN1C(=O)C1=C(NC=2C(=CC(F)=CC=2)F)C(C=CC(=O)N2C=3C=CC=CC=3)=C2S1 PBDWECGFDIPGDS-UHFFFAOYSA-N 0.000 claims description 2
- CFJKIEAOQBNGTG-UHFFFAOYSA-N 3-(2,4-difluoroanilino)-2-(3-hydroxypiperidine-1-carbonyl)-7-phenylthieno[2,3-b]pyridin-6-one Chemical compound C1C(O)CCCN1C(=O)C1=C(NC=2C(=CC(F)=CC=2)F)C(C=CC(=O)N2C=3C=CC=CC=3)=C2S1 CFJKIEAOQBNGTG-UHFFFAOYSA-N 0.000 claims description 2
- SPTVFFRJWFQZAZ-UHFFFAOYSA-N 3-(2,4-difluoroanilino)-2-(4-hydroxypiperidine-1-carbonyl)-7-phenylthieno[2,3-b]pyridin-6-one Chemical compound C1CC(O)CCN1C(=O)C1=C(NC=2C(=CC(F)=CC=2)F)C(C=CC(=O)N2C=3C=CC=CC=3)=C2S1 SPTVFFRJWFQZAZ-UHFFFAOYSA-N 0.000 claims description 2
- ONKCLJOMHUZOJP-OAQYLSRUSA-N 3-(2,4-difluoroanilino)-2-[(2r)-2-(2-hydroxypropan-2-yl)pyrrolidine-1-carbonyl]-7-phenylthieno[2,3-b]pyridin-6-one Chemical compound CC(C)(O)[C@H]1CCCN1C(=O)C1=C(NC=2C(=CC(F)=CC=2)F)C(C=CC(=O)N2C=3C=CC=CC=3)=C2S1 ONKCLJOMHUZOJP-OAQYLSRUSA-N 0.000 claims description 2
- DHGSDRQDAFRFRC-GOSISDBHSA-N 3-(2,4-difluoroanilino)-2-[(2r)-2-(hydroxymethyl)pyrrolidine-1-carbonyl]-7-(4-methylphenyl)thieno[2,3-b]pyridin-6-one Chemical compound C1=CC(C)=CC=C1N1C(=O)C=CC2=C1SC(C(=O)N1[C@H](CCC1)CO)=C2NC1=CC=C(F)C=C1F DHGSDRQDAFRFRC-GOSISDBHSA-N 0.000 claims description 2
- CXWCTQLYHRJMRC-QGZVFWFLSA-N 3-(2,4-difluoroanilino)-2-[(2r)-2-(hydroxymethyl)pyrrolidine-1-carbonyl]-7-phenylthieno[2,3-b]pyridin-6-one Chemical group OC[C@H]1CCCN1C(=O)C1=C(NC=2C(=CC(F)=CC=2)F)C(C=CC(=O)N2C=3C=CC=CC=3)=C2S1 CXWCTQLYHRJMRC-QGZVFWFLSA-N 0.000 claims description 2
- ONKCLJOMHUZOJP-NRFANRHFSA-N 3-(2,4-difluoroanilino)-2-[(2s)-2-(2-hydroxypropan-2-yl)pyrrolidine-1-carbonyl]-7-phenylthieno[2,3-b]pyridin-6-one Chemical compound CC(C)(O)[C@@H]1CCCN1C(=O)C1=C(NC=2C(=CC(F)=CC=2)F)C(C=CC(=O)N2C=3C=CC=CC=3)=C2S1 ONKCLJOMHUZOJP-NRFANRHFSA-N 0.000 claims description 2
- HASSWYBJXSFZRP-GOSISDBHSA-N 3-(2,4-difluoroanilino)-2-[(3r)-3-(dimethylamino)pyrrolidine-1-carbonyl]-7-phenylthieno[2,3-b]pyridin-6-one Chemical compound C1[C@H](N(C)C)CCN1C(=O)C1=C(NC=2C(=CC(F)=CC=2)F)C(C=CC(=O)N2C=3C=CC=CC=3)=C2S1 HASSWYBJXSFZRP-GOSISDBHSA-N 0.000 claims description 2
- CXPNATBGZJDNFX-QGZVFWFLSA-N 3-(2,4-difluoroanilino)-2-[(3r)-3-hydroxypyrrolidine-1-carbonyl]-7-(4-methylphenyl)thieno[2,3-b]pyridin-6-one Chemical compound C1=CC(C)=CC=C1N1C(=O)C=CC2=C1SC(C(=O)N1C[C@H](O)CC1)=C2NC1=CC=C(F)C=C1F CXPNATBGZJDNFX-QGZVFWFLSA-N 0.000 claims description 2
- FFORERRJWIDHHG-MRXNPFEDSA-N 3-(2,4-difluoroanilino)-2-[(3r)-3-hydroxypyrrolidine-1-carbonyl]-7-phenylthieno[2,3-b]pyridin-6-one Chemical compound C1[C@H](O)CCN1C(=O)C1=C(NC=2C(=CC(F)=CC=2)F)C(C=CC(=O)N2C=3C=CC=CC=3)=C2S1 FFORERRJWIDHHG-MRXNPFEDSA-N 0.000 claims description 2
- SAIFBCFTLQJMLA-RTBURBONSA-N 3-(2,4-difluoroanilino)-2-[(3r,4r)-3,4-dihydroxypyrrolidine-1-carbonyl]-7-phenylthieno[2,3-b]pyridin-6-one Chemical compound C1[C@@H](O)[C@H](O)CN1C(=O)C1=C(NC=2C(=CC(F)=CC=2)F)C(C=CC(=O)N2C=3C=CC=CC=3)=C2S1 SAIFBCFTLQJMLA-RTBURBONSA-N 0.000 claims description 2
- HASSWYBJXSFZRP-SFHVURJKSA-N 3-(2,4-difluoroanilino)-2-[(3s)-3-(dimethylamino)pyrrolidine-1-carbonyl]-7-phenylthieno[2,3-b]pyridin-6-one Chemical compound C1[C@@H](N(C)C)CCN1C(=O)C1=C(NC=2C(=CC(F)=CC=2)F)C(C=CC(=O)N2C=3C=CC=CC=3)=C2S1 HASSWYBJXSFZRP-SFHVURJKSA-N 0.000 claims description 2
- CXPNATBGZJDNFX-KRWDZBQOSA-N 3-(2,4-difluoroanilino)-2-[(3s)-3-hydroxypyrrolidine-1-carbonyl]-7-(4-methylphenyl)thieno[2,3-b]pyridin-6-one Chemical compound C1=CC(C)=CC=C1N1C(=O)C=CC2=C1SC(C(=O)N1C[C@@H](O)CC1)=C2NC1=CC=C(F)C=C1F CXPNATBGZJDNFX-KRWDZBQOSA-N 0.000 claims description 2
- FFORERRJWIDHHG-INIZCTEOSA-N 3-(2,4-difluoroanilino)-2-[(3s)-3-hydroxypyrrolidine-1-carbonyl]-7-phenylthieno[2,3-b]pyridin-6-one Chemical compound C1[C@@H](O)CCN1C(=O)C1=C(NC=2C(=CC(F)=CC=2)F)C(C=CC(=O)N2C=3C=CC=CC=3)=C2S1 FFORERRJWIDHHG-INIZCTEOSA-N 0.000 claims description 2
- SIGZJUVYBVWJKF-UHFFFAOYSA-N 3-(2,4-difluoroanilino)-2-[3-(dimethylamino)azetidine-1-carbonyl]-7-phenylthieno[2,3-b]pyridin-6-one Chemical compound C1C(N(C)C)CN1C(=O)C1=C(NC=2C(=CC(F)=CC=2)F)C(C=CC(=O)N2C=3C=CC=CC=3)=C2S1 SIGZJUVYBVWJKF-UHFFFAOYSA-N 0.000 claims description 2
- HHDHJFGTWYVWQH-UHFFFAOYSA-N 3-(2,4-difluoroanilino)-2-[4-(dimethylamino)piperidine-1-carbonyl]-7-phenylthieno[2,3-b]pyridin-6-one Chemical compound C1CC(N(C)C)CCN1C(=O)C1=C(NC=2C(=CC(F)=CC=2)F)C(C=CC(=O)N2C=3C=CC=CC=3)=C2S1 HHDHJFGTWYVWQH-UHFFFAOYSA-N 0.000 claims description 2
- FGBJMPUTPOOUBY-QGZVFWFLSA-N 3-(2,4-difluoroanilino)-7-(4-fluorophenyl)-2-[(2r)-2-(hydroxymethyl)pyrrolidine-1-carbonyl]thieno[2,3-b]pyridin-6-one Chemical compound OC[C@H]1CCCN1C(=O)C1=C(NC=2C(=CC(F)=CC=2)F)C(C=CC(=O)N2C=3C=CC(F)=CC=3)=C2S1 FGBJMPUTPOOUBY-QGZVFWFLSA-N 0.000 claims description 2
- KSYQPLOOMFPBQY-MRXNPFEDSA-N 3-(2,4-difluoroanilino)-7-(4-fluorophenyl)-2-[(3r)-3-hydroxypyrrolidine-1-carbonyl]thieno[2,3-b]pyridin-6-one Chemical compound C1[C@H](O)CCN1C(=O)C1=C(NC=2C(=CC(F)=CC=2)F)C(C=CC(=O)N2C=3C=CC(F)=CC=3)=C2S1 KSYQPLOOMFPBQY-MRXNPFEDSA-N 0.000 claims description 2
- KSYQPLOOMFPBQY-INIZCTEOSA-N 3-(2,4-difluoroanilino)-7-(4-fluorophenyl)-2-[(3s)-3-hydroxypyrrolidine-1-carbonyl]thieno[2,3-b]pyridin-6-one Chemical compound C1[C@@H](O)CCN1C(=O)C1=C(NC=2C(=CC(F)=CC=2)F)C(C=CC(=O)N2C=3C=CC(F)=CC=3)=C2S1 KSYQPLOOMFPBQY-INIZCTEOSA-N 0.000 claims description 2
- AQJLRCGQGFVZMJ-QGZVFWFLSA-N 3-(2-chloroanilino)-2-[(2r)-2-(hydroxymethyl)pyrrolidine-1-carbonyl]-7-phenylthieno[2,3-b]pyridin-6-one Chemical compound OC[C@H]1CCCN1C(=O)C1=C(NC=2C(=CC=CC=2)Cl)C(C=CC(=O)N2C=3C=CC=CC=3)=C2S1 AQJLRCGQGFVZMJ-QGZVFWFLSA-N 0.000 claims description 2
- AQJLRCGQGFVZMJ-KRWDZBQOSA-N 3-(2-chloroanilino)-2-[(2s)-2-(hydroxymethyl)pyrrolidine-1-carbonyl]-7-phenylthieno[2,3-b]pyridin-6-one Chemical compound OC[C@@H]1CCCN1C(=O)C1=C(NC=2C(=CC=CC=2)Cl)C(C=CC(=O)N2C=3C=CC=CC=3)=C2S1 AQJLRCGQGFVZMJ-KRWDZBQOSA-N 0.000 claims description 2
- YJSWKMDYBHKNEJ-QGZVFWFLSA-N 3-(3-chloro-4-fluoroanilino)-2-[(2r)-2-(hydroxymethyl)pyrrolidine-1-carbonyl]-7-phenylthieno[2,3-b]pyridin-6-one Chemical compound OC[C@H]1CCCN1C(=O)C1=C(NC=2C=C(Cl)C(F)=CC=2)C(C=CC(=O)N2C=3C=CC=CC=3)=C2S1 YJSWKMDYBHKNEJ-QGZVFWFLSA-N 0.000 claims description 2
- YJSWKMDYBHKNEJ-KRWDZBQOSA-N 3-(3-chloro-4-fluoroanilino)-2-[(2s)-2-(hydroxymethyl)pyrrolidine-1-carbonyl]-7-phenylthieno[2,3-b]pyridin-6-one Chemical compound OC[C@@H]1CCCN1C(=O)C1=C(NC=2C=C(Cl)C(F)=CC=2)C(C=CC(=O)N2C=3C=CC=CC=3)=C2S1 YJSWKMDYBHKNEJ-KRWDZBQOSA-N 0.000 claims description 2
- DNUAAHKOMCLORC-LJQANCHMSA-N 3-(3-chloroanilino)-2-[(2r)-2-(hydroxymethyl)pyrrolidine-1-carbonyl]-7-phenylthieno[2,3-b]pyridin-6-one Chemical compound OC[C@H]1CCCN1C(=O)C1=C(NC=2C=C(Cl)C=CC=2)C(C=CC(=O)N2C=3C=CC=CC=3)=C2S1 DNUAAHKOMCLORC-LJQANCHMSA-N 0.000 claims description 2
- YYRZYPCDKYKMDT-UHFFFAOYSA-N 3-(4-fluoro-3-methylanilino)-2-(3-hydroxyazetidine-1-carbonyl)-7-phenylthieno[2,3-b]pyridin-6-one Chemical compound C1=C(F)C(C)=CC(NC=2C=3C=CC(=O)N(C=4C=CC=CC=4)C=3SC=2C(=O)N2CC(O)C2)=C1 YYRZYPCDKYKMDT-UHFFFAOYSA-N 0.000 claims description 2
- ZVNGADOJJYQJCO-HXUWFJFHSA-N 3-(4-fluoro-3-methylanilino)-2-[(2r)-2-(hydroxymethyl)pyrrolidine-1-carbonyl]-7-(3-methylphenyl)thieno[2,3-b]pyridin-6-one Chemical compound CC1=CC=CC(N2C(C=CC=3C(NC=4C=C(C)C(F)=CC=4)=C(C(=O)N4[C@H](CCC4)CO)SC=32)=O)=C1 ZVNGADOJJYQJCO-HXUWFJFHSA-N 0.000 claims description 2
- HVAVFNBSKXWFCB-HXUWFJFHSA-N 3-(4-fluoro-3-methylanilino)-2-[(2r)-2-(hydroxymethyl)pyrrolidine-1-carbonyl]-7-(4-methylphenyl)thieno[2,3-b]pyridin-6-one Chemical compound C1=CC(C)=CC=C1N1C(=O)C=CC2=C1SC(C(=O)N1[C@H](CCC1)CO)=C2NC1=CC=C(F)C(C)=C1 HVAVFNBSKXWFCB-HXUWFJFHSA-N 0.000 claims description 2
- KTVQMKFKEQOKAM-LJQANCHMSA-N 3-(4-fluoro-3-methylanilino)-2-[(2r)-2-(hydroxymethyl)pyrrolidine-1-carbonyl]-7-phenylthieno[2,3-b]pyridin-6-one Chemical compound C1=C(F)C(C)=CC(NC=2C=3C=CC(=O)N(C=4C=CC=CC=4)C=3SC=2C(=O)N2[C@H](CCC2)CO)=C1 KTVQMKFKEQOKAM-LJQANCHMSA-N 0.000 claims description 2
- ZVNGADOJJYQJCO-FQEVSTJZSA-N 3-(4-fluoro-3-methylanilino)-2-[(2s)-2-(hydroxymethyl)pyrrolidine-1-carbonyl]-7-(3-methylphenyl)thieno[2,3-b]pyridin-6-one Chemical compound CC1=CC=CC(N2C(C=CC=3C(NC=4C=C(C)C(F)=CC=4)=C(C(=O)N4[C@@H](CCC4)CO)SC=32)=O)=C1 ZVNGADOJJYQJCO-FQEVSTJZSA-N 0.000 claims description 2
- KTVQMKFKEQOKAM-IBGZPJMESA-N 3-(4-fluoro-3-methylanilino)-2-[(2s)-2-(hydroxymethyl)pyrrolidine-1-carbonyl]-7-phenylthieno[2,3-b]pyridin-6-one Chemical compound C1=C(F)C(C)=CC(NC=2C=3C=CC(=O)N(C=4C=CC=CC=4)C=3SC=2C(=O)N2[C@@H](CCC2)CO)=C1 KTVQMKFKEQOKAM-IBGZPJMESA-N 0.000 claims description 2
- PBQADYVWOXUBMB-LJQANCHMSA-N 3-(4-fluoro-3-methylanilino)-2-[(3r)-3-hydroxypyrrolidine-1-carbonyl]-7-(4-methylphenyl)thieno[2,3-b]pyridin-6-one Chemical compound C1=CC(C)=CC=C1N1C(=O)C=CC2=C1SC(C(=O)N1C[C@H](O)CC1)=C2NC1=CC=C(F)C(C)=C1 PBQADYVWOXUBMB-LJQANCHMSA-N 0.000 claims description 2
- YMDQSRTWCIUUNP-GOSISDBHSA-N 3-(4-fluoro-3-methylanilino)-2-[(3r)-3-hydroxypyrrolidine-1-carbonyl]-7-phenylthieno[2,3-b]pyridin-6-one Chemical compound C1=C(F)C(C)=CC(NC=2C=3C=CC(=O)N(C=4C=CC=CC=4)C=3SC=2C(=O)N2C[C@H](O)CC2)=C1 YMDQSRTWCIUUNP-GOSISDBHSA-N 0.000 claims description 2
- PBQADYVWOXUBMB-IBGZPJMESA-N 3-(4-fluoro-3-methylanilino)-2-[(3s)-3-hydroxypyrrolidine-1-carbonyl]-7-(4-methylphenyl)thieno[2,3-b]pyridin-6-one Chemical compound C1=CC(C)=CC=C1N1C(=O)C=CC2=C1SC(C(=O)N1C[C@@H](O)CC1)=C2NC1=CC=C(F)C(C)=C1 PBQADYVWOXUBMB-IBGZPJMESA-N 0.000 claims description 2
- YMDQSRTWCIUUNP-SFHVURJKSA-N 3-(4-fluoro-3-methylanilino)-2-[(3s)-3-hydroxypyrrolidine-1-carbonyl]-7-phenylthieno[2,3-b]pyridin-6-one Chemical compound C1=C(F)C(C)=CC(NC=2C=3C=CC(=O)N(C=4C=CC=CC=4)C=3SC=2C(=O)N2C[C@@H](O)CC2)=C1 YMDQSRTWCIUUNP-SFHVURJKSA-N 0.000 claims description 2
- LHFOMYCGADZKFK-LJQANCHMSA-N 3-(4-fluoro-3-methylanilino)-7-(4-fluorophenyl)-2-[(2r)-2-(hydroxymethyl)pyrrolidine-1-carbonyl]thieno[2,3-b]pyridin-6-one Chemical compound C1=C(F)C(C)=CC(NC=2C=3C=CC(=O)N(C=4C=CC(F)=CC=4)C=3SC=2C(=O)N2[C@H](CCC2)CO)=C1 LHFOMYCGADZKFK-LJQANCHMSA-N 0.000 claims description 2
- VBOIWMTYQYMEDP-SFHVURJKSA-N 3-(4-fluoro-3-methylanilino)-7-(4-fluorophenyl)-2-[(3s)-3-hydroxypyrrolidine-1-carbonyl]thieno[2,3-b]pyridin-6-one Chemical compound C1=C(F)C(C)=CC(NC=2C=3C=CC(=O)N(C=4C=CC(F)=CC=4)C=3SC=2C(=O)N2C[C@@H](O)CC2)=C1 VBOIWMTYQYMEDP-SFHVURJKSA-N 0.000 claims description 2
- MMRUGUMLWZVTLF-HXUWFJFHSA-N 3-[[2-[(2r)-2-(hydroxymethyl)pyrrolidine-1-carbonyl]-6-oxo-7-phenylthieno[2,3-b]pyridin-3-yl]amino]benzonitrile Chemical compound OC[C@H]1CCCN1C(=O)C1=C(NC=2C=C(C=CC=2)C#N)C(C=CC(=O)N2C=3C=CC=CC=3)=C2S1 MMRUGUMLWZVTLF-HXUWFJFHSA-N 0.000 claims description 2
- SAGQSLJZGDMTEN-LJQANCHMSA-N 3-anilino-2-[(2r)-2-(hydroxymethyl)pyrrolidine-1-carbonyl]-7-phenylthieno[2,3-b]pyridin-6-one Chemical compound OC[C@H]1CCCN1C(=O)C1=C(NC=2C=CC=CC=2)C(C=CC(=O)N2C=3C=CC=CC=3)=C2S1 SAGQSLJZGDMTEN-LJQANCHMSA-N 0.000 claims description 2
- TXRBSMDSBAQCBV-HXUWFJFHSA-N 3-anilino-2-[(2r)-2-(methoxymethyl)pyrrolidine-1-carbonyl]-7-phenylthieno[2,3-b]pyridin-6-one Chemical compound COC[C@H]1CCCN1C(=O)C1=C(NC=2C=CC=CC=2)C(C=CC(=O)N2C=3C=CC=CC=3)=C2S1 TXRBSMDSBAQCBV-HXUWFJFHSA-N 0.000 claims description 2
- SAGQSLJZGDMTEN-IBGZPJMESA-N 3-anilino-2-[(2s)-2-(hydroxymethyl)pyrrolidine-1-carbonyl]-7-phenylthieno[2,3-b]pyridin-6-one Chemical compound OC[C@@H]1CCCN1C(=O)C1=C(NC=2C=CC=CC=2)C(C=CC(=O)N2C=3C=CC=CC=3)=C2S1 SAGQSLJZGDMTEN-IBGZPJMESA-N 0.000 claims description 2
- TXRBSMDSBAQCBV-FQEVSTJZSA-N 3-anilino-2-[(2s)-2-(methoxymethyl)pyrrolidine-1-carbonyl]-7-phenylthieno[2,3-b]pyridin-6-one Chemical compound COC[C@@H]1CCCN1C(=O)C1=C(NC=2C=CC=CC=2)C(C=CC(=O)N2C=3C=CC=CC=3)=C2S1 TXRBSMDSBAQCBV-FQEVSTJZSA-N 0.000 claims description 2
- BZDHVVQWOVFAFT-QGZVFWFLSA-N 3-anilino-7-(cyclopropylmethyl)-2-[(2r)-2-(hydroxymethyl)pyrrolidine-1-carbonyl]thieno[2,3-b]pyridin-6-one Chemical compound OC[C@H]1CCCN1C(=O)C1=C(NC=2C=CC=CC=2)C(C=CC(=O)N2CC3CC3)=C2S1 BZDHVVQWOVFAFT-QGZVFWFLSA-N 0.000 claims description 2
- RGLNMNHZWIPXBH-KRWDZBQOSA-N 7-(2-chlorophenyl)-2-[(3s)-3-hydroxypyrrolidine-1-carbonyl]-3-(3-methylanilino)thieno[2,3-b]pyridin-6-one Chemical compound CC1=CC=CC(NC=2C=3C=CC(=O)N(C=4C(=CC=CC=4)Cl)C=3SC=2C(=O)N2C[C@@H](O)CC2)=C1 RGLNMNHZWIPXBH-KRWDZBQOSA-N 0.000 claims description 2
- URXGTOAAPXVXNY-OAHLLOKOSA-N 7-(2-chlorophenyl)-3-(2,4-difluoroanilino)-2-[(2r)-2-(hydroxymethyl)pyrrolidine-1-carbonyl]thieno[2,3-b]pyridin-6-one Chemical compound OC[C@H]1CCCN1C(=O)C1=C(NC=2C(=CC(F)=CC=2)F)C(C=CC(=O)N2C=3C(=CC=CC=3)Cl)=C2S1 URXGTOAAPXVXNY-OAHLLOKOSA-N 0.000 claims description 2
- MBXGVJXHYAZUGN-CQSZACIVSA-N 7-(2-chlorophenyl)-3-(2,4-difluoroanilino)-2-[(3r)-3-hydroxypyrrolidine-1-carbonyl]thieno[2,3-b]pyridin-6-one Chemical compound C1[C@H](O)CCN1C(=O)C1=C(NC=2C(=CC(F)=CC=2)F)C(C=CC(=O)N2C=3C(=CC=CC=3)Cl)=C2S1 MBXGVJXHYAZUGN-CQSZACIVSA-N 0.000 claims description 2
- MBXGVJXHYAZUGN-AWEZNQCLSA-N 7-(2-chlorophenyl)-3-(2,4-difluoroanilino)-2-[(3s)-3-hydroxypyrrolidine-1-carbonyl]thieno[2,3-b]pyridin-6-one Chemical compound C1[C@@H](O)CCN1C(=O)C1=C(NC=2C(=CC(F)=CC=2)F)C(C=CC(=O)N2C=3C(=CC=CC=3)Cl)=C2S1 MBXGVJXHYAZUGN-AWEZNQCLSA-N 0.000 claims description 2
- LCWVTCZBKHWVBD-QGZVFWFLSA-N 7-(2-chlorophenyl)-3-(4-fluoro-3-methylanilino)-2-[(2r)-2-(hydroxymethyl)pyrrolidine-1-carbonyl]thieno[2,3-b]pyridin-6-one Chemical compound C1=C(F)C(C)=CC(NC=2C=3C=CC(=O)N(C=4C(=CC=CC=4)Cl)C=3SC=2C(=O)N2[C@H](CCC2)CO)=C1 LCWVTCZBKHWVBD-QGZVFWFLSA-N 0.000 claims description 2
- UFSFFVRDGAWISZ-INIZCTEOSA-N 7-(2-chlorophenyl)-3-(4-fluoro-3-methylanilino)-2-[(3s)-3-hydroxypyrrolidine-1-carbonyl]thieno[2,3-b]pyridin-6-one Chemical compound C1=C(F)C(C)=CC(NC=2C=3C=CC(=O)N(C=4C(=CC=CC=4)Cl)C=3SC=2C(=O)N2C[C@@H](O)CC2)=C1 UFSFFVRDGAWISZ-INIZCTEOSA-N 0.000 claims description 2
- MVTPZVWCPIJJRE-LJQANCHMSA-N 7-(4-chlorophenyl)-3-(4-fluoro-3-methylanilino)-2-[(2r)-2-(hydroxymethyl)pyrrolidine-1-carbonyl]thieno[2,3-b]pyridin-6-one Chemical compound C1=C(F)C(C)=CC(NC=2C=3C=CC(=O)N(C=4C=CC(Cl)=CC=4)C=3SC=2C(=O)N2[C@H](CCC2)CO)=C1 MVTPZVWCPIJJRE-LJQANCHMSA-N 0.000 claims description 2
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims description 2
- 206010055128 Autoimmune neutropenia Diseases 0.000 claims description 2
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims description 2
- 208000004429 Bacillary Dysentery Diseases 0.000 claims description 2
- 241000713704 Bovine immunodeficiency virus Species 0.000 claims description 2
- 201000006474 Brain Ischemia Diseases 0.000 claims description 2
- 241000282465 Canis Species 0.000 claims description 2
- 206010007572 Cardiac hypertrophy Diseases 0.000 claims description 2
- 208000006029 Cardiomegaly Diseases 0.000 claims description 2
- 206010008909 Chronic Hepatitis Diseases 0.000 claims description 2
- 208000000668 Chronic Pancreatitis Diseases 0.000 claims description 2
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims description 2
- 241000711573 Coronaviridae Species 0.000 claims description 2
- 206010048843 Cytomegalovirus chorioretinitis Diseases 0.000 claims description 2
- 206010012438 Dermatitis atopic Diseases 0.000 claims description 2
- 241000713730 Equine infectious anemia virus Species 0.000 claims description 2
- 241000713800 Feline immunodeficiency virus Species 0.000 claims description 2
- 208000009329 Graft vs Host Disease Diseases 0.000 claims description 2
- 208000003807 Graves Disease Diseases 0.000 claims description 2
- 208000015023 Graves' disease Diseases 0.000 claims description 2
- 208000037357 HIV infectious disease Diseases 0.000 claims description 2
- 206010019233 Headaches Diseases 0.000 claims description 2
- 208000005176 Hepatitis C Diseases 0.000 claims description 2
- 206010019755 Hepatitis chronic active Diseases 0.000 claims description 2
- 206010021143 Hypoxia Diseases 0.000 claims description 2
- 206010061598 Immunodeficiency Diseases 0.000 claims description 2
- 208000029462 Immunodeficiency disease Diseases 0.000 claims description 2
- 208000007766 Kaposi sarcoma Diseases 0.000 claims description 2
- 206010027480 Metastatic malignant melanoma Diseases 0.000 claims description 2
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims description 2
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims description 2
- 208000001132 Osteoporosis Diseases 0.000 claims description 2
- 206010033645 Pancreatitis Diseases 0.000 claims description 2
- 206010033647 Pancreatitis acute Diseases 0.000 claims description 2
- 206010033649 Pancreatitis chronic Diseases 0.000 claims description 2
- 208000002606 Paramyxoviridae Infections Diseases 0.000 claims description 2
- 208000018737 Parkinson disease Diseases 0.000 claims description 2
- 241000725643 Respiratory syncytial virus Species 0.000 claims description 2
- 206010039710 Scleroderma Diseases 0.000 claims description 2
- 206010040550 Shigella infections Diseases 0.000 claims description 2
- 108090000190 Thrombin Proteins 0.000 claims description 2
- 208000007536 Thrombosis Diseases 0.000 claims description 2
- 206010043781 Thyroiditis chronic Diseases 0.000 claims description 2
- 241000713325 Visna/maedi virus Species 0.000 claims description 2
- 201000003229 acute pancreatitis Diseases 0.000 claims description 2
- 230000036592 analgesia Effects 0.000 claims description 2
- 230000002491 angiogenic effect Effects 0.000 claims description 2
- 201000008937 atopic dermatitis Diseases 0.000 claims description 2
- 201000005000 autoimmune gastritis Diseases 0.000 claims description 2
- 210000004556 brain Anatomy 0.000 claims description 2
- 230000000747 cardiac effect Effects 0.000 claims description 2
- 125000004802 cyanophenyl group Chemical group 0.000 claims description 2
- 208000001763 cytomegalovirus retinitis Diseases 0.000 claims description 2
- 125000004212 difluorophenyl group Chemical group 0.000 claims description 2
- 125000001207 fluorophenyl group Chemical group 0.000 claims description 2
- 208000024908 graft versus host disease Diseases 0.000 claims description 2
- 231100000869 headache Toxicity 0.000 claims description 2
- 208000007475 hemolytic anemia Diseases 0.000 claims description 2
- 208000005252 hepatitis A Diseases 0.000 claims description 2
- 208000002672 hepatitis B Diseases 0.000 claims description 2
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 claims description 2
- 206010020718 hyperplasia Diseases 0.000 claims description 2
- 230000007954 hypoxia Effects 0.000 claims description 2
- 230000007813 immunodeficiency Effects 0.000 claims description 2
- 208000014674 injury Diseases 0.000 claims description 2
- 208000028867 ischemia Diseases 0.000 claims description 2
- 125000005647 linker group Chemical group 0.000 claims description 2
- 208000021039 metastatic melanoma Diseases 0.000 claims description 2
- 201000006417 multiple sclerosis Diseases 0.000 claims description 2
- 206010028417 myasthenia gravis Diseases 0.000 claims description 2
- 208000010125 myocardial infarction Diseases 0.000 claims description 2
- 230000002232 neuromuscular Effects 0.000 claims description 2
- 210000000056 organ Anatomy 0.000 claims description 2
- 230000010410 reperfusion Effects 0.000 claims description 2
- 201000005113 shigellosis Diseases 0.000 claims description 2
- 208000010110 spontaneous platelet aggregation Diseases 0.000 claims description 2
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims description 2
- 229960004072 thrombin Drugs 0.000 claims description 2
- 206010043554 thrombocytopenia Diseases 0.000 claims description 2
- 230000008736 traumatic injury Effects 0.000 claims description 2
- 241000701161 unidentified adenovirus Species 0.000 claims description 2
- 241000712461 unidentified influenza virus Species 0.000 claims description 2
- 230000002792 vascular Effects 0.000 claims description 2
- 208000026935 allergic disease Diseases 0.000 claims 2
- SAIFBCFTLQJMLA-OALUTQOASA-N 3-(2,4-difluoroanilino)-2-[(3s,4s)-3,4-dihydroxypyrrolidine-1-carbonyl]-7-phenylthieno[2,3-b]pyridin-6-one Chemical compound C1[C@H](O)[C@@H](O)CN1C(=O)C1=C(NC=2C(=CC(F)=CC=2)F)C(C=CC(=O)N2C=3C=CC=CC=3)=C2S1 SAIFBCFTLQJMLA-OALUTQOASA-N 0.000 claims 1
- 206010008120 Cerebral ischaemia Diseases 0.000 claims 1
- 101000611183 Homo sapiens Tumor necrosis factor Proteins 0.000 claims 1
- 206010008118 cerebral infarction Diseases 0.000 claims 1
- 208000010710 hepatitis C virus infection Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 abstract description 5
- 208000026278 immune system disease Diseases 0.000 abstract description 2
- MQJNETSYXIIIKE-UHFFFAOYSA-N 7h-thieno[2,3-b]pyridin-6-one Chemical class N1C(=O)C=CC2=C1SC=C2 MQJNETSYXIIIKE-UHFFFAOYSA-N 0.000 abstract 1
- 239000000543 intermediate Substances 0.000 description 313
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 247
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 206
- 239000007787 solid Substances 0.000 description 160
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 153
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 149
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 127
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 104
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 74
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 69
- 235000019439 ethyl acetate Nutrition 0.000 description 69
- 239000000203 mixture Substances 0.000 description 65
- 239000000377 silicon dioxide Substances 0.000 description 63
- 239000000243 solution Substances 0.000 description 63
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 61
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 60
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 60
- 239000002904 solvent Substances 0.000 description 60
- 125000001424 substituent group Chemical group 0.000 description 57
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 57
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 49
- 238000004440 column chromatography Methods 0.000 description 46
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 45
- 239000011541 reaction mixture Substances 0.000 description 43
- AFABGHUZZDYHJO-UHFFFAOYSA-N 2-Methylpentane Chemical compound CCCC(C)C AFABGHUZZDYHJO-UHFFFAOYSA-N 0.000 description 40
- 238000010992 reflux Methods 0.000 description 36
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 35
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 35
- 238000005481 NMR spectroscopy Methods 0.000 description 35
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 33
- PXBRQCKWGAHEHS-UHFFFAOYSA-N dichlorodifluoromethane Chemical compound FC(F)(Cl)Cl PXBRQCKWGAHEHS-UHFFFAOYSA-N 0.000 description 33
- 239000012043 crude product Substances 0.000 description 32
- 239000002585 base Substances 0.000 description 30
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 30
- 150000001412 amines Chemical class 0.000 description 29
- 239000002253 acid Substances 0.000 description 25
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 24
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 24
- 229910002092 carbon dioxide Inorganic materials 0.000 description 23
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 22
- 102000018594 Tumour necrosis factor Human genes 0.000 description 21
- 108050007852 Tumour necrosis factor Proteins 0.000 description 21
- 150000001408 amides Chemical class 0.000 description 21
- RAHZWNYVWXNFOC-UHFFFAOYSA-N sulfur dioxide Inorganic materials O=S=O RAHZWNYVWXNFOC-UHFFFAOYSA-N 0.000 description 21
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 20
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 20
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 20
- 210000004027 cell Anatomy 0.000 description 20
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 20
- 239000012267 brine Substances 0.000 description 19
- 235000011167 hydrochloric acid Nutrition 0.000 description 18
- 239000000047 product Substances 0.000 description 18
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 18
- 239000000725 suspension Substances 0.000 description 17
- CYPYTURSJDMMMP-WVCUSYJESA-N (1e,4e)-1,5-diphenylpenta-1,4-dien-3-one;palladium Chemical compound [Pd].[Pd].C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1 CYPYTURSJDMMMP-WVCUSYJESA-N 0.000 description 16
- HVVNJUAVDAZWCB-RXMQYKEDSA-N D-prolinol Chemical compound OC[C@H]1CCCN1 HVVNJUAVDAZWCB-RXMQYKEDSA-N 0.000 description 16
- 125000005843 halogen group Chemical group 0.000 description 16
- 230000008569 process Effects 0.000 description 16
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 16
- 238000004587 chromatography analysis Methods 0.000 description 15
- 125000005842 heteroatom Chemical group 0.000 description 15
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 14
- 230000004913 activation Effects 0.000 description 14
- 239000000460 chlorine Substances 0.000 description 14
- 229910052757 nitrogen Inorganic materials 0.000 description 14
- 238000002360 preparation method Methods 0.000 description 14
- 102000000589 Interleukin-1 Human genes 0.000 description 13
- 108091000080 Phosphotransferase Proteins 0.000 description 13
- 150000004292 cyclic ethers Chemical class 0.000 description 13
- 102000020233 phosphotransferase Human genes 0.000 description 13
- 238000000746 purification Methods 0.000 description 13
- 238000003786 synthesis reaction Methods 0.000 description 13
- 239000003153 chemical reaction reagent Substances 0.000 description 12
- 125000004433 nitrogen atom Chemical group N* 0.000 description 12
- CEPCPXLLFXPZGW-UHFFFAOYSA-N 2,4-difluoroaniline Chemical compound NC1=CC=C(F)C=C1F CEPCPXLLFXPZGW-UHFFFAOYSA-N 0.000 description 11
- NYMDPDNETOLVBS-UHFFFAOYSA-N 4-fluoro-3-methylaniline Chemical compound CC1=CC(N)=CC=C1F NYMDPDNETOLVBS-UHFFFAOYSA-N 0.000 description 11
- 102000004127 Cytokines Human genes 0.000 description 11
- 108090000695 Cytokines Proteins 0.000 description 11
- 102000004890 Interleukin-8 Human genes 0.000 description 11
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical class OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 11
- 125000004429 atom Chemical group 0.000 description 11
- MUALRAIOVNYAIW-UHFFFAOYSA-N binap Chemical group C1=CC=CC=C1P(C=1C(=C2C=CC=CC2=CC=1)C=1C2=CC=CC=C2C=CC=1P(C=1C=CC=CC=1)C=1C=CC=CC=1)C1=CC=CC=C1 MUALRAIOVNYAIW-UHFFFAOYSA-N 0.000 description 11
- 229910000024 caesium carbonate Inorganic materials 0.000 description 11
- 150000002148 esters Chemical class 0.000 description 11
- 150000008282 halocarbons Chemical class 0.000 description 11
- 229920006008 lipopolysaccharide Polymers 0.000 description 11
- 239000012044 organic layer Substances 0.000 description 11
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 11
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 10
- 102000004889 Interleukin-6 Human genes 0.000 description 10
- 125000000217 alkyl group Chemical group 0.000 description 10
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 10
- 229910052801 chlorine Inorganic materials 0.000 description 10
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 9
- SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 9
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 9
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 9
- 239000011737 fluorine Substances 0.000 description 9
- 229910052731 fluorine Inorganic materials 0.000 description 9
- 125000000623 heterocyclic group Chemical group 0.000 description 9
- 230000005764 inhibitory process Effects 0.000 description 9
- 239000012071 phase Substances 0.000 description 9
- 230000000770 proinflammatory effect Effects 0.000 description 9
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 description 8
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide Chemical compound CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 8
- JJYPMNFTHPTTDI-UHFFFAOYSA-N 3-methylaniline Chemical compound CC1=CC=CC(N)=C1 JJYPMNFTHPTTDI-UHFFFAOYSA-N 0.000 description 8
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 8
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 8
- 108010037462 Cyclooxygenase 2 Proteins 0.000 description 8
- YCKRFDGAMUMZLT-UHFFFAOYSA-N Fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 description 8
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 8
- 230000015572 biosynthetic process Effects 0.000 description 8
- 125000004093 cyano group Chemical group *C#N 0.000 description 8
- 230000001404 mediated effect Effects 0.000 description 8
- 229910052751 metal Inorganic materials 0.000 description 8
- 239000002184 metal Substances 0.000 description 8
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 8
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 8
- 210000000440 neutrophil Anatomy 0.000 description 8
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 8
- 239000012074 organic phase Substances 0.000 description 8
- 239000007858 starting material Substances 0.000 description 8
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 description 8
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 8
- 239000003039 volatile agent Substances 0.000 description 8
- XFXPMWWXUTWYJX-UHFFFAOYSA-N Cyanide Chemical compound N#[C-] XFXPMWWXUTWYJX-UHFFFAOYSA-N 0.000 description 7
- BUDQDWGNQVEFAC-UHFFFAOYSA-N Dihydropyran Chemical compound C1COC=CC1 BUDQDWGNQVEFAC-UHFFFAOYSA-N 0.000 description 7
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 7
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 7
- 102100038280 Prostaglandin G/H synthase 2 Human genes 0.000 description 7
- 239000005864 Sulphur Chemical group 0.000 description 7
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 7
- 210000004369 blood Anatomy 0.000 description 7
- 239000008280 blood Substances 0.000 description 7
- 229910052794 bromium Inorganic materials 0.000 description 7
- 229910052799 carbon Inorganic materials 0.000 description 7
- 239000003054 catalyst Substances 0.000 description 7
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 7
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 7
- 239000010410 layer Substances 0.000 description 7
- 239000003960 organic solvent Substances 0.000 description 7
- 239000001301 oxygen Substances 0.000 description 7
- 229910052760 oxygen Inorganic materials 0.000 description 7
- 229910052763 palladium Inorganic materials 0.000 description 7
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 7
- 108090000623 proteins and genes Proteins 0.000 description 7
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 7
- 125000004076 pyridyl group Chemical group 0.000 description 7
- 125000000714 pyrimidinyl group Chemical group 0.000 description 7
- 238000006722 reduction reaction Methods 0.000 description 7
- JHHZLHWJQPUNKB-SCSAIBSYSA-N (3r)-pyrrolidin-3-ol Chemical compound O[C@@H]1CCNC1 JHHZLHWJQPUNKB-SCSAIBSYSA-N 0.000 description 6
- JHHZLHWJQPUNKB-BYPYZUCNSA-N (3s)-pyrrolidin-3-ol Chemical compound O[C@H]1CCNC1 JHHZLHWJQPUNKB-BYPYZUCNSA-N 0.000 description 6
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 6
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical group [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 6
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N N-phenyl amine Natural products NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 6
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 6
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 6
- HVVNJUAVDAZWCB-YFKPBYRVSA-N [(2s)-pyrrolidin-2-yl]methanol Chemical compound OC[C@@H]1CCCN1 HVVNJUAVDAZWCB-YFKPBYRVSA-N 0.000 description 6
- 238000003556 assay Methods 0.000 description 6
- OPQARKPSCNTWTJ-UHFFFAOYSA-L copper(ii) acetate Chemical compound [Cu+2].CC([O-])=O.CC([O-])=O OPQARKPSCNTWTJ-UHFFFAOYSA-L 0.000 description 6
- QTMDXZNDVAMKGV-UHFFFAOYSA-L copper(ii) bromide Chemical compound [Cu+2].[Br-].[Br-] QTMDXZNDVAMKGV-UHFFFAOYSA-L 0.000 description 6
- 230000008878 coupling Effects 0.000 description 6
- 238000010168 coupling process Methods 0.000 description 6
- 238000005859 coupling reaction Methods 0.000 description 6
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 6
- 238000001914 filtration Methods 0.000 description 6
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 6
- 150000007529 inorganic bases Chemical class 0.000 description 6
- UEXQBEVWFZKHNB-UHFFFAOYSA-N intermediate 29 Natural products C1=CC(N)=CC=C1NC1=NC=CC=N1 UEXQBEVWFZKHNB-UHFFFAOYSA-N 0.000 description 6
- 150000002825 nitriles Chemical class 0.000 description 6
- 150000007530 organic bases Chemical class 0.000 description 6
- 239000002953 phosphate buffered saline Substances 0.000 description 6
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 6
- 238000011321 prophylaxis Methods 0.000 description 6
- 125000006239 protecting group Chemical group 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- 230000002441 reversible effect Effects 0.000 description 6
- 239000011734 sodium Substances 0.000 description 6
- WRIKHQLVHPKCJU-UHFFFAOYSA-N sodium bis(trimethylsilyl)amide Chemical compound C[Si](C)(C)N([Na])[Si](C)(C)C WRIKHQLVHPKCJU-UHFFFAOYSA-N 0.000 description 6
- 239000012312 sodium hydride Substances 0.000 description 6
- 229910000104 sodium hydride Inorganic materials 0.000 description 6
- QAEDZJGFFMLHHQ-UHFFFAOYSA-N trifluoroacetic anhydride Chemical compound FC(F)(F)C(=O)OC(=O)C(F)(F)F QAEDZJGFFMLHHQ-UHFFFAOYSA-N 0.000 description 6
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 description 5
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 5
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 5
- 102100033060 Mitogen-activated protein kinase kinase kinase 4 Human genes 0.000 description 5
- JRNVZBWKYDBUCA-UHFFFAOYSA-N N-Chlorosuccinimide Substances ClN1C(=O)CCC1=O JRNVZBWKYDBUCA-UHFFFAOYSA-N 0.000 description 5
- 239000012826 P38 inhibitor Substances 0.000 description 5
- 108010029485 Protein Isoforms Proteins 0.000 description 5
- 102000001708 Protein Isoforms Human genes 0.000 description 5
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 5
- 239000012039 electrophile Substances 0.000 description 5
- 229940088598 enzyme Drugs 0.000 description 5
- 125000002541 furyl group Chemical group 0.000 description 5
- 238000004128 high performance liquid chromatography Methods 0.000 description 5
- 230000007062 hydrolysis Effects 0.000 description 5
- 238000006460 hydrolysis reaction Methods 0.000 description 5
- 230000002757 inflammatory effect Effects 0.000 description 5
- 230000018276 interleukin-1 production Effects 0.000 description 5
- 230000021995 interleukin-8 production Effects 0.000 description 5
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 5
- 125000002950 monocyclic group Chemical group 0.000 description 5
- 125000002757 morpholinyl group Chemical group 0.000 description 5
- 125000003386 piperidinyl group Chemical group 0.000 description 5
- 239000002244 precipitate Substances 0.000 description 5
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 5
- 125000000168 pyrrolyl group Chemical group 0.000 description 5
- 230000009467 reduction Effects 0.000 description 5
- 230000004044 response Effects 0.000 description 5
- 230000011664 signaling Effects 0.000 description 5
- 125000001544 thienyl group Chemical group 0.000 description 5
- 150000003573 thiols Chemical class 0.000 description 5
- 125000004568 thiomorpholinyl group Chemical group 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 description 4
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 4
- KISWVXRQTGLFGD-UHFFFAOYSA-N 2-[[2-[[6-amino-2-[[2-[[2-[[5-amino-2-[[2-[[1-[2-[[6-amino-2-[(2,5-diamino-5-oxopentanoyl)amino]hexanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]-5-(diaminomethylideneamino)p Chemical compound C1CCN(C(=O)C(CCCN=C(N)N)NC(=O)C(CCCCN)NC(=O)C(N)CCC(N)=O)C1C(=O)NC(CO)C(=O)NC(CCC(N)=O)C(=O)NC(CCCN=C(N)N)C(=O)NC(CO)C(=O)NC(CCCCN)C(=O)NC(C(=O)NC(CC(C)C)C(O)=O)CC1=CC=C(O)C=C1 KISWVXRQTGLFGD-UHFFFAOYSA-N 0.000 description 4
- ZNQVEEAIQZEUHB-UHFFFAOYSA-N 2-ethoxyethanol Chemical compound CCOCCO ZNQVEEAIQZEUHB-UHFFFAOYSA-N 0.000 description 4
- 229940093475 2-ethoxyethanol Drugs 0.000 description 4
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 4
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonium chloride Substances [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 4
- 101000624426 Homo sapiens Dual specificity mitogen-activated protein kinase kinase 6 Proteins 0.000 description 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 4
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 4
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 4
- JCXJVPUVTGWSNB-UHFFFAOYSA-N Nitrogen dioxide Chemical compound O=[N]=O JCXJVPUVTGWSNB-UHFFFAOYSA-N 0.000 description 4
- XYFCBTPGUUZFHI-UHFFFAOYSA-N Phosphine Chemical compound P XYFCBTPGUUZFHI-UHFFFAOYSA-N 0.000 description 4
- 102000001253 Protein Kinase Human genes 0.000 description 4
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 238000006254 arylation reaction Methods 0.000 description 4
- 125000002619 bicyclic group Chemical group 0.000 description 4
- 239000003638 chemical reducing agent Substances 0.000 description 4
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 4
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 4
- 235000019253 formic acid Nutrition 0.000 description 4
- 125000000524 functional group Chemical group 0.000 description 4
- 239000007789 gas Substances 0.000 description 4
- 125000002632 imidazolidinyl group Chemical group 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 229910052500 inorganic mineral Inorganic materials 0.000 description 4
- 125000003253 isopropoxy group Chemical group [H]C([H])([H])C([H])(O*)C([H])([H])[H] 0.000 description 4
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- ZCSHNCUQKCANBX-UHFFFAOYSA-N lithium diisopropylamide Chemical compound [Li+].CC(C)[N-]C(C)C ZCSHNCUQKCANBX-UHFFFAOYSA-N 0.000 description 4
- 235000010755 mineral Nutrition 0.000 description 4
- 239000011707 mineral Substances 0.000 description 4
- 239000003921 oil Substances 0.000 description 4
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 4
- KJIFKLIQANRMOU-UHFFFAOYSA-N oxidanium;4-methylbenzenesulfonate Chemical compound O.CC1=CC=C(S(O)(=O)=O)C=C1 KJIFKLIQANRMOU-UHFFFAOYSA-N 0.000 description 4
- 238000007254 oxidation reaction Methods 0.000 description 4
- HXITXNWTGFUOAU-UHFFFAOYSA-N phenylboronic acid Chemical compound OB(O)C1=CC=CC=C1 HXITXNWTGFUOAU-UHFFFAOYSA-N 0.000 description 4
- 230000026731 phosphorylation Effects 0.000 description 4
- 238000006366 phosphorylation reaction Methods 0.000 description 4
- 125000004193 piperazinyl group Chemical group 0.000 description 4
- 230000003389 potentiating effect Effects 0.000 description 4
- 108060006633 protein kinase Proteins 0.000 description 4
- 239000002002 slurry Substances 0.000 description 4
- 150000003384 small molecules Chemical class 0.000 description 4
- 229910000029 sodium carbonate Inorganic materials 0.000 description 4
- 238000010561 standard procedure Methods 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 4
- 125000000335 thiazolyl group Chemical group 0.000 description 4
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical class CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 4
- 230000009466 transformation Effects 0.000 description 4
- 238000000844 transformation Methods 0.000 description 4
- NAWXUBYGYWOOIX-SFHVURJKSA-N (2s)-2-[[4-[2-(2,4-diaminoquinazolin-6-yl)ethyl]benzoyl]amino]-4-methylidenepentanedioic acid Chemical compound C1=CC2=NC(N)=NC(N)=C2C=C1CCC1=CC=C(C(=O)N[C@@H](CC(=C)C(O)=O)C(O)=O)C=C1 NAWXUBYGYWOOIX-SFHVURJKSA-N 0.000 description 3
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 3
- 125000006700 (C1-C6) alkylthio group Chemical group 0.000 description 3
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 description 3
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 description 3
- SGUVLZREKBPKCE-UHFFFAOYSA-N 1,5-diazabicyclo[4.3.0]-non-5-ene Chemical compound C1CCN=C2CCCN21 SGUVLZREKBPKCE-UHFFFAOYSA-N 0.000 description 3
- XBNGYFFABRKICK-UHFFFAOYSA-N 2,3,4,5,6-pentafluorophenol Chemical compound OC1=C(F)C(F)=C(F)C(F)=C1F XBNGYFFABRKICK-UHFFFAOYSA-N 0.000 description 3
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 0 B.CCOC(=O)C1=C(N)C2=C(S1)N(C)C(=O)C=C2.CCOC(C)=O.CN1C(=O)C=CC(C#N)=C1[SH]=[W].CN1C=CC(=O)N(C)C1=O.COC(=O)/C=C\O[W].[20*]C1=C(Br)C2=C(S1)N(C)C(=O)C=C2.[20*]C1=C(N)C2=C(S1)N(C)C(=O)C=C2.[20*]CC.[Ar].[H]N(C)C(=S)CC#N Chemical compound B.CCOC(=O)C1=C(N)C2=C(S1)N(C)C(=O)C=C2.CCOC(C)=O.CN1C(=O)C=CC(C#N)=C1[SH]=[W].CN1C=CC(=O)N(C)C1=O.COC(=O)/C=C\O[W].[20*]C1=C(Br)C2=C(S1)N(C)C(=O)C=C2.[20*]C1=C(N)C2=C(S1)N(C)C(=O)C=C2.[20*]CC.[Ar].[H]N(C)C(=S)CC#N 0.000 description 3
- 229910021590 Copper(II) bromide Inorganic materials 0.000 description 3
- VMQMZMRVKUZKQL-UHFFFAOYSA-N Cu+ Chemical class [Cu+] VMQMZMRVKUZKQL-UHFFFAOYSA-N 0.000 description 3
- 241000701022 Cytomegalovirus Species 0.000 description 3
- 102100023401 Dual specificity mitogen-activated protein kinase kinase 6 Human genes 0.000 description 3
- 101001018147 Homo sapiens Mitogen-activated protein kinase kinase kinase 4 Proteins 0.000 description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- 102000047918 Myelin Basic Human genes 0.000 description 3
- 101710107068 Myelin basic protein Proteins 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 229910006074 SO2NH2 Inorganic materials 0.000 description 3
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 3
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 3
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 3
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 3
- 208000036142 Viral infection Diseases 0.000 description 3
- 230000003213 activating effect Effects 0.000 description 3
- 150000008044 alkali metal hydroxides Chemical class 0.000 description 3
- 150000004703 alkoxides Chemical class 0.000 description 3
- 230000029936 alkylation Effects 0.000 description 3
- 238000005804 alkylation reaction Methods 0.000 description 3
- 150000004945 aromatic hydrocarbons Chemical class 0.000 description 3
- 125000001246 bromo group Chemical group Br* 0.000 description 3
- 125000002837 carbocyclic group Chemical group 0.000 description 3
- 150000001721 carbon Chemical group 0.000 description 3
- 125000004432 carbon atom Chemical group C* 0.000 description 3
- 239000001569 carbon dioxide Substances 0.000 description 3
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 3
- 239000012320 chlorinating reagent Substances 0.000 description 3
- 125000001309 chloro group Chemical group Cl* 0.000 description 3
- 238000002425 crystallisation Methods 0.000 description 3
- 238000010511 deprotection reaction Methods 0.000 description 3
- 230000009977 dual effect Effects 0.000 description 3
- 210000002889 endothelial cell Anatomy 0.000 description 3
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 239000011521 glass Substances 0.000 description 3
- 229910052736 halogen Inorganic materials 0.000 description 3
- 150000002367 halogens Chemical class 0.000 description 3
- 125000000592 heterocycloalkyl group Chemical group 0.000 description 3
- 150000004678 hydrides Chemical class 0.000 description 3
- 239000012442 inert solvent Substances 0.000 description 3
- 230000008595 infiltration Effects 0.000 description 3
- 238000001764 infiltration Methods 0.000 description 3
- 229910052744 lithium Inorganic materials 0.000 description 3
- GLXDVVHUTZTUQK-UHFFFAOYSA-M lithium;hydroxide;hydrate Chemical compound [Li+].O.[OH-] GLXDVVHUTZTUQK-UHFFFAOYSA-M 0.000 description 3
- 239000006166 lysate Substances 0.000 description 3
- 229910052987 metal hydride Inorganic materials 0.000 description 3
- 150000004681 metal hydrides Chemical class 0.000 description 3
- 125000002816 methylsulfanyl group Chemical group [H]C([H])([H])S[*] 0.000 description 3
- 239000002480 mineral oil Substances 0.000 description 3
- 235000010446 mineral oil Nutrition 0.000 description 3
- 239000003226 mitogen Substances 0.000 description 3
- 210000001616 monocyte Anatomy 0.000 description 3
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 3
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 3
- 150000007524 organic acids Chemical class 0.000 description 3
- 125000002971 oxazolyl group Chemical group 0.000 description 3
- 239000007800 oxidant agent Substances 0.000 description 3
- 230000003647 oxidation Effects 0.000 description 3
- IZUPBVBPLAPZRR-UHFFFAOYSA-N pentachloro-phenol Natural products OC1=C(Cl)C(Cl)=C(Cl)C(Cl)=C1Cl IZUPBVBPLAPZRR-UHFFFAOYSA-N 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 229910000027 potassium carbonate Inorganic materials 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 125000003072 pyrazolidinyl group Chemical group 0.000 description 3
- ILVXOBCQQYKLDS-UHFFFAOYSA-N pyridine N-oxide Chemical compound [O-][N+]1=CC=CC=C1 ILVXOBCQQYKLDS-UHFFFAOYSA-N 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 3
- IOGXOCVLYRDXLW-UHFFFAOYSA-N tert-butyl nitrite Chemical compound CC(C)(C)ON=O IOGXOCVLYRDXLW-UHFFFAOYSA-N 0.000 description 3
- 239000012414 tert-butyl nitrite Substances 0.000 description 3
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 3
- 125000004306 triazinyl group Chemical group 0.000 description 3
- 239000003656 tris buffered saline Substances 0.000 description 3
- 230000009385 viral infection Effects 0.000 description 3
- AVAWMINJNRAQFS-ZCFIWIBFSA-N (3r)-n,n-dimethylpyrrolidin-3-amine Chemical compound CN(C)[C@@H]1CCNC1 AVAWMINJNRAQFS-ZCFIWIBFSA-N 0.000 description 2
- AVAWMINJNRAQFS-LURJTMIESA-N (3s)-n,n-dimethylpyrrolidin-3-amine Chemical compound CN(C)[C@H]1CCNC1 AVAWMINJNRAQFS-LURJTMIESA-N 0.000 description 2
- BIWQNIMLAISTBV-UHFFFAOYSA-N (4-methylphenyl)boronic acid Chemical compound CC1=CC=C(B(O)O)C=C1 BIWQNIMLAISTBV-UHFFFAOYSA-N 0.000 description 2
- 125000006274 (C1-C3)alkoxy group Chemical group 0.000 description 2
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 description 2
- AUKXFNABVHIUAC-YFKPBYRVSA-N (S)-pyrrolidin-2-ylmethylamine Chemical compound NC[C@@H]1CCCN1 AUKXFNABVHIUAC-YFKPBYRVSA-N 0.000 description 2
- 125000001637 1-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C(*)=C([H])C([H])=C([H])C2=C1[H] 0.000 description 2
- 125000001622 2-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C(*)C([H])=C([H])C2=C1[H] 0.000 description 2
- NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 2
- XGTHRIXYQVWCLF-UHFFFAOYSA-N CC.CN1C(=O)C=CC2=C1SC([Y]N1CCC1)=C2N.[Ar] Chemical compound CC.CN1C(=O)C=CC2=C1SC([Y]N1CCC1)=C2N.[Ar] XGTHRIXYQVWCLF-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
- KZBUYRJDOAKODT-UHFFFAOYSA-N Chlorine Chemical compound ClCl KZBUYRJDOAKODT-UHFFFAOYSA-N 0.000 description 2
- RENMDAKOXSCIGH-UHFFFAOYSA-N Chloroacetonitrile Chemical compound ClCC#N RENMDAKOXSCIGH-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 102000029816 Collagenase Human genes 0.000 description 2
- 108060005980 Collagenase Proteins 0.000 description 2
- 102100023033 Cyclic AMP-dependent transcription factor ATF-2 Human genes 0.000 description 2
- 102100029145 DNA damage-inducible transcript 3 protein Human genes 0.000 description 2
- 101710156077 DNA damage-inducible transcript 3 protein Proteins 0.000 description 2
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 2
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 2
- 102100023275 Dual specificity mitogen-activated protein kinase kinase 3 Human genes 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- DHCLVCXQIBBOPH-UHFFFAOYSA-N Glycerol 2-phosphate Chemical compound OCC(CO)OP(O)(O)=O DHCLVCXQIBBOPH-UHFFFAOYSA-N 0.000 description 2
- 101710100504 Heat shock protein beta-1 Proteins 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- 101001115394 Homo sapiens Dual specificity mitogen-activated protein kinase kinase 3 Proteins 0.000 description 2
- 101000578774 Homo sapiens MAP kinase-activated protein kinase 5 Proteins 0.000 description 2
- 101000628954 Homo sapiens Mitogen-activated protein kinase 12 Proteins 0.000 description 2
- 101000945096 Homo sapiens Ribosomal protein S6 kinase alpha-5 Proteins 0.000 description 2
- 101001059454 Homo sapiens Serine/threonine-protein kinase MARK2 Proteins 0.000 description 2
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 108010055717 JNK Mitogen-Activated Protein Kinases Proteins 0.000 description 2
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 2
- 108010075647 MAP Kinase Kinase Kinase 4 Proteins 0.000 description 2
- 102100028396 MAP kinase-activated protein kinase 5 Human genes 0.000 description 2
- 108700012928 MAPK14 Proteins 0.000 description 2
- 102000000422 Matrix Metalloproteinase 3 Human genes 0.000 description 2
- 102100026932 Mitogen-activated protein kinase 12 Human genes 0.000 description 2
- 108700015928 Mitogen-activated protein kinase 13 Proteins 0.000 description 2
- 102000056248 Mitogen-activated protein kinase 13 Human genes 0.000 description 2
- 102000054819 Mitogen-activated protein kinase 14 Human genes 0.000 description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 2
- 238000010934 O-alkylation reaction Methods 0.000 description 2
- 229930040373 Paraformaldehyde Natural products 0.000 description 2
- KFSLWBXXFJQRDL-UHFFFAOYSA-N Peracetic acid Chemical compound CC(=O)OO KFSLWBXXFJQRDL-UHFFFAOYSA-N 0.000 description 2
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 102100033645 Ribosomal protein S6 kinase alpha-5 Human genes 0.000 description 2
- 238000000297 Sandmeyer reaction Methods 0.000 description 2
- 229940124639 Selective inhibitor Drugs 0.000 description 2
- 206010070834 Sensitisation Diseases 0.000 description 2
- 102100028904 Serine/threonine-protein kinase MARK2 Human genes 0.000 description 2
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 2
- NJPNCMOUEXEGBL-RZFWHQLPSA-N [(3r)-pyrrolidin-1-ium-3-yl]azanium;dichloride Chemical compound Cl.Cl.N[C@@H]1CCNC1 NJPNCMOUEXEGBL-RZFWHQLPSA-N 0.000 description 2
- QQIRAVWVGBTHMJ-UHFFFAOYSA-N [dimethyl-(trimethylsilylamino)silyl]methane;lithium Chemical compound [Li].C[Si](C)(C)N[Si](C)(C)C QQIRAVWVGBTHMJ-UHFFFAOYSA-N 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 239000012190 activator Substances 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 125000003158 alcohol group Chemical group 0.000 description 2
- 230000001476 alcoholic effect Effects 0.000 description 2
- 125000003342 alkenyl group Chemical group 0.000 description 2
- 125000003545 alkoxy group Chemical group 0.000 description 2
- 125000005278 alkyl sulfonyloxy group Chemical group 0.000 description 2
- 125000004414 alkyl thio group Chemical group 0.000 description 2
- 239000002168 alkylating agent Substances 0.000 description 2
- 229940100198 alkylating agent Drugs 0.000 description 2
- 125000000304 alkynyl group Chemical group 0.000 description 2
- 238000005576 amination reaction Methods 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 125000003277 amino group Chemical group 0.000 description 2
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 2
- 159000000032 aromatic acids Chemical class 0.000 description 2
- 150000004982 aromatic amines Chemical class 0.000 description 2
- 230000002917 arthritic effect Effects 0.000 description 2
- 125000005418 aryl aryl group Chemical group 0.000 description 2
- 125000005279 aryl sulfonyloxy group Chemical group 0.000 description 2
- UQUPQEUNHVVNKW-UHFFFAOYSA-N azetidin-1-ium-3-ol;chloride Chemical compound Cl.OC1CNC1 UQUPQEUNHVVNKW-UHFFFAOYSA-N 0.000 description 2
- 210000003651 basophil Anatomy 0.000 description 2
- 125000004618 benzofuryl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 2
- 125000004619 benzopyranyl group Chemical group O1C(C=CC2=C1C=CC=C2)* 0.000 description 2
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 229910052796 boron Inorganic materials 0.000 description 2
- ILAHWRKJUDSMFH-UHFFFAOYSA-N boron tribromide Chemical compound BrB(Br)Br ILAHWRKJUDSMFH-UHFFFAOYSA-N 0.000 description 2
- 150000001649 bromium compounds Chemical class 0.000 description 2
- AEILLAXRDHDKDY-UHFFFAOYSA-N bromomethylcyclopropane Chemical compound BrCC1CC1 AEILLAXRDHDKDY-UHFFFAOYSA-N 0.000 description 2
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 2
- 150000001735 carboxylic acids Chemical class 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 238000009903 catalytic hydrogenation reaction Methods 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 150000008280 chlorinated hydrocarbons Chemical class 0.000 description 2
- 150000001805 chlorine compounds Chemical class 0.000 description 2
- 229960002424 collagenase Drugs 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 239000013058 crude material Substances 0.000 description 2
- 125000000753 cycloalkyl group Chemical group 0.000 description 2
- MGNZXYYWBUKAII-UHFFFAOYSA-N cyclohexa-1,3-diene Chemical compound C1CC=CC=C1 MGNZXYYWBUKAII-UHFFFAOYSA-N 0.000 description 2
- 230000016396 cytokine production Effects 0.000 description 2
- 125000004786 difluoromethoxy group Chemical group [H]C(F)(F)O* 0.000 description 2
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 230000006353 environmental stress Effects 0.000 description 2
- 125000004185 ester group Chemical group 0.000 description 2
- PVBRSNZAOAJRKO-UHFFFAOYSA-N ethyl 2-sulfanylacetate Chemical compound CCOC(=O)CS PVBRSNZAOAJRKO-UHFFFAOYSA-N 0.000 description 2
- DKBWMIBMQAHLPR-UHFFFAOYSA-N ethyl 3-anilino-6-oxo-7-phenylthieno[2,3-b]pyridine-2-carboxylate Chemical compound O=C1C=CC=2C(NC=3C=CC=CC=3)=C(C(=O)OCC)SC=2N1C1=CC=CC=C1 DKBWMIBMQAHLPR-UHFFFAOYSA-N 0.000 description 2
- PQVSTLUFSYVLTO-UHFFFAOYSA-N ethyl n-ethoxycarbonylcarbamate Chemical compound CCOC(=O)NC(=O)OCC PQVSTLUFSYVLTO-UHFFFAOYSA-N 0.000 description 2
- 125000004705 ethylthio group Chemical group C(C)S* 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 125000001153 fluoro group Chemical group F* 0.000 description 2
- 239000006260 foam Substances 0.000 description 2
- 150000004820 halides Chemical class 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 150000004677 hydrates Chemical class 0.000 description 2
- 238000005984 hydrogenation reaction Methods 0.000 description 2
- 125000002883 imidazolyl group Chemical group 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000011065 in-situ storage Methods 0.000 description 2
- 125000001041 indolyl group Chemical group 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 230000017306 interleukin-6 production Effects 0.000 description 2
- 229910052740 iodine Inorganic materials 0.000 description 2
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 2
- 238000005304 joining Methods 0.000 description 2
- 238000011694 lewis rat Methods 0.000 description 2
- 239000012280 lithium aluminium hydride Substances 0.000 description 2
- 229940040692 lithium hydroxide monohydrate Drugs 0.000 description 2
- UBJFKNSINUCEAL-UHFFFAOYSA-N lithium;2-methylpropane Chemical compound [Li+].C[C-](C)C UBJFKNSINUCEAL-UHFFFAOYSA-N 0.000 description 2
- 238000011068 loading method Methods 0.000 description 2
- 239000007937 lozenge Substances 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 229910001629 magnesium chloride Inorganic materials 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- TZIHFWKZFHZASV-UHFFFAOYSA-N methyl formate Chemical compound COC=O TZIHFWKZFHZASV-UHFFFAOYSA-N 0.000 description 2
- BZLVMXJERCGZMT-UHFFFAOYSA-N methyl tert-butyl ether Substances COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- 201000009240 nasopharyngitis Diseases 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 229920002866 paraformaldehyde Polymers 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 2
- 150000004965 peroxy acids Chemical class 0.000 description 2
- 229910052698 phosphorus Inorganic materials 0.000 description 2
- 239000011574 phosphorus Substances 0.000 description 2
- 229910000073 phosphorus hydride Inorganic materials 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 2
- GPTFURBXHJWNHR-UHFFFAOYSA-N protopine Chemical compound C1=C2C(=O)CC3=CC=C4OCOC4=C3CN(C)CCC2=CC2=C1OCO2 GPTFURBXHJWNHR-UHFFFAOYSA-N 0.000 description 2
- 125000003373 pyrazinyl group Chemical group 0.000 description 2
- 125000002098 pyridazinyl group Chemical group 0.000 description 2
- 150000003222 pyridines Chemical class 0.000 description 2
- 238000010791 quenching Methods 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 239000011347 resin Substances 0.000 description 2
- 229920005989 resin Polymers 0.000 description 2
- 238000003118 sandwich ELISA Methods 0.000 description 2
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- 238000013207 serial dilution Methods 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- QDRKDTQENPPHOJ-UHFFFAOYSA-N sodium ethoxide Chemical compound [Na+].CC[O-] QDRKDTQENPPHOJ-UHFFFAOYSA-N 0.000 description 2
- 229910052938 sodium sulfate Inorganic materials 0.000 description 2
- 235000011152 sodium sulphate Nutrition 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 230000035882 stress Effects 0.000 description 2
- 108091007196 stromelysin Proteins 0.000 description 2
- 125000000547 substituted alkyl group Chemical group 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- DQQJBEAXSOOCPG-ZETCQYMHSA-N tert-butyl n-[(3s)-pyrrolidin-3-yl]carbamate Chemical compound CC(C)(C)OC(=O)N[C@H]1CCNC1 DQQJBEAXSOOCPG-ZETCQYMHSA-N 0.000 description 2
- 150000003512 tertiary amines Chemical class 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 125000004055 thiomethyl group Chemical group [H]SC([H])([H])* 0.000 description 2
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 2
- 230000006433 tumor necrosis factor production Effects 0.000 description 2
- 238000011144 upstream manufacturing Methods 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- QBIJCERNSFSYON-UHFFFAOYSA-N (2,3,4,5,6-pentafluorophenyl) 3-(2,4-difluoroanilino)-6-oxo-7-phenylthieno[2,3-b]pyridine-2-carboxylate Chemical compound FC1=CC(F)=CC=C1NC1=C(C(=O)OC=2C(=C(F)C(F)=C(F)C=2F)F)SC2=C1C=CC(=O)N2C1=CC=CC=C1 QBIJCERNSFSYON-UHFFFAOYSA-N 0.000 description 1
- SDXCBSKWFWUIKX-UHFFFAOYSA-N (2,3,4,5,6-pentafluorophenyl) 3-(2-cyanoanilino)-6-oxo-7-phenylthieno[2,3-b]pyridine-2-carboxylate Chemical compound FC1=C(F)C(F)=C(F)C(F)=C1OC(=O)C1=C(NC=2C(=CC=CC=2)C#N)C(C=CC(=O)N2C=3C=CC=CC=3)=C2S1 SDXCBSKWFWUIKX-UHFFFAOYSA-N 0.000 description 1
- KOQDVUUCOJCDQU-UHFFFAOYSA-N (2,3,4,5,6-pentafluorophenyl) 3-(4-fluoro-3-methylanilino)-6-oxo-7-phenylthieno[2,3-b]pyridine-2-carboxylate Chemical compound C1=C(F)C(C)=CC(NC=2C=3C=CC(=O)N(C=4C=CC=CC=4)C=3SC=2C(=O)OC=2C(=C(F)C(F)=C(F)C=2F)F)=C1 KOQDVUUCOJCDQU-UHFFFAOYSA-N 0.000 description 1
- UERNRFHISLXQFU-DFWYDOINSA-N (2S)-5-oxopyrrolidine-2-carboxylic acid pyridine Chemical compound c1ccncc1.OC(=O)[C@@H]1CCC(=O)N1 UERNRFHISLXQFU-DFWYDOINSA-N 0.000 description 1
- CHPRFKYDQRKRRK-ZCFIWIBFSA-N (2r)-2-(methoxymethyl)pyrrolidine Chemical compound COC[C@H]1CCCN1 CHPRFKYDQRKRRK-ZCFIWIBFSA-N 0.000 description 1
- BJQCPCFFYBKRLM-UHFFFAOYSA-N (3-methylphenyl)boronic acid Chemical compound CC1=CC=CC(B(O)O)=C1 BJQCPCFFYBKRLM-UHFFFAOYSA-N 0.000 description 1
- JCZPOYAMKJFOLA-QWWZWVQMSA-N (3r,4r)-pyrrolidine-3,4-diol Chemical compound O[C@@H]1CNC[C@H]1O JCZPOYAMKJFOLA-QWWZWVQMSA-N 0.000 description 1
- VADWFRGDDJHKNB-HKTIBRIUSA-N (3s,4r)-pyrrolidine-3,4-diol;hydrochloride Chemical compound Cl.O[C@H]1CNC[C@H]1O VADWFRGDDJHKNB-HKTIBRIUSA-N 0.000 description 1
- JCZPOYAMKJFOLA-IMJSIDKUSA-N (3s,4s)-pyrrolidine-3,4-diol Chemical compound O[C@H]1CNC[C@@H]1O JCZPOYAMKJFOLA-IMJSIDKUSA-N 0.000 description 1
- CAYQIZIAYYNFCS-UHFFFAOYSA-N (4-chlorophenyl)boronic acid Chemical compound OB(O)C1=CC=C(Cl)C=C1 CAYQIZIAYYNFCS-UHFFFAOYSA-N 0.000 description 1
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 description 1
- 125000006624 (C1-C6) alkoxycarbonylamino group Chemical group 0.000 description 1
- 125000004890 (C1-C6) alkylamino group Chemical group 0.000 description 1
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 description 1
- 125000006656 (C2-C4) alkenyl group Chemical group 0.000 description 1
- 125000006650 (C2-C4) alkynyl group Chemical group 0.000 description 1
- 125000006590 (C2-C6) alkenylene group Chemical group 0.000 description 1
- 125000006591 (C2-C6) alkynylene group Chemical group 0.000 description 1
- 125000006717 (C3-C10) cycloalkenyl group Chemical group 0.000 description 1
- 125000006376 (C3-C10) cycloalkyl group Chemical group 0.000 description 1
- AUKXFNABVHIUAC-RXMQYKEDSA-N (R)-pyrrolidin-2-ylmethylamine Chemical compound NC[C@H]1CCCN1 AUKXFNABVHIUAC-RXMQYKEDSA-N 0.000 description 1
- CHPRFKYDQRKRRK-LURJTMIESA-N (S)-2-(methoxymethyl)pyrrolidine Chemical compound COC[C@@H]1CCCN1 CHPRFKYDQRKRRK-LURJTMIESA-N 0.000 description 1
- SCYULBFZEHDVBN-UHFFFAOYSA-N 1,1-Dichloroethane Chemical compound CC(Cl)Cl SCYULBFZEHDVBN-UHFFFAOYSA-N 0.000 description 1
- 125000004502 1,2,3-oxadiazolyl group Chemical group 0.000 description 1
- 125000004529 1,2,3-triazinyl group Chemical group N1=NN=C(C=C1)* 0.000 description 1
- 125000001399 1,2,3-triazolyl group Chemical group N1N=NC(=C1)* 0.000 description 1
- 125000004530 1,2,4-triazinyl group Chemical group N1=NC(=NC=C1)* 0.000 description 1
- 125000001376 1,2,4-triazolyl group Chemical group N1N=C(N=C1)* 0.000 description 1
- 125000004506 1,2,5-oxadiazolyl group Chemical group 0.000 description 1
- DDMOUSALMHHKOS-UHFFFAOYSA-N 1,2-dichloro-1,1,2,2-tetrafluoroethane Chemical compound FC(F)(Cl)C(F)(F)Cl DDMOUSALMHHKOS-UHFFFAOYSA-N 0.000 description 1
- AUYBSFAHQLKXSW-UHFFFAOYSA-N 1,2-dichloroethane;3-(ethyliminomethylideneamino)-n,n-dimethylpropan-1-amine;hydrochloride Chemical compound Cl.ClCCCl.CCN=C=NCCCN(C)C AUYBSFAHQLKXSW-UHFFFAOYSA-N 0.000 description 1
- 125000001781 1,3,4-oxadiazolyl group Chemical group 0.000 description 1
- 125000004520 1,3,4-thiadiazolyl group Chemical group 0.000 description 1
- 125000003363 1,3,5-triazinyl group Chemical group N1=C(N=CN=C1)* 0.000 description 1
- MICMHFIQSAMEJG-UHFFFAOYSA-N 1-bromopyrrolidine-2,5-dione Chemical compound BrN1C(=O)CCC1=O.BrN1C(=O)CCC1=O MICMHFIQSAMEJG-UHFFFAOYSA-N 0.000 description 1
- DASSPOJBUMBXLU-UHFFFAOYSA-N 1-chloro-2-isothiocyanatobenzene Chemical compound ClC1=CC=CC=C1N=C=S DASSPOJBUMBXLU-UHFFFAOYSA-N 0.000 description 1
- PWKNBLFSJAVFAB-UHFFFAOYSA-N 1-fluoro-2-nitrobenzene Chemical compound [O-][N+](=O)C1=CC=CC=C1F PWKNBLFSJAVFAB-UHFFFAOYSA-N 0.000 description 1
- JZUMPNUYDJBTNO-UHFFFAOYSA-N 1-hydroxybenzotriazole;hydrate Chemical compound O.C1=CC=C2N(O)N=NC2=C1.C1=CC=C2N(O)N=NC2=C1 JZUMPNUYDJBTNO-UHFFFAOYSA-N 0.000 description 1
- RVWUHFFPEOKYLB-UHFFFAOYSA-N 2,2,6,6-tetramethyl-1-oxidopiperidin-1-ium Chemical compound CC1(C)CCCC(C)(C)[NH+]1[O-] RVWUHFFPEOKYLB-UHFFFAOYSA-N 0.000 description 1
- ZFFMLCVRJBZUDZ-UHFFFAOYSA-N 2,3-dimethylbutane Chemical group CC(C)C(C)C ZFFMLCVRJBZUDZ-UHFFFAOYSA-N 0.000 description 1
- KZDCMKVLEYCGQX-UDPGNSCCSA-N 2-(diethylamino)ethyl 4-aminobenzoate;(2s,5r,6r)-3,3-dimethyl-7-oxo-6-[(2-phenylacetyl)amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid;hydrate Chemical group O.CCN(CC)CCOC(=O)C1=CC=C(N)C=C1.N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 KZDCMKVLEYCGQX-UDPGNSCCSA-N 0.000 description 1
- KQOPQWJUWQBPPM-FYZOBXCZSA-N 2-[(2r)-pyrrolidin-2-yl]propan-2-ol;hydrochloride Chemical compound Cl.CC(C)(O)[C@H]1CCCN1 KQOPQWJUWQBPPM-FYZOBXCZSA-N 0.000 description 1
- PSXWGNIMIRRWRB-LURJTMIESA-N 2-[(2s)-pyrrolidin-2-yl]propan-2-ol Chemical compound CC(C)(O)[C@@H]1CCCN1 PSXWGNIMIRRWRB-LURJTMIESA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- HLCPWBZNUKCSBN-UHFFFAOYSA-N 2-aminobenzonitrile Chemical compound NC1=CC=CC=C1C#N HLCPWBZNUKCSBN-UHFFFAOYSA-N 0.000 description 1
- 125000000022 2-aminoethyl group Chemical group [H]C([*])([H])C([H])([H])N([H])[H] 0.000 description 1
- WYSRTEVFLQJJDN-UHFFFAOYSA-N 2-chloro-1-oxidopyridin-1-ium Chemical compound [O-][N+]1=CC=CC=C1Cl WYSRTEVFLQJJDN-UHFFFAOYSA-N 0.000 description 1
- BAZVFQBTJPBRTJ-UHFFFAOYSA-N 2-chloro-5-nitropyridine Chemical compound [O-][N+](=O)C1=CC=C(Cl)N=C1 BAZVFQBTJPBRTJ-UHFFFAOYSA-N 0.000 description 1
- AKCRQHGQIJBRMN-UHFFFAOYSA-N 2-chloroaniline Chemical compound NC1=CC=CC=C1Cl AKCRQHGQIJBRMN-UHFFFAOYSA-N 0.000 description 1
- JAUPUQRPBNDMDT-UHFFFAOYSA-N 2-chloropyridine-3-carbonitrile Chemical compound ClC1=NC=CC=C1C#N JAUPUQRPBNDMDT-UHFFFAOYSA-N 0.000 description 1
- YEDUAINPPJYDJZ-UHFFFAOYSA-N 2-hydroxybenzothiazole Chemical compound C1=CC=C2SC(O)=NC2=C1 YEDUAINPPJYDJZ-UHFFFAOYSA-N 0.000 description 1
- LEACJMVNYZDSKR-UHFFFAOYSA-N 2-octyldodecan-1-ol Chemical compound CCCCCCCCCCC(CO)CCCCCCCC LEACJMVNYZDSKR-UHFFFAOYSA-N 0.000 description 1
- VSCBATMPTLKTOV-UHFFFAOYSA-N 2-tert-butylimino-n,n-diethyl-1,3-dimethyl-1,3,2$l^{5}-diazaphosphinan-2-amine Chemical compound CCN(CC)P1(=NC(C)(C)C)N(C)CCCN1C VSCBATMPTLKTOV-UHFFFAOYSA-N 0.000 description 1
- PSHHQSIOJOHNRR-QGZVFWFLSA-N 3-(2,4-difluoroanilino)-2-[(2r)-2-(hydroxymethyl)pyrrolidin-1-yl]sulfonyl-7-phenylthieno[2,3-b]pyridin-6-one Chemical compound OC[C@H]1CCCN1S(=O)(=O)C1=C(NC=2C(=CC(F)=CC=2)F)C(C=CC(=O)N2C=3C=CC=CC=3)=C2S1 PSHHQSIOJOHNRR-QGZVFWFLSA-N 0.000 description 1
- IPCMPLWUJNNDND-OSMGYRLQSA-N 3-(2,4-difluoroanilino)-2-[(2r)-2-(oxan-2-yloxymethyl)pyrrolidine-1-carbonyl]-7-phenylthieno[2,3-b]pyridin-6-one Chemical compound FC1=CC(F)=CC=C1NC1=C(C(=O)N2[C@H](CCC2)COC2OCCCC2)SC2=C1C=CC(=O)N2C1=CC=CC=C1 IPCMPLWUJNNDND-OSMGYRLQSA-N 0.000 description 1
- CXWCTQLYHRJMRC-KRWDZBQOSA-N 3-(2,4-difluoroanilino)-2-[(2s)-2-(hydroxymethyl)pyrrolidine-1-carbonyl]-7-phenylthieno[2,3-b]pyridin-6-one Chemical compound OC[C@@H]1CCCN1C(=O)C1=C(NC=2C(=CC(F)=CC=2)F)C(C=CC(=O)N2C=3C=CC=CC=3)=C2S1 CXWCTQLYHRJMRC-KRWDZBQOSA-N 0.000 description 1
- XTGALQMCNGGBTR-OSMGYRLQSA-N 3-(2,4-difluoroanilino)-7-(4-fluorophenyl)-2-[(2r)-2-(oxan-2-yloxymethyl)pyrrolidine-1-carbonyl]thieno[2,3-b]pyridin-6-one Chemical compound C1=CC(F)=CC=C1N1C(=O)C=CC2=C1SC(C(=O)N1[C@H](CCC1)COC1OCCCC1)=C2NC1=CC=C(F)C=C1F XTGALQMCNGGBTR-OSMGYRLQSA-N 0.000 description 1
- DYJVHMQRRYLLMO-VGOKPJQXSA-N 3-(2,4-difluoroanilino)-7-(4-fluorophenyl)-2-[(3r)-3-(oxan-2-yloxy)pyrrolidine-1-carbonyl]thieno[2,3-b]pyridin-6-one Chemical compound C1=CC(F)=CC=C1N1C(=O)C=CC2=C1SC(C(=O)N1C[C@@H](CC1)OC1OCCCC1)=C2NC1=CC=C(F)C=C1F DYJVHMQRRYLLMO-VGOKPJQXSA-N 0.000 description 1
- DYJVHMQRRYLLMO-JINQPTGOSA-N 3-(2,4-difluoroanilino)-7-(4-fluorophenyl)-2-[(3s)-3-(oxan-2-yloxy)pyrrolidine-1-carbonyl]thieno[2,3-b]pyridin-6-one Chemical compound C1=CC(F)=CC=C1N1C(=O)C=CC2=C1SC(C(=O)N1C[C@H](CC1)OC1OCCCC1)=C2NC1=CC=C(F)C=C1F DYJVHMQRRYLLMO-JINQPTGOSA-N 0.000 description 1
- CWLRRAHQAVHLEK-XVPAFAEQSA-N 3-(2,4-difluoroanilino)-7-(4-methylphenyl)-2-[(2r)-2-(oxan-2-yloxymethyl)pyrrolidine-1-carbonyl]thieno[2,3-b]pyridin-6-one Chemical compound C1=CC(C)=CC=C1N1C(=O)C=CC2=C1SC(C(=O)N1[C@H](CCC1)COC1OCCCC1)=C2NC1=CC=C(F)C=C1F CWLRRAHQAVHLEK-XVPAFAEQSA-N 0.000 description 1
- WLEADJMBBGFLIT-UHFFFAOYSA-N 3-(2,4-difluoroanilino)-7-phenylthieno[2,3-b]pyridin-6-one Chemical compound FC1=CC(F)=CC=C1NC1=CSC2=C1C=CC(=O)N2C1=CC=CC=C1 WLEADJMBBGFLIT-UHFFFAOYSA-N 0.000 description 1
- VXYFADLOYYSXTD-GEPVFLLWSA-N 3-(3-chloroanilino)-2-[(2r)-2-(oxan-2-yloxymethyl)pyrrolidine-1-carbonyl]-7-phenylthieno[2,3-b]pyridin-6-one Chemical compound ClC1=CC=CC(NC=2C=3C=CC(=O)N(C=4C=CC=CC=4)C=3SC=2C(=O)N2[C@H](CCC2)COC2OCCCC2)=C1 VXYFADLOYYSXTD-GEPVFLLWSA-N 0.000 description 1
- UNRKZADXPKDQJJ-DXDQHDRFSA-N 3-(3-methylanilino)-2-[(2r)-2-(oxan-2-yloxymethyl)pyrrolidine-1-carbonyl]-7-phenylthieno[2,3-b]pyridin-6-one Chemical compound CC1=CC=CC(NC=2C=3C=CC(=O)N(C=4C=CC=CC=4)C=3SC=2C(=O)N2[C@H](CCC2)COC2OCCCC2)=C1 UNRKZADXPKDQJJ-DXDQHDRFSA-N 0.000 description 1
- NGMXVGSPLYQSGS-RXVAYIKUSA-N 3-(3-methylanilino)-7-(4-methylphenyl)-2-[(2r)-2-(oxan-2-yloxymethyl)pyrrolidine-1-carbonyl]thieno[2,3-b]pyridin-6-one Chemical compound C1=CC(C)=CC=C1N1C(=O)C=CC2=C1SC(C(=O)N1[C@H](CCC1)COC1OCCCC1)=C2NC1=CC=CC(C)=C1 NGMXVGSPLYQSGS-RXVAYIKUSA-N 0.000 description 1
- QRPQGUJFCOQHGY-BRIWLPCBSA-N 3-(4-fluoro-3-methylanilino)-7-(4-fluorophenyl)-2-[(2r)-2-(oxan-2-yloxymethyl)pyrrolidine-1-carbonyl]thieno[2,3-b]pyridin-6-one Chemical compound C1=C(F)C(C)=CC(NC=2C=3C=CC(=O)N(C=4C=CC(F)=CC=4)C=3SC=2C(=O)N2[C@H](CCC2)COC2OCCCC2)=C1 QRPQGUJFCOQHGY-BRIWLPCBSA-N 0.000 description 1
- OPIICBBYUIDUSB-CHQVSRGASA-N 3-(4-fluoro-3-methylanilino)-7-(4-fluorophenyl)-2-[(3s)-3-(oxan-2-yloxy)pyrrolidine-1-carbonyl]thieno[2,3-b]pyridin-6-one Chemical compound C1=C(F)C(C)=CC(NC=2C=3C=CC(=O)N(C=4C=CC(F)=CC=4)C=3SC=2C(=O)N2C[C@H](CC2)OC2OCCCC2)=C1 OPIICBBYUIDUSB-CHQVSRGASA-N 0.000 description 1
- ULMVXBUHPXCZKQ-RIBGEGAISA-N 3-(4-fluoro-3-methylanilino)-7-(4-methylphenyl)-2-[(2r)-2-(oxan-2-yloxymethyl)pyrrolidine-1-carbonyl]thieno[2,3-b]pyridin-6-one Chemical compound C1=CC(C)=CC=C1N1C(=O)C=CC2=C1SC(C(=O)N1[C@H](CCC1)COC1OCCCC1)=C2NC1=CC=C(F)C(C)=C1 ULMVXBUHPXCZKQ-RIBGEGAISA-N 0.000 description 1
- XBPSUNVKGWMYJQ-UHFFFAOYSA-N 3-amino-7-(2-chlorophenyl)-6-oxothieno[2,3-b]pyridine-2-carbonitrile Chemical compound O=C1C=CC=2C(N)=C(C#N)SC=2N1C1=CC=CC=C1Cl XBPSUNVKGWMYJQ-UHFFFAOYSA-N 0.000 description 1
- NJXPYZHXZZCTNI-UHFFFAOYSA-N 3-aminobenzonitrile Chemical compound NC1=CC=CC(C#N)=C1 NJXPYZHXZZCTNI-UHFFFAOYSA-N 0.000 description 1
- IMUULJNNHTVXMF-UHFFFAOYSA-N 3-bromo-2-(3-hydroxyazetidine-1-carbonyl)-7-phenylthieno[2,3-b]pyridin-6-one Chemical compound C1C(O)CN1C(=O)C1=C(Br)C(C=CC(=O)N2C=3C=CC=CC=3)=C2S1 IMUULJNNHTVXMF-UHFFFAOYSA-N 0.000 description 1
- WXZGGMYVNMOFBJ-CQSZACIVSA-N 3-bromo-2-[(2r)-2-(hydroxymethyl)pyrrolidine-1-carbonyl]-7-(4-methylphenyl)thieno[2,3-b]pyridin-6-one Chemical compound C1=CC(C)=CC=C1N1C(=O)C=CC2=C1SC(C(=O)N1[C@H](CCC1)CO)=C2Br WXZGGMYVNMOFBJ-CQSZACIVSA-N 0.000 description 1
- MMZHEMDITPMCDI-CYBMUJFWSA-N 3-bromo-2-[(2r)-2-(hydroxymethyl)pyrrolidine-1-carbonyl]-7-phenylthieno[2,3-b]pyridin-6-one Chemical compound OC[C@H]1CCCN1C(=O)C1=C(Br)C(C=CC(=O)N2C=3C=CC=CC=3)=C2S1 MMZHEMDITPMCDI-CYBMUJFWSA-N 0.000 description 1
- HHJSARJLBFGTSQ-DIAVIDTQSA-N 3-bromo-2-[(2r)-2-(oxan-2-yloxymethyl)pyrrolidine-1-carbonyl]-7-phenylthieno[2,3-b]pyridin-6-one Chemical compound O=C1C=CC=2C(Br)=C(C(=O)N3[C@H](CCC3)COC3OCCCC3)SC=2N1C1=CC=CC=C1 HHJSARJLBFGTSQ-DIAVIDTQSA-N 0.000 description 1
- WLLFPHQKCXXQQG-CYBMUJFWSA-N 3-bromo-2-[(3r)-3-hydroxypyrrolidine-1-carbonyl]-7-(4-methylphenyl)thieno[2,3-b]pyridin-6-one Chemical compound C1=CC(C)=CC=C1N1C(=O)C=CC2=C1SC(C(=O)N1C[C@H](O)CC1)=C2Br WLLFPHQKCXXQQG-CYBMUJFWSA-N 0.000 description 1
- WLLFPHQKCXXQQG-ZDUSSCGKSA-N 3-bromo-2-[(3s)-3-hydroxypyrrolidine-1-carbonyl]-7-(4-methylphenyl)thieno[2,3-b]pyridin-6-one Chemical compound C1=CC(C)=CC=C1N1C(=O)C=CC2=C1SC(C(=O)N1C[C@@H](O)CC1)=C2Br WLLFPHQKCXXQQG-ZDUSSCGKSA-N 0.000 description 1
- FDZZZXYTLKCUGU-UHFFFAOYSA-N 3-bromo-2-[3-(oxan-2-yloxy)azetidine-1-carbonyl]-7-phenylthieno[2,3-b]pyridin-6-one Chemical compound O=C1C=CC=2C(Br)=C(C(=O)N3CC(C3)OC3OCCCC3)SC=2N1C1=CC=CC=C1 FDZZZXYTLKCUGU-UHFFFAOYSA-N 0.000 description 1
- SPQNZLOPADOQSN-UHFFFAOYSA-N 3-bromo-6-oxo-7-phenylthieno[2,3-b]pyridine-2-carboxylic acid Chemical compound O=C1C=CC=2C(Br)=C(C(=O)O)SC=2N1C1=CC=CC=C1 SPQNZLOPADOQSN-UHFFFAOYSA-N 0.000 description 1
- PSCTXLKINLDTBW-LLVKDONJSA-N 3-bromo-7-(2-chlorophenyl)-2-[(2r)-2-(hydroxymethyl)pyrrolidine-1-carbonyl]thieno[2,3-b]pyridin-6-one Chemical compound OC[C@H]1CCCN1C(=O)C1=C(Br)C(C=CC(=O)N2C=3C(=CC=CC=3)Cl)=C2S1 PSCTXLKINLDTBW-LLVKDONJSA-N 0.000 description 1
- ZGXKFKHRKFUWIV-IWPPFLRJSA-N 3-bromo-7-(2-chlorophenyl)-2-[(2r)-2-(oxan-2-yloxymethyl)pyrrolidine-1-carbonyl]thieno[2,3-b]pyridin-6-one Chemical compound ClC1=CC=CC=C1N1C(=O)C=CC2=C1SC(C(=O)N1[C@H](CCC1)COC1OCCCC1)=C2Br ZGXKFKHRKFUWIV-IWPPFLRJSA-N 0.000 description 1
- ZZZOKRFRKSQKTI-MJTSIZKDSA-N 3-bromo-7-(2-chlorophenyl)-2-[(3r)-3-(oxan-2-yloxy)pyrrolidine-1-carbonyl]thieno[2,3-b]pyridin-6-one Chemical compound ClC1=CC=CC=C1N1C(=O)C=CC2=C1SC(C(=O)N1C[C@@H](CC1)OC1OCCCC1)=C2Br ZZZOKRFRKSQKTI-MJTSIZKDSA-N 0.000 description 1
- HORUHMYBZBWWSM-SNVBAGLBSA-N 3-bromo-7-(2-chlorophenyl)-2-[(3r)-3-hydroxypyrrolidine-1-carbonyl]thieno[2,3-b]pyridin-6-one Chemical compound C1[C@H](O)CCN1C(=O)C1=C(Br)C(C=CC(=O)N2C=3C(=CC=CC=3)Cl)=C2S1 HORUHMYBZBWWSM-SNVBAGLBSA-N 0.000 description 1
- ZZZOKRFRKSQKTI-KTQQKIMGSA-N 3-bromo-7-(2-chlorophenyl)-2-[(3s)-3-(oxan-2-yloxy)pyrrolidine-1-carbonyl]thieno[2,3-b]pyridin-6-one Chemical compound ClC1=CC=CC=C1N1C(=O)C=CC2=C1SC(C(=O)N1C[C@H](CC1)OC1OCCCC1)=C2Br ZZZOKRFRKSQKTI-KTQQKIMGSA-N 0.000 description 1
- HORUHMYBZBWWSM-JTQLQIEISA-N 3-bromo-7-(2-chlorophenyl)-2-[(3s)-3-hydroxypyrrolidine-1-carbonyl]thieno[2,3-b]pyridin-6-one Chemical compound C1[C@@H](O)CCN1C(=O)C1=C(Br)C(C=CC(=O)N2C=3C(=CC=CC=3)Cl)=C2S1 HORUHMYBZBWWSM-JTQLQIEISA-N 0.000 description 1
- JCVKWNMKSGEFRV-UHFFFAOYSA-N 3-bromo-7-(2-chlorophenyl)-6-oxothieno[2,3-b]pyridine-2-carbonitrile Chemical compound ClC1=CC=CC=C1N1C(=O)C=CC2=C1SC(C#N)=C2Br JCVKWNMKSGEFRV-UHFFFAOYSA-N 0.000 description 1
- WALMQMPNDMGHIU-UHFFFAOYSA-N 3-bromo-7-(2-chlorophenyl)-6-oxothieno[2,3-b]pyridine-2-carboxylic acid Chemical compound O=C1C=CC=2C(Br)=C(C(=O)O)SC=2N1C1=CC=CC=C1Cl WALMQMPNDMGHIU-UHFFFAOYSA-N 0.000 description 1
- SSOAIWQZJSHHJG-CYBMUJFWSA-N 3-bromo-7-(4-fluorophenyl)-2-[(2r)-2-(hydroxymethyl)pyrrolidine-1-carbonyl]thieno[2,3-b]pyridin-6-one Chemical compound OC[C@H]1CCCN1C(=O)C1=C(Br)C(C=CC(=O)N2C=3C=CC(F)=CC=3)=C2S1 SSOAIWQZJSHHJG-CYBMUJFWSA-N 0.000 description 1
- UPZABAPRYUREJO-DIAVIDTQSA-N 3-bromo-7-(4-fluorophenyl)-2-[(2r)-2-(oxan-2-yloxymethyl)pyrrolidine-1-carbonyl]thieno[2,3-b]pyridin-6-one Chemical compound C1=CC(F)=CC=C1N1C(=O)C=CC2=C1SC(C(=O)N1[C@H](CCC1)COC1OCCCC1)=C2Br UPZABAPRYUREJO-DIAVIDTQSA-N 0.000 description 1
- NWCLVYQLKPDHNF-VTBWFHPJSA-N 3-bromo-7-(4-fluorophenyl)-2-[(3r)-3-(oxan-2-yloxy)pyrrolidine-1-carbonyl]thieno[2,3-b]pyridin-6-one Chemical compound C1=CC(F)=CC=C1N1C(=O)C=CC2=C1SC(C(=O)N1C[C@@H](CC1)OC1OCCCC1)=C2Br NWCLVYQLKPDHNF-VTBWFHPJSA-N 0.000 description 1
- YVUHYRCLOKBJDV-GFCCVEGCSA-N 3-bromo-7-(4-fluorophenyl)-2-[(3r)-3-hydroxypyrrolidine-1-carbonyl]thieno[2,3-b]pyridin-6-one Chemical compound C1[C@H](O)CCN1C(=O)C1=C(Br)C(C=CC(=O)N2C=3C=CC(F)=CC=3)=C2S1 YVUHYRCLOKBJDV-GFCCVEGCSA-N 0.000 description 1
- NWCLVYQLKPDHNF-UCFFOFKASA-N 3-bromo-7-(4-fluorophenyl)-2-[(3s)-3-(oxan-2-yloxy)pyrrolidine-1-carbonyl]thieno[2,3-b]pyridin-6-one Chemical compound C1=CC(F)=CC=C1N1C(=O)C=CC2=C1SC(C(=O)N1C[C@H](CC1)OC1OCCCC1)=C2Br NWCLVYQLKPDHNF-UCFFOFKASA-N 0.000 description 1
- YVUHYRCLOKBJDV-LBPRGKRZSA-N 3-bromo-7-(4-fluorophenyl)-2-[(3s)-3-hydroxypyrrolidine-1-carbonyl]thieno[2,3-b]pyridin-6-one Chemical compound C1[C@@H](O)CCN1C(=O)C1=C(Br)C(C=CC(=O)N2C=3C=CC(F)=CC=3)=C2S1 YVUHYRCLOKBJDV-LBPRGKRZSA-N 0.000 description 1
- RUXOPFDFXSGGRE-UHFFFAOYSA-N 3-bromo-7-(4-fluorophenyl)-6-oxothieno[2,3-b]pyridine-2-carbonyl chloride Chemical compound C1=CC(F)=CC=C1N1C(=O)C=CC2=C1SC(C(Cl)=O)=C2Br RUXOPFDFXSGGRE-UHFFFAOYSA-N 0.000 description 1
- JHRKFHZMPIWDSR-UHFFFAOYSA-N 3-bromo-7-(4-fluorophenyl)-6-oxothieno[2,3-b]pyridine-2-carboxylic acid Chemical compound O=C1C=CC=2C(Br)=C(C(=O)O)SC=2N1C1=CC=C(F)C=C1 JHRKFHZMPIWDSR-UHFFFAOYSA-N 0.000 description 1
- TUWVQMSBDQENPG-ITUIMRKVSA-N 3-bromo-7-(4-methylphenyl)-2-[(2r)-2-(oxan-2-yloxymethyl)pyrrolidine-1-carbonyl]thieno[2,3-b]pyridin-6-one Chemical compound C1=CC(C)=CC=C1N1C(=O)C=CC2=C1SC(C(=O)N1[C@H](CCC1)COC1OCCCC1)=C2Br TUWVQMSBDQENPG-ITUIMRKVSA-N 0.000 description 1
- CLBKTGYVOJIYBT-UHFFFAOYSA-N 3-bromo-7-(4-methylphenyl)-6-oxothieno[2,3-b]pyridine-2-carboxylic acid Chemical compound C1=CC(C)=CC=C1N1C(=O)C=CC2=C1SC(C(O)=O)=C2Br CLBKTGYVOJIYBT-UHFFFAOYSA-N 0.000 description 1
- YSEMCVGMNUUNRK-UHFFFAOYSA-N 3-chloro-4-fluoroaniline Chemical compound NC1=CC=C(F)C(Cl)=C1 YSEMCVGMNUUNRK-UHFFFAOYSA-N 0.000 description 1
- ZJQWXXSZXSTKHW-UHFFFAOYSA-N 3-chlorobenzenecarboperoxoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1.OOC(=O)C1=CC=CC(Cl)=C1 ZJQWXXSZXSTKHW-UHFFFAOYSA-N 0.000 description 1
- QZVQQUVWFIZUBQ-UHFFFAOYSA-N 3-fluoroaniline Chemical compound NC1=CC=CC(F)=C1 QZVQQUVWFIZUBQ-UHFFFAOYSA-N 0.000 description 1
- LBUNNMJLXWQQBY-UHFFFAOYSA-N 4-fluorophenylboronic acid Chemical compound OB(O)C1=CC=C(F)C=C1 LBUNNMJLXWQQBY-UHFFFAOYSA-N 0.000 description 1
- 125000004606 5,6,7,8-tetrahydroisoquinolinyl group Chemical group C1(=NC=CC=2CCCCC12)* 0.000 description 1
- 125000004608 5,6,7,8-tetrahydroquinolinyl group Chemical group N1=C(C=CC=2CCCCC12)* 0.000 description 1
- JSDBKAHWADVXFU-UHFFFAOYSA-N 5-amino-1Hpyrazole-4-carboxylic acid Natural products CN1C=CC(=O)N(C)C1=O JSDBKAHWADVXFU-UHFFFAOYSA-N 0.000 description 1
- TVJZIZKGJUZCNP-ICCFGIFFSA-N 7-(2-chlorophenyl)-3-(2,4-difluoroanilino)-2-[(2r)-2-(oxan-2-yloxymethyl)pyrrolidine-1-carbonyl]thieno[2,3-b]pyridin-6-one Chemical compound FC1=CC(F)=CC=C1NC1=C(C(=O)N2[C@H](CCC2)COC2OCCCC2)SC2=C1C=CC(=O)N2C1=CC=CC=C1Cl TVJZIZKGJUZCNP-ICCFGIFFSA-N 0.000 description 1
- HZSWWCLCICSSMT-YDONVPIESA-N 7-(2-chlorophenyl)-3-(2,4-difluoroanilino)-2-[(3r)-3-(oxan-2-yloxy)pyrrolidine-1-carbonyl]thieno[2,3-b]pyridin-6-one Chemical compound FC1=CC(F)=CC=C1NC1=C(C(=O)N2C[C@@H](CC2)OC2OCCCC2)SC2=C1C=CC(=O)N2C1=CC=CC=C1Cl HZSWWCLCICSSMT-YDONVPIESA-N 0.000 description 1
- HZSWWCLCICSSMT-CPFIQGLUSA-N 7-(2-chlorophenyl)-3-(2,4-difluoroanilino)-2-[(3s)-3-(oxan-2-yloxy)pyrrolidine-1-carbonyl]thieno[2,3-b]pyridin-6-one Chemical compound FC1=CC(F)=CC=C1NC1=C(C(=O)N2C[C@H](CC2)OC2OCCCC2)SC2=C1C=CC(=O)N2C1=CC=CC=C1Cl HZSWWCLCICSSMT-CPFIQGLUSA-N 0.000 description 1
- KGVYRFLNUNQYEG-GVNKFJBHSA-N 7-(2-chlorophenyl)-3-(3-methylanilino)-2-[(3s)-3-(oxan-2-yloxy)pyrrolidine-1-carbonyl]thieno[2,3-b]pyridin-6-one Chemical compound CC1=CC=CC(NC=2C=3C=CC(=O)N(C=4C(=CC=CC=4)Cl)C=3SC=2C(=O)N2C[C@H](CC2)OC2OCCCC2)=C1 KGVYRFLNUNQYEG-GVNKFJBHSA-N 0.000 description 1
- QJIPQFRZOXFYIJ-XJQHNOHDSA-N 7-(2-chlorophenyl)-3-(4-fluoro-3-methylanilino)-2-[(2r)-2-(oxan-2-yloxymethyl)pyrrolidine-1-carbonyl]thieno[2,3-b]pyridin-6-one Chemical compound C1=C(F)C(C)=CC(NC=2C=3C=CC(=O)N(C=4C(=CC=CC=4)Cl)C=3SC=2C(=O)N2[C@H](CCC2)COC2OCCCC2)=C1 QJIPQFRZOXFYIJ-XJQHNOHDSA-N 0.000 description 1
- YPMSUAMHFWYCOT-DQUNLGLBSA-N 7-(2-chlorophenyl)-3-(4-fluoro-3-methylanilino)-2-[(3s)-3-(oxan-2-yloxy)pyrrolidine-1-carbonyl]thieno[2,3-b]pyridin-6-one Chemical compound C1=C(F)C(C)=CC(NC=2C=3C=CC(=O)N(C=4C(=CC=CC=4)Cl)C=3SC=2C(=O)N2C[C@H](CC2)OC2OCCCC2)=C1 YPMSUAMHFWYCOT-DQUNLGLBSA-N 0.000 description 1
- 206010001513 AIDS related complex Diseases 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 108010044688 Activating Transcription Factor 2 Proteins 0.000 description 1
- 102000007481 Activating Transcription Factor 6 Human genes 0.000 description 1
- 108010085405 Activating Transcription Factor 6 Proteins 0.000 description 1
- 208000010370 Adenoviridae Infections Diseases 0.000 description 1
- 206010060931 Adenovirus infection Diseases 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 206010003645 Atopy Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- QFZXWPGKSKWRBI-UHFFFAOYSA-N C.C1CNC1.C1CNC1.CC.CC.CC.CC.CC(=O)C1=C(N[Ar])C2=C(S1)N(C)C(=O)C=C2.CC(=O)C1=C(N[Ar])C2=C(S1)N(C)C(=O)C=C2.CN1C(=O)C=CC2=C1SC(C(=O)N1CCC1)=C2N[Ar].CN1C(=O)C=CC2=C1SC(C(=O)N1CCC1)=C2N[Ar].CN1C(=O)C=CC2=C1SC(C(=O)OP(F)P)=C2N[Ar] Chemical compound C.C1CNC1.C1CNC1.CC.CC.CC.CC.CC(=O)C1=C(N[Ar])C2=C(S1)N(C)C(=O)C=C2.CC(=O)C1=C(N[Ar])C2=C(S1)N(C)C(=O)C=C2.CN1C(=O)C=CC2=C1SC(C(=O)N1CCC1)=C2N[Ar].CN1C(=O)C=CC2=C1SC(C(=O)N1CCC1)=C2N[Ar].CN1C(=O)C=CC2=C1SC(C(=O)OP(F)P)=C2N[Ar] QFZXWPGKSKWRBI-UHFFFAOYSA-N 0.000 description 1
- XRAZQTJZPAKMIU-UHFFFAOYSA-N C.C1CNC1.CC.CC.CCOC(=O)C1=C(N[Ar])C2=C(S1)N(C)C(=O)C=C2.CN1C(=O)C=CC2=C1SC(C(=O)N1CCC1)=C2N[Ar] Chemical compound C.C1CNC1.CC.CC.CCOC(=O)C1=C(N[Ar])C2=C(S1)N(C)C(=O)C=C2.CN1C(=O)C=CC2=C1SC(C(=O)N1CCC1)=C2N[Ar] XRAZQTJZPAKMIU-UHFFFAOYSA-N 0.000 description 1
- 125000006577 C1-C6 hydroxyalkyl group Chemical group 0.000 description 1
- KXNCCPUROHHOLN-UHFFFAOYSA-N C1CNC1.C1CNC1.CC.CC.CC.CC.CN1C(=O)C=CC2=C1SC(C(=O)Cl)=C2Br.CN1C(=O)C=CC2=C1SC(C(=O)N1CCC1)=C2Br.CN1C(=O)C=CC2=C1SC(C(=O)N1CCC1)=C2N[Ar].CN1C(=O)C=CC2=C1SC(C(=O)O)=C2Br Chemical compound C1CNC1.C1CNC1.CC.CC.CC.CC.CN1C(=O)C=CC2=C1SC(C(=O)Cl)=C2Br.CN1C(=O)C=CC2=C1SC(C(=O)N1CCC1)=C2Br.CN1C(=O)C=CC2=C1SC(C(=O)N1CCC1)=C2N[Ar].CN1C(=O)C=CC2=C1SC(C(=O)O)=C2Br KXNCCPUROHHOLN-UHFFFAOYSA-N 0.000 description 1
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 description 1
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 description 1
- KGSWLJPBVLQUPD-UHFFFAOYSA-N CC#N.CC1=NC=CC=C1C#N.CCOC(=O)C1=C(Br)C2=C(NC(=O)C=C2)S1.CCOC(=O)C1=C(Br)C2=C(NC(=O)C=C2)S1.CCOC(=O)C1=C(Br)C2=C(S1)N(C)C(=O)C=C2.CCOC(=O)C1=C(Br)C2=C(S1)N(CC)C(=O)C=C2.CCOC(=O)C1=C(Br)C2=CC=CN=C2S1.CCOC(=O)C1=C(Br)C2=CC=C[N+]([O-])=C2S1.CCOC(=O)C1=C(N)C2=CC=CN=C2S1.CCOC(=O)C1=C(N[Ar])C2=C(S1)N(C)C(=O)C=C2.CCOC(=O)C1=C(N[Ar])C2=C(S1)N(CC)C(=O)C=C2.CCOC(=O)CS Chemical compound CC#N.CC1=NC=CC=C1C#N.CCOC(=O)C1=C(Br)C2=C(NC(=O)C=C2)S1.CCOC(=O)C1=C(Br)C2=C(NC(=O)C=C2)S1.CCOC(=O)C1=C(Br)C2=C(S1)N(C)C(=O)C=C2.CCOC(=O)C1=C(Br)C2=C(S1)N(CC)C(=O)C=C2.CCOC(=O)C1=C(Br)C2=CC=CN=C2S1.CCOC(=O)C1=C(Br)C2=CC=C[N+]([O-])=C2S1.CCOC(=O)C1=C(N)C2=CC=CN=C2S1.CCOC(=O)C1=C(N[Ar])C2=C(S1)N(C)C(=O)C=C2.CCOC(=O)C1=C(N[Ar])C2=C(S1)N(CC)C(=O)C=C2.CCOC(=O)CS KGSWLJPBVLQUPD-UHFFFAOYSA-N 0.000 description 1
- SWVMMWSNPVAAOF-UHFFFAOYSA-N CCBr.CCOC(=O)C1=C(Br)C2=C(N=C(OCC)C=C2)S1.CCOC(=O)C1=C(N[Ar])C2=C(N=C(OCC)C=C2)S1.CCOC(=O)C1=C(N[Ar])C2=C(S1)N(CC)C(=O)C=C2.[H]N1C(=O)C=CC2=C1SC(C(=O)OCC)=C2Br.[H]N1C(=O)C=CC2=C1SC(C(=O)OCC)=C2N[Ar] Chemical compound CCBr.CCOC(=O)C1=C(Br)C2=C(N=C(OCC)C=C2)S1.CCOC(=O)C1=C(N[Ar])C2=C(N=C(OCC)C=C2)S1.CCOC(=O)C1=C(N[Ar])C2=C(S1)N(CC)C(=O)C=C2.[H]N1C(=O)C=CC2=C1SC(C(=O)OCC)=C2Br.[H]N1C(=O)C=CC2=C1SC(C(=O)OCC)=C2N[Ar] SWVMMWSNPVAAOF-UHFFFAOYSA-N 0.000 description 1
- SHOVAMDJCLQLPF-UHFFFAOYSA-N CN1C(=O)C=CC2=C1SC(C#N)=C2Br.CN1C(=O)C=CC2=C1SC(C(=O)O)=C2Br Chemical compound CN1C(=O)C=CC2=C1SC(C#N)=C2Br.CN1C(=O)C=CC2=C1SC(C(=O)O)=C2Br SHOVAMDJCLQLPF-UHFFFAOYSA-N 0.000 description 1
- GAWIXWVDTYZWAW-UHFFFAOYSA-N C[CH]O Chemical group C[CH]O GAWIXWVDTYZWAW-UHFFFAOYSA-N 0.000 description 1
- 101100289995 Caenorhabditis elegans mac-1 gene Proteins 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- JPVYNHNXODAKFH-UHFFFAOYSA-N Cu2+ Chemical compound [Cu+2] JPVYNHNXODAKFH-UHFFFAOYSA-N 0.000 description 1
- 102100028559 Death domain-associated protein 6 Human genes 0.000 description 1
- 101710091772 Death domain-associated protein 6 Proteins 0.000 description 1
- 239000004338 Dichlorodifluoromethane Substances 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 239000004150 EU approved colour Substances 0.000 description 1
- 101150033452 Elk1 gene Proteins 0.000 description 1
- 206010014824 Endotoxic shock Diseases 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 108090000371 Esterases Proteins 0.000 description 1
- 244000166102 Eucalyptus leucoxylon Species 0.000 description 1
- 235000004694 Eucalyptus leucoxylon Nutrition 0.000 description 1
- 229910052693 Europium Inorganic materials 0.000 description 1
- 108700024394 Exon Proteins 0.000 description 1
- 108010007457 Extracellular Signal-Regulated MAP Kinases Proteins 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
- 108010070675 Glutathione transferase Proteins 0.000 description 1
- 241000126965 Gonytrichum caesium Species 0.000 description 1
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 1
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 206010020164 HIV infection CDC Group III Diseases 0.000 description 1
- 102100039165 Heat shock protein beta-1 Human genes 0.000 description 1
- 102000002812 Heat-Shock Proteins Human genes 0.000 description 1
- 108010004889 Heat-Shock Proteins Proteins 0.000 description 1
- 102100029100 Hematopoietic prostaglandin D synthase Human genes 0.000 description 1
- 208000009889 Herpes Simplex Diseases 0.000 description 1
- 208000007514 Herpes zoster Diseases 0.000 description 1
- 108010093488 His-His-His-His-His-His Proteins 0.000 description 1
- 102100022893 Histone acetyltransferase KAT5 Human genes 0.000 description 1
- 101000974934 Homo sapiens Cyclic AMP-dependent transcription factor ATF-2 Proteins 0.000 description 1
- 101000997829 Homo sapiens Glial cell line-derived neurotrophic factor Proteins 0.000 description 1
- 101001046686 Homo sapiens Integrin alpha-M Proteins 0.000 description 1
- 101000935040 Homo sapiens Integrin beta-2 Proteins 0.000 description 1
- 101001112229 Homo sapiens Neutrophil cytosol factor 1 Proteins 0.000 description 1
- 101001050288 Homo sapiens Transcription factor Jun Proteins 0.000 description 1
- 241000725303 Human immunodeficiency virus Species 0.000 description 1
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 1
- 241000713340 Human immunodeficiency virus 2 Species 0.000 description 1
- LELOWRISYMNNSU-UHFFFAOYSA-N Hydrocyanic acid Natural products N#C LELOWRISYMNNSU-UHFFFAOYSA-N 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical class Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- 101000668058 Infectious salmon anemia virus (isolate Atlantic salmon/Norway/810/9/99) RNA-directed RNA polymerase catalytic subunit Proteins 0.000 description 1
- 102100022338 Integrin alpha-M Human genes 0.000 description 1
- 102100025390 Integrin beta-2 Human genes 0.000 description 1
- 108010044467 Isoenzymes Proteins 0.000 description 1
- 229930194542 Keto Natural products 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- HBBGRARXTFLTSG-UHFFFAOYSA-N Lithium ion Chemical compound [Li+] HBBGRARXTFLTSG-UHFFFAOYSA-N 0.000 description 1
- 108020002496 Lysophospholipase Proteins 0.000 description 1
- 102100034069 MAP kinase-activated protein kinase 2 Human genes 0.000 description 1
- 101710141394 MAP kinase-activated protein kinase 2 Proteins 0.000 description 1
- 102100028397 MAP kinase-activated protein kinase 3 Human genes 0.000 description 1
- 101710141393 MAP kinase-activated protein kinase 3 Proteins 0.000 description 1
- 102100026299 MAP kinase-interacting serine/threonine-protein kinase 1 Human genes 0.000 description 1
- 101710139011 MAP kinase-interacting serine/threonine-protein kinase 1 Proteins 0.000 description 1
- 102000055120 MEF2 Transcription Factors Human genes 0.000 description 1
- 108010018650 MEF2 Transcription Factors Proteins 0.000 description 1
- 102000007651 Macrophage Colony-Stimulating Factor Human genes 0.000 description 1
- 108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 235000019759 Maize starch Nutrition 0.000 description 1
- LSDPWZHWYPCBBB-UHFFFAOYSA-N Methanethiol Chemical compound SC LSDPWZHWYPCBBB-UHFFFAOYSA-N 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 108090000744 Mitogen-Activated Protein Kinase Kinases Proteins 0.000 description 1
- 102000004232 Mitogen-Activated Protein Kinase Kinases Human genes 0.000 description 1
- 102100024193 Mitogen-activated protein kinase 1 Human genes 0.000 description 1
- 102000056243 Mitogen-activated protein kinase 12 Human genes 0.000 description 1
- 108700015929 Mitogen-activated protein kinase 12 Proteins 0.000 description 1
- HSHXDCVZWHOWCS-UHFFFAOYSA-N N'-hexadecylthiophene-2-carbohydrazide Chemical compound CCCCCCCCCCCCCCCCNNC(=O)c1cccs1 HSHXDCVZWHOWCS-UHFFFAOYSA-N 0.000 description 1
- 102100023620 Neutrophil cytosol factor 1 Human genes 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 239000004264 Petrolatum Substances 0.000 description 1
- 102100026918 Phospholipase A2 Human genes 0.000 description 1
- 101710096328 Phospholipase A2 Proteins 0.000 description 1
- 108010064785 Phospholipases Proteins 0.000 description 1
- 102000015439 Phospholipases Human genes 0.000 description 1
- 108700019535 Phosphoprotein Phosphatases Proteins 0.000 description 1
- 102000045595 Phosphoprotein Phosphatases Human genes 0.000 description 1
- ATTZFSUZZUNHBP-UHFFFAOYSA-N Piperonyl sulfoxide Chemical compound CCCCCCCCS(=O)C(C)CC1=CC=C2OCOC2=C1 ATTZFSUZZUNHBP-UHFFFAOYSA-N 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 206010036030 Polyarthritis Diseases 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-N Propionic acid Chemical class CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 1
- 102000004005 Prostaglandin-endoperoxide synthases Human genes 0.000 description 1
- 108090000459 Prostaglandin-endoperoxide synthases Proteins 0.000 description 1
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 1
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 1
- 229910019020 PtO2 Inorganic materials 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 101100287693 Rattus norvegicus Kcnh4 gene Proteins 0.000 description 1
- 101100287705 Rattus norvegicus Kcnh8 gene Proteins 0.000 description 1
- 208000033464 Reiter syndrome Diseases 0.000 description 1
- 206010061603 Respiratory syncytial virus infection Diseases 0.000 description 1
- 206010062106 Respiratory tract infection viral Diseases 0.000 description 1
- 208000005074 Retroviridae Infections Diseases 0.000 description 1
- 206010061494 Rhinovirus infection Diseases 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 239000004141 Sodium laurylsulphate Substances 0.000 description 1
- HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical class OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 108090000925 TNF receptor-associated factor 2 Proteins 0.000 description 1
- 102000008889 TNF receptor-associated factor TRAF Human genes 0.000 description 1
- 108050000808 TNF receptor-associated factor TRAF Proteins 0.000 description 1
- 102100034779 TRAF family member-associated NF-kappa-B activator Human genes 0.000 description 1
- JQAWYCUUFIMTHE-WLTAIBSBSA-N Thr-Gly-Tyr Chemical group [H]N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O JQAWYCUUFIMTHE-WLTAIBSBSA-N 0.000 description 1
- ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 102100023132 Transcription factor Jun Human genes 0.000 description 1
- 108010000134 Vascular Cell Adhesion Molecule-1 Proteins 0.000 description 1
- 102100023543 Vascular cell adhesion protein 1 Human genes 0.000 description 1
- MZVQCMJNVPIDEA-UHFFFAOYSA-N [CH2]CN(CC)CC Chemical group [CH2]CN(CC)CC MZVQCMJNVPIDEA-UHFFFAOYSA-N 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 125000000738 acetamido group Chemical group [H]C([H])([H])C(=O)N([H])[*] 0.000 description 1
- 150000001242 acetic acid derivatives Chemical class 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- YBCVMFKXIKNREZ-UHFFFAOYSA-N acoh acetic acid Chemical compound CC(O)=O.CC(O)=O YBCVMFKXIKNREZ-UHFFFAOYSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 231100000354 acute hepatitis Toxicity 0.000 description 1
- 230000010933 acylation Effects 0.000 description 1
- 238000005917 acylation reaction Methods 0.000 description 1
- YKIOKAURTKXMSB-UHFFFAOYSA-N adams's catalyst Chemical compound O=[Pt]=O YKIOKAURTKXMSB-UHFFFAOYSA-N 0.000 description 1
- 102000035181 adaptor proteins Human genes 0.000 description 1
- 108091005764 adaptor proteins Proteins 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 208000011589 adenoviridae infectious disease Diseases 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 125000004450 alkenylene group Chemical group 0.000 description 1
- 150000003973 alkyl amines Chemical class 0.000 description 1
- 125000003282 alkyl amino group Chemical group 0.000 description 1
- 150000001350 alkyl halides Chemical class 0.000 description 1
- 229940045714 alkyl sulfonate alkylating agent Drugs 0.000 description 1
- 150000008052 alkyl sulfonates Chemical class 0.000 description 1
- 150000001356 alkyl thiols Chemical class 0.000 description 1
- 125000005530 alkylenedioxy group Chemical group 0.000 description 1
- 125000004419 alkynylene group Chemical group 0.000 description 1
- 125000006598 aminocarbonylamino group Chemical group 0.000 description 1
- 125000004202 aminomethyl group Chemical group [H]N([H])C([H])([H])* 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- VZTDIZULWFCMLS-UHFFFAOYSA-N ammonium formate Chemical compound [NH4+].[O-]C=O VZTDIZULWFCMLS-UHFFFAOYSA-N 0.000 description 1
- 235000011114 ammonium hydroxide Nutrition 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 150000008064 anhydrides Chemical class 0.000 description 1
- 150000001448 anilines Chemical class 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 210000003423 ankle Anatomy 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 229940124599 anti-inflammatory drug Drugs 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000008135 aqueous vehicle Substances 0.000 description 1
- 229940114079 arachidonic acid Drugs 0.000 description 1
- 235000021342 arachidonic acid Nutrition 0.000 description 1
- 125000005228 aryl sulfonate group Chemical group 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- MJIBPYPIBCKZHV-UHFFFAOYSA-N azanium;3-anilino-6-oxo-7-phenylthieno[2,3-b]pyridine-2-carboxylate Chemical compound [NH4+].O=C1C=CC=2C(NC=3C=CC=CC=3)=C(C(=O)[O-])SC=2N1C1=CC=CC=C1 MJIBPYPIBCKZHV-UHFFFAOYSA-N 0.000 description 1
- 239000003899 bactericide agent Substances 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
- 125000004603 benzisoxazolyl group Chemical group O1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 150000001558 benzoic acid derivatives Chemical class 0.000 description 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000003354 benzotriazolyl group Chemical group N1N=NC2=C1C=CC=C2* 0.000 description 1
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 1
- AGEZXYOZHKGVCM-UHFFFAOYSA-N benzyl bromide Chemical compound BrCC1=CC=CC=C1 AGEZXYOZHKGVCM-UHFFFAOYSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000036983 biotransformation Effects 0.000 description 1
- 238000006664 bond formation reaction Methods 0.000 description 1
- ZADPBFCGQRWHPN-UHFFFAOYSA-N boronic acid Chemical compound OBO ZADPBFCGQRWHPN-UHFFFAOYSA-N 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000000337 buffer salt Substances 0.000 description 1
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 1
- 125000001589 carboacyl group Chemical group 0.000 description 1
- 150000001718 carbodiimides Chemical class 0.000 description 1
- 150000001722 carbon compounds Chemical class 0.000 description 1
- 229960004424 carbon dioxide Drugs 0.000 description 1
- 125000005518 carboxamido group Chemical group 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 229940081733 cetearyl alcohol Drugs 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003610 charcoal Substances 0.000 description 1
- 238000012822 chemical development Methods 0.000 description 1
- 239000002975 chemoattractant Substances 0.000 description 1
- 239000005482 chemotactic factor Substances 0.000 description 1
- 230000035605 chemotaxis Effects 0.000 description 1
- 229960002152 chlorhexidine acetate Drugs 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 208000037893 chronic inflammatory disorder Diseases 0.000 description 1
- 150000001860 citric acid derivatives Chemical class 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 239000013068 control sample Substances 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 150000001879 copper Chemical class 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 125000000392 cycloalkenyl group Chemical group 0.000 description 1
- 125000000000 cycloalkoxy group Chemical group 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000001887 cyclopentyloxy group Chemical group C1(CCCC1)O* 0.000 description 1
- 230000003436 cytoskeletal effect Effects 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- DEZRYPDIMOWBDS-UHFFFAOYSA-N dcm dichloromethane Chemical compound ClCCl.ClCCl DEZRYPDIMOWBDS-UHFFFAOYSA-N 0.000 description 1
- 238000006114 decarboxylation reaction Methods 0.000 description 1
- 230000003226 decolorizating effect Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 239000003405 delayed action preparation Substances 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 125000004663 dialkyl amino group Chemical group 0.000 description 1
- 235000019700 dicalcium phosphate Nutrition 0.000 description 1
- 235000019404 dichlorodifluoromethane Nutrition 0.000 description 1
- 229940042935 dichlorodifluoromethane Drugs 0.000 description 1
- 239000002027 dichloromethane extract Substances 0.000 description 1
- 229940087091 dichlorotetrafluoroethane Drugs 0.000 description 1
- 125000004177 diethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 150000005332 diethylamines Chemical class 0.000 description 1
- 125000001664 diethylamino group Chemical group [H]C([H])([H])C([H])([H])N(*)C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- NCBFTYFOPLPRBX-UHFFFAOYSA-N dimethyl azodicarboxylate Substances COC(=O)N=NC(=O)OC NCBFTYFOPLPRBX-UHFFFAOYSA-N 0.000 description 1
- WQOXQRCZOLPYPM-UHFFFAOYSA-N dimethyl disulfide Chemical compound CSSC WQOXQRCZOLPYPM-UHFFFAOYSA-N 0.000 description 1
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 description 1
- UXGNZZKBCMGWAZ-UHFFFAOYSA-N dimethylformamide dmf Chemical compound CN(C)C=O.CN(C)C=O UXGNZZKBCMGWAZ-UHFFFAOYSA-N 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- CETRZFQIITUQQL-UHFFFAOYSA-N dmso dimethylsulfoxide Chemical compound CS(C)=O.CS(C)=O CETRZFQIITUQQL-UHFFFAOYSA-N 0.000 description 1
- 238000000132 electrospray ionisation Methods 0.000 description 1
- 210000001671 embryonic stem cell Anatomy 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000008387 emulsifying waxe Substances 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 238000010931 ester hydrolysis Methods 0.000 description 1
- OLAMWIPURJGSKE-UHFFFAOYSA-N et2o diethylether Chemical compound CCOCC.CCOCC OLAMWIPURJGSKE-UHFFFAOYSA-N 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-N ethanesulfonic acid Chemical class CCS(O)(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-N 0.000 description 1
- OCLXJTCGWSSVOE-UHFFFAOYSA-N ethanol etoh Chemical compound CCO.CCO OCLXJTCGWSSVOE-UHFFFAOYSA-N 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- AEOCXXJPGCBFJA-UHFFFAOYSA-N ethionamide Chemical compound CCC1=CC(C(N)=S)=CC=N1 AEOCXXJPGCBFJA-UHFFFAOYSA-N 0.000 description 1
- XFYLVJXPLPTBOT-UHFFFAOYSA-N ethyl 3-(2,4-difluoroanilino)-6-oxo-7-phenylthieno[2,3-b]pyridine-2-carboxylate Chemical compound O=C1C=CC=2C(NC=3C(=CC(F)=CC=3)F)=C(C(=O)OCC)SC=2N1C1=CC=CC=C1 XFYLVJXPLPTBOT-UHFFFAOYSA-N 0.000 description 1
- CIBJXTFSLPYVNT-UHFFFAOYSA-N ethyl 3-(2-chloroanilino)-6-oxo-7-phenylthieno[2,3-b]pyridine-2-carboxylate Chemical compound O=C1C=CC=2C(NC=3C(=CC=CC=3)Cl)=C(C(=O)OCC)SC=2N1C1=CC=CC=C1 CIBJXTFSLPYVNT-UHFFFAOYSA-N 0.000 description 1
- LSLIMTBVXKPCTB-UHFFFAOYSA-N ethyl 3-(2-cyanoanilino)-6-oxo-7-phenylthieno[2,3-b]pyridine-2-carboxylate Chemical compound O=C1C=CC=2C(NC=3C(=CC=CC=3)C#N)=C(C(=O)OCC)SC=2N1C1=CC=CC=C1 LSLIMTBVXKPCTB-UHFFFAOYSA-N 0.000 description 1
- KCRMASBEVFDTGB-UHFFFAOYSA-N ethyl 3-(3-chloro-4-fluoroanilino)-6-oxo-7-phenylthieno[2,3-b]pyridine-2-carboxylate Chemical compound O=C1C=CC=2C(NC=3C=C(Cl)C(F)=CC=3)=C(C(=O)OCC)SC=2N1C1=CC=CC=C1 KCRMASBEVFDTGB-UHFFFAOYSA-N 0.000 description 1
- HKRBMTFPMKRFBJ-UHFFFAOYSA-N ethyl 3-(3-cyanoanilino)-6-oxo-7-phenylthieno[2,3-b]pyridine-2-carboxylate Chemical compound O=C1C=CC=2C(NC=3C=C(C=CC=3)C#N)=C(C(=O)OCC)SC=2N1C1=CC=CC=C1 HKRBMTFPMKRFBJ-UHFFFAOYSA-N 0.000 description 1
- CYCKZOJJIKSJTB-UHFFFAOYSA-N ethyl 3-(3-methylanilino)-7-(3-methylphenyl)-6-oxothieno[2,3-b]pyridine-2-carboxylate Chemical compound O=C1C=CC=2C(NC=3C=C(C)C=CC=3)=C(C(=O)OCC)SC=2N1C1=CC=CC(C)=C1 CYCKZOJJIKSJTB-UHFFFAOYSA-N 0.000 description 1
- VOOOWXFDEDSACU-UHFFFAOYSA-N ethyl 3-(4-fluoro-3-methylanilino)-6-oxo-7-phenylthieno[2,3-b]pyridine-2-carboxylate Chemical compound O=C1C=CC=2C(NC=3C=C(C)C(F)=CC=3)=C(C(=O)OCC)SC=2N1C1=CC=CC=C1 VOOOWXFDEDSACU-UHFFFAOYSA-N 0.000 description 1
- WGUVKCCRFQFUGC-UHFFFAOYSA-N ethyl 3-(4-fluoro-3-methylanilino)-7-(3-methylphenyl)-6-oxothieno[2,3-b]pyridine-2-carboxylate Chemical compound O=C1C=CC=2C(NC=3C=C(C)C(F)=CC=3)=C(C(=O)OCC)SC=2N1C1=CC=CC(C)=C1 WGUVKCCRFQFUGC-UHFFFAOYSA-N 0.000 description 1
- AUJJFABSVFWUNT-UHFFFAOYSA-N ethyl 3-anilino-7-(cyclopropylmethyl)-6-oxothieno[2,3-b]pyridine-2-carboxylate Chemical compound O=C1C=CC=2C(NC=3C=CC=CC=3)=C(C(=O)OCC)SC=2N1CC1CC1 AUJJFABSVFWUNT-UHFFFAOYSA-N 0.000 description 1
- DNEIYMMNBIAHBL-UHFFFAOYSA-N ethyl 3-bromo-6-oxo-7-phenylthieno[2,3-b]pyridine-2-carboxylate Chemical compound O=C1C=CC=2C(Br)=C(C(=O)OCC)SC=2N1C1=CC=CC=C1 DNEIYMMNBIAHBL-UHFFFAOYSA-N 0.000 description 1
- DJOUQHDPEWXNSZ-UHFFFAOYSA-N ethyl 3-bromo-6-oxo-7h-thieno[2,3-b]pyridine-2-carboxylate Chemical compound N1C(=O)C=CC2=C1SC(C(=O)OCC)=C2Br DJOUQHDPEWXNSZ-UHFFFAOYSA-N 0.000 description 1
- UJQZLTUEOZKURY-UHFFFAOYSA-N ethyl 3-bromo-7-(3-methylphenyl)-6-oxothieno[2,3-b]pyridine-2-carboxylate Chemical compound O=C1C=CC=2C(Br)=C(C(=O)OCC)SC=2N1C1=CC=CC(C)=C1 UJQZLTUEOZKURY-UHFFFAOYSA-N 0.000 description 1
- RMNAZZBYHBZENC-UHFFFAOYSA-N ethyl 3-bromo-7-(4-chlorophenyl)-6-oxothieno[2,3-b]pyridine-2-carboxylate Chemical compound O=C1C=CC=2C(Br)=C(C(=O)OCC)SC=2N1C1=CC=C(Cl)C=C1 RMNAZZBYHBZENC-UHFFFAOYSA-N 0.000 description 1
- QKWNFXDKMILPMQ-UHFFFAOYSA-N ethyl 3-bromo-7-(4-fluorophenyl)-6-oxothieno[2,3-b]pyridine-2-carboxylate Chemical compound O=C1C=CC=2C(Br)=C(C(=O)OCC)SC=2N1C1=CC=C(F)C=C1 QKWNFXDKMILPMQ-UHFFFAOYSA-N 0.000 description 1
- XXMPWIUHAHTGMN-UHFFFAOYSA-N ethyl 3-bromo-7-(4-methylphenyl)-6-oxothieno[2,3-b]pyridine-2-carboxylate Chemical compound O=C1C=CC=2C(Br)=C(C(=O)OCC)SC=2N1C1=CC=C(C)C=C1 XXMPWIUHAHTGMN-UHFFFAOYSA-N 0.000 description 1
- DPLNLNDEPYUCLI-UHFFFAOYSA-N ethyl 3-bromo-7-(cyclopropylmethyl)-6-oxothieno[2,3-b]pyridine-2-carboxylate Chemical compound O=C1C=CC=2C(Br)=C(C(=O)OCC)SC=2N1CC1CC1 DPLNLNDEPYUCLI-UHFFFAOYSA-N 0.000 description 1
- DTQFDIKLQCMMRJ-UHFFFAOYSA-N ethyl 3-bromo-7-oxidothieno[2,3-b]pyridin-7-ium-2-carboxylate Chemical compound C1=CC=C2C(Br)=C(C(=O)OCC)SC2=[N+]1[O-] DTQFDIKLQCMMRJ-UHFFFAOYSA-N 0.000 description 1
- SFDIRKDBTVHEEY-UHFFFAOYSA-N ethyl 3-bromothieno[2,3-b]pyridine-2-carboxylate Chemical compound C1=CC=C2C(Br)=C(C(=O)OCC)SC2=N1 SFDIRKDBTVHEEY-UHFFFAOYSA-N 0.000 description 1
- QROINBSJLMRMTO-UHFFFAOYSA-N ethyl 7-(4-chlorophenyl)-3-(4-fluoro-3-methylanilino)-6-oxothieno[2,3-b]pyridine-2-carboxylate Chemical compound O=C1C=CC=2C(NC=3C=C(C)C(F)=CC=3)=C(C(=O)OCC)SC=2N1C1=CC=C(Cl)C=C1 QROINBSJLMRMTO-UHFFFAOYSA-N 0.000 description 1
- 239000002024 ethyl acetate extract Substances 0.000 description 1
- 125000004494 ethyl ester group Chemical group 0.000 description 1
- 125000000031 ethylamino group Chemical group [H]C([H])([H])C([H])([H])N([H])[*] 0.000 description 1
- 125000006260 ethylaminocarbonyl group Chemical group [H]N(C(*)=O)C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000000816 ethylene group Chemical group [H]C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
- OJCSPXHYDFONPU-UHFFFAOYSA-N etoac etoac Chemical compound CCOC(C)=O.CCOC(C)=O OJCSPXHYDFONPU-UHFFFAOYSA-N 0.000 description 1
- OGPBJKLSAFTDLK-UHFFFAOYSA-N europium atom Chemical compound [Eu] OGPBJKLSAFTDLK-UHFFFAOYSA-N 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 239000012997 ficoll-paque Substances 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000012065 filter cake Substances 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 210000002683 foot Anatomy 0.000 description 1
- 230000022244 formylation Effects 0.000 description 1
- 238000006170 formylation reaction Methods 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-L fumarate(2-) Chemical class [O-]C(=O)\C=C\C([O-])=O VZCYOOQTPOCHFL-OWOJBTEDSA-L 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 239000000417 fungicide Substances 0.000 description 1
- 230000008570 general process Effects 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 150000004795 grignard reagents Chemical class 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 125000004438 haloalkoxy group Chemical group 0.000 description 1
- 125000001188 haloalkyl group Chemical group 0.000 description 1
- 125000004969 haloethyl group Chemical group 0.000 description 1
- 230000002140 halogenating effect Effects 0.000 description 1
- 230000026030 halogenation Effects 0.000 description 1
- 238000005658 halogenation reaction Methods 0.000 description 1
- 125000004970 halomethyl group Chemical group 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- UBHWBODXJBSFLH-UHFFFAOYSA-N hexadecan-1-ol;octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO.CCCCCCCCCCCCCCCCCCO UBHWBODXJBSFLH-UHFFFAOYSA-N 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 102000053478 human MAP2K6 Human genes 0.000 description 1
- 150000003840 hydrochlorides Chemical class 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical class I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- VLECDMDGMKPUSK-UHFFFAOYSA-N hydron;piperidin-3-ol;chloride Chemical compound Cl.OC1CCCNC1 VLECDMDGMKPUSK-UHFFFAOYSA-N 0.000 description 1
- 150000004679 hydroxides Chemical class 0.000 description 1
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 1
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 125000005946 imidazo[1,2-a]pyridyl group Chemical group 0.000 description 1
- 150000003949 imides Chemical class 0.000 description 1
- 125000001841 imino group Chemical group [H]N=* 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 description 1
- 125000003454 indenyl group Chemical group C1(C=CC2=CC=CC=C12)* 0.000 description 1
- 125000003387 indolinyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 102000006495 integrins Human genes 0.000 description 1
- 108010044426 integrins Proteins 0.000 description 1
- 230000004068 intracellular signaling Effects 0.000 description 1
- 230000007728 intracellular signaling mechanism Effects 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- 150000002540 isothiocyanates Chemical class 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- 210000002510 keratinocyte Anatomy 0.000 description 1
- 125000000468 ketone group Chemical group 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 150000003893 lactate salts Chemical class 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- CFHGBZLNZZVTAY-UHFFFAOYSA-N lawesson's reagent Chemical compound C1=CC(OC)=CC=C1P1(=S)SP(=S)(C=2C=CC(OC)=CC=2)S1 CFHGBZLNZZVTAY-UHFFFAOYSA-N 0.000 description 1
- 208000021601 lentivirus infection Diseases 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 229910001416 lithium ion Inorganic materials 0.000 description 1
- ZBEZXGZBLZOGMR-UHFFFAOYSA-M lithium;3-(2,4-difluoroanilino)-6-oxo-7-phenylthieno[2,3-b]pyridine-2-carboxylate Chemical compound [Li+].O=C1C=CC=2C(NC=3C(=CC(F)=CC=3)F)=C(C(=O)[O-])SC=2N1C1=CC=CC=C1 ZBEZXGZBLZOGMR-UHFFFAOYSA-M 0.000 description 1
- MSLDPSUVBYALEN-UHFFFAOYSA-M lithium;3-(2-cyanoanilino)-6-oxo-7-phenylthieno[2,3-b]pyridine-2-carboxylate Chemical compound [Li+].O=C1C=CC=2C(NC=3C(=CC=CC=3)C#N)=C(C(=O)[O-])SC=2N1C1=CC=CC=C1 MSLDPSUVBYALEN-UHFFFAOYSA-M 0.000 description 1
- DEYGBUDNOWTMSK-UHFFFAOYSA-M lithium;3-(4-fluoro-3-methylanilino)-6-oxo-7-phenylthieno[2,3-b]pyridine-2-carboxylate Chemical compound [Li+].C1=C(F)C(C)=CC(NC=2C=3C=CC(=O)N(C=4C=CC=CC=4)C=3SC=2C([O-])=O)=C1 DEYGBUDNOWTMSK-UHFFFAOYSA-M 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000003760 magnetic stirring Methods 0.000 description 1
- 150000002688 maleic acid derivatives Chemical class 0.000 description 1
- 150000002690 malonic acid derivatives Chemical class 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- COTNUBDHGSIOTA-UHFFFAOYSA-N meoh methanol Chemical compound OC.OC COTNUBDHGSIOTA-UHFFFAOYSA-N 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Natural products C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-M methanesulfonate group Chemical class CS(=O)(=O)[O-] AFVFQIVMOAPDHO-UHFFFAOYSA-M 0.000 description 1
- NCBFTYFOPLPRBX-AATRIKPKSA-N methyl (ne)-n-methoxycarbonyliminocarbamate Chemical compound COC(=O)\N=N\C(=O)OC NCBFTYFOPLPRBX-AATRIKPKSA-N 0.000 description 1
- 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 description 1
- 125000004458 methylaminocarbonyl group Chemical group [H]N(C(*)=O)C([H])([H])[H] 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940042472 mineral oil Drugs 0.000 description 1
- 108010085212 mitogen and stress-activated protein kinase 1 Proteins 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 210000005087 mononuclear cell Anatomy 0.000 description 1
- GFWOMJATTSHQFM-UHFFFAOYSA-N n-ethyl-2-propan-2-ylcycloheptane-1-carboxamide Chemical compound CCNC(=O)C1CCCCCC1C(C)C GFWOMJATTSHQFM-UHFFFAOYSA-N 0.000 description 1
- WOOWBQQQJXZGIE-UHFFFAOYSA-N n-ethyl-n-propan-2-ylpropan-2-amine Chemical compound CCN(C(C)C)C(C)C.CCN(C(C)C)C(C)C WOOWBQQQJXZGIE-UHFFFAOYSA-N 0.000 description 1
- 125000005893 naphthalimidyl group Chemical group 0.000 description 1
- 125000004593 naphthyridinyl group Chemical group N1=C(C=CC2=CC=CN=C12)* 0.000 description 1
- 230000027405 negative regulation of phosphorylation Effects 0.000 description 1
- 230000011242 neutrophil chemotaxis Effects 0.000 description 1
- 229910052759 nickel Inorganic materials 0.000 description 1
- 238000006396 nitration reaction Methods 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- PSACHCMMPFMFAJ-UHFFFAOYSA-N nmm n-methylmorpholine Chemical compound CN1CCOCC1.CN1CCOCC1 PSACHCMMPFMFAJ-UHFFFAOYSA-N 0.000 description 1
- 210000000929 nociceptor Anatomy 0.000 description 1
- 231100000344 non-irritating Toxicity 0.000 description 1
- 239000002687 nonaqueous vehicle Substances 0.000 description 1
- 238000007339 nucleophilic aromatic substitution reaction Methods 0.000 description 1
- 238000010534 nucleophilic substitution reaction Methods 0.000 description 1
- HEGSGKPQLMEBJL-RKQHYHRCSA-N octyl beta-D-glucopyranoside Chemical compound CCCCCCCCO[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HEGSGKPQLMEBJL-RKQHYHRCSA-N 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 150000003891 oxalate salts Chemical class 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 125000000538 pentafluorophenyl group Chemical group FC1=C(F)C(F)=C(*)C(F)=C1F 0.000 description 1
- 235000019271 petrolatum Nutrition 0.000 description 1
- 229940066842 petrolatum Drugs 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- 125000000286 phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 1
- PDTFCHSETJBPTR-UHFFFAOYSA-N phenylmercuric nitrate Chemical compound [O-][N+](=O)O[Hg]C1=CC=CC=C1 PDTFCHSETJBPTR-UHFFFAOYSA-N 0.000 description 1
- 125000004344 phenylpropyl group Chemical group 0.000 description 1
- 125000003356 phenylsulfanyl group Chemical group [*]SC1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- UHZYTMXLRWXGPK-UHFFFAOYSA-N phosphorus pentachloride Chemical compound ClP(Cl)(Cl)(Cl)Cl UHZYTMXLRWXGPK-UHFFFAOYSA-N 0.000 description 1
- FAIAAWCVCHQXDN-UHFFFAOYSA-N phosphorus trichloride Chemical compound ClP(Cl)Cl FAIAAWCVCHQXDN-UHFFFAOYSA-N 0.000 description 1
- 125000004592 phthalazinyl group Chemical group C1(=NN=CC2=CC=CC=C12)* 0.000 description 1
- 125000005544 phthalimido group Chemical group 0.000 description 1
- 125000005545 phthalimidyl group Chemical group 0.000 description 1
- HDOWRFHMPULYOA-UHFFFAOYSA-N piperidin-4-ol Chemical compound OC1CCNCC1 HDOWRFHMPULYOA-UHFFFAOYSA-N 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 208000030428 polyarticular arthritis Diseases 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 description 1
- 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 description 1
- 229920001451 polypropylene glycol Polymers 0.000 description 1
- 229940113124 polysorbate 60 Drugs 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 159000000001 potassium salts Chemical class 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- MCSINKKTEDDPNK-UHFFFAOYSA-N propyl propionate Chemical compound CCCOC(=O)CC MCSINKKTEDDPNK-UHFFFAOYSA-N 0.000 description 1
- 239000002599 prostaglandin synthase inhibitor Substances 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 239000012264 purified product Substances 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- 150000005299 pyridinones Chemical class 0.000 description 1
- 125000005030 pyridylthio group Chemical group N1=C(C=CC=C1)S* 0.000 description 1
- 230000000171 quenching effect Effects 0.000 description 1
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 1
- 208000002574 reactive arthritis Diseases 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000007115 recruitment Effects 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 238000005932 reductive alkylation reaction Methods 0.000 description 1
- 230000008521 reorganization Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 230000019254 respiratory burst Effects 0.000 description 1
- 208000030925 respiratory syncytial virus infectious disease Diseases 0.000 description 1
- 230000003938 response to stress Effects 0.000 description 1
- 210000003705 ribosome Anatomy 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 150000003354 serine derivatives Chemical class 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 239000012279 sodium borohydride Substances 0.000 description 1
- 229910000033 sodium borohydride Inorganic materials 0.000 description 1
- VILMUCRZVVVJCA-UHFFFAOYSA-M sodium glycolate Chemical compound [Na+].OCC([O-])=O VILMUCRZVVVJCA-UHFFFAOYSA-M 0.000 description 1
- 229910001415 sodium ion Inorganic materials 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- VAMAIZRVOKIAAR-UHFFFAOYSA-M sodium;3-(2-chloroanilino)-6-oxo-7-phenylthieno[2,3-b]pyridine-2-carboxylate Chemical compound [Na+].O=C1C=CC=2C(NC=3C(=CC=CC=3)Cl)=C(C(=O)[O-])SC=2N1C1=CC=CC=C1 VAMAIZRVOKIAAR-UHFFFAOYSA-M 0.000 description 1
- GARAFOWDHJBJDS-UHFFFAOYSA-M sodium;3-(3-chloro-4-fluoroanilino)-6-oxo-7-phenylthieno[2,3-b]pyridine-2-carboxylate Chemical compound [Na+].O=C1C=CC=2C(NC=3C=C(Cl)C(F)=CC=3)=C(C(=O)[O-])SC=2N1C1=CC=CC=C1 GARAFOWDHJBJDS-UHFFFAOYSA-M 0.000 description 1
- SNDAHOKVVYOISB-UHFFFAOYSA-M sodium;3-(3-methylanilino)-7-(3-methylphenyl)-6-oxothieno[2,3-b]pyridine-2-carboxylate Chemical compound [Na+].CC1=CC=CC(NC=2C=3C=CC(=O)N(C=4C=C(C)C=CC=4)C=3SC=2C([O-])=O)=C1 SNDAHOKVVYOISB-UHFFFAOYSA-M 0.000 description 1
- MIRCCGDXLJECBZ-UHFFFAOYSA-M sodium;3-(4-fluoro-3-methylanilino)-7-(3-methylphenyl)-6-oxothieno[2,3-b]pyridine-2-carboxylate Chemical compound [Na+].CC1=CC=CC(N2C(C=CC=3C(NC=4C=C(C)C(F)=CC=4)=C(C([O-])=O)SC=32)=O)=C1 MIRCCGDXLJECBZ-UHFFFAOYSA-M 0.000 description 1
- PYAFYEHRZIWICS-UHFFFAOYSA-M sodium;7-(4-chlorophenyl)-3-(4-fluoro-3-methylanilino)-6-oxothieno[2,3-b]pyridine-2-carboxylate Chemical compound [Na+].C1=C(F)C(C)=CC(NC=2C=3C=CC(=O)N(C=4C=CC(Cl)=CC=4)C=3SC=2C([O-])=O)=C1 PYAFYEHRZIWICS-UHFFFAOYSA-M 0.000 description 1
- 239000011343 solid material Substances 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 239000001587 sorbitan monostearate Substances 0.000 description 1
- 235000011076 sorbitan monostearate Nutrition 0.000 description 1
- 229940035048 sorbitan monostearate Drugs 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 230000003019 stabilising effect Effects 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 150000003890 succinate salts Chemical class 0.000 description 1
- NVBFHJWHLNUMCV-UHFFFAOYSA-N sulfamide Chemical compound NS(N)(=O)=O NVBFHJWHLNUMCV-UHFFFAOYSA-N 0.000 description 1
- FDDDEECHVMSUSB-UHFFFAOYSA-N sulfanilamide Chemical compound NC1=CC=C(S(N)(=O)=O)C=C1 FDDDEECHVMSUSB-UHFFFAOYSA-N 0.000 description 1
- 229940124530 sulfonamide Drugs 0.000 description 1
- 125000000565 sulfonamide group Chemical group 0.000 description 1
- 125000001174 sulfone group Chemical group 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- 230000000153 supplemental effect Effects 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 201000004595 synovitis Diseases 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 150000003892 tartrate salts Chemical class 0.000 description 1
- 125000004213 tert-butoxy group Chemical group [H]C([H])([H])C(O*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000006633 tert-butoxycarbonylamino group Chemical group 0.000 description 1
- YLHLTWZLVAEMCW-UHFFFAOYSA-N tert-butyl n-(2,4-difluorophenyl)-n-(6-oxo-7-phenylthieno[2,3-b]pyridin-3-yl)carbamate Chemical compound C=1C=C(F)C=C(F)C=1N(C(=O)OC(C)(C)C)C(C=1C=CC2=O)=CSC=1N2C1=CC=CC=C1 YLHLTWZLVAEMCW-UHFFFAOYSA-N 0.000 description 1
- IXYBRHITNGMYQN-HXUWFJFHSA-N tert-butyl n-(2,4-difluorophenyl)-n-[2-[(2r)-2-(hydroxymethyl)pyrrolidin-1-yl]sulfonyl-6-oxo-7-phenylthieno[2,3-b]pyridin-3-yl]carbamate Chemical compound C=1C=C(F)C=C(F)C=1N(C(=O)OC(C)(C)C)C(C=1C=CC2=O)=C(S(=O)(=O)N3[C@H](CCC3)CO)SC=1N2C1=CC=CC=C1 IXYBRHITNGMYQN-HXUWFJFHSA-N 0.000 description 1
- NEMXVXVJGXZDRR-UHFFFAOYSA-N tert-butyl n-(azetidin-3-yl)carbamate Chemical compound CC(C)(C)OC(=O)NC1CNC1 NEMXVXVJGXZDRR-UHFFFAOYSA-N 0.000 description 1
- LXFQMCRISRUBKT-SFHVURJKSA-N tert-butyl n-[(3s)-1-[3-(2,4-difluoroanilino)-6-oxo-7-phenylthieno[2,3-b]pyridine-2-carbonyl]pyrrolidin-3-yl]carbamate Chemical compound C1[C@@H](NC(=O)OC(C)(C)C)CCN1C(=O)C1=C(NC=2C(=CC(F)=CC=2)F)C(C=CC(=O)N2C=3C=CC=CC=3)=C2S1 LXFQMCRISRUBKT-SFHVURJKSA-N 0.000 description 1
- OTCXGVBTJUPCDH-FQEVSTJZSA-N tert-butyl n-[(3s)-1-[3-(4-fluoro-3-methylanilino)-6-oxo-7-phenylthieno[2,3-b]pyridine-2-carbonyl]pyrrolidin-3-yl]carbamate Chemical compound C1=C(F)C(C)=CC(NC=2C=3C=CC(=O)N(C=4C=CC=CC=4)C=3SC=2C(=O)N2C[C@H](CC2)NC(=O)OC(C)(C)C)=C1 OTCXGVBTJUPCDH-FQEVSTJZSA-N 0.000 description 1
- GIXPAPCPAGRVRW-UHFFFAOYSA-N tert-butyl n-[1-[3-(2,4-difluoroanilino)-6-oxo-7-phenylthieno[2,3-b]pyridine-2-carbonyl]azetidin-3-yl]carbamate Chemical compound C1C(NC(=O)OC(C)(C)C)CN1C(=O)C1=C(NC=2C(=CC(F)=CC=2)F)C(C=CC(=O)N2C=3C=CC=CC=3)=C2S1 GIXPAPCPAGRVRW-UHFFFAOYSA-N 0.000 description 1
- YVSBPSIWEAMUMC-UHFFFAOYSA-N tert-butyl n-[1-[3-(2,4-difluoroanilino)-6-oxo-7-phenylthieno[2,3-b]pyridine-2-carbonyl]piperidin-4-yl]carbamate Chemical compound C1CC(NC(=O)OC(C)(C)C)CCN1C(=O)C1=C(NC=2C(=CC(F)=CC=2)F)C(C=CC(=O)N2C=3C=CC=CC=3)=C2S1 YVSBPSIWEAMUMC-UHFFFAOYSA-N 0.000 description 1
- LXFQMCRISRUBKT-UHFFFAOYSA-N tert-butyl n-[1-[3-(2,4-difluoroanilino)-6-oxo-7-phenylthieno[2,3-b]pyridine-2-carbonyl]pyrrolidin-3-yl]carbamate Chemical compound C1C(NC(=O)OC(C)(C)C)CCN1C(=O)C1=C(NC=2C(=CC(F)=CC=2)F)C(C=CC(=O)N2C=3C=CC=CC=3)=C2S1 LXFQMCRISRUBKT-UHFFFAOYSA-N 0.000 description 1
- CKXZPVPIDOJLLM-UHFFFAOYSA-N tert-butyl n-piperidin-4-ylcarbamate Chemical compound CC(C)(C)OC(=O)NC1CCNCC1 CKXZPVPIDOJLLM-UHFFFAOYSA-N 0.000 description 1
- DQQJBEAXSOOCPG-UHFFFAOYSA-N tert-butyl n-pyrrolidin-3-ylcarbamate Chemical compound CC(C)(C)OC(=O)NC1CCNC1 DQQJBEAXSOOCPG-UHFFFAOYSA-N 0.000 description 1
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- MHXBHWLGRWOABW-UHFFFAOYSA-N tetradecyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCCCCCCCCCCCCC MHXBHWLGRWOABW-UHFFFAOYSA-N 0.000 description 1
- WHRNULOCNSKMGB-UHFFFAOYSA-N tetrahydrofuran thf Chemical compound C1CCOC1.C1CCOC1 WHRNULOCNSKMGB-UHFFFAOYSA-N 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 125000001984 thiazolidinyl group Chemical group 0.000 description 1
- 238000005636 thioacylation reaction Methods 0.000 description 1
- 125000002813 thiocarbonyl group Chemical group *C(*)=S 0.000 description 1
- 125000004014 thioethyl group Chemical group [H]SC([H])([H])C([H])([H])* 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- 239000003104 tissue culture media Substances 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 125000005270 trialkylamine group Chemical group 0.000 description 1
- 125000005208 trialkylammonium group Chemical group 0.000 description 1
- 125000001425 triazolyl group Chemical group 0.000 description 1
- CYRMSUTZVYGINF-UHFFFAOYSA-N trichlorofluoromethane Chemical compound FC(Cl)(Cl)Cl CYRMSUTZVYGINF-UHFFFAOYSA-N 0.000 description 1
- 229940029284 trichlorofluoromethane Drugs 0.000 description 1
- WTVXIBRMWGUIMI-UHFFFAOYSA-N trifluoro($l^{1}-oxidanylsulfonyl)methane Chemical group [O]S(=O)(=O)C(F)(F)F WTVXIBRMWGUIMI-UHFFFAOYSA-N 0.000 description 1
- 238000001665 trituration Methods 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 210000003556 vascular endothelial cell Anatomy 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 238000013389 whole blood assay Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Definitions
- This invention relates to a series of thienopyridone derivatives, to compositions containing them, to processes for their preparation and to their use in medicine.
- Immune and inflammatory responses involve a variety of cell types with control and co-ordination of the various interactions occurring via both cell-cell contacts (e.g. integrin interactions with their receptors) and by way of intercellular signalling molecules.
- a large number of different signalling molecules are involved, including cytokines, lymphocytes, chemokines and growth factors.
- Cells respond to such intercellular signalling molecules by means of intracellular signalling mechanisms that include protein kinases, phosphatases and phospholipases.
- protein kinases There are five classes of protein kinase of which the major ones are the tyrosine kinases and the serine/threonine kinases [Hunter, T., Methods in Enzymology (Protein Kinase Classification), p. 3, Hunter, T. and Sefton, B. M. eds., vol. 200, Academic Press, San Diego, 1991].
- MAP mitogen activating protein
- ERKs extracellular regulated kinases
- JNKs or SAP kinases stress activated kinases
- p38 kinases which have a threonine-glycine-tyrosine (TGY) activation motif.
- TGY threonine-glycine-tyrosine activation motif.
- Both the JNKs and p38 MAP kinases are primarily activated by stress stimuli including, but not limited to, proinflammatory cytokines, e.g. tumour necrosis factor (TNF) and interleukin-1 (IL-1), ultraviolet light, endotoxin and chemical or osmotic shock.
- proinflammatory cytokines e.g. tumour necrosis factor (TNF) and interleukin-1 (IL-1)
- IL-1 interleukin-1
- CSBP-1 CSAID binding protein-1
- CSBP-2 CSAID binding protein-1
- CSBP-2 differs from CSBP-1 in an internal sequence of 25 amino acids as a result of differential splicing of two exons that are conserved in both mouse and human [McDonnell, P. C. et al., Genomics, 1995, 29, 301-2].
- CSBP-1 and p38 ⁇ are expressed ubiquitously and there is no difference between the two isoforms with respect to tissue distribution, activation profile, substrate preference or CSAID binding.
- a second isoform is p38 ⁇ which has 70% identity with p38 ⁇ .
- a second form of p38 ⁇ termed p38 ⁇ 2 is also known and of the two this is believed to be the major form.
- p38 ⁇ and p38 ⁇ 2 are expressed in many different tissues. However in monocytes and macrophages p38 ⁇ is the predominant kinase activity [Lee, J. C., ibid; Jing, Y. et al., J. Biol. Chem., 1996, 271, 10531-34; Hale, K. K.
- p38 ⁇ and p38 ⁇ (also termed SAP kinase-3 and SAP kinase-4 respectively) have ⁇ 63% and ⁇ 61% homology to p38 ⁇ respectively.
- p38 ⁇ is predominantly expressed in skeletal muscle whilst p38 ⁇ is found in testes, pancreas, prostate, small intestine and in certain endocrine tissues.
- All p38 homologues and splice variants contain a 12 amino acid activation loop that includes a Thr-Gly-Tyr motif. Dual phosphorylation of both Thr-180 and Tyr-182 in the TGY motif by a dual specificity upstream kinase is essential for the activation of p38 and results in a >1000-fold increase in specific activity of these enzymes [Doza, Y. N. et al., FEBS Left., 1995, 364, 7095-8012]. This dual phosphorylation is effected by MKK6 and under certain conditions the related enzyme MKK3 [Enslen, H. et al., J. Biol. Chem., 1998, 273, 1741-48].
- MKK3 and MKK6 belong to a family of enzymes termed MAPKK (mitogen activating protein kinase kinase) which are in turn activated by MAPKKK (mitogen activating kinase kinase kinase) otherwise known as MAP3K.
- MAPKK mitogen activating protein kinase kinase
- MAPKKK mitogen activating kinase kinase kinase
- MEKK4/MTK1 MAP or ERK kinase kinase/MAP three kinase-1
- ASK1 apoptosis stimulated kinase
- TAK1 TGF- ⁇ -activated kinase
- TAK1 has been shown to activate MKK6 in response to transforming growth factor- ⁇ (TGF- ⁇ ).
- TNF-stimulated activation of p38 is believed to be mediated by the recruitment of TRAF2 [TNF receptor associated factor] and the Fas adaptor protein, Daxx, which results in the activation of ASK1 and subsequently p38.
- MAPK activated protein kinase 2/3/5 MAPK activated protein kinase 2/3/5
- PRAK p38 regulated/activated protein kinase
- MNK1/2 MAP kinase-interacting kinase 1/2
- MSK1/RLPK mitogen- and stress-activated protein kinase 1
- RSK-B ribosomal S6 kinase-B
- ATF2/6 activating transcription factor 2/6
- MEF2A/C monocyte-enhancer factor-2A/C
- C/EBP homologous protein C/EBP homologous protein
- Elk1 and Sap-1a1 activating transcription factor 2/6
- MEF2A/C monocyte-enhancer factor-2A/C
- C/EBP homologous protein C/EBP homologous protein
- Elk1 and Sap-1a1 substrates
- MAPKAP K2 is activated by p38 in response to environmental stress. Mice engineered to lack MAPKAP K2 do not produce TNF in response to lipopolysaccharide (LPS). Production of several other cytokines such as IL-1, IL-6, IFN-g and IL-10 is also partially inhibited [Kotlyarov, A. et al., Nature Cell Biol., 1999, 1, 94-7]. Further, MAPKAP K2 from embryonic stem cells from p38 ⁇ null mice was not activated in response to stress and these cells did not produce IL-6 in response to IL-1 [Allen, M. et al., J. Exp. Med., 2000, 191, 859-69].
- MAPKAP K2 is not only essential for TNF and IL-1 production but also for signalling induced by cytokines.
- MAPKAP K2/3 phosphorylate and thus regulate heat shock proteins HSP 25 and HSP 27 which are involved in cytoskeletal reorganization.
- these small molecule inhibitors are known to decrease the synthesis of a wide variety of pro-inflammatory proteins including IL-6, IL-8, granulocyte/macrophage colony-stimulating factor (GM-CSF) and cyclooxygenase-2 (COX-2).
- IL-6 IL-6
- IL-8 granulocyte/macrophage colony-stimulating factor
- COX-2 cyclooxygenase-2
- TNF-induced phosphorylation and activation of cytosolic PLA2 TNF-induced expression of VCAM-1 on endothelial cells and IL-1 stimulated synthesis of collagenase and stromelysin are also inhibited by small molecule inhibitors of p38 [Cohen, P., Trends Cell Biol., 1997, 7, 353-61].
- TNF and IL-1 A variety of cells including monocytes and macrophages produce TNF and IL-1. Excessive or unregulated TNF production is implicated in a number of disease states including Crohn's disease, ulcerative colitis, pyresis, rheumatoid arthritis, rheumatoid spondylitis, osteoarthritis, gouty arthritis and other arthritic conditions, toxic shock syndrome, endotoxic shock, sepsis, septic shock, gram negative sepsis, bone resorption diseases, reperfusion injury, graft vs.
- IL-1 has been implicated in rheumatoid arthritis, osteoarthritis, traumatic arthritis, rubella arthritis, acute synovitis, psoriatic arthritis, cachexia, Reiter's syndrome, endotoxemia, toxic shock syndrome, tuberculosis, atherosclerosis, muscle degeneration, and other acute or chronic inflammatory diseases such as the inflammatory reaction induced by endotoxin or inflammatory bowel disease.
- IL-1 has been linked to diabetes and pancreatic ⁇ cell destruction [Dinarello, C. A., J. Clinical Immunology, 1985, 5, 287-97].
- IL-8 is a chemotactic factor produced by various cell types including endothelial cells, mononuclear cells, fibroblasts and keratinocytes. IL-1, TNF and LPS all induce the production of IL-8 by endothelial cells.
- IL-8 has been shown to have a number of functions including being a chemoattractant for neutrophils, T-lymphocytes and basophils.
- IL-8 has also been shown to increase the surface expression of Mac-1 (CD11b/CD18) on neutrophils without de novo protein synthesis which may contribute to increased adhesion of neutrophils to vascular endothelial cells. Many diseases are characterised by massive neutrophil infiltration. Histamine release from basophils (in both atopic and normal individuals) is induced by IL-8 as is lysozomal enzyme release and respiratory burst from neutrophils.
- p38 occupies within the cascade of signalling molecules mediating extracellular to intracellular signalling and its influence over not only IL-1, TNF and IL-8 production but also the synthesis and/or action of other pro-inflammatory proteins (e.g. IL-6, GM-CSF, COX-2, collagenase and stromelysin) make it an attractive target for inhibition by small molecule inhibitors with the expectation that such inhibition would be a highly effective mechanism for regulating the excessive and destructive activation of the immune system.
- pro-inflammatory proteins e.g. IL-6, GM-CSF, COX-2, collagenase and stromelysin
- Y is a linking group —C(O)— or —S(O) 2 —; n is zero or the integer 1; m is the integer 1, 2, 3 or 4; p is the integer 1, 2, 3 or 4; R d is an —OH, -(Alk 2 )OH (where Alk 2 is a straight or branched C 1-4 alkylene chain), —OR 1 (where R 1 is a straight or branched C 1-6 alkyl group), -(Alk 2 )OR 1 , —NR 2 R 3 (where R 2 and R 3 may be the same or different and is each independently a hydrogen atom or a straight or branched C 1-6 alkyl group), -(Alk 2 )NR 2 R 3 or straight or branched C 1-6 alkyl group; Alk 1 is a straight or branched C 1-4 alkylene chain; Cy 1 is an optionally substituted cycloali
- compounds of formula (1) may have one or more chiral centres, and exist as enantiomers or diastereomers.
- the invention is to be understood to extend to all such enantiomers, diastereomers and mixtures thereof in any proportion, including racemates.
- Formula (1) and the formulae hereinafter are intended to represent all individual isomers and mixtures thereof, unless stated or shown otherwise.
- compounds of formula (1) may exist as tautomers, for example keto (CH 2 C ⁇ O)-enol (CH ⁇ CHOH) tautomers.
- Formula (1) and the formulae hereinafter are intended to represent all individual tautomers and mixtures thereof, unless stated otherwise.
- alkyl whether present as a group or part of a group includes straight or branched C 1-6 alkyl groups, for example C 1-4 alkyl groups such as methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl or tert-butyl groups.
- alkenyl or “alkynyl” are intended to mean straight or branched C 2-6 alkenyl or C 2-6 alkynyl groups such as C 2-4 alkenyl or C 2-4 alkynyl groups.
- the optional substituents which may be present on these groups include one, two, three or more substituents where each substituent may be the same or different and is selected from halogen atoms, e.g. fluorine, chlorine, bromine or iodine atoms, or —OH, —CO 2 H, —CO 2 R 4 [where R 4 is an optionally substituted straight or branched C 1-6 alkyl group, and is in particular a straight or branched C 1-4 alkyl group], e.g. —CO 2 CH 3 or —CO 2 C(CH 3 ) 3 , —CONHR 4 , e.g. —CONHCH 3 , —CON(R 4 ) 2 , e.g.
- —CON(CH 3 ) 2 , —COR 4 e.g. —COCH 3 , C 1-6 alkoxy, e.g. methoxy or ethoxy, haloC 1-6 alkoxy, e.g. trifluoromethoxy or difluoromethoxy, thiol (—SH), —S(O)R 4 , e.g. —S(O)CH 3 , —S(O) 2 R 4 , e.g. —S(O) 2 CH 3 , C 1-6 alkylthio, e.g. methylthio or ethylthio, amino, —NHR 4 , e.g. —NHCH 3 , or —N(R 4 ) 2 , e.g. —N(CH 3 ) 2 , groups. Where two R 4 groups are present in any of the above substituents these may be the same or different.
- heterocyclic rings may be optionally interrupted by a further heteroatom or heteroatom-containing group selected from —O—, —S—, —N(R 4 )—, —C(O)— or —C(S)— groups.
- heterocyclic rings include piperidinyl, pyrazolidinyl, morpholinyl, thiomorpholinyl, pyrrolidinyl, imidazolidinyl and piperazinyl rings.
- halogen is intended to include fluorine, chlorine, bromine or iodine atoms.
- haloalkyl is intended to include those alkyl groups just mentioned substituted by one, two or three of the halogen atoms just described. Particular examples of such groups include —CF 3 , —CCl 3 , —CHF 2 , —CHCl 2 , —CH 2 F and —CH 2 Cl groups.
- alkoxy as used herein is intended to include straight or branched C 1-6 alkoxy, e.g. C 1-4 alkoxy such as methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, sec-butoxy, isobutoxy and tert-butoxy.
- Haloalkoxy as used herein includes any of these alkoxy groups substituted by one, two or three halogen atoms as described above. Particular examples include —OCF 3 , —OCCl 3 , —OCHF 2 , —OCHCl 2 , —OCH 2 F and —OCH 2 Cl groups.
- alkylthio is intended to include straight or branched C 1-6 alkylthio, e.g. C 1-4 alkylthio such as methylthio or ethylthio.
- alkylamino or “dialkylamino” is intended to include the groups —NHR 1a and —N(R 1a )(R 1b ) where R 1a and R 1b is each independently an optionally substituted straight or branched alkyl group or both together with the N atom to which they are attached form an optionally substituted heterocycloalkyl group which may contain a further heteroatom or heteroatom-containing group such as an —O— or —S— atom or —N(R 1a )— group.
- optionally substituted heterocycloalkyl groups include optionally substituted pyrrolidinyl, piperidinyl, morpholinyl, thiomorpholinyl and N′-C 1-6 alkylpiperazinyl groups.
- the optional substituents which may be present on such heterocycloalkyl groups include those optional substituents as described above in relation to the term “alkyl”.
- alkylene chains represented by Alk 1 and/or Alk 2 when each is present in compounds of the invention include —CH 2 —, —CH 2 CH 2 —, —CH(CH 3 )CH 2 —, —(CH 2 ) 2 CH 2 —, —C(CH 3 ) 2 —, —(CH 2 ) 3 CH 2 —, —CH 2 CH(CH 3 )CH 2 —, —C(CH 3 ) 2 CH 2 — or —CH(CH 3 )CH 2 CH 2 — chains.
- Optionally substituted cycloaliphatic groups represented by the group Cy 1 in compounds of the invention include optionally substituted C 3-10 cycloaliphatic groups.
- Particular examples include optionally substituted C 3-10 cycloalkyl, e.g. C 3-7 cycloalkyl, or C 3-10 cycloalkenyl, e.g. C 3-7 cycloalkenyl, groups.
- cycloaliphatic groups represented by the group Cy 1 include optionally substituted cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, 2-cyclobuten-1-yl, 2-cyclopenten-1-yl and 3-cyclopenten-1-yl groups, especially cyclopropyl.
- the optional substituents which may be present on the cycloaliphatic groups represented by the group Cy 1 include one, two, three or more substituents selected from halogen atoms, or C 1-6 alkyl, e.g. methyl or ethyl, haloC 1-6 alkyl, e.g. halomethyl or haloethyl such as difluoromethyl or trifluoromethyl, optionally substituted by hydroxyl, e.g. —C(OH)(CF 3 ) 2 , C 1-6 alkoxy, e.g. methoxy or ethoxy, haloC 1-6 alkoxy, e.g.
- halomethoxy or haloethoxy such as difluoromethoxy or trifluoromethoxy, thiol, C 1-6 alkylthiol, e.g. methylthiol or ethylthiol, carbonyl ( ⁇ O), thiocarbonyl ( ⁇ S), imino ( ⁇ NR 4a ) [where R 4a is an —OH group or a C 1-6 alkyl group], or -(Alk 3 ) v R 5 groups in which Alk 3 is a straight or branched C 1-3 alkylene chain, v is zero or the integer 1 and R 5 is a C 3-8 cycloalkyl, —OH, —SH, —N(R 6 )(R 7 ) [in which R 6 and R 7 is each independently selected from a hydrogen atom or an optionally substituted alkyl or C 3-8 cycloalkyl group], —OR 6 , —SR 6 , —CN, —NO 2 ,
- Alk 3 chains include —CH 2 —, —CH 2 CH 2 —, —CH 2 CH 2 CH 2 — and —CH(CH 3 )CH 2 — chains.
- R 5 , R 6 , R 7 and/or R 8 is present as a C 3-8 cycloalkyl group it may be for example a cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl group.
- Optional substituents which may be present on such groups include for example one, two or three substituents which may be the same or different selected from halogen atoms, for example fluorine, chlorine, bromine or iodine atoms, or hydroxy or C 1-6 alkoxy, e.g. methoxy, ethoxy or isopropoxy, groups.
- heterocyclic rings may be optionally interrupted by a further heteroatom or heteroatom-containing group selected from —O—, —S—, —N(R 7 )—, —C(O)— or —C(S)— groups.
- Particular examples of such heterocyclic rings include piperidinyl, pyrazolidinyl, morpholinyl, thiomorpholinyl, pyrrolidinyl, imidazolidinyl and piperazinyl rings.
- R 5 is an optionally substituted aromatic or heteroaromatic group it may be any such group as described hereinafter in relation to Cy 1 .
- optionally substituted aromatic groups represented by the group Cy 1 include for example monocyclic or bicyclic fused ring C 6-12 aromatic groups, such as phenyl, 1- or 2-naphthyl, 1- or 2-tetrahydronaphthyl, indanyl or indenyl groups, especially phenyl.
- Heteroaromatic groups represented by the group Cy 1 include for example C 1-9 heteroaromatic groups containing for example one, two, three or four heteroatoms selected from oxygen, sulphur or nitrogen atoms.
- the heteroaromatic groups may be for example monocyclic or bicyclic fused ring heteroaromatic groups.
- Monocyclic heteroaromatic groups include for example five- or six-membered heteroaromatic groups containing one, two, three or four heteroatoms selected from oxygen, sulphur or nitrogen atoms.
- Bicyclic heteroaromatic groups include for example eight- to thirteen-membered fused ring heteroaromatic groups containing one, two or more heteroatoms selected from oxygen, sulphur or nitrogen atoms.
- heteroaromatic groups of these types include pyrrolyl, furyl, thienyl, imidazolyl, N—C 1-6 alkylimidazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, pyrazolyl, 1,2,3-triazolyl, 1,2,4-triazolyl, 1,2,3-oxadiazolyl, 1,2,5-oxadiazolyl, 1,3,4-oxadiazolyl, 1,3,4-thiadiazolyl, pyridyl, pyrimidinyl, pyridazinyl, pyrazinyl, 1,3,5-triazinyl, 1,2,4-triazinyl, 1,2,3-triazinyl, benzofuryl, [2,3-dihydro]benzofuryl, benzothienyl, [2,3-dihydro]benzothienyl, benzotriazolyl, indolyl,
- phthalimidyl or naphthalimidyl such as 1,8-naphthalimidyl, pyr
- Optional substituents which may be present on aromatic or heteroaromatic groups represented by the group Cy 1 include one, two, three or more substituents, each selected from an atom or group R 10 in which R 10 is R 10a or -L 6 Alk 5 (R 10a ) r , where R 10a is a halogen atom, or an amino (—NH 2 ), substituted amino, nitro, cyano, hydroxyl (—OH), substituted hydroxyl, formyl, carboxyl (—CO 2 H), esterified carboxyl, thiol (—SH), substituted thiol, —COR 11 [where R 11 is an -L 6 Alk 3 (R 10a ) r , aryl or heteroaryl group], —CSR 11 , —SO 3 H, —SOR 11 , —SO 2 R 11 , —SO 3 R 11 , —SO 2 NH 2 , —SO 2 NHR 11 , —SO 2 N(R 11 ) 2
- L 6 in the group -L 6 Alk 5 (R 10a ) r is a linker atom or group it may be for example any divalent linking atom or group.
- Particular examples include —O— or —S— atoms or —C(O)—, —C(O)O—, —OC(O)—, —C(S)—, —S(O)—, —S(O) 2 —, —N(R 3 )— [where R 3 is a hydrogen atom or a straight or branched alkyl group], —N(R 3 )O—, —N(R 3 )N—, —CON(R 3 )—, —OC(O)N(R 3 )—, —CSN(R 3 )—, —N(R 3 )CO—, —N(R 3 )C(O)O—, —N(R 3 )CS—, —S(O) 2 N(R 3 )—,
- r is an integer 1, 2 or 3, it is to be understood that the substituent or substituents R 10a may be present on any suitable carbon atom in -Alk 5 . Where more than one R 10a substituent is present these may be the same or different and may be present on the same or different atom in -Alk 5 . Clearly, when r is zero and no substituent R 10a is present the alkylene, alkenylene or alkynylene chain represented by Alk 5 becomes an alkyl, alkenyl or alkynyl group.
- R 10a is a substituted amino group it may be for example a group —NHR 11 [where R 11 is as defined above] or a group —N(R 11 ) 2 wherein each R 11 group is the same or different.
- R 10a is a halogen atom it may be for example a fluorine, chlorine, bromine, or iodine atom.
- R 10a is a substituted hydroxyl or substituted thiol group it may be for example a group —OR 11 or —SR 12 respectively.
- Esterified carboxyl groups represented by the group R 10a include groups of formula —CO 2 Alk 6 wherein Alk 6 is a straight or branched, optionally substituted C 1-8 alkyl group such as a methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl or tert-butyl group; a C 6-12 arylC 1-8 alkyl group such as an optionally substituted benzyl, phenylethyl, phenylpropyl, 1-naphthylmethyl or 2-naphthylmethyl group; a C 6-12 aryl group such as an optionally substituted phenyl, 1-naphthyl or 2-naphthyl group; a C 6-12 aryloxyC 1-8 alkyl group such as an optionally substituted phenyloxymethyl, phenyloxyethyl, 1-naphth
- Alk 5 When Alk 5 is present in or as a substituent it may be for example a —CH 2 —, —CH(CH 3 )—, —C(CH 3 ) 2 —, —CH 2 CH 2 —, —CH 2 CH 2 CH 2 —, —CH(CH 3 )CH 2 —, —CH 2 CH 2 CH 2 CH 2 —, —CH 2 CH(CH 3 )CH 2 —, —CH(CH 3 )CH 2 CH 2 —, —C(CH 3 ) 2 CH 2 —, —CH ⁇ CH—, —CH ⁇ CHCH 2 —, —CH 2 CH ⁇ CH—, —CH ⁇ CHCH 2 CH 2 —, —CH 2 CH ⁇ CHCH 2 —, —C ⁇ C—, —C ⁇ CCH 2 —, —CH 2 C ⁇ C—, —C ⁇ CCH 2 CH 2 —, —CH 2 C ⁇ CCH 2 CH 2 —, —CH 2 C ⁇ CCH 2
- Aryl or heteroaryl groups represented by the groups R 10a or R 11 include mono- or bicyclic optionally substituted C 6-12 aromatic or C 1-9 heteroaromatic groups as described above for the group Cy 1 .
- the aromatic and heteroaromatic groups may be attached to the group Cy 1 in compounds of formula (1) by any carbon atom or heteroatom, e.g. nitrogen atom, as appropriate.
- each may be for example an optionally substituted pyrrolidinyl, imidazolidinyl, pyrazolidinyl, piperazinyl, morpholinyl, thiomorpholinyl, piperidinyl or thiazolidinyl group.
- Het may represent, for example, an optionally substituted cyclopentyl or cyclohexyl group.
- Optional substituents which may be present on —NHet 1 include those substituents described above when Cy 1 is a heterocycloaliphatic group.
- Particularly useful atoms or groups represented by R 10 include fluorine, chlorine, bromine or iodine atoms, or C 1-6 alkyl, e.g. methyl, ethyl, n-propyl, isopropyl, n-butyl or tert-butyl, optionally substituted phenyl, pyridyl, pyrimidinyl, pyrrolyl, furyl, thiazolyl, or thienyl, C 1-6 hydroxyalkyl, e.g. hydroxymethyl or hydroxyethyl, carboxyC 1-6 alkyl, e.g. carboxyethyl, C 1-6 alkylthio, e.g.
- methylthio or ethylthio carboxyC 1-6 alkylthio, e.g. carboxymethylthio, 2-carboxyethylthio or 3-carboxy-propylthio, C 1-6 alkoxy, e.g. methoxy or ethoxy, hydroxyC 1-6 alkoxy, e.g. 2-hydroxyethoxy, optionally substituted phenoxy, pyridyloxy, thiazolyoxy, phenylthio or pyridylthio, C 3-7 cycloalkyl, e.g. cyclobutyl or cyclopentyl, C 5-7 cycloalkoxy, e.g.
- cyclopentyloxy haloC 1-6 alkyl, e.g. trifluoromethyl, haloC 1-6 alkoxy, e.g. trifluoromethoxy, C 1-6 alkylamino, e.g. methylamino or ethylamino, —CH(CH 3 )NH 2 or —C(CH 3 ) 2 NH 2 , haloC 1-6 alkylamino, e.g. fluoroC 1-6 alkylamino, —CH(CF 3 )NH 2 or —C(CF 3 ) 2 NH 2 , amino (—NH 2 ), aminoC 1-6 alkyl, e.g.
- C 1-6 dialkylamino e.g. dimethylamino or diethylamino
- C 1-6 alkylaminoC 1-6 alkyl e.g. ethylaminoethyl
- C 1-6 dialkylaminoC 1-6 alkyl e.g. diethylaminoethyl
- aminoC 1-6 alkoxy e.g. aminoethoxy, C 1-6 alkylaminoC 1-6 alkoxy, e.g. methylaminoethoxy, C 1-6 dialkyl-aminoC 1-6 alkoxy, e.g.
- sulphonyl (—SO 3 H), C 1-6 alkylsulphonyl, e.g. methylsulphonyl, aminosulphonyl (—SO 2 NH 2 ), C 1-6 alkylaminosulphonyl, e.g. methylaminosulphonyl or ethylaminosulphonyl, C 1-6 dialkylaminosulphonyl, e.g. dimethylaminosulphonyl or diethylaminosulphonyl, phenylaminosulphonyl, carboxamido (—CONH 2 ), C 1-6 alkylaminocarbonyl, e.g.
- methylaminocarbonyl or ethylaminocarbonyl C 1-6 dialkylaminocarbonyl, e.g. dimethylaminocarbonyl or diethylaminocarbonyl, aminoC 1-6 alkylaminocarbonyl, e.g. aminoethylaminocarbonyl, C 1-6 dialkylaminoC 1-6 alkylaminocarbonyl, e.g. diethylaminoethylaminocarbonyl, aminocarbonylamino, C 1-6 alkylaminocarbonylamino, e.g.
- C 1-6 dialkylaminocarbonylamino e.g. dimethylaminocarbonylamino or diethylaminocarbonylamino
- C 1-6 alkylaminocabonylC 1-6 alkylamino e.g. methylaminocarbonylmethylamino, aminothiocarbonylamino, C 1-6 alkylaminothiocarbonylamino, e.g. methylaminothiocarbonylamino or ethylaminothiocarbonylamino
- C 1-6 dialkylaminothiocarbonylamino e.g.
- C 1-6 alkylaminothiocarbonylC 1-6 alkylamino e.g. ethylaminothiocarbonylmethylamino, —CONHC( ⁇ NH)NH 2
- C 1-6 alkylsulphonylamino e.g. methylsulphonylamino or ethylsulphonylamino
- C 1-6 dialkylsulphonylamino e.g.
- dimethylsulphonylamino or diethylsulphonylamino optionally substituted phenylsulphonylamino, aminosulphonylamino (—NHSO 2 NH 2 ), C 1-6 alkylaminosulphonylamino, e.g. methylaminosulphonylamino or ethylaminosulphonylamino, C 1-6 dialkylaminosulphonylamino, e.g.
- dimethylaminosulphonylamino or diethylaminosulphonylamino optionally substituted morpholinesulphonylamino or morpholinesulphonylC 1-6 alkylamino, optionally substituted phenylaminosulphonylamino, C 1-6 alkanoylamino, e.g. acetylamino, aminoC 1-6 alkanoylamino, e.g. aminoacetylamino, C 1-6 dialkylaminoC 1-6 alkanoylamino, e.g. dimethylaminoacetylamino, C 1-6 alkanoylaminoC 1-6 alkyl, e.g.
- acetylaminomethyl C 1-6 alkanoylaminoC 1-6 alkylamino, e.g. acetamidoethylamino, C 1-6 alkoxycarbonylamino, e.g. methoxycarbonylamino, ethoxycarbonylamino or tert-butoxycarbonylamino, or optionally substituted benzyloxy, pyridylmethoxy, thiazolylmethoxy, benzyloxycarbonylamino, benzyloxycarbonylaminoC 1-6 alkyl, e.g. benzyloxycarbonylaminoethyl, benzothio, pyridylmethylthio or thiazolylmethylthio groups.
- a further particularly useful group of substituents represented by R 10 when present on aromatic or heteroaromatic groups includes substituents of formula -L 6 Alk 5 R 10a where L 6 is preferably a covalent bond or an —O— or —S— atom or —N(R 3 )—, —C(O)—, —C(O)O—, —O—C(O)—, —N(R 3 )CO—, —CON(R 3 )— or —N(R 3 )S(O) 2 — group, Alk 5 is an optionally substituted C 1-6 alkyl group optionally interrupted by one or two —O— or —S— atoms or —N(R 12 )—, —C(O)—, —C(S)—, —CON(R 12 — or —N(R 12 )CO— groups, and R 10a is an optionally substituted Het group as herein defined or an optionally substituted heteroaromatic group as hereinbefore
- two R 10 substituents may be linked together to form a cyclic group such as a cyclic ether, e.g. a C 1-6 alkylenedioxy group such as methylenedioxy or ethylenedioxy.
- a cyclic ether e.g. a C 1-6 alkylenedioxy group such as methylenedioxy or ethylenedioxy.
- R 10 substituents are present, these need not necessarily be the same atoms and/or groups.
- the substituent(s) may be present at any available ring position on the aromatic or heteroaromatic group represented by the group Cy 1 .
- the substituted aromatic or heteroaromatic group represented by Ar in compounds of the invention may be any aromatic or heteroaromatic group as hereinbefore described for Cy 1 .
- Optional substituents which may be present include those R 10 atoms and groups as generally or particularly described in relation to Cy 1 aromatic and heteroaromatic groups.
- Suitable salts include pharmaceutically acceptable salts, for example acid addition salts derived from inorganic or organic acids, and salts derived from inorganic and organic bases.
- Acid addition salts include hydrochlorides, hydrobromides, hydroiodides, alkylsulfonates, e.g. methanesulfonates, ethanesulfonates, or isothionates, arylsulfonates, e.g. p-toluenesulfonates, besylates or napsylates, phosphates, sulphates, hydrogensulphates, acetates, trifluoroacetates, propionates, citrates, maleates, fumarates, malonates, succinates, lactates, oxalates, tartrates and benzoates.
- Salts derived from inorganic or organic bases include alkali metal salts such as sodium or potassium salts, alkaline earth metal salts such as magnesium or calcium salts, and organic amine salts such as morpholine, piperidine, dimethylamine or diethylamine salts.
- Particularly useful salts of compounds according to the invention include pharmaceutically acceptable salts, especially acid addition pharmaceutically acceptable salts.
- Y is —C(O)—. In another embodiment, Y is —S(O) 2 —.
- n is the integer 1.
- Alk 1 is preferably a —CH 2 CH 2 — chain or more especially is —CH 2 —.
- n is zero.
- Cy 1 optionally substituted cycloaliphatic groups include optionally substituted C 3-7 cycloalkyl groups, especially cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl groups. Cy 1 is in particular a cyclopropyl group.
- Each of these preferred Cy 1 cycloalkyl groups may be unsubstituted.
- substituents these may in particular include halogen atoms, especially fluorine, chlorine or bromine atoms, or C 1-6 alkyl groups, especially C 1-3 alkyl groups, most especially a methyl group, or haloC 1-6 alkyl groups, especially fluoroC 1-6 alkyl groups, most especially a —CF 3 group, or C 1-6 alkoxy groups, especially a methoxy, ethoxy, propoxy or isopropoxy group, or haloC 1-6 alkoxy groups, especially fluoroC 1-6 alkoxy groups, most especially a —OCF 3 group, or a cyano (—CN), esterified carboxyl, especially —CO 2 CH 3 or —CO 2 C(CH 3 ) 3 , nitro (—NO 2 ), amino (—NH 2 ), substituted amino, especially —NHCH 3 or —N(CH 3 ) 2 , —
- Particularly preferred Cy 1 aromatic groups include optionally substituted phenyl groups.
- Particularly preferred heteroaromatic groups include optionally substituted monocyclic heteroaromatic groups, especially optionally substituted five- or six-membered heteroaromatic groups containing one, two, three or four heteroatoms selected from oxygen, sulphur or nitrogen atoms.
- Particularly preferred optionally substituted monocyclic heteroaromatic groups include optionally substituted furyl, thienyl, pyrrolyl, oxazolyl, thiazolyl, pyridyl, pyrimidinyl and triazinyl groups.
- the heteroaromatic group may be an eight- to thirteen-membered bicyclic fused ring containing one or two oxygen, sulphur or nitrogen atoms.
- Particularly useful groups of this type include optionally substituted indolyl groups.
- Particularly preferred optional substituents which may be present on Cy 1 aromatic or heteroaromatic groups include one, two or three atoms or groups —R 10a or -L 6 Alk 5 (R 10a ) r as hereinbefore defined.
- Particularly useful optional substituents include halogen atoms, especially fluorine, chlorine or bromine atoms, or C 1-6 alkyl groups, especially C 1-3 alkyl groups, most especially a methyl group, or haloC 1-6 alkyl groups, especially fluoroC 1-6 alkyl groups, most especially a —CF 3 group, or C 1-6 alkoxy groups, especially a methoxy, ethoxy, propoxy or isopropoxy group, or haloC 1-6 alkoxy groups, especially fluoroC 1-6 alkoxy groups, most especially a —OCF 3 group, or a cyano (—CN), carboxyl (—CO 2 H), esterified carboxyl (—CO 2 Alk 6 ), especially —CO 2 CH
- Cy 1 aromatic or heteroaromatic groups include groups of formula -L 6 Alk 5 (R 10a ) r in which r is the integer 1 or 2, L 6 is a covalent bond or an —O— or —S— atom or a —N(R 3 )—, especially —NH— or —N(CH 3 )—, —C(O)—, —C(S)—, —C(O)O—, —OC(O)—, —N(R 3 )CO—, especially —NHCO—, or —CON(R 3 )—, especially —CONH—, group, Alk 5 is a C 1-6 alkylene chain, especially a —CH 2 —, —CH 2 CH 2 —, —CH 2 CH 2 CH 2 — or —CH 2 CH 2 CH 2 CH 2 — chain, and R 10a is a hydroxyl or substituted hydroxyl group, especially a —OCH 3
- R 10a is an optionally substituted heteroaromatic group, especially a five- or six-membered monocyclic heteroaromatic group containing one, two, three or four heteroatoms selected from oxygen, sulphur or nitrogen atoms, such as optionally substituted pyrrolyl, furyl, thienyl, imidazolyl, triazolyl, pyridyl, pyrimidinyl, triazinyl, pyridazinyl, or pyrazinyl group.
- Particularly preferred optional substituents on the -Het groups just described include hydroxyl (—OH) and carboxyl (—CO 2 H) groups or those preferred optional substituents just described in relation to the group Cy 1 , especially when Cy 1 is a cycloalkyl group.
- Cy 1 is an optionally substituted phenyl group, especially a phenyl group optionally substituted by one, two or three substituents where at least one, and preferably two, substituents are located ortho to the bond joining Cy 1 to the remainder of the compound of formula (1).
- Particularly preferred ortho substituents include halogen atoms, especially fluorine or chlorine atoms, or C 1-3 alkyl groups, especially methyl, C 1-3 alkoxy groups, especially methoxy, haloC 1-3 alkyl groups, especially —CF 3 , haloC 1-3 alkoxy groups, especially —OCF 3 , or cyano (—CN), groups.
- a second or third optional substituent when present in a position other than the ortho positions of the ring Cy 1 may be preferably an atom or group —R 10a or -L 6 Alk 5 (R 10a ) r as herein generally and particularly described.
- the Cy 1 phenyl group may have a substituent para to the bond joining Cy 1 to the remainder of the compound of formula (1).
- Particular para substituents include those particularly preferred ortho substituents just described.
- the pare substituent may be present with other ortho or meta substituents as just mentioned.
- Cy 1 examples include halogen (especially fluoro or chloro) and C 1-4 alkyl (especially methyl).
- Cy 1 groups include phenyl, fluorophenyl, chlorophenyl, methylphenyl and cyclopropyl.
- Particularly preferred Ar aromatic groups in compounds of formula (1) include optionally substituted phenyl groups.
- Particularly preferred heteroaromatic groups include optionally substituted monocyclic heteroaromatic groups, especially optionally substituted five- or six-membered heteroaromatic groups containing one, two, three or four heteroatoms selected from oxygen, sulphur or nitrogen atoms.
- Particularly preferred optionally substituted monocyclic heteroaromatic groups include optionally substituted furyl, thienyl, pyrrolyl, oxazolyl, thiazolyl, pyridyl, pyrimidinyl and triazinyl groups.
- Particularly preferred optional substituents which may be present on Ar aromatic or heteroaromatic groups include atoms or groups —R 10a or -L 6 Alk 5 (R 10a ) r as hereinbefore defined.
- Particularly useful optional substituents include halogen atoms, especially fluorine, chlorine or bromine atoms, or C 1-6 alkyl groups, especially C 1-3 alkyl groups, most especially a methyl group, or haloC 1-6 alkyl groups, especially fluoroC 1-6 alkyl groups, most especially a —CF 3 group, or C 1-6 alkoxy groups, especially a methoxy, ethoxy, propoxy or isopropoxy group, or haloC 1-6 alkoxy groups, especially fluoroC 1-6 alkoxy groups, most especially a —OCF 3 group, or a cyano (—CN), esterified carboxyl, especially —CO 2 CH 3 or —CO 2 C(CH 3 ) 3 , nitro (—NO 2 ),
- Ar groups in compounds of formula (1) include phenyl and mono- or disubstituted phenyl groups in which each substituent is in particular a —R 10a or -L 6 Alk 5 (R 10a ) r atom or group as just defined and is especially a halogen atom or a C 1-3 alkyl, C 1-3 alkoxy or —CN group.
- Examples of specific substituents on Ar include halogen (especially fluoro or chloro), cyano and C 1-4 alkyl (especially methyl).
- Ar groups include phenyl, difluorophenyl, (chloro)(fluoro)phenyl, (fluoro)(methyl)phenyl, chlorophenyl, cyanophenyl and methylphenyl.
- Alk 2 when present in compounds of the invention include —CH 2 —, —CH 2 CH 2 —, —C(CH 3 ) 2 — and —CH(CH 3 )CH 2 —.
- Alk 2 is —CH 2 —.
- Alk 2 is —C(CH 3 ) 2 —.
- R 1 is methyl
- R 2 is hydrogen or methyl.
- R 3 is hydrogen or methyl. In one embodiment, R 2 and R 3 are both hydrogen. In another embodiment, R 2 and R 3 are both methyl.
- m may be selected to vary the ring size from a ring having, in addition to the nitrogen atom, a minimum of 3 carbon atoms up to 6 carbon atoms.
- Particularly advantageous rings are those wherein m is the integer 1 or 2.
- n is the integer 2. In another embodiment, m is the integer 1. In a further embodiment, m is the integer 3.
- p is the integer 1. In another embodiment, p is the integer 2.
- Each substituent R d may be present on any ring carbon atom. In one particular class of compounds of the invention one or two R d substituents are present.
- Suitable values of R d include —OH, -(Alk 2 )OH, -(Alk 2 )OR 1 , —NR 2 R 3 and -(Alk 2 )NR 2 R 3 .
- R d Detailed values of R d include —OH, —CH 2 OH, —C(CH 3 ) 2 OH, —CH 2 OCH 3 , —NH 2 , —N(CH 3 ) 2 and —CH 2 NH 2 .
- R d Representative values include —OH, -(Alk 2 )OH and -(Alk 2 )OR 1 .
- R d Illustrative values of R d include —OH, —CH 2 OH, —C(CH 3 ) 2 OH and —CH 2 OCH 3 .
- R d substituents include —OH, —CH 2 OH, —CH(CH 3 )OH and —C(CH 3 ) 2 OH groups.
- Particularly useful compounds of the invention include each of the compounds described in the Examples hereinafter, and the salts, solvates, hydrates and N-oxides thereof.
- Compounds according to the invention are potent and selective inhibitors of p38 kinases, including all isoforms and splice variants thereof. More specifically the compounds of the invention are inhibitors of p38 ⁇ , p38 ⁇ and p38 ⁇ 2. The ability of the compounds to act in this way may be simply determined by employing tests such as those described in the Examples hereinafter.
- the compounds of formula (1) are of use in modulating the activity of p38 kinases and in particular are of use in the prophylaxis and treatment of any p38 kinase mediated diseases or disorders in a human, or other mammal.
- the invention extends to such a use and to the use of the compounds for the manufacture of a medicament for treating such diseases or disorders. Further the invention extends to the administration to a human of an effective amount of a p38 inhibitor for treating any such disease or disorder.
- the invention also extends to the prophylaxis or treatment of any disease or disorder in which p38 kinase plays a role including conditions caused by excessive or unregulated pro-inflammatory cytokine production including for example excessive or unregulated TNF, IL-1, IL-6 and IL-8 production in a human, or other mammal.
- the invention extends to such a use and to the use of the compounds for the manufacture of a medicament for treating such cytokine-mediated diseases or disorders. Further the invention extends to the administration to a human of an effective amount of a p38 inhibitor for treating any such disease or disorder.
- cytokines including the cytokines TNF, IL-1, IL-6 and IL-8
- autoimmune diseases include without limitation autoimmune diseases, inflammatory diseases, destructive bone disorders, proliferative disorders, neurodegenerative disorders, viral diseases, allergies, infectious diseases, heart attacks, angiogenic disorders, reperfusion/ischemia in stroke, vascular hyperplasia, organ hypoxia, cardiac hypertrophy, thrombin-induced platelet aggregation and conditions associated with prostaglandin endoperoxidase synthetase-2 (COX-2).
- Autoimmune diseases which may be prevented or treated include but are not limited to rheumatoid arthritis, inflammatory bowel disease, ulcerative colitis, Crohn's disease, multiple sclerosis, diabetes, glomerulonephritis, systemic lupus erythematosus, scleroderma, chronic thyroiditis, Grave's disease, hemolytic anemia, autoimmune gastritis, autoimmune neutropenia, thrombocytopenia, chronic active hepatitis, myasthenia gravis, atopic dermatitis, graft vs host disease and psoriasis.
- the invention further extends to the particular autoimmune disease rheumatoid arthritis.
- Inflammatory diseases which may be prevented or treated include but are not limited to asthma, allergies, respiratory distress syndrome and acute or chronic pancreatitis.
- Destructive bone disorders which may be prevented or treated include but are not limited to osteoporosis, osteoarthritis and multiple myeloma-related bone disorder.
- Proliferative diseases which may be prevented or treated include but are not limited to acute or chronic myelogenous leukemia, Kaposi's sarcoma, metastatic melanoma and multiple myeloma.
- Neurodegenerative diseases which may be prevented or treated include but are not limited to Parkinson's disease, Alzheimer's disease, cerebral ischemias and neurodegenerative disease caused by traumatic injury.
- Viral diseases which may be prevented or treated include but are not limited to acute hepatitis infection (including hepatitis A, hepatitis B and hepatitis C), HIV infection and CMV retinitis.
- Infectious diseases which may be prevented or treated include but are not limited to septic shock, sepsis and Shigellosis.
- p38 inhibitors of this invention also exhibit inhibition of expression of inducible pro-inflammatory proteins such as prostaglandin endoperoxidase synthetase-2, otherwise known as cyclooxygenase-2 (COX-2), and are therefore of use in therapy.
- Pro-inflammatory mediators of the cyclooxygenase pathway derived from arachidonic acid are produced by inducible COX-2 enzyme. Regulation of COX-2 would regulate these pro-inflammatory mediators such as prostaglandins, which affect a wide variety of cells and are important and critical inflammatory mediators of a wide variety of disease states and conditions. In particular these inflammatory mediators have been implicated in pain, such as in the sensitization of pain receptors, or edema. Accordingly additional p38 mediated conditions which may be prevented or treated include edema, analgesia, fever and pain such as neuromuscular pain, headache, dental pain, arthritis pain and pain caused by cancer.
- compounds of the invention have utility in the prevention and treatment of diseases associated with cytokine production including but not limited to those diseases associated with TNF, IL-1, IL-6 and IL-8 production.
- TNF mediated diseases or conditions include for example rheumatoid arthritis, rheumatoid spondylitis, osteoarthritis, gouty arthritis and other arthritic conditions, sepsis, septic shock syndrome, adult respiratory distress syndrome, cerebral malaria, chronic pulmonary inflammatory disease, silicosis, pulmonary sarcoidosis, bone resorption disease, reperfusion injury, graft vs.
- viral infections such as HIV, CMV, influenza and herpes
- veterinary viral infections such as lentivirus infections, including but not limited to equine infectious anemia virus, caprine arthritis virus, visna virus or maedi virus; or retrovirus infections, including feline immunodeficiency virus, bovine immunodeficiency virus and canine immunodeficiency virus.
- viruses of the invention may also be used in the treatment of viral infections, where such viruses elicit TNF production in vivo or are sensitive to upregulation by TNF.
- viruses include those that produce TNF as a result of infection and those that are sensitive to inhibition, for instance as a result of decreased replication, directly or indirectly by the TNF inhibiting compounds of the invention.
- viruses include, but are not limited to, HIV-1, HIV-2 and HIV-3, Cytomegalovirus (CMV), Influenza, adenovirus and the Herpes group of viruses such as Herpes Zoster and Herpes Simplex.
- IL-1 mediated diseases or conditions include for example rheumatoid arthritis, osteoarthritis, psoriatic arthritis, traumatic arthritis, rubella arthritis, inflammatory bowel disease, stroke, endotoxemia and/or toxic shock syndrome, inflammatory reaction induced by endotoxin, diabetes, pancreatic ⁇ -cell disease, Alzheimer's disease, tuberculosis, atherosclerosis, muscle degeneration and cachexia.
- IL-8 mediated diseases and conditions include for example those characterized by massive neutrophil infiltration such as psoriasis, inflammatory bowel disease, asthma, cardiac, brain and renal reperfusion injury, adult respiratory distress syndrome, thrombosis and glomerulonephritis.
- massive neutrophil infiltration such as psoriasis, inflammatory bowel disease, asthma, cardiac, brain and renal reperfusion injury, adult respiratory distress syndrome, thrombosis and glomerulonephritis.
- the increased IL-8 production associated with each of these diseases is responsible for the chemotaxis of neutrophils into inflammatory sites. This is due to the unique property of IL-8 (in comparison to TNF, IL-1 and IL-6) of promoting neutrophil chemotaxis and activation. Therefore, inhibition of IL-8 production would lead to a direct reduction in neutrophil infiltration.
- both IL-6 and IL-8 are produced during rhinovirus (HRV) infections and contribute to the pathogenesis of the common cold and exacerbation of asthma associated with HRV infection [Turner et al., Clin. Infec. Dis., 1997, 26, 840; Grunberg et al., Am. J. Crit. Care Med., 1997, 155, 1362; Zhu et al., J. Clin. Invest., 1996, 97, 421]. It has also been demonstrated in vitro that infection of pulmonary epithelial cells (which represent the primary site of infection by HRV) with HRV results in production of IL-6 and IL-8 [Sabauste et al., J. Clin.
- p38 inhibitors of the invention may be used for the treatment or prophylaxis of the common cold or respiratory viral infection caused by human rhinovirus infection (HRV), other enteroviruses, coronavirus, influenza virus, parainfluenza virus, respiratory syncytial virus or adenovirus infection.
- HRV human rhinovirus infection
- the compounds according to the invention may be administered to a human or mammal as pharmaceutical compositions, and according to a further aspect of the invention we provide a pharmaceutical composition which comprises a compound of formula (1) together with one or more pharmaceutically acceptable carriers, excipients or diluents.
- compositions according to the invention may take a form suitable for oral, buccal, parenteral, nasal, topical, ophthalmic or rectal administration, or a form suitable for administration by inhalation or insufflation.
- the pharmaceutical compositions may take the form of, for example, tablets, lozenges or capsules prepared by conventional means with pharmaceutically acceptable excipients such as binding agents (e.g. pregelatinised maize starch, polyvinylpyrrolidone or hydroxypropyl methylcellulose); fillers (e.g. lactose, microcrystalline cellulose or calcium hydrogenphosphate); lubricants (e.g. magnesium stearate, talc or silica); disintegrants (e.g. potato starch or sodium glycollate); or wetting agents (e.g. sodium lauryl sulphate).
- binding agents e.g. pregelatinised maize starch, polyvinylpyrrolidone or hydroxypropyl methylcellulose
- fillers e.g. lactose, microcrystalline cellulose or calcium hydrogenphosphate
- lubricants e.g. magnesium stearate, talc or silica
- disintegrants e.g. potato starch or sodium glycollate
- Liquid preparations for oral administration may take the form of, for example, solutions, syrups or suspensions, or they may be presented as a dry product for constitution with water or other suitable vehicle before use.
- Such liquid preparations may be prepared by conventional means with pharmaceutically acceptable additives such as suspending agents, emulsifying agents, non-aqueous vehicles and preservatives.
- the preparations may also contain buffer salts, flavouring, colouring and sweetening agents as appropriate.
- Preparations for oral administration may be suitably formulated to give controlled release of the active compound.
- compositions may take the form of tablets or lozenges formulated in conventional manner.
- the compounds of formula (1) may be formulated for parenteral administration by injection, e.g. by bolus injection or infusion.
- Formulations for injection may be presented in unit dosage form, e.g. in glass ampoules or multi-dose containers, e.g. glass vials.
- the compositions for injection may take such forms as suspensions, solutions or emulsions in oily or aqueous vehicles, and may contain formulatory agents such as suspending, stabilising, preserving and/or dispersing agents.
- the active ingredient may be in powder form for constitution with a suitable vehicle, e.g. sterile pyrogen-free water, before use.
- the compounds of formula (1) may also be formulated as a depot preparation. Such long-acting formulations may be administered by implantation or by intramuscular injection.
- the compounds for use according to the present invention are conveniently delivered in the form of an aerosol spray presentation for pressurised packs or a nebuliser, with the use of suitable propellant, e.g. dichlorodifluoromethane, trichloro-fluoromethane, dichlorotetrafluoroethane, carbon dioxide or other suitable gas or mixture of gases.
- suitable propellant e.g. dichlorodifluoromethane, trichloro-fluoromethane, dichlorotetrafluoroethane, carbon dioxide or other suitable gas or mixture of gases.
- compositions may, if desired, be presented in a pack or dispenser device which may contain one or more unit dosage forms containing the active ingredient.
- the pack or dispensing device may be accompanied by instructions for administration.
- the compounds for use according to the present invention may be conveniently formulated in a suitable ointment containing the active component suspended or dissolved in one or more pharmaceutically acceptable carriers.
- Particular carriers include, for example, mineral oil, liquid petroleum, propylene glycol, polyoxyethylene, polyoxypropylene, emulsifying wax and water.
- the compounds for use according to the present invention may be formulated in a suitable lotion containing the active component suspended or dissolved in one or more pharmaceutically acceptable carriers.
- Particular carriers include, for example, mineral oil, sorbitan monostearate, polysorbate 60, cetyl esters wax, cetearyl alcohol, benzyl alcohol, 2-octyldodecanol and water.
- the compounds for use according to the present invention may be conveniently formulated as microionized suspensions in isotonic, pH adjusted sterile saline, either with or without a preservative such as a bactericidal or fungicidal agent, for example phenylmercuric nitrate, benzylalkonium chloride or chlorhexidine acetate.
- a preservative such as a bactericidal or fungicidal agent, for example phenylmercuric nitrate, benzylalkonium chloride or chlorhexidine acetate.
- a bactericidal or fungicidal agent for example phenylmercuric nitrate, benzylalkonium chloride or chlorhexidine acetate.
- ointment such as petrolatum.
- the compounds for use according to the present invention may be conveniently formulated as suppositories. These can be prepared by mixing the active component with a suitable non-irritating excipient which is solid at room temperature but liquid at rectal temperature and so will melt in the rectum to release the active component.
- suitable non-irritating excipient include for example cocoa butter, beeswax and polyethylene glycols.
- daily dosages may range from around 100 ng/kg to 100 mg/kg, e.g. around 0.01 mg/kg to 40 mg/kg body weight, for oral or buccal administration, from around 10 ng/kg to 50 mg/kg body weight for parenteral administration, and around 0.05 mg to around 1000 mg, e.g. around 0.5 mg to around 1000 mg, for nasal administration or administration by inhalation or insufflation.
- the compounds of the invention may be prepared by a number of processes as generally described below and more specifically in the Examples hereinafter.
- the symbols Ar, Cy 1 , Alk 1 , n, R d , p, m and Y when used in the formulae depicted are to be understood to represent those groups described above in relation to formula (1) unless otherwise indicated.
- reactive functional groups for example hydroxy, amino, thio or carboxy groups, where these are desired in the final product, to avoid their unwanted participation in the reactions.
- Conventional protecting groups may be used in accordance with standard practice [see, for example, Greene, T. W. in “Protective Groups in Organic Synthesis”, John Wiley and Sons, 1999].
- deprotection may be the final step in the synthesis of a compound of formula (1) and the processes according to the invention described hereinafter are to be understood to extend to such removal of protecting groups.
- a compound of formula (1) in which Y is a —C(O)— group may be prepared from a carboxylic acid of formula (2) or ester of formula (5) according to amide bond forming reactions well known to those skilled in the art.
- Such reactions are set forth in references such as March's Advanced Organic Chemistry (John Wiley and Sons 1992), Larock's Comprehensive Organic Transformations (VCH Publishers Inc., 1992) and Comprehensive Organic Functional Group Transformations , ed. Katritzky et al., volumes 1-8, 1984, and volumes 1-11, 1994 (Pergamon). Examples of such methods that may be employed to give compounds of formula (1a) are set out, but not limited to the reactions, in Scheme 1 and Scheme 2 below.
- amides of formula (1a) may be formed by reaction of a carboxylate salt of formula (2) [where M + is metal counterion such as a sodium or lithium ion or is alternatively an ammonium or trialkylammonium counterion] with an amine of formula (3) in the presence of a coupling reagent such as a carbodiimide, e.g. 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide (EDC) or N,N′-dicyclohexylcarbodiimide, optionally in the presence of a base such as an amine, e.g. triethylamine or N-methylmorpholine.
- a coupling reagent such as a carbodiimide, e.g. 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide (EDC) or N,N′-dicyclohexylcarbodiimide, optionally in the presence of
- a solvent such as an amide solvent, e.g. N,N-dimethyl-formamide (DMF), or an ether, e.g. a cyclic ether such as tetrahydrofuran or 1,4-dioxane, or a halogenated solvent such as dichloromethane, at around ambient temperature to 60° C.
- amide solvent e.g. N,N-dimethyl-formamide (DMF)
- an ether e.g. a cyclic ether such as tetrahydrofuran or 1,4-dioxane
- a halogenated solvent such as dichloromethane
- a pentafluorophenyl ester of formula (4) may be prepared by reaction of a carboxylic acid of formula (2) with pentafluorophenol in the presence of a coupling reagent such as 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide in a solvent such as an amide solvent, e.g. DMF, at around ambient temperature.
- a coupling reagent such as 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide
- a solvent such as an amide solvent, e.g. DMF
- Amides of formula (1a) can then be prepared by reaction of the pentafluorophenyl ester with amines of formula (3) in an organic solvent such as a halogenated hydrocarbon, e.g.
- the intermediate acids of formula (2) may be prepared by hydrolysis of esters of formula (5) using a base such as an alkali metal hydroxide, e.g. sodium hydroxide or lithium hydroxide, in water and a solvent such as tetrahydrofuran or an alcohol such as ethanol at a temperature from around ambient to reflux.
- a base such as an alkali metal hydroxide, e.g. sodium hydroxide or lithium hydroxide
- a solvent such as tetrahydrofuran or an alcohol such as ethanol at a temperature from around ambient to reflux.
- Amides of formula (1a) can also be prepared directly from esters of formula (5) by heating with an amine of formula (3) up to the reflux temperature of the amine optionally in the presence of a solvent such as 2-ethoxyethanol either at atmospheric pressure or under pressure in a sealed tube (Scheme 2).
- the intermediate esters of formula (5) may be prepared by the methods set out in Scheme 3 below. In the Scheme the preparation of an ethyl ester is specifically shown, but it will be appreciated that other esters may be obtained by simply varying the ester starting material and if appropriate any reaction conditions.
- a compound of formula (5a) or (5b) may be prepared by reaction of a compound of formula (6) or (7) with an amine ArNH 2 in the presence of a palladium catalyst.
- the reaction may be conveniently carried out in a solvent such as toluene at an elevated temperature, e.g. the reflux temperature, using a catalyst such as tris(dibenzylideneacetone)-dipalladium(0), a phosphine ligand such as 2,2′-bis(diphenylphosphino)-1,1′-binaphthyl, and a base such as caesium carbonate.
- Intermediates of formula (7) may be prepared by reaction of a compound of formula (8) with an alkylating agent of formula Cy 1 (Alk 1 ) n Z, where Z is a leaving group such as a halogen atom, e.g. a chlorine, bromine or iodine atom, or a sulphonyloxy group such as an alkylsulphonyloxy, e.g. trifluoromethylsulphonyloxy, or arylsulphonyloxy, e.g. phenylsulphonyloxy, group.
- Z is a leaving group such as a halogen atom, e.g. a chlorine, bromine or iodine atom, or a sulphonyloxy group such as an alkylsulphonyloxy, e.g. trifluoromethylsulphonyloxy, or arylsulphonyloxy, e.g. phenylsulphonyloxy,
- the reaction may be performed in the presence of a solvent, for example a substituted amide such as N,N-dimethylformamide, optionally in the presence of a base, for example an inorganic base such as sodium hydride, or an organic base such as an organic amine, e.g. a cyclic amine such as 1,5-diazabicyclo[4.3.0]non-5-ene, or a resin-bound organic amine such as resin-bound 2-tert-butylimino-2-diethylamino-1,3-dimethylperhydro-1,3,2-diaza-phosphorine (PS-BEMP), at an elevated temperature, for example 80 to 100° C.
- a solvent for example a substituted amide such as N,N-dimethylformamide
- a base for example an inorganic base such as sodium hydride, or an organic base such as an organic amine, e.g. a cyclic amine such as 1,5-diazabicyclo[4.3.0]n
- Intermediates of formula (6) may be prepared by the reaction of a compound of formula (8) with a boronic acid of formula Cy 1 B(OH) 2 in which Cy 1 is an aryl or heteroaryl group.
- the reaction may be performed in an organic solvent, for example a halogenated hydrocarbon such as dichloromethane or dichloroethane, in the presence of a copper reagent, for example a copper(I) salt such as CuI, or for example a copper(II) reagent such as copper(II) acetate, optionally in the presence of an oxidant, for example 2,2,6,6-tetramethylpiperidine-1-oxide or pyridine-N-oxide, optionally in the presence of a base, for example an organic amine such as an alkylamine, e.g.
- the reactions just described may be carried out in the reverse order so that the amination using ArNH 2 is performed first with the intermediate of formula (8) followed by alkylation/arylation to yield the compound of formula (5). It may be necessary to protect the nitrogen function of compounds of formula (8) during the course of these reactions. Such protection may be achieved by O-alkylation with an alkyl halide, e.g. cyclopropylmethyl bromide, or an arylalkyl bromide, e.g. benzyl bromide, as shown in Scheme 4.
- an alkyl halide e.g. cyclopropylmethyl bromide
- an arylalkyl bromide e.g. benzyl bromide
- the O-alkylation reaction may be performed in an organic solvent such as DMF in the presence of a base, for example an inorganic base such as Cs 2 CO 3 or an organic base such as an amine, e.g. a cyclic amine such as 1,5-diazabicyclo[4.3.0]non-5-ene, at an elevated temperature, e.g. 80 to 100° C., to give a compound of formula (13).
- Reaction of the protected compound (13) with ArNH 2 under palladium catalysis can then be performed as previously described to give a compound of formula (14). Deprotection can then be achieved by treating a solution of this compound in an alcohol, e.g.
- Intermediate pyridinones of formula (8) may be prepared from pyridine N-oxides of formula (9) by sequential reaction with an anhydride, for example acetic anhydride, at an elevated temperature, for example the reflux temperature, followed by reaction with an inorganic base, for example a carbonate such as aqueous potassium carbonate, in a solvent such as an ether, for example a cyclic ether, e.g. tetrahydrofuran, at around ambient temperature.
- anhydride for example acetic anhydride
- an inorganic base for example a carbonate such as aqueous potassium carbonate
- a solvent such as an ether
- a cyclic ether e.g. tetrahydrofuran
- Pyridine N-oxides of formula (9) may be formed by oxidation of pyridines of formula (10) using an oxidising agent such as hydrogen peroxide in the presence of an acid such as acetic acid, at an elevated temperature, for example around 70° C. to 80° C., or alternatively by reaction with a peracid such as peracetic acid or m-chloroperoxybenzoic acid in a solvent such as a halogenated hydrocarbon, e.g. dichloromethane, or an alcohol, e.g. tert-butanol, at a temperature from the ambient temperature to the reflux temperature.
- an oxidising agent such as hydrogen peroxide in the presence of an acid such as acetic acid, at an elevated temperature, for example around 70° C. to 80° C.
- a peracid such as peracetic acid or m-chloroperoxybenzoic acid
- a solvent such as a halogenated hydrocarbon, e.g. dichloromethane,
- a bromide of formula (10) may be prepared by treatment of an aryl amine of formula (11) with an alkyl nitrite, for example tert-butyl nitrite, and a copper salt, for example copper(II) bromide, in the presence of a solvent, for example a nitrile such as acetonitrile, at a temperature from about 0° to around 65° C.
- a solvent for example a nitrile such as acetonitrile
- Amines of formula (11) may be formed from 2-halopyridine-3-carbonitriles of formula (12) by reaction with a reagent such as ethyl 2-mercaptoacetate.
- the reaction may be performed in the presence of a solvent such as a substituted amide, for example N,N-dimethylformamide, or an ether, e.g. a cyclic ether such as tetrahydrofuran, or an alcohol such as ethanol, in the presence of a base, for example an inorganic base such as sodium carbonate or a hydride, e.g.
- esters of formula (5a) may be prepared by the reactions set out in Scheme 5.
- R 20 represents an ester or nitrile and LG represents a leaving group such as a halogen atom, e.g. chlorine or bromine, or a sulfonyloxy group such as an alkylsulfonyloxy group, e.g. trifluoromethylsulfonyloxy, or an arylsulfonyloxy group, e.g. p-toluenesulfonyloxy.
- a leaving group such as a halogen atom, e.g. chlorine or bromine
- a sulfonyloxy group such as an alkylsulfonyloxy group, e.g. trifluoromethylsulfonyloxy, or an arylsulfonyloxy group, e.g. p-toluenesulfonyloxy.
- a compound of formula (17) or (18), where Rx is an optionally substituted alkyl group, e.g. methyl, and W is a hydrogen atom, metal ion or amine salt may be reacted with a thioamide of formula (19).
- the reaction may be performed in the presence of a base.
- Appropriate bases may include, but are not limited to, lithium bases such as n-butyl- or tert-butyllithium or lithium diisopropylamide (LDA), silazanes, e.g.
- lithium hexamethyldisilazane LiHMDS
- sodium hexamethyldisilazane NaHMDS
- carbonates e.g. potassium carbonate
- alkoxides e.g. sodium ethoxide, sodium methoxide or potassium tert-butoxide
- hydroxides e.g. NaOH
- hydrides e.g. sodium hydride
- organic amines e.g. triethylamine or diisopropylethylamine or a cyclic amine such as N-methylmorpholine or pyridine.
- the reaction may be performed in an organic solvent such as an amide, e.g.
- a substituted amide such as N,N-dimethylformamide
- an ether e.g. a cyclic ether such as tetrahydrofuran or 1,4-dioxane
- an alcohol e.g. methanol, ethanol or propanol, or acetonitrile
- the reaction is achieved using an alkoxide base, especially sodium ethoxide or sodium methoxide, in an alcoholic solvent, especially ethanol, at reflux temperature.
- Intermediates of formula (17), where not commercially available may be prepared using standard methodology (see, for example, Mir Hedayatullah, J. Heterocyclic Chem., 1981, 18, 339).
- intermediates of formula (18), where not commercially available may be prepared using standard methodology. For example, they may be prepared in situ by reaction of an acetate, e.g. ethyl acetate, with a base such as sodium methoxide followed by addition of a formate, e.g. methyl formate.
- intermediates of formula (19) may be prepared using methods known to those skilled in the art (see, for example, Adhikari et al., Aust. J. Chem., 1999, 52, 63-67).
- an isothiocyanate of formula Cy 1 NCS may be reacted with acetonitrile in the presence of a base, e.g. NaHMDS, in a suitable solvent, e.g. tetrahydrofuran, optionally at a low temperature, e.g. around ⁇ 78° C.
- a base e.g. NaHMDS
- a suitable solvent e.g. tetrahydrofuran
- the intermediate of formula (19) may be prepared in situ, for example using the methods as described herein, followed by subsequent addition of a compound of formula (17) or (18).
- an intermediate of formula (20) may be formed. If desired the intermediate may be isolated at the end of step (A) and subsequently reacted with intermediate (21) to form the desired amine (22). In some instances, however, it may advantageous not to isolate the intermediate of formula (20) and reaction (B) may be carried out directly with the reaction mixture of step (A).
- step (A) may be used in the next stage or they may be purified, for example by crystallisation, to yield an isolated intermediate, such as a compound of formula (20).
- an intermediate of formula (21) may then be added to the reaction mixture or to the crude solids or purified product from step (A) in a suitable solvent.
- suitable solvents include, but are not limited to, amides, e.g. a substituted amide such as N,N-dimethylformamide, alcohols, e.g. ethanol, methanol or isopropyl alcohol, ethers, e.g. a cyclic ether such as tetrahydrofuran or 1,4-dioxane, and acetonitrile.
- the reaction may be performed at a temperature from ambient up to the reflux temperature.
- an intermediate of formula (24) may be observed or even isolated, depending upon the nature of the group R 20 .
- the intermediate of formula (24) may be converted to a compound of formula (22) using the methods described above.
- a base in order for the reaction to proceed to completion.
- Appropriate bases include carbonates, e.g. caesium or potassium carbonate, alkoxides, e.g. potassium tert-butoxide, hydrides, e.g. sodium hydride, or organic amines, e.g. triethylamine or diisopropylethylamine or cyclic amines such as N-methylmorpholine or pyridine.
- Amines of formula (22) can be converted to bromides of formula (23) by standard methods such as for example by the Sandmeyer reaction as previously described for compounds of formula (11).
- Compounds of formula (5a) can then be prepared from these bromides by the palladium-catalysed amination reactions already described.
- intermediates of formula (21), where not commercially available, may be prepared using standard methods known to those skilled in the art.
- alcohol groups may be converted into leaving groups, such as halogen atoms or sulfonyloxy groups, using conditions known to the skilled artisan.
- an alcohol may be reacted with thionyl chloride in a halogenated hydrocarbon, e.g., dichloromethane, to yield the corresponding chloride.
- a base e.g. triethylamine, may also be used in the reaction.
- This reaction may be performed by hydrolysis of the nitrile (23a) with a base such as an alkali metal hydroxide, e.g. a 2M aqueous solution of sodium hydroxide in an alcoholic solvent such as methanol or ethanol at reflux.
- a base such as an alkali metal hydroxide, e.g. a 2M aqueous solution of sodium hydroxide in an alcoholic solvent such as methanol or ethanol at reflux.
- intermediates such as intermediates (17), (18), (19) or (21), if not available commercially, may also be prepared by methods known to those skilled in the art following procedures set forth in references such as Rodd's Chemistry of Carbon Compounds , volumes 1-15 and Supplementals (Elsevier Science Publishers, 1989), Fieser and Fieser's Reagents for Organic Synthesis , volumes 1-19 (John Wiley and Sons, 1999), Comprehensive Heterocyclic Chemistry , ed. Katritzky et al., volumes 1-8, 1984, and volumes 1-11, 1994 (Pergamon), Comprehensive Organic Functional Group Transformations , ed.
- amides of formula (1a) may be prepared by the reactions detailed in Scheme 6 below.
- acids of formula (25) or (25a) may be converted to amides of formula (27) by reaction with amines of formula (3) in the presence of coupling reagents in the same way as previously described for the conversion of compounds (2) to amides of formula (1a).
- the carboxylic acids may be converted to acid chlorides of formula (26) by reaction with a chlorinating agent such as oxalyl chloride optionally in the presence of a catalytic amount of DMF in a solvent such as a halogenated hydrocarbon, e.g. dichloromethane, or an ether, e.g.
- a cyclic ether such as tetrahydrofuran, at around ambient temperature; or with a chlorinating agent such as thionyl chloride, typically in a solvent such as toluene, at the reflux temperature.
- the resultant acid chlorides may then be reacted with amines of formula (3) in a solvent such as a halogenated hydrocarbon, e.g. dichloromethane, in the presence of an amine base such as triethylamine at around ambient temperature to give amides of formula (27).
- Amides of formula (1a) may then be prepared from amides of formula (27) using a palladium-catalysed arylation procedure previously described in Scheme 1.
- R d substituents may be present.
- Conventional protecting groups may be used in accordance with standard practice [see, for example, Greene, T. W. in “Protective Groups in Organic Synthesis”, John Wiley and Sons, 1999].
- deprotection may be the final step in the synthesis of a compound of formula (1a) and the processes according to the invention described hereinafter are to be understood to extend to such removal of protecting groups.
- a compound of formula (1) in which Y is an —S(O) 2 — group may be prepared by the route set out in Scheme 7.
- a compound of formula (29) can be obtained by reaction of a compound of formula (28) with a metal amide base such as sodium bis(trimethylsilyl)amide in a solvent such as an ether, e.g. a cyclic ether such as tetrahydrofuran, at a temperature of around 0° C. and then adding di-tert-butyl dicarbonate in a solvent such as tetrahydrofuran and stirring at ambient temperature.
- a compound of formula (1) can then be prepared by the following reaction sequence.
- a compound of formula (29) is treated with a base such as an alkyl lithium, e.g. n-butyllithium, in a solvent such as an ether, e.g.
- a cyclic ether such as tetrahydrofuran
- Sulfur dioxide gas is bubbled through the reaction mixture before allowing the reaction to warm to room temperature.
- Solvents are removed in vacuo and the crude material dissolved in a solvent such as a halogenated hydrocarbon, e.g. dichloromethane, and the mixture treated with a chlorinating reagent such as N-chlorosuccinimide at around ambient temperature.
- a sulphonamide of formula (1) can then be prepared by treating a compound of formula (30) with an acid, e.g.
- a mineral acid such as HCl or an organic acid such as trifluoroacetic acid
- a solvent such as a halogenated hydrocarbon, e.g. dichloromethane.
- Intermediates of formula (28) may be obtained by decarboxylation of compounds of formula (2) with an acid such as a mineral acid, e.g. HCl, in a solvent such as an ether, e.g. a cyclic ether such as tetrahydrofuran or 1,4-dioxane, at a temperature from 50° C. up to the reflux temperature.
- aromatic halogen substituents in the compounds may be subjected to halogen-metal exchange with a base, for example a lithium base such as n-butyl- or tert-butyllithium, optionally at a low temperature, e.g. around ⁇ 78° C., in a solvent such as tetrahydrofuran and then quenched with an electrophile to introduce a desired substituent.
- a base for example a lithium base such as n-butyl- or tert-butyllithium
- a solvent such as tetrahydrofuran
- a formyl group may be introduced by using N,N-dimethylformamide as the electrophile
- a thiomethyl group may be introduced by using dimethyldisulphide as the electrophile
- an alcohol group may be introduced by using an aldehyde as the electrophile
- an acid may be introduced by using carbon dioxide as the electrophile.
- Aromatic acids of formula ArCO 2 H may also be generated by quenching Grignard reagents of formula ArMgHal with carbon dioxide.
- Aromatic acids of formula ArCO 2 H generated by this method and acid-containing compounds in general may be converted to activated derivatives, e.g. acid halides, by reaction with a halogenating agent such as a thionyl halide, e.g. thionyl chloride, a phosphorus trihalide such as phosphorus trichloride, or a phosphorus pentahalide such as phosphorus pentachloride, optionally in an inert solvent such as an aromatic hydrocarbon, e.g. toluene, or a chlorinated hydrocarbon, e.g. dichloromethane, at a temperature from about 0° C.
- a halogenating agent such as a thionyl halide, e.g. thionyl chloride, a phosphorus trihalide such as phosphorus trichloride, or a phosphorus pentahalide such as phosphorus pentachloride
- Ester groups such as —CO 2 Alk 6 and —CO 2 R 4 in the compound of formula (1) and intermediates thereto may be converted to the corresponding acid [—CO 2 H] by acid- or base-catalysed hydrolysis depending on the nature of the group Alk 6 or R 4 .
- Acid- or -base-catalysed hydrolysis may be achieved for example by treatment with an organic or inorganic acid, e.g. trifluoroacetic acid, in an organic solvent, e.g. dichloromethane, or a mineral acid such as hydrochloric acid in a solvent such as 1,4-dioxane, or an alkali metal hydroxide, e.g. lithium hydroxide, in an aqueous alcohol, e.g. aqueous methanol.
- an organic or inorganic acid e.g. trifluoroacetic acid
- an organic solvent e.g. dichloromethane
- a mineral acid such as hydrochloric acid
- —OR 6 [where R 6 represents an alkyl group such as methyl] in compounds of formula (1) and intermediates thereto may be cleaved to the corresponding alcohol —OH by reaction with boron tribromide in a solvent such as a halogenated hydrocarbon, e.g. dichloromethane, at a low temperature, e.g. around ⁇ 78° C.
- a solvent such as a halogenated hydrocarbon, e.g. dichloromethane
- Alcohol [—OH] groups may also be obtained by hydrogenation of a corresponding —OCH 2 R 31 group (where R 31 is an aryl group) using a metal catalyst, for example palladium, on a support such as carbon in a solvent such as ethanol in the presence of ammonium formate, cyclohexadiene or hydrogen, from around ambient to the reflux temperature.
- —OH groups may be generated from the corresponding ester [e.g. —CO 2 Alk 6 ] or aldehyde [—CHO] by reduction, using for example a complex metal hydride such as lithium aluminium hydride or sodium borohydride in a solvent such as methanol.
- alcohol [—OH] groups in the compounds may be converted to a corresponding —OR 6 group by coupling with a reagent R 6 OH in a solvent such as tetrahydrofuran in the presence of a phosphine, e.g. triphenylphosphine, and an activator such as diethyl, diisopropyl or dimethyl azodicarboxylate.
- a phosphine e.g. triphenylphosphine
- an activator such as diethyl, diisopropyl or dimethyl azodicarboxylate.
- Aminosulphonylamino [—NHSO 2 NH 2 ] groups in the compounds may be obtained, in another example, by reaction of a corresponding amine [—NH 2 ] with sulphamide in the presence of an organic base such as pyridine at an elevated temperature, e.g. the reflux temperature.
- compounds containing a —NHCSR 7 or —CSNHR 7 group may be prepared by treating a corresponding compound containing a —NHCOR 7 or —CONHR 7 group with a thiation reagent, such as Lawesson's Reagent or P 2 S 5 , in an anhydrous solvent, for example a cyclic ether such as tetrahydrofuran, at an elevated temperature such as the reflux temperature.
- a thiation reagent such as Lawesson's Reagent or P 2 S 5
- amine [—NH 2 ] groups may be alkylated using a reductive alkylation process employing an aldehyde and a reducing agent.
- Suitable reducing agents include borohydrides, for example sodium triacetoxyborohyride or sodium cyanoborohydride.
- the reduction may be carried out in a solvent such as a halogenated hydrocarbon, e.g. dichloromethane, a ketone such as acetone, or an alcohol, e.g. ethanol, where necessary in the presence of an acid such as acetic acid at around ambient temperature.
- the amine and aldehyde may be initially reacted in a solvent such as an aromatic hydrocarbon, e.g. toluene, and then subjected to hydrogenation in the presence of a metal catalyst, for example palladium, on a support such as carbon, in a solvent such as an alcohol, e.g. ethanol.
- amine [—NH 2 ] groups in compounds of formula (1) and intermediates thereto may be obtained by hydrolysis from a corresponding imide by reaction with hydrazine in a solvent such as an alcohol, e.g. ethanol, at ambient temperature.
- a nitro [—NO 2 ] group may be reduced to an amine [—NH 2 ], for example by catalytic hydrogenation using for example hydrogen in the presence of a metal catalyst, for example palladium, on a support such as carbon in a solvent such as an ether, e.g. tetrahydrofuran, or an alcohol, e.g. methanol, or by chemical reduction using for example a metal, e.g. tin or iron, in the presence of an acid such as hydrochloric acid.
- a metal catalyst for example palladium
- amine [—CH 2 NH 2 ] groups in compounds of formula (1) and intermediates thereto may be obtained by reduction of nitriles [—CN], for example by catalytic hydrogenation using for example hydrogen in the presence of a metal catalyst, for example palladium on a support such as carbon, or Raney® nickel, in a solvent such as an ether, e.g. a cyclic ether such as tetrahydrofuran, or an alcohol, e.g. methanol or ethanol, optionally in the presence of ammonia solution at a temperature from ambient to the reflux temperature, or by chemical reduction using for example a metal hydride, e.g. lithium aluminium hydride, in a solvent such as an ether, e.g. a cyclic ether such as tetrahydrofuran, at a temperature from 0° C. to the reflux temperature.
- a metal catalyst for example palladium on a support such as carbon, or Raney® nickel
- a solvent such as an
- sulphur atoms in the compounds may be oxidised to the corresponding sulphoxide or sulphone using an oxidising agent such as a peroxyacid, e.g. 3-chloroperoxybenzoic acid, in an inert solvent such as a halogenated hydrocarbon, e.g. dichloromethane, at around ambient temperature.
- an oxidising agent such as a peroxyacid, e.g. 3-chloroperoxybenzoic acid
- an inert solvent such as a halogenated hydrocarbon, e.g. dichloromethane
- N-oxides of compounds of formula (1) may in general be prepared for example by oxidation of the corresponding nitrogen base as described above in relation to the preparation of intermediates of formula (5).
- Salts of compounds of formula (1) may be prepared by reaction of compounds of formula (1) with an appropriate base in a suitable solvent or mixture of solvents, e.g. an organic solvent such as an ether, e.g. diethyl ether, or an alcohol, e.g. ethanol, using conventional procedures.
- a suitable solvent or mixture of solvents e.g. an organic solvent such as an ether, e.g. diethyl ether, or an alcohol, e.g. ethanol, using conventional procedures.
- diastereomeric derivatives e.g. salts
- a mixture of enantiomers of formula (1) e.g. a racemate
- an appropriate chiral compound e.g. a chiral base
- the diastereomers may then be separated by any convenient means, for example by crystallisation, and the desired enantiomer recovered, e.g. by treatment with an acid in the instance where the diastereomer is a salt.
- a racemate of formula (1) may be separated using chiral High Performance Liquid Chromatography.
- a particular enantiomer may be obtained by using an appropriate chiral intermediate in one of the processes described above.
- a particular enantiomer may be obtained by performing an enantiomer-specific enzymatic biotransformation, e.g. an ester hydrolysis using an esterase, and then purifying only the enantiomerically pure hydrolysed acid from the unreacted ester antipode.
- NMM N-methylmorpholine
- EtOAc ethyl acetate
- DIPEA diisopropylethylamine
- EtOH ethanol
- DMSO dimethylsulphoxide
- iPr isopropyl
- MCPBA 3-chloroperoxybenzoicacid
- NBS N-bromosuccinimide
- FMOC 9-fluorenylmethoxycarbonyl
- r.t. room temperature
- DMF N,N-dimethylformamide
- dba dibenzylideneacetone
- Tris(dibenzylideneacetone)dipalladium(0) (1.21 g, 1.32 mmol) was added to a mixture of Intermediate 5 (10 g, 26.4 mmol), caesium carbonate (12.05 g, 37.0 mmol), 2,4-difluoroaniline (4.1 g, 3.23 mL, 31.7 mmol) and BINAP (1.65 g, 2.64 mmol) in anhydrous toluene (80 mL) and the reaction heated to reflux under nitrogen for 4 days. The reaction was cooled, partitioned between DCM and water and the organic phase dried (MgSO 4 ) and evaporated in vacuo.
- the Intermediate esters 14-26 were prepared following a procedure similar to that described for Intermediate 13. Therefore to an oven dried reaction flask was added a magnetic stirrer, the appropriate substituted aniline (1.2 equiv.), anhydrous toluene, Intermediate 5 (1.0 equiv.), caesium carbonate (1.4 equiv.), tris(dibenzylideneacetone)dipalladium(0) (5 mol %) and BINAP (10 mol %). The reactions were heated to reflux under nitrogen and with magnetic stirring for 24-48 h. Each reaction was then diluted with DCM, washed with water, dried (MgSO 4 ) and concentrated in vacuo. The crude products were either purified on silica eluting with a gradient of EtOAc in DCM or alternatively by trituration with methanol or ethyl acetate to give the title compounds as solids.
- Acetonitrile (10 mL) was added to a solution of sodium bis(trimethylsilyl)amide (100 mL, 1.0M in THF, 100 mmol) in THF (50 mL) at ⁇ 78° C. to give a thick white precipitate.
- 2-Chlorophenyl isothiocyanate (7.72 g, 45.45 mmol) was added to give a brown solution. The mixture was allowed to warm to r.t. over 1 h then diluted with EtOH (50 mL). N,N-Dimethyluracil (6.4 g, 45 mmol) was added and the mixture heated at reflux for 24 h.
- n-Butyllithium (0.54 mL of a 2.5M solution in hexanes, 1.35 mmol) was added to a solution of Intermediate 61 (600 mg, 1.32 mmol) in THF (30 mL) at ⁇ 78° C. After 20 min, sulfur dioxide gas was bubbled through the solution for 5 min.
- the title compound was prepared from 3-hydroxyazetidine hydrochloride (110 mg, 1.05 mmol) and Intermediate 35 (200 mg, 0.35 mmol) with the addition of diisopropylethylamine (0.195 mL, 1.12 mmol) following the method of Example 28 to give the title compound as a white solid (64 mg).
- the title compound was prepared from 2-[(2S)pyrrolidin-2-yl]propan-2-ol (140 mg, 1.05 mmol) and Intermediate 35 (200 mg, 0.35 mmol) following the method of Example 28 to give the title compound as a pale yellow solid (140 mg).
- the title compound was prepared from 2-[(2R)-pyrrolidin-2-yl]propan-2-ol hydrochloride (165 mg, 1.05 mmol) and Intermediate 35 (200 mg, 0.35 mmol) with the addition of diisopropylethylamine (0.20 mL, 1.12 mmol) following the method of Example 28 to give the title compound as an off-white solid (89 mg).
- Examples 42-53 were all prepared from the appropriate pentafluorophenyl ester intermediate and amine starting materials following the method described for Example 41. Where necessary reactions were run in the presence of a tertiary amine base such as triethylamine to neutralise acid salts of the starting materials.
- a tertiary amine base such as triethylamine to neutralise acid salts of the starting materials.
- Example 68 (111 mg, 0.23 mmol), paraformaldehyde (70 mg, 0.56 mmol) and sodium cyanoborohydride (36 mg, 0.54 mmol) in MeOH (10 mL) were stirred at r.t. for 18 h.
- the reaction mixture was acidified using aq HCl (2N) and stirred for 20 min.
- the acidic mixture was neutralised with 10% aq. NaOH and extracted with DCM.
- the DCM extract was dried (Na 2 SO 4 ) and concentrated in vacuo.
- the crude product was purified by chromatography (silica, 2% MeOH in DCM) to give the title compound as an off-white solid (30 mg, 25%).
- Example 69 From Example 69 (168 mg, 0.37 mmol), paraformaldehyde (103 mg, 0.82 mmol) and sodium cyanoborohydride (52 mg, 0.82 mmol) by the method of Example 70 to give the title compound as an off-white solid (130 mg, 70%).
- Human p38 ⁇ incorporating an N-terminal (His)6 tag, was expressed in baculovirus-infected High-FiveTM cells (Invitrogen) according to the manufacturer's instructions.
- the cells were harvested 72 h post-infection and lysed in phosphate buffered saline (PBS) containing 1% (w/v) ⁇ -octylglucoside and Complete, EDTA-freeTM protease inhibitors (Roche Molecular Biochemicals).
- PBS phosphate buffered saline
- the lysate was centrifuged at 35000 ⁇ g for 30 min at 4° C. and the supernatant applied to a NiNTATM column (Qiagen).
- Bound protein was eluted by 150 mM imidazole in PBS (after a wash with 15 mM imidazole in PBS) and directly applied to a HiTrap Q ⁇ column (AP Biotech). Bound protein was eluted using a 20 column volume, 0 to 1M NaCl gradient. Fractions containing (His)6-p38 were aliquotted and stored at ⁇ 70° C. prior to their activation.
- E. coli BL21 pLysS expressing the constitutively activated form of human MKK6 fused with an N-terminal glutathione-S-transferase tag (GST-MKK6EE) were harvested by centrifugation and frozen at ⁇ 70° C.
- Cells were lysed by resuspension in 1/10th the culture volume of PBS containing Complete, EDTA-freeTM protease inhibitors followed by sonication on ice for 4 ⁇ 15 sec. Cell debris was removed by centrifugation at 35,000 ⁇ g and the resultant supernatant stored in aliquots at ⁇ 70° C.
- the inhibition of p38 catalysed phosphorylation of biotinylated MBP is measured using a DELFIA based format.
- the assay was performed in a buffer comprising 20 mM HEPES (pH 7.4), 5 mM MgCl 2 and 3 mM DTT.
- biotinylated MBP 2.5 ⁇ M was incubated at room temperature in a streptavidin-coated microtitre plate together with activated gst-p38 (10 nM) and ATP (1 ⁇ M) in the presence of a range of inhibitor concentrations (final concentration of DMSO is 2 percent). After fifteen minutes the reaction was terminated by the addition of EDTA (75 mM).
- microtitre plate was then washed with Tris buffered saline (TBS), prior to the addition of 100 ⁇ l of anti-phospho MBP antibody (mouse) together with europium-labeled anti-mouse IgG antibody. After one hour at room temperature the plate was again washed in TBS followed by the addition of Enhancement solution (PerkinElmer Wallac). Fluorescence measurements were performed after a further fifteen minutes at room temperature.
- TBS Tris buffered saline
- Enhancement solution PerkinElmer Wallac
- IC 50 values are determined from the plot of log 10 inhibitor concentration (x-axis) versus percentage inhibition of the fluorescence generated by a control sample in the absence of inhibitor (y-axis).
- PBMC Peripheral blood mononuclear cells
- Inhibitor stocks (20 mM) were kept as a frozen solution ( ⁇ 20° C.) in DMSO. Serial dilutions of inhibitors were performed in DMSO as 250-times concentrated stocks. Inhibitors were diluted 1 in 250 into tissue culture media, prewarmed to 37° C. and transferred to plates containing PBMC. PBMC and inhibitors were incubated together for 30 min prior to addition of LPS. Inhibitors used in whole blood assays were prepared according to a different regime. Using the same stock solution serial dilutions of inhibitors were performed in DMSO. Inhibitors were then diluted 1 in 500 straight into whole blood in a volume of 1 ⁇ l. Inhibitor was incubated with whole blood for 30 min prior to the addition of LPS.
- PBMC peripheral blood mononuclear cells
- PBMC peripheral blood mononuclear cells
- LPS E coli strain B5:055, Sigma, at a final concentration of 1 ⁇ g ml ⁇ 1
- TNF- ⁇ levels were measured from cell free supernatants by sandwich ELISA (BioSource #CHC1751).
- mice Male Lewis rats (180-200 g) are anaesthetised with Isofluor and injected i.v. with LPS* in a volume of 0.5 ml sterile saline. After 90 minutes blood is collected into EDTA tubes for preparation of plasma samples. Plasma is stored at ⁇ 70° C. prior to assay for TNF- ⁇ by commercial ELISA.
- Female Lewis rats (180-200 g) are anaesthetised with Isofluor and immunised i.d. at the base of the tail with 2 ⁇ 100 ⁇ l of emulsion containing 4 mg/ml bovine collagen II in 0.01M acetic acid and Freund's Incomplete Adjuvant at a ratio of 1:1.
- a polyarthritis develops with onset from about 13 days post sensitisation. The disease is mainly confined to the ankles and is quantified by plethysmometry. Results are expressed as change in paw volume over time.
- compounds of the invention have IC 50 values of around 1 ⁇ M and below.
- the compounds of the invention are clearly potent inhibitors of p38 kinase, especially p38 ⁇ kinase.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
- This invention relates to a series of thienopyridone derivatives, to compositions containing them, to processes for their preparation and to their use in medicine.
- Immune and inflammatory responses involve a variety of cell types with control and co-ordination of the various interactions occurring via both cell-cell contacts (e.g. integrin interactions with their receptors) and by way of intercellular signalling molecules. A large number of different signalling molecules are involved, including cytokines, lymphocytes, chemokines and growth factors.
- Cells respond to such intercellular signalling molecules by means of intracellular signalling mechanisms that include protein kinases, phosphatases and phospholipases. There are five classes of protein kinase of which the major ones are the tyrosine kinases and the serine/threonine kinases [Hunter, T., Methods in Enzymology (Protein Kinase Classification), p. 3, Hunter, T. and Sefton, B. M. eds., vol. 200, Academic Press, San Diego, 1991].
- One sub-class of serine/threonine kinases is the mitogen activating protein (MAP) kinases of which there are at least three families which differ in the sequence and size of the activation loop [Adams, J. L. et al., Progress in Medicinal Chemistry, pp. 1-60, King, F. D. and Oxford, A. W. eds., vol. 38, Elsevier Science, 2001]: (i) the extracellular regulated kinases (ERKs); (ii) the c-Jun NH2 terminal kinases or stress activated kinases (JNKs or SAP kinases); and (iii) the p38 kinases which have a threonine-glycine-tyrosine (TGY) activation motif. Both the JNKs and p38 MAP kinases are primarily activated by stress stimuli including, but not limited to, proinflammatory cytokines, e.g. tumour necrosis factor (TNF) and interleukin-1 (IL-1), ultraviolet light, endotoxin and chemical or osmotic shock.
- Four isoforms of p38 have been described (p38α/β/γ/δ). The human p38α enzyme was initially identified as a target of cytokine-suppressive anti-inflammatory drugs (CSAIDs) and the two isoenzymes found were initially termed CSAID binding protein-1 (CSBP-1) and CSBP-2 [Lee, J. C. et al., Nature (London), 1994, 372, 739-46]. CSBP-2 is now widely referred to as p38α and differs from CSBP-1 in an internal sequence of 25 amino acids as a result of differential splicing of two exons that are conserved in both mouse and human [McDonnell, P. C. et al., Genomics, 1995, 29, 301-2]. CSBP-1 and p38α are expressed ubiquitously and there is no difference between the two isoforms with respect to tissue distribution, activation profile, substrate preference or CSAID binding. A second isoform is p38β which has 70% identity with p38α. A second form of p38β termed p38β2 is also known and of the two this is believed to be the major form. p38α and p38β2 are expressed in many different tissues. However in monocytes and macrophages p38α is the predominant kinase activity [Lee, J. C., ibid; Jing, Y. et al., J. Biol. Chem., 1996, 271, 10531-34; Hale, K. K. et al., J. Immun., 1999, 162, 4246-52]. p38γ and p38δ (also termed SAP kinase-3 and SAP kinase-4 respectively) have ˜63% and ˜61% homology to p38α respectively. p38γ is predominantly expressed in skeletal muscle whilst p38δ is found in testes, pancreas, prostate, small intestine and in certain endocrine tissues.
- All p38 homologues and splice variants contain a 12 amino acid activation loop that includes a Thr-Gly-Tyr motif. Dual phosphorylation of both Thr-180 and Tyr-182 in the TGY motif by a dual specificity upstream kinase is essential for the activation of p38 and results in a >1000-fold increase in specific activity of these enzymes [Doza, Y. N. et al., FEBS Left., 1995, 364, 7095-8012]. This dual phosphorylation is effected by MKK6 and under certain conditions the related enzyme MKK3 [Enslen, H. et al., J. Biol. Chem., 1998, 273, 1741-48]. MKK3 and MKK6 belong to a family of enzymes termed MAPKK (mitogen activating protein kinase kinase) which are in turn activated by MAPKKK (mitogen activating kinase kinase kinase) otherwise known as MAP3K.
- Several MAP3Ks have been identified that are activated by a wide variety of stimuli including environmental stress, inflammatory cytokines and other factors. MEKK4/MTK1 (MAP or ERK kinase kinase/MAP three kinase-1), ASK1 (apoptosis stimulated kinase) and TAK1 (TGF-β-activated kinase) are some of the enzymes identified as upstream activators of MAPKKs. MEKK4/MTK1 is thought to be activated by several GADD-45-like genes that are induced in response to environmental stimuli and which eventually lead to p38 activation [Takekawa, M. and Saito, H., Cell, 1998, 95, 521-30]. TAK1 has been shown to activate MKK6 in response to transforming growth factor-β (TGF-β). TNF-stimulated activation of p38 is believed to be mediated by the recruitment of TRAF2 [TNF receptor associated factor] and the Fas adaptor protein, Daxx, which results in the activation of ASK1 and subsequently p38.
- Several substrates of p38 have been identified including other kinases [e.g. MAPK activated protein kinase 2/3/5 (MAPKAP 2/3/5), p38 regulated/activated protein kinase (PRAK), MAP kinase-interacting kinase 1/2 (MNK1/2), mitogen- and stress-activated protein kinase 1 (MSK1/RLPK) and ribosomal S6 kinase-B (RSK-B)]; transcription factors [e.g. activating transcription factor 2/6 (ATF2/6), monocyte-enhancer factor-2A/C (MEF2A/C), C/EBP homologous protein (CHOP), Elk1 and Sap-1a1]; and other substrates [e.g. cPLA2, p47phox].
- MAPKAP K2 is activated by p38 in response to environmental stress. Mice engineered to lack MAPKAP K2 do not produce TNF in response to lipopolysaccharide (LPS). Production of several other cytokines such as IL-1, IL-6, IFN-g and IL-10 is also partially inhibited [Kotlyarov, A. et al., Nature Cell Biol., 1999, 1, 94-7]. Further, MAPKAP K2 from embryonic stem cells from p38α null mice was not activated in response to stress and these cells did not produce IL-6 in response to IL-1 [Allen, M. et al., J. Exp. Med., 2000, 191, 859-69]. These results indicate that MAPKAP K2 is not only essential for TNF and IL-1 production but also for signalling induced by cytokines. In addition MAPKAP K2/3 phosphorylate and thus regulate heat shock proteins HSP 25 and HSP 27 which are involved in cytoskeletal reorganization.
- Several small molecule inhibitors of p38 have been reported which inhibit IL-1 and TNF synthesis in human monocytes at concentrations in the low μM range [Lee, J. C. et al., Int. J. Immunopharm., 1988, 10, 835] and exhibit activity in animal models which are refractory to cyclooxygenase inhibitors [Lee, J. C. et al., Annals N. Y. Acad. Sci., 1993, 696, 149]. In addition these small molecule inhibitors are known to decrease the synthesis of a wide variety of pro-inflammatory proteins including IL-6, IL-8, granulocyte/macrophage colony-stimulating factor (GM-CSF) and cyclooxygenase-2 (COX-2). TNF-induced phosphorylation and activation of cytosolic PLA2, TNF-induced expression of VCAM-1 on endothelial cells and IL-1 stimulated synthesis of collagenase and stromelysin are also inhibited by small molecule inhibitors of p38 [Cohen, P., Trends Cell Biol., 1997, 7, 353-61].
- A variety of cells including monocytes and macrophages produce TNF and IL-1. Excessive or unregulated TNF production is implicated in a number of disease states including Crohn's disease, ulcerative colitis, pyresis, rheumatoid arthritis, rheumatoid spondylitis, osteoarthritis, gouty arthritis and other arthritic conditions, toxic shock syndrome, endotoxic shock, sepsis, septic shock, gram negative sepsis, bone resorption diseases, reperfusion injury, graft vs. host reaction, allograft rejection, adult respiratory distress syndrome, chronic pulmonary inflammatory disease, silicosis, pulmonary sarcoidosis, cerebral malaria, scar tissue formation, keloid formation, fever and myalgias due to infection, such as influenza, cachexia secondary to acquired immune deficiency syndrome (AIDS), cachexia secondary to infection or malignancy, AIDS or AIDS related complex.
- Excessive or unregulated IL-1 production has been implicated in rheumatoid arthritis, osteoarthritis, traumatic arthritis, rubella arthritis, acute synovitis, psoriatic arthritis, cachexia, Reiter's syndrome, endotoxemia, toxic shock syndrome, tuberculosis, atherosclerosis, muscle degeneration, and other acute or chronic inflammatory diseases such as the inflammatory reaction induced by endotoxin or inflammatory bowel disease. In addition IL-1 has been linked to diabetes and pancreatic β cell destruction [Dinarello, C. A., J. Clinical Immunology, 1985, 5, 287-97].
- IL-8 is a chemotactic factor produced by various cell types including endothelial cells, mononuclear cells, fibroblasts and keratinocytes. IL-1, TNF and LPS all induce the production of IL-8 by endothelial cells. In vitro IL-8 has been shown to have a number of functions including being a chemoattractant for neutrophils, T-lymphocytes and basophils. IL-8 has also been shown to increase the surface expression of Mac-1 (CD11b/CD18) on neutrophils without de novo protein synthesis which may contribute to increased adhesion of neutrophils to vascular endothelial cells. Many diseases are characterised by massive neutrophil infiltration. Histamine release from basophils (in both atopic and normal individuals) is induced by IL-8 as is lysozomal enzyme release and respiratory burst from neutrophils.
- The central role of IL-1 and TNF together with other leukocyte derived cytokines as important and critical inflammatory mediators is well documented. The inhibition of these cytokines has been shown or would be expected to be of benefit in controlling, alleviating or reducing many of these disease states.
- The central position that p38 occupies within the cascade of signalling molecules mediating extracellular to intracellular signalling and its influence over not only IL-1, TNF and IL-8 production but also the synthesis and/or action of other pro-inflammatory proteins (e.g. IL-6, GM-CSF, COX-2, collagenase and stromelysin) make it an attractive target for inhibition by small molecule inhibitors with the expectation that such inhibition would be a highly effective mechanism for regulating the excessive and destructive activation of the immune system. Such an expectation is supported by the potent and diverse anti-inflammatory activities described for p38 kinase inhibitors [Adams, ibid; Badger et al., J. Pharm. Exp. Ther., 1996, 279, 1453-61; Griswold et al., Pharmacol. Comm., 1996, 7, 323-29].
- We have now found a group of compounds which are potent and selective inhibitors of p38 kinase (p38α, β, δ and γ) and the isoforms and splice variants thereof, especially p38α, p38β and p38β2. The compounds are thus of use in medicine, for example in the prophylaxis and treatment of immune or inflammatory disorders as described herein.
- Thus according to one aspect of the invention we provide a compound of formula (1):
wherein:
Y is a linking group —C(O)— or —S(O)2—;
n is zero or the integer 1;
m is the integer 1, 2, 3 or 4;
p is the integer 1, 2, 3 or 4;
Rd is an —OH, -(Alk2)OH (where Alk2 is a straight or branched C1-4 alkylene chain), —OR1 (where R1 is a straight or branched C1-6 alkyl group), -(Alk2)OR1, —NR2R3 (where R2 and R3 may be the same or different and is each independently a hydrogen atom or a straight or branched C1-6 alkyl group), -(Alk2)NR2R3 or straight or branched C1-6 alkyl group;
Alk1 is a straight or branched C1-4 alkylene chain;
Cy1 is an optionally substituted cycloaliphatic, aromatic or heteroaromatic group; and
Ar is an optionally substituted aromatic or heteroaromatic group;
and the salts, solvates, hydrates and N-oxides thereof. - It will be appreciated that compounds of formula (1) may have one or more chiral centres, and exist as enantiomers or diastereomers. The invention is to be understood to extend to all such enantiomers, diastereomers and mixtures thereof in any proportion, including racemates. Formula (1) and the formulae hereinafter are intended to represent all individual isomers and mixtures thereof, unless stated or shown otherwise. In addition, compounds of formula (1) may exist as tautomers, for example keto (CH2C═O)-enol (CH═CHOH) tautomers. Formula (1) and the formulae hereinafter are intended to represent all individual tautomers and mixtures thereof, unless stated otherwise.
- The following general terms as used herein in relation to compounds of the invention and intermediates thereto have the stated meaning below unless specifically defined otherwise.
- Thus as used herein the term “alkyl” whether present as a group or part of a group includes straight or branched C1-6 alkyl groups, for example C1-4 alkyl groups such as methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl or tert-butyl groups. Similarly, the terms “alkenyl” or “alkynyl” are intended to mean straight or branched C2-6 alkenyl or C2-6 alkynyl groups such as C2-4 alkenyl or C2-4 alkynyl groups. The optional substituents which may be present on these groups include one, two, three or more substituents where each substituent may be the same or different and is selected from halogen atoms, e.g. fluorine, chlorine, bromine or iodine atoms, or —OH, —CO2H, —CO2R4 [where R4 is an optionally substituted straight or branched C1-6 alkyl group, and is in particular a straight or branched C1-4 alkyl group], e.g. —CO2CH3 or —CO2C(CH3)3, —CONHR4, e.g. —CONHCH3, —CON(R4)2, e.g. —CON(CH3)2, —COR4, e.g. —COCH3, C1-6 alkoxy, e.g. methoxy or ethoxy, haloC1-6alkoxy, e.g. trifluoromethoxy or difluoromethoxy, thiol (—SH), —S(O)R4, e.g. —S(O)CH3, —S(O)2R4, e.g. —S(O)2CH3, C1-6 alkylthio, e.g. methylthio or ethylthio, amino, —NHR4, e.g. —NHCH3, or —N(R4)2, e.g. —N(CH3)2, groups. Where two R4 groups are present in any of the above substituents these may be the same or different.
- In addition when two R4 alkyl groups are present in any of the optional substituents just described these groups may be joined, together with the N atom to which they are attached, to form a heterocyclic ring. Such heterocyclic rings may be optionally interrupted by a further heteroatom or heteroatom-containing group selected from —O—, —S—, —N(R4)—, —C(O)— or —C(S)— groups. Particular examples of such heterocyclic rings include piperidinyl, pyrazolidinyl, morpholinyl, thiomorpholinyl, pyrrolidinyl, imidazolidinyl and piperazinyl rings.
- The term halogen is intended to include fluorine, chlorine, bromine or iodine atoms.
- The term “haloalkyl” is intended to include those alkyl groups just mentioned substituted by one, two or three of the halogen atoms just described. Particular examples of such groups include —CF3, —CCl3, —CHF2, —CHCl2, —CH2F and —CH2Cl groups.
- The term “alkoxy” as used herein is intended to include straight or branched C1-6 alkoxy, e.g. C1-4 alkoxy such as methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, sec-butoxy, isobutoxy and tert-butoxy. “Haloalkoxy” as used herein includes any of these alkoxy groups substituted by one, two or three halogen atoms as described above. Particular examples include —OCF3, —OCCl3, —OCHF2, —OCHCl2, —OCH2F and —OCH2Cl groups.
- As used herein the term “alkylthio” is intended to include straight or branched C1-6 alkylthio, e.g. C1-4 alkylthio such as methylthio or ethylthio.
- As used herein the term “alkylamino” or “dialkylamino” is intended to include the groups —NHR1a and —N(R1a)(R1b) where R1a and R1b is each independently an optionally substituted straight or branched alkyl group or both together with the N atom to which they are attached form an optionally substituted heterocycloalkyl group which may contain a further heteroatom or heteroatom-containing group such as an —O— or —S— atom or —N(R1a)— group. Particular examples of such optionally substituted heterocycloalkyl groups include optionally substituted pyrrolidinyl, piperidinyl, morpholinyl, thiomorpholinyl and N′-C1-6alkylpiperazinyl groups. The optional substituents which may be present on such heterocycloalkyl groups include those optional substituents as described above in relation to the term “alkyl”.
- Particular examples of alkylene chains represented by Alk1 and/or Alk2 when each is present in compounds of the invention include —CH2—, —CH2CH2—, —CH(CH3)CH2—, —(CH2)2CH2—, —C(CH3)2—, —(CH2)3CH2—, —CH2CH(CH3)CH2—, —C(CH3)2CH2— or —CH(CH3)CH2CH2— chains.
- Optionally substituted cycloaliphatic groups represented by the group Cy1 in compounds of the invention include optionally substituted C3-10 cycloaliphatic groups. Particular examples include optionally substituted C3-10 cycloalkyl, e.g. C3-7 cycloalkyl, or C3-10 cycloalkenyl, e.g. C3-7 cycloalkenyl, groups.
- Particular examples of cycloaliphatic groups represented by the group Cy1 include optionally substituted cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, 2-cyclobuten-1-yl, 2-cyclopenten-1-yl and 3-cyclopenten-1-yl groups, especially cyclopropyl.
- The optional substituents which may be present on the cycloaliphatic groups represented by the group Cy1 include one, two, three or more substituents selected from halogen atoms, or C1-6 alkyl, e.g. methyl or ethyl, haloC1-6alkyl, e.g. halomethyl or haloethyl such as difluoromethyl or trifluoromethyl, optionally substituted by hydroxyl, e.g. —C(OH)(CF3)2, C1-6 alkoxy, e.g. methoxy or ethoxy, haloC1-6alkoxy, e.g. halomethoxy or haloethoxy such as difluoromethoxy or trifluoromethoxy, thiol, C1-6 alkylthiol, e.g. methylthiol or ethylthiol, carbonyl (═O), thiocarbonyl (═S), imino (═NR4a) [where R4a is an —OH group or a C1-6 alkyl group], or -(Alk3)vR5 groups in which Alk3 is a straight or branched C1-3alkylene chain, v is zero or the integer 1 and R5 is a C3-8 cycloalkyl, —OH, —SH, —N(R6)(R7) [in which R6 and R7 is each independently selected from a hydrogen atom or an optionally substituted alkyl or C3-8 cycloalkyl group], —OR6, —SR6, —CN, —NO2, —CO2R6, —SOR6, —SO2R6, —SO3R6, —OCO2R6, —C(O)R6, —OC(O)R6, —C(S)R6, —C(O)N(R6)(R7), —OC(O)N(R6)(R7), —N(R6)C(O)R7, —C(S)N(R6)(R7), —N(R6)C(S)R7, —SO2N(R6)(R7), —N(R6)SO2R7, —N(R6)C(O)N(R7)(R8) [where R8 is as defined for R6], —N(R6)C(S)N(R7)(R8), —N(R6)SO2N(R7)(R8) or an optionally substituted aromatic or heteroaromatic group.
- Particular examples of Alk3 chains include —CH2—, —CH2CH2—, —CH2CH2CH2— and —CH(CH3)CH2— chains.
- When R5, R6, R7 and/or R8 is present as a C3-8 cycloalkyl group it may be for example a cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl group. Optional substituents which may be present on such groups include for example one, two or three substituents which may be the same or different selected from halogen atoms, for example fluorine, chlorine, bromine or iodine atoms, or hydroxy or C1-6 alkoxy, e.g. methoxy, ethoxy or isopropoxy, groups.
- When the groups R6 and R7 or R7 and R8 are both alkyl groups these groups may be joined, together with the N atom to which they are attached, to form a heterocyclic ring. Such heterocyclic rings may be optionally interrupted by a further heteroatom or heteroatom-containing group selected from —O—, —S—, —N(R7)—, —C(O)— or —C(S)— groups. Particular examples of such heterocyclic rings include piperidinyl, pyrazolidinyl, morpholinyl, thiomorpholinyl, pyrrolidinyl, imidazolidinyl and piperazinyl rings.
- When R5 is an optionally substituted aromatic or heteroaromatic group it may be any such group as described hereinafter in relation to Cy1.
- In general, optionally substituted aromatic groups represented by the group Cy1 include for example monocyclic or bicyclic fused ring C6-12 aromatic groups, such as phenyl, 1- or 2-naphthyl, 1- or 2-tetrahydronaphthyl, indanyl or indenyl groups, especially phenyl.
- Heteroaromatic groups represented by the group Cy1 include for example C1-9 heteroaromatic groups containing for example one, two, three or four heteroatoms selected from oxygen, sulphur or nitrogen atoms. In general, the heteroaromatic groups may be for example monocyclic or bicyclic fused ring heteroaromatic groups. Monocyclic heteroaromatic groups include for example five- or six-membered heteroaromatic groups containing one, two, three or four heteroatoms selected from oxygen, sulphur or nitrogen atoms. Bicyclic heteroaromatic groups include for example eight- to thirteen-membered fused ring heteroaromatic groups containing one, two or more heteroatoms selected from oxygen, sulphur or nitrogen atoms.
- Particular examples of heteroaromatic groups of these types include pyrrolyl, furyl, thienyl, imidazolyl, N—C1-6alkylimidazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, pyrazolyl, 1,2,3-triazolyl, 1,2,4-triazolyl, 1,2,3-oxadiazolyl, 1,2,5-oxadiazolyl, 1,3,4-oxadiazolyl, 1,3,4-thiadiazolyl, pyridyl, pyrimidinyl, pyridazinyl, pyrazinyl, 1,3,5-triazinyl, 1,2,4-triazinyl, 1,2,3-triazinyl, benzofuryl, [2,3-dihydro]benzofuryl, benzothienyl, [2,3-dihydro]benzothienyl, benzotriazolyl, indolyl, indolinyl, indazolinyl, benzimidazolyl, imidazo[1,2-a]pyridyl, benzothiazolyl, benzoxazolyl, benzisoxazolyl, benzopyranyl, [3,4-dihydro]benzopyranyl, quinazolinyl, quinoxalinyl, naphthyridinyl, imidazo[1,5-a]pyridinyl, imidazo[1,5-a]pyrazinyl, imidazo[1,5-c]pyrimidinyl, pyrido[3,4-b]pyridyl, pyrido[3,2-b]pyridyl, pyrido[4,3-b]pyridyl, quinolinyl, isoquinolinyl, phthalazinyl, tetrazolyl, 5,6,7,8-tetrahydroquinolinyl, 5,6,7,8-tetrahydroisoquinolinyl, imidyl, e.g. succinimidyl, phthalimidyl or naphthalimidyl such as 1,8-naphthalimidyl, pyrazolo[4,3-d]pyrimidinyl, furo[3,2-c]pyrimidinyl, thieno[3,2-d]pyrimidinyl, pyrrolo[3,2-d]pyrimidinyl, pyrazolo[3,2-b]pyridinyl, furo[3,2-b]pyridinyl, thieno[3,2-b]pyridinyl, pyrrolo[3,2-b]pyridinyl, thiazolo[3,2-a]pyridinyl, pyrido[1,2-a]pyrimidinyl, tetrahydroimidazo[1,2-a]pyrimidinyl and dihydroimidazo[1,2-a]pyrimidinyl groups.
- Optional substituents which may be present on aromatic or heteroaromatic groups represented by the group Cy1 include one, two, three or more substituents, each selected from an atom or group R10 in which R10 is R10a or -L6Alk5(R10a)r, where R10a is a halogen atom, or an amino (—NH2), substituted amino, nitro, cyano, hydroxyl (—OH), substituted hydroxyl, formyl, carboxyl (—CO2H), esterified carboxyl, thiol (—SH), substituted thiol, —COR11 [where R11 is an -L6Alk3(R10a)r, aryl or heteroaryl group], —CSR11, —SO3H, —SOR11, —SO2R11, —SO3R11, —SO2NH2, —SO2NHR11, —SO2N(R11)2, —CONH2, —CSNH2, —CONHR11, —CSNHR11, —CON(R11)2, —CSN(R11)2, —N(R12)SO2R11 [where R12 is a hydrogen atom or a straight or branched alkyl group], —N(SO2R11)2, —N(R12)SO2NH2, —N(R12)SO2NHR11, —N(R12)SO2N(R11)2, —N(R12)COR11, —N(R12)CONH2, —N(R12)CONHR11, —N(R12)CON(R11)2, —N(R12)CSNH2, —N(R12)CSNHR11, —N(R12)CSN(R11)2, —N(R12)CSR11, —N(R12)C(O)OR11, —C═NR12(NR12), —SO2NHet1 [where —NHet1 is an optionally substituted C3-7 cyclicamino group optionally containing one or more other —O— or —S— atoms or —N(R12), —C(O)— or —C(S)— groups], —CONHet1, —CSNHet1, —N(R12)SO2NHet1, —N(R12)CONHet1, —N(R12)CSNHet1, —SO2N(R12)Het [where -Het is an optionally substituted monocyclic C3-7 carbocyclic group optionally containing one or more other —O— or —S— atoms or —N(R12)—, —C(O)—, —S(O)— or —S(O)2—groups], -Het, —CON(R12)Het, —CSN(R12)Het, —N(R12)CON(R12)Het, —N(R12)CSN(R12)Het, —N(R12)SO2N(R12)Het, aryl or heteroaryl groups; L6 is a covalent bond or a linker atom or group; Alk5 is an optionally substituted straight or branched C1-6 alkylene, C2-6 alkenylene or C2-6 alkynylene chain, optionally interrupted by one, two or three —O— or —S— atoms or —S(O)k— [where k is an integer 1 or 2] or —N(R12)—, e.g. —N(CH3)—, groups; and r is zero or the integer 1, 2, or 3. It will be appreciated that when two R11 or R12 groups are present in one of the above substituents the R11 and R12 groups may be the same or different.
- When L6 in the group -L6Alk5(R10a)r is a linker atom or group it may be for example any divalent linking atom or group. Particular examples include —O— or —S— atoms or —C(O)—, —C(O)O—, —OC(O)—, —C(S)—, —S(O)—, —S(O)2—, —N(R3)— [where R3 is a hydrogen atom or a straight or branched alkyl group], —N(R3)O—, —N(R3)N—, —CON(R3)—, —OC(O)N(R3)—, —CSN(R3)—, —N(R3)CO—, —N(R3)C(O)O—, —N(R3)CS—, —S(O)2N(R3)—, —N(R3)S(O)2—, —N(R3)CON(R3)—, —N(R3)CSN(R3)— or —N(R3)SO2N(R3)— groups. Where L6 contains two R3 groups these may be the same or different.
- When in the group -L6Alk5(R10a)r is an integer 1, 2 or 3, it is to be understood that the substituent or substituents R10a may be present on any suitable carbon atom in -Alk5. Where more than one R10a substituent is present these may be the same or different and may be present on the same or different atom in -Alk5. Clearly, when r is zero and no substituent R10a is present the alkylene, alkenylene or alkynylene chain represented by Alk5 becomes an alkyl, alkenyl or alkynyl group.
- When R10a is a substituted amino group it may be for example a group —NHR11 [where R11 is as defined above] or a group —N(R11)2 wherein each R11 group is the same or different.
- When R10a is a halogen atom it may be for example a fluorine, chlorine, bromine, or iodine atom.
- When R10a is a substituted hydroxyl or substituted thiol group it may be for example a group —OR11 or —SR12 respectively.
- Esterified carboxyl groups represented by the group R10a include groups of formula —CO2Alk6 wherein Alk6 is a straight or branched, optionally substituted C1-8 alkyl group such as a methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl or tert-butyl group; a C6-12arylC1-8alkyl group such as an optionally substituted benzyl, phenylethyl, phenylpropyl, 1-naphthylmethyl or 2-naphthylmethyl group; a C6-12aryl group such as an optionally substituted phenyl, 1-naphthyl or 2-naphthyl group; a C6-12aryloxyC1-8alkyl group such as an optionally substituted phenyloxymethyl, phenyloxyethyl, 1-naphthyloxymethyl, or 2-naphthyloxymethyl group; an optionally substituted C1-8alkanoyloxyC1-8alkyl group, such as a pivaloyloxymethyl, propionyloxyethyl or propionyloxypropyl group; or a C6-12aroyloxyC1-8alkyl group such as an optionally substituted benzoyloxyethyl or benzoyloxypropyl group. Optional substituents present on the Alk6 group include R10a atoms and groups as described above.
- When Alk5 is present in or as a substituent it may be for example a —CH2—, —CH(CH3)—, —C(CH3)2—, —CH2CH2—, —CH2CH2CH2—, —CH(CH3)CH2—, —CH2CH2CH2CH2—, —CH2CH(CH3)CH2—, —CH(CH3)CH2CH2—, —C(CH3)2CH2—, —CH═CH—, —CH═CHCH2—, —CH2CH═CH—, —CH═CHCH2CH2—, —CH2CH═CHCH2—, —CH2CH2CH═CH—, —C≡C—, —C≡CCH2—, —CH2C≡C—, —C≡CCH2CH2—, —CH2C≡CCH2— or —CH2CH2C≡C— chain, optionally interrupted by one, two, or three —O— or —S— atoms or —S(O)—, —S(O)2— or —N(R12)—, e.g. —N(CH3)—, groups. The aliphatic chains represented by Alk5 may be optionally substituted by one, two or three halogen atoms in addition to any R10a groups that may be present.
- Aryl or heteroaryl groups represented by the groups R10a or R11 include mono- or bicyclic optionally substituted C6-12 aromatic or C1-9 heteroaromatic groups as described above for the group Cy1. The aromatic and heteroaromatic groups may be attached to the group Cy1 in compounds of formula (1) by any carbon atom or heteroatom, e.g. nitrogen atom, as appropriate.
- It will be appreciated that when —NHet1 or -Het forms part of a substituent R10 the heteroatoms or heteroatom-containing groups that may be present within the ring —NHet1 or -Het take the place of carbon atoms within the parent carbocyclic ring.
- Thus when —NHet1 or -Het forms part of a substituent R10 each may be for example an optionally substituted pyrrolidinyl, imidazolidinyl, pyrazolidinyl, piperazinyl, morpholinyl, thiomorpholinyl, piperidinyl or thiazolidinyl group. Additionally Het may represent, for example, an optionally substituted cyclopentyl or cyclohexyl group. Optional substituents which may be present on —NHet1 include those substituents described above when Cy1 is a heterocycloaliphatic group.
- Particularly useful atoms or groups represented by R10 include fluorine, chlorine, bromine or iodine atoms, or C1-6 alkyl, e.g. methyl, ethyl, n-propyl, isopropyl, n-butyl or tert-butyl, optionally substituted phenyl, pyridyl, pyrimidinyl, pyrrolyl, furyl, thiazolyl, or thienyl, C1-6 hydroxyalkyl, e.g. hydroxymethyl or hydroxyethyl, carboxyC1-6alkyl, e.g. carboxyethyl, C1-6 alkylthio, e.g. methylthio or ethylthio, carboxyC1-6alkylthio, e.g. carboxymethylthio, 2-carboxyethylthio or 3-carboxy-propylthio, C1-6 alkoxy, e.g. methoxy or ethoxy, hydroxyC1-6alkoxy, e.g. 2-hydroxyethoxy, optionally substituted phenoxy, pyridyloxy, thiazolyoxy, phenylthio or pyridylthio, C3-7 cycloalkyl, e.g. cyclobutyl or cyclopentyl, C5-7 cycloalkoxy, e.g. cyclopentyloxy, haloC1-6alkyl, e.g. trifluoromethyl, haloC1-6alkoxy, e.g. trifluoromethoxy, C1-6 alkylamino, e.g. methylamino or ethylamino, —CH(CH3)NH2 or —C(CH3)2NH2, haloC1-6alkylamino, e.g. fluoroC1-6alkylamino, —CH(CF3)NH2 or —C(CF3)2NH2, amino (—NH2), aminoC1-6alkyl, e.g. aminomethyl or aminoethyl, C1-6dialkylamino, e.g. dimethylamino or diethylamino, C1-6alkylaminoC1-6alkyl, e.g. ethylaminoethyl, C1-6dialkylaminoC1-6alkyl, e.g. diethylaminoethyl, aminoC1-6alkoxy, e.g. aminoethoxy, C1-6alkylaminoC1-6alkoxy, e.g. methylaminoethoxy, C1-6dialkyl-aminoC1-6alkoxy, e.g. dimethylaminoethoxy, diethylaminoethoxy, diisopropylaminoethoxy or dimethylaminopropoxy, imido, such as phthalimido or naphthalimido, e.g. 1,8-naphthalimido, nitro, cyano, hydroxyl (—OH), formyl [HC(O)—], carboxyl (—CO2H), —CO2Alk6 [where Alk6 is as defined above], C1-6 alkanoyl, e.g. acetyl, optionally substituted benzoyl, thiol (—SH), thioC1-6alkyl, e.g. thiomethyl or thioethyl, sulphonyl (—SO3H), C1-6alkylsulphonyl, e.g. methylsulphonyl, aminosulphonyl (—SO2NH2), C1-6alkylaminosulphonyl, e.g. methylaminosulphonyl or ethylaminosulphonyl, C1-6dialkylaminosulphonyl, e.g. dimethylaminosulphonyl or diethylaminosulphonyl, phenylaminosulphonyl, carboxamido (—CONH2), C1-6alkylaminocarbonyl, e.g. methylaminocarbonyl or ethylaminocarbonyl, C1-6dialkylaminocarbonyl, e.g. dimethylaminocarbonyl or diethylaminocarbonyl, aminoC1-6alkylaminocarbonyl, e.g. aminoethylaminocarbonyl, C1-6dialkylaminoC1-6alkylaminocarbonyl, e.g. diethylaminoethylaminocarbonyl, aminocarbonylamino, C1-6alkylaminocarbonylamino, e.g. methylaminocarbonylamino or ethylaminocarbonylamino, C1-6dialkylaminocarbonylamino, e.g. dimethylaminocarbonylamino or diethylaminocarbonylamino, C1-6alkylaminocabonylC1-6alkylamino, e.g. methylaminocarbonylmethylamino, aminothiocarbonylamino, C1-6alkylaminothiocarbonylamino, e.g. methylaminothiocarbonylamino or ethylaminothiocarbonylamino, C1-6dialkylaminothiocarbonylamino, e.g. dimethylaminothiocarbonylamino or diethylaminothiocarbonylamino, C1-6alkylaminothiocarbonylC1-6alkylamino, e.g. ethylaminothiocarbonylmethylamino, —CONHC(═NH)NH2, C1-6alkylsulphonylamino, e.g. methylsulphonylamino or ethylsulphonylamino, C1-6dialkylsulphonylamino, e.g. dimethylsulphonylamino or diethylsulphonylamino, optionally substituted phenylsulphonylamino, aminosulphonylamino (—NHSO2NH2), C1-6alkylaminosulphonylamino, e.g. methylaminosulphonylamino or ethylaminosulphonylamino, C1-6dialkylaminosulphonylamino, e.g. dimethylaminosulphonylamino or diethylaminosulphonylamino, optionally substituted morpholinesulphonylamino or morpholinesulphonylC1-6alkylamino, optionally substituted phenylaminosulphonylamino, C1-6alkanoylamino, e.g. acetylamino, aminoC1-6alkanoylamino, e.g. aminoacetylamino, C1-6dialkylaminoC1-6alkanoylamino, e.g. dimethylaminoacetylamino, C1-6alkanoylaminoC1-6alkyl, e.g. acetylaminomethyl, C1-6alkanoylaminoC1-6alkylamino, e.g. acetamidoethylamino, C1-6alkoxycarbonylamino, e.g. methoxycarbonylamino, ethoxycarbonylamino or tert-butoxycarbonylamino, or optionally substituted benzyloxy, pyridylmethoxy, thiazolylmethoxy, benzyloxycarbonylamino, benzyloxycarbonylaminoC1-6alkyl, e.g. benzyloxycarbonylaminoethyl, benzothio, pyridylmethylthio or thiazolylmethylthio groups.
- A further particularly useful group of substituents represented by R10 when present on aromatic or heteroaromatic groups includes substituents of formula -L6Alk5R10a where L6 is preferably a covalent bond or an —O— or —S— atom or —N(R3)—, —C(O)—, —C(O)O—, —O—C(O)—, —N(R3)CO—, —CON(R3)— or —N(R3)S(O)2— group, Alk5 is an optionally substituted C1-6alkyl group optionally interrupted by one or two —O— or —S— atoms or —N(R12)—, —C(O)—, —C(S)—, —CON(R12— or —N(R12)CO— groups, and R10a is an optionally substituted Het group as herein defined or an optionally substituted heteroaromatic group as hereinbefore described in relation to Cy1.
- Where desired, two R10 substituents may be linked together to form a cyclic group such as a cyclic ether, e.g. a C1-6 alkylenedioxy group such as methylenedioxy or ethylenedioxy.
- It will be appreciated that where two or more R10 substituents are present, these need not necessarily be the same atoms and/or groups. In general, the substituent(s) may be present at any available ring position on the aromatic or heteroaromatic group represented by the group Cy1.
- The substituted aromatic or heteroaromatic group represented by Ar in compounds of the invention may be any aromatic or heteroaromatic group as hereinbefore described for Cy1. Optional substituents which may be present include those R10 atoms and groups as generally or particularly described in relation to Cy1 aromatic and heteroaromatic groups.
- The presence of certain substituents in the compounds of formula (1) may enable salts of the compounds to be formed. Suitable salts include pharmaceutically acceptable salts, for example acid addition salts derived from inorganic or organic acids, and salts derived from inorganic and organic bases.
- Acid addition salts include hydrochlorides, hydrobromides, hydroiodides, alkylsulfonates, e.g. methanesulfonates, ethanesulfonates, or isothionates, arylsulfonates, e.g. p-toluenesulfonates, besylates or napsylates, phosphates, sulphates, hydrogensulphates, acetates, trifluoroacetates, propionates, citrates, maleates, fumarates, malonates, succinates, lactates, oxalates, tartrates and benzoates.
- Salts derived from inorganic or organic bases include alkali metal salts such as sodium or potassium salts, alkaline earth metal salts such as magnesium or calcium salts, and organic amine salts such as morpholine, piperidine, dimethylamine or diethylamine salts.
- Particularly useful salts of compounds according to the invention include pharmaceutically acceptable salts, especially acid addition pharmaceutically acceptable salts.
- In one embodiment, Y is —C(O)—. In another embodiment, Y is —S(O)2—.
- In one class of compounds of formula (1) n is the integer 1. When in compounds of formula (1) n is the integer 1, Alk1 is preferably a —CH2CH2— chain or more especially is —CH2—.
- In one class of compounds of formula (1) n is zero.
- Particularly preferred Cy1 optionally substituted cycloaliphatic groups include optionally substituted C3-7 cycloalkyl groups, especially cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl groups. Cy1 is in particular a cyclopropyl group.
- Each of these preferred Cy1 cycloalkyl groups may be unsubstituted. When substituents are present these may in particular include halogen atoms, especially fluorine, chlorine or bromine atoms, or C1-6 alkyl groups, especially C1-3 alkyl groups, most especially a methyl group, or haloC1-6alkyl groups, especially fluoroC1-6alkyl groups, most especially a —CF3 group, or C1-6 alkoxy groups, especially a methoxy, ethoxy, propoxy or isopropoxy group, or haloC1-6alkoxy groups, especially fluoroC1-6alkoxy groups, most especially a —OCF3 group, or a cyano (—CN), esterified carboxyl, especially —CO2CH3 or —CO2C(CH3)3, nitro (—NO2), amino (—NH2), substituted amino, especially —NHCH3 or —N(CH3)2, —C(O)R6, especially —C(O)CH3, or —N(R6)C(O)R7, especially —NHCOCH3, group.
- Particularly preferred Cy1 aromatic groups include optionally substituted phenyl groups. Particularly preferred heteroaromatic groups include optionally substituted monocyclic heteroaromatic groups, especially optionally substituted five- or six-membered heteroaromatic groups containing one, two, three or four heteroatoms selected from oxygen, sulphur or nitrogen atoms. Particularly preferred optionally substituted monocyclic heteroaromatic groups include optionally substituted furyl, thienyl, pyrrolyl, oxazolyl, thiazolyl, pyridyl, pyrimidinyl and triazinyl groups. In a further preference, the heteroaromatic group may be an eight- to thirteen-membered bicyclic fused ring containing one or two oxygen, sulphur or nitrogen atoms. Particularly useful groups of this type include optionally substituted indolyl groups.
- Particularly preferred optional substituents which may be present on Cy1 aromatic or heteroaromatic groups include one, two or three atoms or groups —R10a or -L6Alk5(R10a)r as hereinbefore defined. Particularly useful optional substituents include halogen atoms, especially fluorine, chlorine or bromine atoms, or C1-6 alkyl groups, especially C1-3 alkyl groups, most especially a methyl group, or haloC1-6alkyl groups, especially fluoroC1-6alkyl groups, most especially a —CF3 group, or C1-6alkoxy groups, especially a methoxy, ethoxy, propoxy or isopropoxy group, or haloC1-6alkoxy groups, especially fluoroC1-6alkoxy groups, most especially a —OCF3 group, or a cyano (—CN), carboxyl (—CO2H), esterified carboxyl (—CO2Alk6), especially —CO2CH3, —CO2CH2CH3, or —CO2C(CH3)3, nitro (—NO2), amino (—NH2), substituted amino, especially —NHCH3 or —N(CH3)2, —COR11, especially —COCH3, or —N(R12)COR11, especially —NHCOCH3, group.
- Further preferred optional substituents which may be present on Cy1 aromatic or heteroaromatic groups include groups of formula -L6Alk5(R10a)r in which r is the integer 1 or 2, L6 is a covalent bond or an —O— or —S— atom or a —N(R3)—, especially —NH— or —N(CH3)—, —C(O)—, —C(S)—, —C(O)O—, —OC(O)—, —N(R3)CO—, especially —NHCO—, or —CON(R3)—, especially —CONH—, group, Alk5 is a C1-6alkylene chain, especially a —CH2—, —CH2CH2—, —CH2CH2CH2— or —CH2CH2CH2CH2— chain, and R10a is a hydroxyl or substituted hydroxyl group, especially a —OCH3, —OCH2CH3 or —OCH(CH3)2 group, or a —NH2 or substituted amino group, especially a —N(CH3)2 or —N(CH2CH3)2 group, or a -Het group, especially an optionally substituted monocyclic C5-7 carbocyclic group containing one, two or three —O—, —S—, —N(R12)—, especially —NH— or —N(CH3)—, or —C(O)— groups within the ring structure as previously described, most especially an optionally substituted pyrrolidinyl, imidazolidinyl, piperidinyl, e.g. N-methylpiperidinyl, morpholinyl, thiomorpholinyl or piperazinyl group, or R10a is an optionally substituted heteroaromatic group, especially a five- or six-membered monocyclic heteroaromatic group containing one, two, three or four heteroatoms selected from oxygen, sulphur or nitrogen atoms, such as optionally substituted pyrrolyl, furyl, thienyl, imidazolyl, triazolyl, pyridyl, pyrimidinyl, triazinyl, pyridazinyl, or pyrazinyl group. Particularly preferred optional substituents on the -Het groups just described include hydroxyl (—OH) and carboxyl (—CO2H) groups or those preferred optional substituents just described in relation to the group Cy1, especially when Cy1 is a cycloalkyl group.
- In one particularly preferred group of compounds of formula (1) Cy1 is an optionally substituted phenyl group, especially a phenyl group optionally substituted by one, two or three substituents where at least one, and preferably two, substituents are located ortho to the bond joining Cy1 to the remainder of the compound of formula (1). Particularly preferred ortho substituents include halogen atoms, especially fluorine or chlorine atoms, or C1-3 alkyl groups, especially methyl, C1-3 alkoxy groups, especially methoxy, haloC1-3alkyl groups, especially —CF3, haloC1-3alkoxy groups, especially —OCF3, or cyano (—CN), groups. In this class of compounds a second or third optional substituent when present in a position other than the ortho positions of the ring Cy1 may be preferably an atom or group —R10a or -L6Alk5(R10a)r as herein generally and particularly described. In another preference, the Cy1 phenyl group may have a substituent para to the bond joining Cy1 to the remainder of the compound of formula (1). Particular para substituents include those particularly preferred ortho substituents just described. Where desired, the pare substituent may be present with other ortho or meta substituents as just mentioned.
- Examples of specific substituents on Cy1 include halogen (especially fluoro or chloro) and C1-4 alkyl (especially methyl).
- Specific Cy1 groups include phenyl, fluorophenyl, chlorophenyl, methylphenyl and cyclopropyl.
- Particularly preferred Ar aromatic groups in compounds of formula (1) include optionally substituted phenyl groups. Particularly preferred heteroaromatic groups include optionally substituted monocyclic heteroaromatic groups, especially optionally substituted five- or six-membered heteroaromatic groups containing one, two, three or four heteroatoms selected from oxygen, sulphur or nitrogen atoms. Particularly preferred optionally substituted monocyclic heteroaromatic groups include optionally substituted furyl, thienyl, pyrrolyl, oxazolyl, thiazolyl, pyridyl, pyrimidinyl and triazinyl groups.
- Particularly preferred optional substituents which may be present on Ar aromatic or heteroaromatic groups include atoms or groups —R10a or -L6Alk5(R10a)r as hereinbefore defined. Particularly useful optional substituents include halogen atoms, especially fluorine, chlorine or bromine atoms, or C1-6 alkyl groups, especially C1-3 alkyl groups, most especially a methyl group, or haloC1-6alkyl groups, especially fluoroC1-6alkyl groups, most especially a —CF3 group, or C1-6 alkoxy groups, especially a methoxy, ethoxy, propoxy or isopropoxy group, or haloC1-6alkoxy groups, especially fluoroC1-6alkoxy groups, most especially a —OCF3 group, or a cyano (—CN), esterified carboxyl, especially —CO2CH3 or —CO2C(CH3)3, nitro (—NO2), amino (—NH2), substituted amino, especially —NHCH3 or —N(CH3)2, —COR11, especially —COCH3, or —N(R12)COR11, especially —NHCOCH3, group.
- Particularly useful Ar groups in compounds of formula (1) include phenyl and mono- or disubstituted phenyl groups in which each substituent is in particular a —R10a or -L6Alk5(R10a)r atom or group as just defined and is especially a halogen atom or a C1-3 alkyl, C1-3 alkoxy or —CN group.
- Examples of specific substituents on Ar include halogen (especially fluoro or chloro), cyano and C1-4 alkyl (especially methyl).
- Specific Ar groups include phenyl, difluorophenyl, (chloro)(fluoro)phenyl, (fluoro)(methyl)phenyl, chlorophenyl, cyanophenyl and methylphenyl.
- Particular examples of Alk2 when present in compounds of the invention include —CH2—, —CH2CH2—, —C(CH3)2— and —CH(CH3)CH2—. In one embodiment, Alk2 is —CH2—. In another embodiment, Alk2 is —C(CH3)2—.
- Suitably, R1 is methyl.
- Suitably, R2 is hydrogen or methyl. Suitably, R3 is hydrogen or methyl. In one embodiment, R2 and R3 are both hydrogen. In another embodiment, R2 and R3 are both methyl.
- In compounds of the invention, m may be selected to vary the ring size from a ring having, in addition to the nitrogen atom, a minimum of 3 carbon atoms up to 6 carbon atoms. Particularly advantageous rings are those wherein m is the integer 1 or 2.
- In a preferred embodiment, m is the integer 2. In another embodiment, m is the integer 1. In a further embodiment, m is the integer 3.
- In a particular embodiment, p is the integer 1. In another embodiment, p is the integer 2.
- Each substituent Rd may be present on any ring carbon atom. In one particular class of compounds of the invention one or two Rd substituents are present.
- Suitable values of Rd include —OH, -(Alk2)OH, -(Alk2)OR1, —NR2R3 and -(Alk2)NR2R3.
- Detailed values of Rd include —OH, —CH2OH, —C(CH3)2OH, —CH2OCH3, —NH2, —N(CH3)2 and —CH2NH2.
- Representative values of Rd include —OH, -(Alk2)OH and -(Alk2)OR1.
- Illustrative values of Rd include —OH, —CH2OH, —C(CH3)2OH and —CH2OCH3.
- Particular Rd substituents include —OH, —CH2OH, —CH(CH3)OH and —C(CH3)2OH groups.
- Particularly useful compounds of the invention include each of the compounds described in the Examples hereinafter, and the salts, solvates, hydrates and N-oxides thereof.
- Compounds according to the invention are potent and selective inhibitors of p38 kinases, including all isoforms and splice variants thereof. More specifically the compounds of the invention are inhibitors of p38α, p38βand p38β2. The ability of the compounds to act in this way may be simply determined by employing tests such as those described in the Examples hereinafter.
- The compounds of formula (1) are of use in modulating the activity of p38 kinases and in particular are of use in the prophylaxis and treatment of any p38 kinase mediated diseases or disorders in a human, or other mammal. The invention extends to such a use and to the use of the compounds for the manufacture of a medicament for treating such diseases or disorders. Further the invention extends to the administration to a human of an effective amount of a p38 inhibitor for treating any such disease or disorder.
- The invention also extends to the prophylaxis or treatment of any disease or disorder in which p38 kinase plays a role including conditions caused by excessive or unregulated pro-inflammatory cytokine production including for example excessive or unregulated TNF, IL-1, IL-6 and IL-8 production in a human, or other mammal. The invention extends to such a use and to the use of the compounds for the manufacture of a medicament for treating such cytokine-mediated diseases or disorders. Further the invention extends to the administration to a human of an effective amount of a p38 inhibitor for treating any such disease or disorder.
- Diseases or disorders in which p38 kinase plays a role either directly or via pro-inflammatory cytokines including the cytokines TNF, IL-1, IL-6 and IL-8 include without limitation autoimmune diseases, inflammatory diseases, destructive bone disorders, proliferative disorders, neurodegenerative disorders, viral diseases, allergies, infectious diseases, heart attacks, angiogenic disorders, reperfusion/ischemia in stroke, vascular hyperplasia, organ hypoxia, cardiac hypertrophy, thrombin-induced platelet aggregation and conditions associated with prostaglandin endoperoxidase synthetase-2 (COX-2).
- Autoimmune diseases which may be prevented or treated include but are not limited to rheumatoid arthritis, inflammatory bowel disease, ulcerative colitis, Crohn's disease, multiple sclerosis, diabetes, glomerulonephritis, systemic lupus erythematosus, scleroderma, chronic thyroiditis, Grave's disease, hemolytic anemia, autoimmune gastritis, autoimmune neutropenia, thrombocytopenia, chronic active hepatitis, myasthenia gravis, atopic dermatitis, graft vs host disease and psoriasis.
- The invention further extends to the particular autoimmune disease rheumatoid arthritis.
- Inflammatory diseases which may be prevented or treated include but are not limited to asthma, allergies, respiratory distress syndrome and acute or chronic pancreatitis.
- Destructive bone disorders which may be prevented or treated include but are not limited to osteoporosis, osteoarthritis and multiple myeloma-related bone disorder.
- Proliferative diseases which may be prevented or treated include but are not limited to acute or chronic myelogenous leukemia, Kaposi's sarcoma, metastatic melanoma and multiple myeloma.
- Neurodegenerative diseases which may be prevented or treated include but are not limited to Parkinson's disease, Alzheimer's disease, cerebral ischemias and neurodegenerative disease caused by traumatic injury.
- Viral diseases which may be prevented or treated include but are not limited to acute hepatitis infection (including hepatitis A, hepatitis B and hepatitis C), HIV infection and CMV retinitis.
- Infectious diseases which may be prevented or treated include but are not limited to septic shock, sepsis and Shigellosis.
- In addition, p38 inhibitors of this invention also exhibit inhibition of expression of inducible pro-inflammatory proteins such as prostaglandin endoperoxidase synthetase-2, otherwise known as cyclooxygenase-2 (COX-2), and are therefore of use in therapy. Pro-inflammatory mediators of the cyclooxygenase pathway derived from arachidonic acid are produced by inducible COX-2 enzyme. Regulation of COX-2 would regulate these pro-inflammatory mediators such as prostaglandins, which affect a wide variety of cells and are important and critical inflammatory mediators of a wide variety of disease states and conditions. In particular these inflammatory mediators have been implicated in pain, such as in the sensitization of pain receptors, or edema. Accordingly additional p38 mediated conditions which may be prevented or treated include edema, analgesia, fever and pain such as neuromuscular pain, headache, dental pain, arthritis pain and pain caused by cancer.
- As a result of their p38 inhibitory activity, compounds of the invention have utility in the prevention and treatment of diseases associated with cytokine production including but not limited to those diseases associated with TNF, IL-1, IL-6 and IL-8 production.
- Thus, TNF mediated diseases or conditions include for example rheumatoid arthritis, rheumatoid spondylitis, osteoarthritis, gouty arthritis and other arthritic conditions, sepsis, septic shock syndrome, adult respiratory distress syndrome, cerebral malaria, chronic pulmonary inflammatory disease, silicosis, pulmonary sarcoidosis, bone resorption disease, reperfusion injury, graft vs. host reaction, allograft rejections, fever and myalgias due to infection, cachexia secondary to infection, AIDS, ARC or malignancy, keloid formation, scar tissue formation, Crohn's disease, ulcerative colitis, pyresis, viral infections such as HIV, CMV, influenza and herpes; and veterinary viral infections, such as lentivirus infections, including but not limited to equine infectious anemia virus, caprine arthritis virus, visna virus or maedi virus; or retrovirus infections, including feline immunodeficiency virus, bovine immunodeficiency virus and canine immunodeficiency virus.
- Compounds of the invention may also be used in the treatment of viral infections, where such viruses elicit TNF production in vivo or are sensitive to upregulation by TNF. Such viruses include those that produce TNF as a result of infection and those that are sensitive to inhibition, for instance as a result of decreased replication, directly or indirectly by the TNF inhibiting compounds of the invention. Such viruses include, but are not limited to, HIV-1, HIV-2 and HIV-3, Cytomegalovirus (CMV), Influenza, adenovirus and the Herpes group of viruses such as Herpes Zoster and Herpes Simplex.
- IL-1 mediated diseases or conditions include for example rheumatoid arthritis, osteoarthritis, psoriatic arthritis, traumatic arthritis, rubella arthritis, inflammatory bowel disease, stroke, endotoxemia and/or toxic shock syndrome, inflammatory reaction induced by endotoxin, diabetes, pancreatic β-cell disease, Alzheimer's disease, tuberculosis, atherosclerosis, muscle degeneration and cachexia.
- IL-8 mediated diseases and conditions include for example those characterized by massive neutrophil infiltration such as psoriasis, inflammatory bowel disease, asthma, cardiac, brain and renal reperfusion injury, adult respiratory distress syndrome, thrombosis and glomerulonephritis. The increased IL-8 production associated with each of these diseases is responsible for the chemotaxis of neutrophils into inflammatory sites. This is due to the unique property of IL-8 (in comparison to TNF, IL-1 and IL-6) of promoting neutrophil chemotaxis and activation. Therefore, inhibition of IL-8 production would lead to a direct reduction in neutrophil infiltration.
- It is also known that both IL-6 and IL-8 are produced during rhinovirus (HRV) infections and contribute to the pathogenesis of the common cold and exacerbation of asthma associated with HRV infection [Turner et al., Clin. Infec. Dis., 1997, 26, 840; Grunberg et al., Am. J. Crit. Care Med., 1997, 155, 1362; Zhu et al., J. Clin. Invest., 1996, 97, 421]. It has also been demonstrated in vitro that infection of pulmonary epithelial cells (which represent the primary site of infection by HRV) with HRV results in production of IL-6 and IL-8 [Sabauste et al., J. Clin. Invest., 1995, 96, 549]. Therefore, p38 inhibitors of the invention may be used for the treatment or prophylaxis of the common cold or respiratory viral infection caused by human rhinovirus infection (HRV), other enteroviruses, coronavirus, influenza virus, parainfluenza virus, respiratory syncytial virus or adenovirus infection.
- For the prophylaxis or treatment of a p38 or pro-inflammatory cytokine mediated disease the compounds according to the invention may be administered to a human or mammal as pharmaceutical compositions, and according to a further aspect of the invention we provide a pharmaceutical composition which comprises a compound of formula (1) together with one or more pharmaceutically acceptable carriers, excipients or diluents.
- Pharmaceutical compositions according to the invention may take a form suitable for oral, buccal, parenteral, nasal, topical, ophthalmic or rectal administration, or a form suitable for administration by inhalation or insufflation.
- For oral administration, the pharmaceutical compositions may take the form of, for example, tablets, lozenges or capsules prepared by conventional means with pharmaceutically acceptable excipients such as binding agents (e.g. pregelatinised maize starch, polyvinylpyrrolidone or hydroxypropyl methylcellulose); fillers (e.g. lactose, microcrystalline cellulose or calcium hydrogenphosphate); lubricants (e.g. magnesium stearate, talc or silica); disintegrants (e.g. potato starch or sodium glycollate); or wetting agents (e.g. sodium lauryl sulphate). The tablets may be coated by methods well known in the art. Liquid preparations for oral administration may take the form of, for example, solutions, syrups or suspensions, or they may be presented as a dry product for constitution with water or other suitable vehicle before use. Such liquid preparations may be prepared by conventional means with pharmaceutically acceptable additives such as suspending agents, emulsifying agents, non-aqueous vehicles and preservatives. The preparations may also contain buffer salts, flavouring, colouring and sweetening agents as appropriate.
- Preparations for oral administration may be suitably formulated to give controlled release of the active compound.
- For buccal administration the compositions may take the form of tablets or lozenges formulated in conventional manner.
- The compounds of formula (1) may be formulated for parenteral administration by injection, e.g. by bolus injection or infusion. Formulations for injection may be presented in unit dosage form, e.g. in glass ampoules or multi-dose containers, e.g. glass vials. The compositions for injection may take such forms as suspensions, solutions or emulsions in oily or aqueous vehicles, and may contain formulatory agents such as suspending, stabilising, preserving and/or dispersing agents. Alternatively, the active ingredient may be in powder form for constitution with a suitable vehicle, e.g. sterile pyrogen-free water, before use.
- In addition to the formulations described above, the compounds of formula (1) may also be formulated as a depot preparation. Such long-acting formulations may be administered by implantation or by intramuscular injection.
- For nasal administration or administration by inhalation, the compounds for use according to the present invention are conveniently delivered in the form of an aerosol spray presentation for pressurised packs or a nebuliser, with the use of suitable propellant, e.g. dichlorodifluoromethane, trichloro-fluoromethane, dichlorotetrafluoroethane, carbon dioxide or other suitable gas or mixture of gases.
- The compositions may, if desired, be presented in a pack or dispenser device which may contain one or more unit dosage forms containing the active ingredient. The pack or dispensing device may be accompanied by instructions for administration.
- For topical administration the compounds for use according to the present invention may be conveniently formulated in a suitable ointment containing the active component suspended or dissolved in one or more pharmaceutically acceptable carriers. Particular carriers include, for example, mineral oil, liquid petroleum, propylene glycol, polyoxyethylene, polyoxypropylene, emulsifying wax and water. Alternatively the compounds for use according to the present invention may be formulated in a suitable lotion containing the active component suspended or dissolved in one or more pharmaceutically acceptable carriers. Particular carriers include, for example, mineral oil, sorbitan monostearate, polysorbate 60, cetyl esters wax, cetearyl alcohol, benzyl alcohol, 2-octyldodecanol and water.
- For ophthalmic administration the compounds for use according to the present invention may be conveniently formulated as microionized suspensions in isotonic, pH adjusted sterile saline, either with or without a preservative such as a bactericidal or fungicidal agent, for example phenylmercuric nitrate, benzylalkonium chloride or chlorhexidine acetate. Alternatively for ophthalmic administration compounds may be formulated in an ointment such as petrolatum.
- For rectal administration the compounds for use according to the present invention may be conveniently formulated as suppositories. These can be prepared by mixing the active component with a suitable non-irritating excipient which is solid at room temperature but liquid at rectal temperature and so will melt in the rectum to release the active component. Such materials include for example cocoa butter, beeswax and polyethylene glycols.
- The quantity of a compound of the invention required for the prophylaxis or treatment of a particular condition will vary depending on the compound chosen, and the condition of the patient to be treated. In general, however, daily dosages may range from around 100 ng/kg to 100 mg/kg, e.g. around 0.01 mg/kg to 40 mg/kg body weight, for oral or buccal administration, from around 10 ng/kg to 50 mg/kg body weight for parenteral administration, and around 0.05 mg to around 1000 mg, e.g. around 0.5 mg to around 1000 mg, for nasal administration or administration by inhalation or insufflation.
- The compounds of the invention may be prepared by a number of processes as generally described below and more specifically in the Examples hereinafter. In the following process description, the symbols Ar, Cy1, Alk1, n, Rd, p, m and Y when used in the formulae depicted are to be understood to represent those groups described above in relation to formula (1) unless otherwise indicated. In the reactions described below, it may be necessary to protect reactive functional groups, for example hydroxy, amino, thio or carboxy groups, where these are desired in the final product, to avoid their unwanted participation in the reactions. Conventional protecting groups may be used in accordance with standard practice [see, for example, Greene, T. W. in “Protective Groups in Organic Synthesis”, John Wiley and Sons, 1999]. In some instances, deprotection may be the final step in the synthesis of a compound of formula (1) and the processes according to the invention described hereinafter are to be understood to extend to such removal of protecting groups.
- Thus, according to a further aspect of the invention a compound of formula (1) in which Y is a —C(O)— group may be prepared from a carboxylic acid of formula (2) or ester of formula (5) according to amide bond forming reactions well known to those skilled in the art. Such reactions are set forth in references such as March's Advanced Organic Chemistry (John Wiley and Sons 1992), Larock's Comprehensive Organic Transformations (VCH Publishers Inc., 1992) and Comprehensive Organic Functional Group Transformations, ed. Katritzky et al., volumes 1-8, 1984, and volumes 1-11, 1994 (Pergamon). Examples of such methods that may be employed to give compounds of formula (1a) are set out, but not limited to the reactions, in Scheme 1 and Scheme 2 below.
- Thus, amides of formula (1a) may be formed by reaction of a carboxylate salt of formula (2) [where M+ is metal counterion such as a sodium or lithium ion or is alternatively an ammonium or trialkylammonium counterion] with an amine of formula (3) in the presence of a coupling reagent such as a carbodiimide, e.g. 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide (EDC) or N,N′-dicyclohexylcarbodiimide, optionally in the presence of a base such as an amine, e.g. triethylamine or N-methylmorpholine. These reactions may be performed in a solvent such as an amide solvent, e.g. N,N-dimethyl-formamide (DMF), or an ether, e.g. a cyclic ether such as tetrahydrofuran or 1,4-dioxane, or a halogenated solvent such as dichloromethane, at around ambient temperature to 60° C. In another procedure a pentafluorophenyl ester of formula (4) may be prepared by reaction of a carboxylic acid of formula (2) with pentafluorophenol in the presence of a coupling reagent such as 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide in a solvent such as an amide solvent, e.g. DMF, at around ambient temperature. Amides of formula (1a) can then be prepared by reaction of the pentafluorophenyl ester with amines of formula (3) in an organic solvent such as a halogenated hydrocarbon, e.g. dichloromethane, at around ambient temperature, optionally in the presence of a tertiary amine base such as triethylamine or diisopropylethylamine. The intermediate acids of formula (2) may be prepared by hydrolysis of esters of formula (5) using a base such as an alkali metal hydroxide, e.g. sodium hydroxide or lithium hydroxide, in water and a solvent such as tetrahydrofuran or an alcohol such as ethanol at a temperature from around ambient to reflux.
- Amides of formula (1a) can also be prepared directly from esters of formula (5) by heating with an amine of formula (3) up to the reflux temperature of the amine optionally in the presence of a solvent such as 2-ethoxyethanol either at atmospheric pressure or under pressure in a sealed tube (Scheme 2).
- The intermediate esters of formula (5) may be prepared by the methods set out in Scheme 3 below. In the Scheme the preparation of an ethyl ester is specifically shown, but it will be appreciated that other esters may be obtained by simply varying the ester starting material and if appropriate any reaction conditions.
- Thus, in Scheme 3 a compound of formula (5a) or (5b) may be prepared by reaction of a compound of formula (6) or (7) with an amine ArNH2 in the presence of a palladium catalyst. The reaction may be conveniently carried out in a solvent such as toluene at an elevated temperature, e.g. the reflux temperature, using a catalyst such as tris(dibenzylideneacetone)-dipalladium(0), a phosphine ligand such as 2,2′-bis(diphenylphosphino)-1,1′-binaphthyl, and a base such as caesium carbonate. Where desired, alternative reaction conditions may be used, for example as described in the literature [Luker et al., Tetrahedron Lett., 2001, 41, 7731; Buchwald, S. L., J. Org. Chem., 2000, 65, 1144; Hartwig, J. F., Angew. Chem. Int. Ed. Engl., 1998, 37, 2046].
- Intermediates of formula (7) may be prepared by reaction of a compound of formula (8) with an alkylating agent of formula Cy1(Alk1)nZ, where Z is a leaving group such as a halogen atom, e.g. a chlorine, bromine or iodine atom, or a sulphonyloxy group such as an alkylsulphonyloxy, e.g. trifluoromethylsulphonyloxy, or arylsulphonyloxy, e.g. phenylsulphonyloxy, group.
- The reaction may be performed in the presence of a solvent, for example a substituted amide such as N,N-dimethylformamide, optionally in the presence of a base, for example an inorganic base such as sodium hydride, or an organic base such as an organic amine, e.g. a cyclic amine such as 1,5-diazabicyclo[4.3.0]non-5-ene, or a resin-bound organic amine such as resin-bound 2-tert-butylimino-2-diethylamino-1,3-dimethylperhydro-1,3,2-diaza-phosphorine (PS-BEMP), at an elevated temperature, for example 80 to 100° C.
- Intermediates of formula (6) may be prepared by the reaction of a compound of formula (8) with a boronic acid of formula Cy1B(OH)2 in which Cy1 is an aryl or heteroaryl group. The reaction may be performed in an organic solvent, for example a halogenated hydrocarbon such as dichloromethane or dichloroethane, in the presence of a copper reagent, for example a copper(I) salt such as CuI, or for example a copper(II) reagent such as copper(II) acetate, optionally in the presence of an oxidant, for example 2,2,6,6-tetramethylpiperidine-1-oxide or pyridine-N-oxide, optionally in the presence of a base, for example an organic amine such as an alkylamine, e.g. triethylamine, or an aromatic amine, e.g. pyridine, at a temperature from around ambient to the reflux temperature [see for example Chan, D. T. et al., Tetrahedron Letters, 1998, 2933; Lam, P. Y. S. et al., Tetrahedron Letters, 2001, 3415].
- Intermediates of formula (6) where Cy1 is an aryl or heteroaryl group may also be prepared by nucleophilic aromatic substitution of a suitably activated aryl or heteroaryl halide with a compound of formula (8). The reaction may be performed in a dialkylamide solvent such as DMF in the presence of a base such as a metal hydride, e.g. sodium hydride, at a temperature from around ambient to 100° C. Suitably activated aryl or heteroaryl halides are those with an electron-withdrawing substituent such as a nitro, cyano or ester group, e.g. a chloro- or fluoro-nitrobenzene or 2-chloro-5-nitropyridine. Alternatively a nitrogen-containing heteroaryl halide can be activated to nucleophilic substitution by N-oxidation, e.g. 2-chloropyridine N-oxide.
- It will be appreciated that if desired the reactions just described may be carried out in the reverse order so that the amination using ArNH2 is performed first with the intermediate of formula (8) followed by alkylation/arylation to yield the compound of formula (5). It may be necessary to protect the nitrogen function of compounds of formula (8) during the course of these reactions. Such protection may be achieved by O-alkylation with an alkyl halide, e.g. cyclopropylmethyl bromide, or an arylalkyl bromide, e.g. benzyl bromide, as shown in Scheme 4.
- The O-alkylation reaction may be performed in an organic solvent such as DMF in the presence of a base, for example an inorganic base such as Cs2CO3 or an organic base such as an amine, e.g. a cyclic amine such as 1,5-diazabicyclo[4.3.0]non-5-ene, at an elevated temperature, e.g. 80 to 100° C., to give a compound of formula (13). Reaction of the protected compound (13) with ArNH2 under palladium catalysis can then be performed as previously described to give a compound of formula (14). Deprotection can then be achieved by treating a solution of this compound in an alcohol, e.g. MeOH, with a mineral acid such as concentrated HCl at an elevated temperature, e.g. the reflux temperature, to give a compound of formula (15). Alternatively when benzyl protection is employed then this group may be removed reductively by treating a solution of compound (14) in an organic solvent such as EtOH using a palladium or platinum catalyst, e.g. palladium on carbon or PtO2, under an elevated pressure of hydrogen at a temperature from around ambient to 60° C. Compounds of formula (15) can then undergo alkylation/arylation reactions as previously described to give compounds of formula (5).
- Intermediate pyridinones of formula (8) may be prepared from pyridine N-oxides of formula (9) by sequential reaction with an anhydride, for example acetic anhydride, at an elevated temperature, for example the reflux temperature, followed by reaction with an inorganic base, for example a carbonate such as aqueous potassium carbonate, in a solvent such as an ether, for example a cyclic ether, e.g. tetrahydrofuran, at around ambient temperature. Alternatively the reaction may be performed using trifluoroacetic anhydride in N,N-dimethylformamide from 0° C. to ambient temperature conditions [see for example Konno et al., Heterocycles, 1986, 24, 2169].
- Pyridine N-oxides of formula (9) may be formed by oxidation of pyridines of formula (10) using an oxidising agent such as hydrogen peroxide in the presence of an acid such as acetic acid, at an elevated temperature, for example around 70° C. to 80° C., or alternatively by reaction with a peracid such as peracetic acid or m-chloroperoxybenzoic acid in a solvent such as a halogenated hydrocarbon, e.g. dichloromethane, or an alcohol, e.g. tert-butanol, at a temperature from the ambient temperature to the reflux temperature.
- Intermediate pyridines of formula (10) in Scheme 3 may be obtained by standard methods such as for example by the Sandmeyer reaction. Thus, for example, a bromide of formula (10) may be prepared by treatment of an aryl amine of formula (11) with an alkyl nitrite, for example tert-butyl nitrite, and a copper salt, for example copper(II) bromide, in the presence of a solvent, for example a nitrile such as acetonitrile, at a temperature from about 0° to around 65° C.
- Amines of formula (11) may be formed from 2-halopyridine-3-carbonitriles of formula (12) by reaction with a reagent such as ethyl 2-mercaptoacetate. The reaction may be performed in the presence of a solvent such as a substituted amide, for example N,N-dimethylformamide, or an ether, e.g. a cyclic ether such as tetrahydrofuran, or an alcohol such as ethanol, in the presence of a base, for example an inorganic base such as sodium carbonate or a hydride, e.g. sodium hydride, or an organic base such as 1,5-diazabicyclo[4.3.0]non-5-ene or a trialkylamine such as triethylamine, at a temperature between about 0° C. and 100° C. The carbonitrile starting materials are readily available or may be obtained from known compounds using standard procedures.
- In another process intermediate esters of formula (5a) may be prepared by the reactions set out in Scheme 5. In the Scheme below R20 represents an ester or nitrile and LG represents a leaving group such as a halogen atom, e.g. chlorine or bromine, or a sulfonyloxy group such as an alkylsulfonyloxy group, e.g. trifluoromethylsulfonyloxy, or an arylsulfonyloxy group, e.g. p-toluenesulfonyloxy.
- Thus, in step (A) of the reaction scheme a compound of formula (17) or (18), where Rx is an optionally substituted alkyl group, e.g. methyl, and W is a hydrogen atom, metal ion or amine salt, may be reacted with a thioamide of formula (19). The reaction may be performed in the presence of a base. Appropriate bases may include, but are not limited to, lithium bases such as n-butyl- or tert-butyllithium or lithium diisopropylamide (LDA), silazanes, e.g. lithium hexamethyldisilazane (LiHMDS) or sodium hexamethyldisilazane (NaHMDS), carbonates, e.g. potassium carbonate, alkoxides, e.g. sodium ethoxide, sodium methoxide or potassium tert-butoxide, hydroxides, e.g. NaOH, hydrides, e.g. sodium hydride, and organic amines, e.g. triethylamine or diisopropylethylamine or a cyclic amine such as N-methylmorpholine or pyridine. The reaction may be performed in an organic solvent such as an amide, e.g. a substituted amide such as N,N-dimethylformamide, an ether, e.g. a cyclic ether such as tetrahydrofuran or 1,4-dioxane, an alcohol, e.g. methanol, ethanol or propanol, or acetonitrile, at a temperature from ambient to the reflux temperature. In one particular aspect of the process the reaction is achieved using an alkoxide base, especially sodium ethoxide or sodium methoxide, in an alcoholic solvent, especially ethanol, at reflux temperature.
- Intermediates of formula (17), where not commercially available, may be prepared using standard methodology (see, for example, Mir Hedayatullah, J. Heterocyclic Chem., 1981, 18, 339). Similarly, intermediates of formula (18), where not commercially available, may be prepared using standard methodology. For example, they may be prepared in situ by reaction of an acetate, e.g. ethyl acetate, with a base such as sodium methoxide followed by addition of a formate, e.g. methyl formate.
- In a similar manner, intermediates of formula (19), if not commercially available, may be prepared using methods known to those skilled in the art (see, for example, Adhikari et al., Aust. J. Chem., 1999, 52, 63-67). For example, an isothiocyanate of formula Cy1NCS may be reacted with acetonitrile in the presence of a base, e.g. NaHMDS, in a suitable solvent, e.g. tetrahydrofuran, optionally at a low temperature, e.g. around −78° C. According to the nature of the group Cy1, the intermediate of formula (19) may be prepared in situ, for example using the methods as described herein, followed by subsequent addition of a compound of formula (17) or (18).
- During the course of this process an intermediate of formula (20) may be formed. If desired the intermediate may be isolated at the end of step (A) and subsequently reacted with intermediate (21) to form the desired amine (22). In some instances, however, it may advantageous not to isolate the intermediate of formula (20) and reaction (B) may be carried out directly with the reaction mixture of step (A).
- If a different solvent is used during the second stage of the process, it may be necessary to evaporate the solvent, in vacuo, from the first stage of the process before proceeding with the second stage. Once evaporated, the crude solids from step (A) may be used in the next stage or they may be purified, for example by crystallisation, to yield an isolated intermediate, such as a compound of formula (20).
- During step (B) of the process an intermediate of formula (21) may then be added to the reaction mixture or to the crude solids or purified product from step (A) in a suitable solvent. Suitable solvents include, but are not limited to, amides, e.g. a substituted amide such as N,N-dimethylformamide, alcohols, e.g. ethanol, methanol or isopropyl alcohol, ethers, e.g. a cyclic ether such as tetrahydrofuran or 1,4-dioxane, and acetonitrile. The reaction may be performed at a temperature from ambient up to the reflux temperature.
- During the course of step (B) an intermediate of formula (24):
may be observed or even isolated, depending upon the nature of the group R20. The intermediate of formula (24) may be converted to a compound of formula (22) using the methods described above. In this situation it may be necessary to add a base, in order for the reaction to proceed to completion. Appropriate bases include carbonates, e.g. caesium or potassium carbonate, alkoxides, e.g. potassium tert-butoxide, hydrides, e.g. sodium hydride, or organic amines, e.g. triethylamine or diisopropylethylamine or cyclic amines such as N-methylmorpholine or pyridine. - Amines of formula (22) can be converted to bromides of formula (23) by standard methods such as for example by the Sandmeyer reaction as previously described for compounds of formula (11). Compounds of formula (5a) can then be prepared from these bromides by the palladium-catalysed amination reactions already described.
- It will be appreciated that intermediates of formula (21), where not commercially available, may be prepared using standard methods known to those skilled in the art. For example, alcohol groups may be converted into leaving groups, such as halogen atoms or sulfonyloxy groups, using conditions known to the skilled artisan. For example, an alcohol may be reacted with thionyl chloride in a halogenated hydrocarbon, e.g., dichloromethane, to yield the corresponding chloride. A base, e.g. triethylamine, may also be used in the reaction.
- The nitriles of formula (23a), which may be prepared from the reaction scheme depicted in Scheme 5 by providing that R20 is —CN, are useful intermediates in the synthesis of intermediate carboxylic acids of formula (25a). This reaction may be performed by hydrolysis of the nitrile (23a) with a base such as an alkali metal hydroxide, e.g. a 2M aqueous solution of sodium hydroxide in an alcoholic solvent such as methanol or ethanol at reflux.
- It will be appreciated that intermediates, such as intermediates (17), (18), (19) or (21), if not available commercially, may also be prepared by methods known to those skilled in the art following procedures set forth in references such as Rodd's Chemistry of Carbon Compounds, volumes 1-15 and Supplementals (Elsevier Science Publishers, 1989), Fieser and Fieser's Reagents for Organic Synthesis, volumes 1-19 (John Wiley and Sons, 1999), Comprehensive Heterocyclic Chemistry, ed. Katritzky et al., volumes 1-8, 1984, and volumes 1-11, 1994 (Pergamon), Comprehensive Organic Functional Group Transformations, ed. Katritzky et al., volumes 1-7, 1995 (Pergamon), Comprehensive Organic Synthesis, ed. Trost and Fleming, volumes 1-9 (Pergamon, 1991), Encyclopedia of Reagents for Organic Synthesis, ed. Paquette, volumes 1-8 (John Wiley and Sons, 1995), Larock's Comprehensive Organic Transformations (VCH Publishers Inc., 1989) and March's Advanced Organic Chemistry (John Wiley and Sons, 1992).
-
- Thus, acids of formula (25) or (25a) may be converted to amides of formula (27) by reaction with amines of formula (3) in the presence of coupling reagents in the same way as previously described for the conversion of compounds (2) to amides of formula (1a). Alternatively, the carboxylic acids may be converted to acid chlorides of formula (26) by reaction with a chlorinating agent such as oxalyl chloride optionally in the presence of a catalytic amount of DMF in a solvent such as a halogenated hydrocarbon, e.g. dichloromethane, or an ether, e.g. a cyclic ether such as tetrahydrofuran, at around ambient temperature; or with a chlorinating agent such as thionyl chloride, typically in a solvent such as toluene, at the reflux temperature. The resultant acid chlorides may then be reacted with amines of formula (3) in a solvent such as a halogenated hydrocarbon, e.g. dichloromethane, in the presence of an amine base such as triethylamine at around ambient temperature to give amides of formula (27). Amides of formula (1a) may then be prepared from amides of formula (27) using a palladium-catalysed arylation procedure previously described in Scheme 1. During the course of the reactions described above it may be advantageous or necessary to protect the Rd substituents that may be present. Conventional protecting groups may be used in accordance with standard practice [see, for example, Greene, T. W. in “Protective Groups in Organic Synthesis”, John Wiley and Sons, 1999]. In some instances, deprotection may be the final step in the synthesis of a compound of formula (1a) and the processes according to the invention described hereinafter are to be understood to extend to such removal of protecting groups.
-
- Thus, a compound of formula (29) can be obtained by reaction of a compound of formula (28) with a metal amide base such as sodium bis(trimethylsilyl)amide in a solvent such as an ether, e.g. a cyclic ether such as tetrahydrofuran, at a temperature of around 0° C. and then adding di-tert-butyl dicarbonate in a solvent such as tetrahydrofuran and stirring at ambient temperature. A compound of formula (1) can then be prepared by the following reaction sequence. A compound of formula (29) is treated with a base such as an alkyl lithium, e.g. n-butyllithium, in a solvent such as an ether, e.g. a cyclic ether such as tetrahydrofuran, at a temperature of around −78° C. Sulfur dioxide gas is bubbled through the reaction mixture before allowing the reaction to warm to room temperature. Solvents are removed in vacuo and the crude material dissolved in a solvent such as a halogenated hydrocarbon, e.g. dichloromethane, and the mixture treated with a chlorinating reagent such as N-chlorosuccinimide at around ambient temperature. An amine of formula (3) can then be added to the reaction mixture to produce a compound of formula (30), where R=tert-butoxycarbonyl. A sulphonamide of formula (1) can then be prepared by treating a compound of formula (30) with an acid, e.g. a mineral acid such as HCl or an organic acid such as trifluoroacetic acid, in a solvent such as a halogenated hydrocarbon, e.g. dichloromethane. Intermediates of formula (28) may be obtained by decarboxylation of compounds of formula (2) with an acid such as a mineral acid, e.g. HCl, in a solvent such as an ether, e.g. a cyclic ether such as tetrahydrofuran or 1,4-dioxane, at a temperature from 50° C. up to the reflux temperature.
- Where in the general processes described above intermediates such as alkylating agents of formula Cy1(Alk1)nZ, reagents of formula HSCH2CO2Et and any other intermediates required in the synthesis of compounds of the invention are not available commercially or known in the literature, they may be readily obtained from simpler known compounds by one or more standard synthetic methods employing substitution, oxidation, reduction or cleavage reactions. Particular substitution approaches include conventional alkylation, arylation, heteroarylation, acylation, thioacylation, halogenation, sulphonylation, nitration, formylation and coupling procedures. It will be appreciated that these methods may also be used to obtain or modify other intermediates and in particular compounds of formula (1) where appropriate functional groups exist in these compounds. Particular examples of such methods are given in the Examples hereinafter.
- Thus for example aromatic halogen substituents in the compounds may be subjected to halogen-metal exchange with a base, for example a lithium base such as n-butyl- or tert-butyllithium, optionally at a low temperature, e.g. around −78° C., in a solvent such as tetrahydrofuran and then quenched with an electrophile to introduce a desired substituent. Thus, for example, a formyl group may be introduced by using N,N-dimethylformamide as the electrophile, a thiomethyl group may be introduced by using dimethyldisulphide as the electrophile, an alcohol group may be introduced by using an aldehyde as the electrophile, and an acid may be introduced by using carbon dioxide as the electrophile. Aromatic acids of formula ArCO2H may also be generated by quenching Grignard reagents of formula ArMgHal with carbon dioxide.
- Aromatic acids of formula ArCO2H generated by this method and acid-containing compounds in general may be converted to activated derivatives, e.g. acid halides, by reaction with a halogenating agent such as a thionyl halide, e.g. thionyl chloride, a phosphorus trihalide such as phosphorus trichloride, or a phosphorus pentahalide such as phosphorus pentachloride, optionally in an inert solvent such as an aromatic hydrocarbon, e.g. toluene, or a chlorinated hydrocarbon, e.g. dichloromethane, at a temperature from about 0° C. to the reflux temperature, or may be converted into Weinreb amides of formula ArC(O)N(OMe)Me by conversion to the acid halide as just described and subsequent reaction with an amine of formula HN(OMe)Me or a salt thereof, optionally in the presence of a base such as an organic amine, e.g. triethylamine, in an inert solvent such as an aromatic hydrocarbon, e.g. toluene, or a chlorinated hydrocarbon, e.g. dichloromethane, at a temperature from about 0° C. to ambient temperature.
- Ester groups such as —CO2Alk6 and —CO2R4 in the compound of formula (1) and intermediates thereto may be converted to the corresponding acid [—CO2H] by acid- or base-catalysed hydrolysis depending on the nature of the group Alk6 or R4. Acid- or -base-catalysed hydrolysis may be achieved for example by treatment with an organic or inorganic acid, e.g. trifluoroacetic acid, in an organic solvent, e.g. dichloromethane, or a mineral acid such as hydrochloric acid in a solvent such as 1,4-dioxane, or an alkali metal hydroxide, e.g. lithium hydroxide, in an aqueous alcohol, e.g. aqueous methanol.
- In a further example, —OR6 [where R6 represents an alkyl group such as methyl] in compounds of formula (1) and intermediates thereto may be cleaved to the corresponding alcohol —OH by reaction with boron tribromide in a solvent such as a halogenated hydrocarbon, e.g. dichloromethane, at a low temperature, e.g. around −78° C.
- Alcohol [—OH] groups may also be obtained by hydrogenation of a corresponding —OCH2R31 group (where R31 is an aryl group) using a metal catalyst, for example palladium, on a support such as carbon in a solvent such as ethanol in the presence of ammonium formate, cyclohexadiene or hydrogen, from around ambient to the reflux temperature. In another example, —OH groups may be generated from the corresponding ester [e.g. —CO2Alk6] or aldehyde [—CHO] by reduction, using for example a complex metal hydride such as lithium aluminium hydride or sodium borohydride in a solvent such as methanol.
- In another example, alcohol [—OH] groups in the compounds may be converted to a corresponding —OR6 group by coupling with a reagent R6OH in a solvent such as tetrahydrofuran in the presence of a phosphine, e.g. triphenylphosphine, and an activator such as diethyl, diisopropyl or dimethyl azodicarboxylate.
- Aminosulphonylamino [—NHSO2NH2] groups in the compounds may be obtained, in another example, by reaction of a corresponding amine [—NH2] with sulphamide in the presence of an organic base such as pyridine at an elevated temperature, e.g. the reflux temperature.
- In another example, compounds containing a —NHCSR7 or —CSNHR7 group may be prepared by treating a corresponding compound containing a —NHCOR7 or —CONHR7 group with a thiation reagent, such as Lawesson's Reagent or P2S5, in an anhydrous solvent, for example a cyclic ether such as tetrahydrofuran, at an elevated temperature such as the reflux temperature.
- In a further example, amine [—NH2] groups may be alkylated using a reductive alkylation process employing an aldehyde and a reducing agent. Suitable reducing agents include borohydrides, for example sodium triacetoxyborohyride or sodium cyanoborohydride. The reduction may be carried out in a solvent such as a halogenated hydrocarbon, e.g. dichloromethane, a ketone such as acetone, or an alcohol, e.g. ethanol, where necessary in the presence of an acid such as acetic acid at around ambient temperature. Alternatively, the amine and aldehyde may be initially reacted in a solvent such as an aromatic hydrocarbon, e.g. toluene, and then subjected to hydrogenation in the presence of a metal catalyst, for example palladium, on a support such as carbon, in a solvent such as an alcohol, e.g. ethanol.
- In a further example, amine [—NH2] groups in compounds of formula (1) and intermediates thereto may be obtained by hydrolysis from a corresponding imide by reaction with hydrazine in a solvent such as an alcohol, e.g. ethanol, at ambient temperature.
- In another example, a nitro [—NO2] group may be reduced to an amine [—NH2], for example by catalytic hydrogenation using for example hydrogen in the presence of a metal catalyst, for example palladium, on a support such as carbon in a solvent such as an ether, e.g. tetrahydrofuran, or an alcohol, e.g. methanol, or by chemical reduction using for example a metal, e.g. tin or iron, in the presence of an acid such as hydrochloric acid.
- In a further example, amine [—CH2NH2] groups in compounds of formula (1) and intermediates thereto may be obtained by reduction of nitriles [—CN], for example by catalytic hydrogenation using for example hydrogen in the presence of a metal catalyst, for example palladium on a support such as carbon, or Raney® nickel, in a solvent such as an ether, e.g. a cyclic ether such as tetrahydrofuran, or an alcohol, e.g. methanol or ethanol, optionally in the presence of ammonia solution at a temperature from ambient to the reflux temperature, or by chemical reduction using for example a metal hydride, e.g. lithium aluminium hydride, in a solvent such as an ether, e.g. a cyclic ether such as tetrahydrofuran, at a temperature from 0° C. to the reflux temperature.
- In another example, sulphur atoms in the compounds, for example when present in a group L1 or L2, may be oxidised to the corresponding sulphoxide or sulphone using an oxidising agent such as a peroxyacid, e.g. 3-chloroperoxybenzoic acid, in an inert solvent such as a halogenated hydrocarbon, e.g. dichloromethane, at around ambient temperature.
- In a further example N-oxides of compounds of formula (1) may in general be prepared for example by oxidation of the corresponding nitrogen base as described above in relation to the preparation of intermediates of formula (5).
- Salts of compounds of formula (1) may be prepared by reaction of compounds of formula (1) with an appropriate base in a suitable solvent or mixture of solvents, e.g. an organic solvent such as an ether, e.g. diethyl ether, or an alcohol, e.g. ethanol, using conventional procedures.
- Where it is desired to obtain a particular enantiomer of a compound of formula (1) this may be produced from a corresponding mixture of enantiomers using any suitable conventional procedure for resolving enantiomers.
- Thus for example diastereomeric derivatives, e.g. salts, may be produced by reaction of a mixture of enantiomers of formula (1), e.g. a racemate, and an appropriate chiral compound, e.g. a chiral base. The diastereomers may then be separated by any convenient means, for example by crystallisation, and the desired enantiomer recovered, e.g. by treatment with an acid in the instance where the diastereomer is a salt.
- In another resolution process a racemate of formula (1) may be separated using chiral High Performance Liquid Chromatography. Alternatively, if desired, a particular enantiomer may be obtained by using an appropriate chiral intermediate in one of the processes described above. Alternatively, a particular enantiomer may be obtained by performing an enantiomer-specific enzymatic biotransformation, e.g. an ester hydrolysis using an esterase, and then purifying only the enantiomerically pure hydrolysed acid from the unreacted ester antipode.
- Chromatography, recrystallisation and other conventional separation procedures may also be used with intermediates or final products where it is desired to obtain a particular geometric isomer of the invention.
- The following Examples illustrate the invention. All temperatures are in 0° C. The following abbreviations are used:
- NMM—N-methylmorpholine; EtOAc—ethyl acetate;
- MeOH—methanol; BOC—tert-butoxycarbonyl;
- DCM—dichloromethane; AcOH—acetic acid;
- DIPEA—diisopropylethylamine; EtOH—ethanol;
- Pyr—pyridine; Ar—aryl;
- DMSO—dimethylsulphoxide; iPr—isopropyl;
- Et2O—diethyl ether; Me—methyl;
- THF—tetrahydrofuran; h—hour;
- MCPBA—3-chloroperoxybenzoicacid; NBS—N-bromosuccinimide;
- FMOC—9-fluorenylmethoxycarbonyl; r.t.—room temperature;
- DBU—1,8-diazabicyclo[5,4,0]undec-7-ene;
- EDC—1-[3-(dimethylamino)propyl]-3-ethylcarbodiimide hydrochloride;
- HOBT—1-hydroxybenzotriazole hydrate;
- BINAP—-2,2′-bis(diphenylphosphino)-1-1′-binaphthyl;
- DMF—N,N-dimethylformamide; dba—dibenzylideneacetone;
- DME—ethylene glycol dimethyl ether;
- p.s.i.—pounds per square inch;
- MTBE—methyl tert-butyl ether;
- m.p.—melting point.
- All NMRs were obtained either at 300 MHz or 400 MHz.
- Compounds were named with the aid of either Beilstein Autonom supplied by MDL Information Systems GmbH, Theodor-Heuss-Allee 108, D-60486 Frankfurt, Germany, or ACD Labs Name (v.6.0) supplied by Advanced Chemical Development, Toronto, Canada.
- LCMS retention times (RT) quoted were generated on a Hewlett Packard 1100 LC/MS using the following method: Phenomenex Luna 3 μC18(2) 50×4.6 mm column; mobile phase A=0.1% formic acid in water; mobile phase B=0.1% formic acid in MeCN; flow rate of 0.9 mLmin−1, column temperature 40° C.
- Gradient:—
Time (minutes) % B % A Initial 5 95 2.0 95 5 3.0 95 5 5.0 5 95 5.5 end end - Where stated alternative LCMS conditions (Conditions B) were used:
- LCMS retention times (RT) quoted were generated on a Hewlett Packard 1100/ThermoFinnigan LCQ Duo LC/MS system using Electrospray ionisation and the following LC method: Phenomenex Luna C18(2) 5μ 100 mm×4.6 mm column; mobile phase A=0.08% formic acid in water; mobile phase B=0.08% formic acid in MeCN; flow rate of 3.0 mLmin−1, column temperature 35° C.
- Gradient:—
Time (min) % A % B 0.00 95.0 5.0 4.40 5.0 95.0 5.30 5.0 95.0 5.32 95.0 5.0 6.50 95.0 5.0
Intermediate 1 - A mixture of 2-chloro-3-cyanopyridine (330 g, 2.3 mol), ethyl 2-mercaptoacetate (361.2 g, 3.0 mol), sodium carbonate (265 g, 2.5 mol) and EtOH (1.2 L) was heated to reflux for 4.5 hours. The reaction mixture was cooled to ambient temperature and added to water (15 L). The resultant precipitate was stirred for 30 minutes and then filtered. The filter cake was washed with two portions of water (2×2.5 L) and dried to constant weight under vacuum at 45° C. to yield the title compound as a brown solid (493.1 g, 93.2%). δH (CDCl3) 8.68 (1H, dd, J 4.7, 1.2 Hz), 7.93 (1H, dd, J 8.5, 1.2 Hz), 7.29 (1H, dd, J 8.5, 4.7 Hz), 5.90 (2H, b), 4.38 (2H, q, J 7.0 Hz), 1.40 (3H, t, J 7.0 Hz). LCMS RT 2.9 minutes, 223 (M+H)+.
- Intermediate 2
- Intermediate 1 (363.6 g) was added in portions over two hours to a mixture of copper(II) bromide (403.3 g), tert-butyl nitrite (220.6 g) and acetonitrile (3.6 L) stirred at a temperature of 20 to 25° C. The mixture was stirred at 20° C. for 2 hours before it was slowly added to 2M HCl(aq) (4.2 L). The reaction mixture slurry was filtered and the solids were washed with water (500 mL). The combined filtrate was extracted with ethyl acetate (8 L); this ethyl acetate solution was washed with 2M HCl(aq) (2.2 L). The solids were dissolved in ethyl acetate (6 L); this solution was washed twice with 2M HCl(aq) (4.4 L and 2.2 L). The two ethyl acetate solutions were then combined and washed with 2M HCl(aq) (2.2 L) and twice with water (2×2 L). The ethyl acetate solution was then dried (MgSO4), filtered and concentrated in vacuo at 40 mbar and 60° C. to give a solid residue. This was broken up and dried to constant weight under vacuum at 45° C. to yield the title compound as a brown solid (458.5 g, 97.9%). δH (DMSO-d6) 8.89 (1H, d, J 4.7 Hz), 8.47 (1H, d, J 8.6 Hz), 7.71 (1H, dd, J 8.6, 4.7 Hz), 4.46 (2H, q, J 7.2 Hz), 1.40 (3H, t, J 7.2 Hz). LCMS RT 3.8 minutes, 288 (M+H)+.
- Intermediate 3
- To a slurry of Intermediate 2 (214 g, 0.747 mol) in DCM (2140 mL) under nitrogen was added 70% mCPBA (240 g, 0.97 mol) portionwise over 0.5 h. The reaction was then stirred at room temperature for 18 h. The reaction mixture was quenched with water (800 mL) and pH adjusted to 8.5 with 10% w/v sodium carbonate solution (1250 mL). The basic aqueous layer was removed and the organic layer washed with water until pH 7. The organic layer was concentrated in vacuo and the crude title product was recovered as a tan solid. The crude product was purified by slurrying in MTBE (600 mL) for 1 h at 0-5° C. to give the title compound (174 g, 77%). δH (CDCl3) 8.44 (1H, dd, J 6.2, 0.8 Hz), 7.87 (1H, dd, J 8.3, 0.8 Hz), 7.48 (1H, dd, J 8.3, 6.2 Hz), 4.49 (2H, q, J 7.1 Hz), 1.48 (3H, t, J 7.1 Hz). LCMS (ES+) RT 2.61 minutes, 302 (M+H)+.
- Intermediate 4
- To a suspension of Intermediate 3 (95 g, 0.32 mol) in DMF (950 mL) and stirred at room temperature was added trifluoroacetic anhydride (198 g, 131 mL, 0.94 mol) dropwise over a 30 minute period (slight exotherm observed). After complete addition the reaction was stirred for a further 45 minutes at room temperature. The excess trifluoroacetic anhydride was removed under vacuum and the reaction mixture concentrated to approximately half the original volume. The resulting dark coloured solution was then poured onto a mixture of water (1 L) and toluene (400 mL). The mixture was left to stand for around 10 minutes and then the precipitate was collected by filtration. The precipitate was washed with toluene (3×50 mL) and then dried in a vacuum oven at 50-60° C. This gave the title compound as a beige coloured solid (68.5 g, 72.1%). δH (DMSO-d6) 12.20 (1H, brs), 7.75 (1H, d, J 9.0 Hz), 6.50 (1H, d, J 9.0 Hz), 4.15 (2H, q, J 7.1 Hz), 1.12 (3H, t, J 7.1 Hz). LCMS (ES+) RT 2.86 minutes, 302 (M+H)+. m.p. 261.7-268.1° C.
- Intermediate 5
- Method A
- A 3 L jacketed vessel was charged with Intermediate 4 (100 g, 0.332 mol), CuI (15.8 g, 0.083 mol), phenylboronic acid (80 g, 0.664 mol), pyridine (104 g, 1.32 mol) and acetonitrile (2.0 L) and the mixture stirred at 40° C. Compressed air was vigorously blown through the reaction mixture for 6 hours. The compressed air was then turned off and the reaction mixture left to stir at 40° C. overnight. The next day the same process was repeated. After approximately 36 hours, HPLC indicated >97% conversion of starting material to the product. The resulting dark coloured reaction mixture was poured onto a mixture of water (1.2 L) and concentrated hydrochloric acid (300 mL). The mixture was extracted with dichloromethane (2×1.5 L) and the combined organics washed with 2M HCl(aq) (2×1.5 L). The organic layer was separated, passed through a pad of MgSO4, and concentrated in vacuo. The crude residue was recrystallised from toluene (600 ml) to give the title compound as a beige solid (93.85 g, 75.0%). δH (CDCl3) 7.82 (1H, d, J 8.5 Hz), 7.70-7.62 (3H, m), 7.54-7.42 (2H, m), 6.70 (1H, d, J 8.5 Hz), 4.15 (2H, q, J 7.1 Hz), 1.14 (3H, t, J 7.1 Hz). LCMS (ES+) RT 3.75 minutes, 378 (M+H)+. MP=201.6-206.0° C.
- Method B (Alternative Procedure)
- To a 2 necked round bottomed flask was added in sequence Intermediate 4 (302 mg, 1.00 mmol), copper(II) acetate (278 mg, 1.50 mmol), phenylboronic acid (488 mg, 4.00 mmol), DCM (5 mL) and pyridine (158 mg, 2.00 mmol). The reaction was stirred at room temperature for 18 h with the exclusion of moisture. The reaction was then diluted with DCM (50 mL), washed with 2M HCl(aq) (50 mL), the aqueous was re-extracted with DCM (50 mL). The combined organics were then washed with water (50 mL), dried (MgSO4) and concentrated in vacuo. The crude product was purified by a slurry in methanol (12 mL), to give the title compound as a beige solid (270 mg, 72%). δH (CDCl3) 7.82 (1H, d, J 8.5 Hz), 7.70-7.62 (3H, m), 7.54-7.42 (2H, m), 6.70 (1H, d, J 8.5 Hz), 4.15 (2H, q, J 7.1 Hz), 1.14 (3H, t, J 7.1 Hz). LCMS (ES+) RT 3.75 minutes, 378 (M+H)+.
- Intermediate 6
- A flask was charged with Intermediate 4 (15.1 g, 0.05 mol), copper(II) acetate (13.62 g, 0.075 mol), 4-tolylboronic acid (14.0 g, 0.1 mol), DCM (500 mL) and pyridine (25 mL, 0.3 mol) and the mixture stirred at r.t. for 24 h. The reaction mixture was washed with 2M HCl (2×200 mL), 5% NaOH (aq) (200 mL), brine (200 mL) and dried (MgSO4). Solvent was removed in vacuo and the resultant solid triturated with methanol to give the title compound as a solid (15.7 g). δH (CDCl3) 7.76 (1H, d, J 9.7 Hz), 7.33 (2H, d, J 8.3 Hz), 7.18 (2H, d, J 8.3 Hz), 6.64 (1H, d, J 9.7 Hz), 4.24 (2H, q, J 7.1 Hz), 2.39 (3H, s), 1.26 (3H, t, J 7.1 Hz). LCMS (ES+) RT 3.86 minutes, 394 (M+H)+.
- Intermediate 7
- From Intermediate 4 and 4-fluorophenylboronic acid by the method of Intermediate 6. White solid. δH (CDCl3) 7.84 (1H, d, J 9.7 Hz), 7.41-7.37 (2H, m), 7.32-7.25 (2H, m), 6.72 (1H, d, J 9.7 Hz), 4.33 (2H, q, J 7.1 Hz), 1.34 (3H, t, J 7.1 Hz). LCMS (ES+) RT 3.729 minutes, 397.8 (M+H)+.
- Intermediate 8
- From Intermediate 4 and 4-chlorophenylboronic acid by the method of Intermediate 6. δH (CDCl3) 7.86 (1H, d, J 9.6 Hz), 7.60 (2H, d, J 8.5 Hz), 7.37 (2H, d, J 8.5 Hz), 6.74 (1H, d, J 9.6 Hz), 4.35 (2H, q, J 7.1 Hz), 1.36 (3H, t, J 7.1 Hz). LCMS (ES+) RT 3.937 minutes, 413 (M+H)+.
- Intermediate 9
- From Intermediate 4 and 3-methylphenylboronic acid by the method of Intermediate 6. δH (CDCl3) 7.85 (1H, d, J 9.6 Hz), 7.51-7.48 (1H, m), 7.38-7.27 (1H, m), 7.29 (2H, br m), 6.75 (1H, d, J 9.6 Hz), 4.34 (2H, q, J 7.1 Hz), 2.46 (3H, s), 1.35 (3H, t, J 7.1 Hz). LCMS (ES+) RT 3.865 minutes, 393 (M+H)+.
- Intermediate 11
- Sodium hydride (60% in mineral oil) (3.27 g, 81.4 mmol) was added in portions to a solution of Intermediate 4 (22.3 g, 74 mmol) in DMF (300 mL) at 0° C. The mixture was stirred at r.t. for 30 min then cyclopropylmethyl bromide (10 g, 74 mmol) was added slowly and the mixture heated at 60° C. overnight. The DMF was removed in vacuo and the residue partitioned between EtOAc and brine. The organic phase was dried (MgSO4) and concentrated in vacuo. Purification by column chromatography (silica, 0% to 10% EtOAc in DCM) gave the title compound as a yellow solid (12.5 g, 47%). δH (CDCl3) 7.57 (1H, d, J 9.5 Hz), 6.47 (1H, d, J 9.5 Hz), 4.22 (2H, q, J 7.0 Hz), 3.87 (2H, d, J 7.1 Hz), 1.26-1.19 (4H, m), 0.43-0.37 (4H, m). LCMS (ES+) RT 3.80 minutes, 357 (M+H)+.
- Intermediate 12
- Intermediate 5 (1.00 g, 2.64 mmol), tris(dibenzylideneacetone)dipalladium(0) (0.121 g, 0.132 mmol) and BINAP (0.164 g, 0.264 mmol) were stirred in toluene (12 mL) for 5 min. 4-Fluoro-3-methylaniline (0.397 g, 3.172 mmol) and cesium carbonate (1.205 g, 3.701 mmol) were added and the mixture was heated at reflux under N2 for 24 h. The mixture was dissolved in THF (100 mL) and washed with water. The combined organics were dried (Na2SO4) and concentrated in vacuo. The residue was triturated with MeOH to produce the title compound as a white solid (0.754 g). δH (DMSO-d6) 8.72 (1H, s), 7.67-7.60 (3H, m), 7.51-7.49 (2H, m), 7.18-7.10 (3H, m), 7.09-6.99 (1H, m), 6.39 (1H, d, J 9.7 Hz), 4.15 (2H, q, J 7.07 Hz), 2.22 (3H, s), 1.72 (3H, t, J 7.08 Hz). LCMS (ES+) 423 (M+H)+.
- Intermediate 13
- Tris(dibenzylideneacetone)dipalladium(0) (1.21 g, 1.32 mmol) was added to a mixture of Intermediate 5 (10 g, 26.4 mmol), caesium carbonate (12.05 g, 37.0 mmol), 2,4-difluoroaniline (4.1 g, 3.23 mL, 31.7 mmol) and BINAP (1.65 g, 2.64 mmol) in anhydrous toluene (80 mL) and the reaction heated to reflux under nitrogen for 4 days. The reaction was cooled, partitioned between DCM and water and the organic phase dried (MgSO4) and evaporated in vacuo. The crude residue was triturated with methanol to give the title compound as a white solid (9.87 g). δH (CDCl3) 8.49 (1H, bs), 7.58-7.40 (3H, m), 7.32-7.25 (2H, m), 7.13-7.04(1H, m), 7.01 (1H, d, J 9.8 Hz), 6.93-6.86 (1H, m), 6.82-6.75 (1H, m), 6.31 (1H, d, J, 9.8 Hz), 4.20 (2H, q, J 7.1 Hz), 1.23 (3H, J 7.1 Hz). LCMS (ES+) RT 4.06 minutes, 427 (M+H)+.
- The Intermediate esters 14-26 were prepared following a procedure similar to that described for Intermediate 13. Therefore to an oven dried reaction flask was added a magnetic stirrer, the appropriate substituted aniline (1.2 equiv.), anhydrous toluene, Intermediate 5 (1.0 equiv.), caesium carbonate (1.4 equiv.), tris(dibenzylideneacetone)dipalladium(0) (5 mol %) and BINAP (10 mol %). The reactions were heated to reflux under nitrogen and with magnetic stirring for 24-48 h. Each reaction was then diluted with DCM, washed with water, dried (MgSO4) and concentrated in vacuo. The crude products were either purified on silica eluting with a gradient of EtOAc in DCM or alternatively by trituration with methanol or ethyl acetate to give the title compounds as solids.
- Intermediate 14
- From Intermediate 5 and aniline to give the title compound as a white solid. δH (CDCl3) 8.70 (1H, bs), 7.57-7.47 (3H, m), 7.33-7.25 (4H, m), 7.20-7.10 (4H, m), 6.27 (1H, d, J 9.7 Hz), 4.19 (2H, q, J 7.1 Hz), 1.22 (3H, t, J 7.1 Hz). LCMS (ES+) RT 4.10 minutes, 391 (M+H)+.
- Intermediate 15
- From 2-chloroaniline and Intermediate 5 to give the title compound as a solid. δH (CDCl3) 8.60 (1H, bs), 7.56-7.48 (3H, m), 7.40-7.38 (1H, m), 7.36-7.32 (2H, m), 7.20-7.15 (2H, m), 7.14-7.05 (1H, m), 7.05-6.98 (1H, m), 6.35 (1H, d, J 9.8 Hz), 4.21 (2H q, J 7.1 Hz), 1.23 (3H, t, J 7.1 Hz). LCMS (ES+) RT 4.38 minutes, 425 (M+H)+.
- Intermediate 16
- From 3-cyanoaniline and Intermediate 5 to give the title compound an off-white solid. δH (CDCl3) 8.58 (1H, bs), 7.61-7.43 (3H, m), 7.40-7.20 (6H, m), 7.14 (1H, d, J 9.8 Hz), 6.38 (1H, d, J 9.8 Hz), 4.19 (2H, q, J 7.1 Hz), 1.23 (3H, t, J 7.1 Hz). LCMS (ES+) RT 3.78 minutes, 416 (M+H)+.
- Intermediate 17
- From 2-cyanoaniline and Intermediate 5 to give the title compound. δH (CDCl3) 8.72 (1H, bs), 7.61-7.47 (4H, m), 7.43-7.40 (1H, m), 7.36-7.31 (2H, m), 7.22-7.15 (1H, m), 7.11-7.00 (2H, m), 6.40 (1H, d, J 9.8 Hz), 4.22 (2H, q, J 7.1 Hz), 1.24 (3H, t, J 7.1 Hz). LCMS (ES+) RT 3.80 minutes, 416 (M+H)+.
- Intermediate 20
- From Intermediate 5 and 3-chloro-4-fluoroaniline to give the title compound as a solid. δH (CDCl3) 8.70 (1H, s), 7.67-7.59 (3H, m), 7.44-7.41 (2H, m), 7.24-7.02 (4H, m), 6.43 (1H, d, J 9.8 Hz), 4.28 (2H, q, J 7.1 Hz), 1.31 (3H, t, J 7.1 Hz). LCMS (ES+) RT 4.245 minutes, 443 (M+H)+.
- Intermediate 22
- From Intermediate 8 and 4-fluoro-3-methylaniline to give the title compound as a solid. δH (CDCl3) 8.72 (1H, br s), 7.58-7.38 (2H, m), 7.35-7.28 (2H, m), 6.99-6.98 (4H, m), 6.34 (1H, d, J 9.8 Hz), 4.28 (2H, q, J 7.1 Hz), 2.29 (3H, s), 1.32 (3H, t, J 7.1 Hz). LCMS (ES+) RT 4.57 minutes, 457 (M+H)+.
- Intermediate 23
- From Intermediate 9 and 4-fluoro-3-methylaniline to give the title compound as a solid. δH (CDCl3) 8.63 (1H, br s), 7.40-7.15 (1H, m), 7.30-7.27 (1H, m), 7.18-7.10 (2H,m), 7.04-6.90 (4H, m), 6.27 (1H, d, J 9.7 Hz), 4.18 (2H, q, J 7.1 Hz), 2.21 (3H, s), 2.20 (3H, s), 1.21 (3H, t, J 7.1 Hz). LCMS (ES+) RT 4.469 minutes, 437 (M+H)+.
- Intermediate 24
- From Intermediate 9 and 3-methylaniline to give the title compound as a solid. δH (CDCl3) 8.55 (1H, br s), 7.32-7.28 (1H, m), 7.27-7.17 (1H, m), 7.08-7.00 (4H, m), 7.88-7.75 (3H, m), 6.15 (1H, d, J 9.8 Hz), 4.08 (2H, q, J 7.1 Hz), 2.27 (3H, s), 2.17 (3H, s), 1.12 (3H, t, J 7.1 Hz). LCMS (ES+) RT 4.543 minutes, 419 (M+H)+.
- Intermediate 26
- From Intermediate 11 and aniline to give the title compound. Pale yellow solid. δH (CDCl3) 8.71 (1H, br s), 7.29-7.22 (2H, m), 7.10-6.97 (4H, m), 6.18 (1H, d, J 9.7 Hz), 4.27 (2H, q, J 7.1 Hz), 3.94 (2H, d, J 7.2 Hz), 1.40-1.33 (1H, m), 1.32 (3H, t, J 7.1 Hz), 0.53-0.48 (4H, m). LCMS (ES+) RT 3.79 minutes, 369.0 (M+H)+.
- Intermediate 27
- Intermediate 12 (0.494 g, 1.170 mmol) was dissolved in EtOH/THF/H2O (2:1:1) (20 mL), heated to 80° C. and treated with LiOH.H2O (0.054 g, 1.287 mmol). Reaction was continued until no starting material remained (as judged by TLC). The solvent was removed in vacuo and the residue azeotroped with toluene to give the title compound as a beige solid (0.284 g). δH (DMSO-d6) 7.81-7.75 (3H, m), 7.64-7.62 (2H, m), 7.41-7.38 (1H, d, J 9.55 Hz), 7.20-7.15 (1H, t, J 9.01 Hz), 7.04-7.03 (1H, br m), 6.93-6.90 (1H, br m), 6.48-6.46 (1H, d, J 9.54 Hz), 2.35 (3H, s). LCMS (ES+) 395 (M+H)+.
- Intermediate 28
- The title compound was prepared from Intermediate 13 (6.34 g, 14.9 mmol) and lithium hydroxide monohydrate (686 mg, 16.4 mmol) following the method of intermediate 27. δH (DMSO-d6) 10.04 (1H, bs), 7.81 (3H, m), 7.69 (2H, m), 7.50 (1H, m), 7.48 (1H, d, J 9.6 Hz), 7.16 (2H, m), 7.56 (1H, d, J 9.6 Hz).
- Intermediate 29
- A solution of sodium hydroxide (339 mg, 8.5 mmol, 1.1 equiv.) in water (20 mL) was added to a suspension of Intermediate 14 (3.0 g, 7.7 mmol, 1.0 equiv.) in ethanol (50 mL) and the mixture heated at reflux for 2 h. The bulk of the ethanol was removed in vacuo and the residue treated with sat. ammonium chloride solution(aq) (30 mL). The resultant solid was collected by filtration, washed with water (2×20 mL), Et2O (2×20 mL) and dried in vacuo at room temperature to give the title compound as a white solid in quantitative yield. δH (DMSO-d6) 9.60 (1H, bs), 7.65-7.57 (3H, m), 7.49-7.46 (2H, m), 7.29-7.18 (3H, m), 6.97-6.91 (3H, m), 6.34 (1H, d, J 9.6 Hz). LCMS (ES+) RT 3.24 minutes, 363 (M+H)+.
- Intermediate 30
- The title compound was prepared from Intermediate 22 (1.0 g, 2.1 mmol) and sodium hydroxide (100 mg, 2.6 mmol, 1.2 equiv.) following a procedure analogous to that used for Intermediate 29. Instead of treating with a saturated ammonium chloride solution the volatiles were removed in vacuo and the residue triturated with EtOAc to give the title compound as a solid (800 mg). δH (DMSO-d6) 9.74 (1H, bs), 7.67 (2H, dd, J 6.6, 2.1 Hz), 7.54 (2H, dd, J 6.6, 2.1 Hz), 7.24 (1H, d, J 9.6 Hz), 7.20-7.01 (1H, m), 6.90-6.80 (1H, m), 6.85-6.75 (1H, m), 6.31 (1H, d, J 9.5 Hz), 4.68 (3H, s). LCMS (ES+) RT 3.51 minutes, 429 (M+H)+.
- Intermediate 31
- The title compound was prepared from Intermediate 23 (1.0 g, 2.2 mmol) and sodium hydroxide (183 mg, 4.4 mmol) following the procedure of Intermediate 30 to give the title compound as a solid (1.0 g). δH (DMSO-d6) 7.56 (1H, t, J 7.7 Hz), 7.44 (1H, d, J 7.7 Hz), 7.38-7.24 (3H, m), 7.07 (1H, t, J 9.1 Hz), 6.96-6.91 (1H, m), 6.88-6.75 (1H, m), 6.37 (1H, d, J 9.6 Hz), 2.47 (3H, s), 2.25 (3H, s).
- Intermediate 32
- The title compound was prepared from Intermediate 24 (1.0 g, 2.3 mmol) and sodium hydroxide (140 mg, 3.5 mmol) following the procedure of Intermediate 30 to give the title compound as a solid (842 mg). δH (DMSO-d6) 9.81 (1H, bs), 7.55 (1H, t, J 7.6 Hz), 7.47 (1H, d, J 12 Hz), 7.42-7.24 (3H, m), 7.18 (1H, t, J 7.7 Hz), 6.80-6.75 (3H, m), 6.37 (1H, J 9.5 Hz), 2.46 (3H, s), 2.31 (3H, s).
- Intermediate 33
- The title compound was prepared from Intermediate 20 (1.0 g, 2.2 mmol) and sodium hydroxide (100 mg, 2.69 mmol) following the procedure of Intermediate 30 to give the title compound as a solid (680 mg). δH (DMSO-d6) 9.78 (1H, bs), 7.61-7.59 (3H, m), 7.55-7.46 (2H, m), 7.30-7.24 (2H, m), 7.09-7.06 (1H, m), 6.90-6.88 (1H, m), 6.34 (1H, d, J 9.4 Hz). LCMS (ES+) RT 3.41 minutes, 414 (M+H)+.
- Intermediate 34
- EDC (0.163 g, 0.852 mmol) was added to a solution of Intermediate 27 (0.284 g, 0.710 mmol) in DMF (10 mL) and the mixture stirred at r.t. for 30 min. Pentafluorophenol (0.196 g, 1.065 mmol) was added and the mixture stirred at r.t. for 24 h. The solvent was removed in vacuo and the residue was dissolved in DCM which was then washed with water, dried (MgSO4) and concentrated in vacuo. Purification by column chromatography (silica, 50% Hexane/EtOAc) to produce the title compound as a white solid (0.226 g). δH (DMSO-d6) 8.96 (1H, s), 7.07-6.95 (5H, br m), 7.55-7.39 (4H, br m), 6.29 (1H, d, J 9.86 Hz), 2.08 (3H, s). LCMS (ES+) 561 (M+H)+.
- Intermediate 35
- The title compound was prepared from Intermediate 28 following the method of Intermediate 34 to give the product as a white solid. δH (CDCl3) 8.66 (1H, bs), 7.76 (3H, m), 7.58 (2H, m), 7.47 (1H, m), 7.14 (3H, m), 6.54 (1H, d, J 9.9 Hz). LCMS (ES+) RT 4.57 minutes, 565 (M+H)+.
- Intermediate 36
- Sodium hydroxide (1.83 g, 45.8 mmol, 1.1 equiv.) was added to a suspension of Intermediate 5 (15.75 g, 41.6 mmol, 1.0 equiv.) in ethanol (78 mL) and water (78 ml) at room temperature. The reaction mixture was then heated to reflux. Once reflux was attained the solid material had gone into solution and analysis by HPLC indicated complete conversion to the acid. The reaction mixture was then cooled to ˜70° C. and c.hydrochloric acid (46 ml) added over a 10 minute period. The reaction was allowed to cool to room temperature and the resultant solid collected by filtration, washed with water (3×25 ml) and dried in vacuo to give the title compound as a beige solid (13.81 g, 97%). δH (DMSO-d6) 8.13 (1H, d, J 9.6 Hz), 7.92-7.80 (3H, m), 7.78-7.74 (2H, m), 6.92 (1H, d, J 9.6 Hz).
- Intermediate 37
- The title compound was prepared from Intermediate 6 (16.0 g, 40.3 mmol) following the method of Intermediate 36 to give the product as a solid (13.84 g). δH (DMSO-d6) 7.85 (1H, d, J 9.6 Hz), 7.45-7.38 (4H, m), 6.65 (1H, d, J 9.6 Hz), 2.42 (3H, s).
- Intermediate 38
- A solution of lithium hydroxide monohydrate (0.87 g, 20.8 mmol) in water (30 mL) was added to a solution of Intermediate 7 (5.5 g, 13.9 mmol) in dioxane (100 mL) and the reaction stirred at r.t. for 4 h. Concentrated hydrochloric acid was added dropwise until the product had precipitated. The resultant solid was collected by filtration, washed with water (2×30 mL), diethyl ether (2×30 mL) and dried in a vacuum oven to give the title compound as a solid (4.65 g, 91%). δH (DMSO-d6) 7.66 (1H, d, J 9.6 Hz), 7.43-7.38 (2H, m), 7.30-7.24 (2H, m), 6.46 (1H, d, J 9.6 Hz).
- Intermediate 39
- To a solution of Intermediate 36 (10.0 g, 28.6 mmol) and DMF (2 drops) in THF (150 mL) was added oxalyl chloride (3.26 mL, 37.4 mmol), via syringe, over a 30 minute period. The reaction mixture was stirred for a further 30 minutes at room temperature before removing solvent and excess reagent in vacuo to give the intermediate acid chloride as a beige solid. This acid chloride was dissolved in DCM (150 mL) and added over 45 minutes to a mixture of (R)-2-pyrrolidinemethanol (2.88 g, 28.5 mmol) and triethylamine (4.36 mL, 31.3 mmol) in 100 mL of dichloromethane. After complete addition the reaction was stirred for 1 h at ambient temperature. The reaction mixture was poured onto water (200 mL), the DCM layer separated and the aqueous re-extracted with DCM (100 mL). The combined organic layers were then washed with water (200 mL), dried (MgSO4) and evaporated to give the title compound as a light brown solid (12.83 g). δH (CDCl3) 7.70 (1H, d, J 9.6 Hz), 7.50-7.60 (3H, m), 7.35-7.45 (2H, m), 6.75 (1H, d, J 9.6 Hz), 4.25-4.35 (1H, m), 4.00 (1H, br s), 3.45-3.80 (4H, m), 1.52-2.55 (4H, m). LCMS (ES+) RT 2.52 minutes, 433.1 (M+H)+.
- Intermediate 40
- To a suspension of Intermediate 37 (6.4 g, 17.5 mmol) in DCM (80 mL) was added EDC (5.04 g, 26 mmol) and the reaction stirred at r.t. for 1 h. (R)-2-pyrrolidinemethanol (2.6 mL, 26 mmol) was added and the reaction stirred for 18 h at room temperature. The reaction was diluted with DCM (10 mL), washed with brine, dried (MgSO4) and concentrated in vacuo. The crude residue was purified by chromatography (silica, 30-50% EtOAc in DCM) to give the title compound as a white solid (3.44 g, 43%). δH (CDCl3) 7.65 (1H, d, J 9.6 Hz), 7.37 (2H, d, J 8.2 Hz), 7.20-7.19 (2H, m), 6.66 (1H, d, J 9.6 Hz), 4.25-4.23 (1H, m), 3.80-3.40 (4H, m), 2.37 (3H, s), 2.13-2.04 (1H, m), 1.79-1.53 (3H, m). LCMS (ES+) RT 2.92 minutes, 449 (M+H)+.
- Intermediate 41
- The title compound was prepared from Intermediate 38 and (R)-2-pyrrolidinemethanol following the method described for Intermediate 40 to give the product as a solid. LCMS (ES+) RT 2.83 minutes, 452 (M+H)+.
- Intermediate 42
- To a 1 L round bottomed flask was added the Intermediate 39 (12.5 g, 28.8 mmol), dihydropyran (12.1 g, 144.8 mmol), p-toluenesulphonic acid (55 mg, 0.29 mmol) and dichloromethane (5000 mL). The reaction mixture was then stirred at room temperature for 5 hours. The reaction mixture was poured onto water (200 mL), saturated brine (100 mL) and sodium bicarbonate solution (100 mL). The layers were separated and the aqueous layer re-extracted with dichloromethane (100 mL). The combined organic layers were then washed with the above aqueous mixture, dried (MgSO4) and evaporated to dryness. Purification by column chromatography (270 g silica gel) eluting with ethyl acetate gave the title compound as a light brown solid/foam (12.73 g). δH (DMSO-d6) 7.80 (1H, d, J 9.6 Hz), 7.70-7.45 (5H, m), 6.60 (1H, d, J 9.6 Hz), 4.50 (1H, m), 4.15 (1H, br s), 3.35-3.80 (5H, m), 1.30-2.00 (10H, m). LCMS (ES+) RT 3.65 minutes, 519.1 (M+H)+.
- Intermediate 43
- The title compound was prepared from Intermediate 40 (3.44 g, 7.6 mmol) following the procedure used for Intermediate 42. This gave the title compound as a light brown solid (4.85 g). δH (CDCl3) 7.63 (1H, d, J 9.6 Hz), 7.28 (2H, d, J 7.8 Hz), 7.17 (2H, m), 6.63 (1H, d, J 9.6 Hz), 4.48-4.28 (2H, m), 3.85-3.30 (6H, m), 2.36 (3H, s), 2.15-1.70 (7H, m), 1.48-1.46 (3H, m). LCMS (ES+) RT 3.69 minutes, 533 (M)+.
- Intermediate 44
- The title compound was prepared from Intermediate 41 (1.0 g, 2.21 mmol) following the procedure used for Intermediate 42. This gave the title compound as a light brown oil (0.95 g). δH (CDCl3) 7.90 (1H, d, J 9.6 Hz), 7.69 (2H, m), 7.56 (2H, t, J 8.7 Hz), 6.73 (1H, d, J 9.6 Hz), 4.61-4.57 (1H, m), 3.97-3.37 (8H, m), 1.97-1.50 (9H, m). LCMS (ES+) RT 3.51 minutes, 560 (M+Na)+.
- Intermediate 45
- To a dry 500 ml 2 necked round bottomed flask, fitted with nitrogen inlet/outlet, was added Cs2CO3 (11.2 g, 31.7 mmol), (+/−)-BINAP (1.53 g, 2.46 mmol), Intermediate 42 (12.73 g, 24.6 mmol) and Pd2(dba)3 (1.12 g, 1.22 mmol). To this mixture was added anhydrous toluene (200 mL), which had been thoroughly degassed, and then 2,4-difluoroaniline (3.49 g, 27.0 mmol) and the reaction heated at reflux under nitrogen for 48 h. The reaction mixture was cooled to ambient and then poured onto 1.0M HCl(aq) (300 mL). This was extracted with dichloromethane (2×100 mL) and the combined organics washed with 1.0M HCl(aq) (2×300 mL), dried (MgSO4) and concentrated in vacuo to give a brown oil. The crude product was purified by column chromatography (silica, 3:2 ethyl acetate:heptane) to give the title compound as a light yellow solid (7.32 g). δH (DMSO-d6) 8.75 (1H, s), 7.75 (1H, d, J 8.3 Hz), 7.70-7.60 (3H, m), 7.55-7.43 (2H, m), 7.35-7.22 (1H, m), 7.05-6.88 (2H, m), 6.50 (1H, d, J 9.6 Hz), 4.62 (1H, bs), 4.45-4.30 (1H, m), 3.65-2.75 (6H, m), 1.90-1.20 (10H, m). LCMS (ES+) RT 3.01 minutes, 566 (M+H)+.
- Intermediate 46
- The title compound was prepared from Intermediate 42 (2.5 g, 4.84 mmol) and m-toluidine (0.62 mL, 5.8 mmol) following the method of Intermediate 45 to give the product as an orange solid (2.27 g). δH (CDCl3) 7.76 (3H, m), 7.66 (3H, m), 7.30 (1H, m), 7.00 (3H, m), 6.54 (1H, d, J 9.7 Hz), 4.68 (1H, m), 4.65 (1H, m), 3.90-3.50 (6H, m), 2.46 (3H, s), 2.10-1.50 (10H, m). LCMS (ES+) RT 3.99 minutes, 544 (M+H)+.
- Intermediate 47
- The title compound was prepared from Intermediate 42 (1.7 g, 3.3 mmol) and 3-choroaniline (0.42 mL, 3.9 mmol) following the method of Intermediate 45 to give the product as a brown solid (900 mg). δH (CDCl3) 7.66 (3H, m), 7.35 (3H, m), 7.19 (1H, m), 6.94 (2H, m), 6.93 (1H, m), 6.42 (1H, d, J 9.67 Hz), 4.53 (1H, m), 4.48 (1H, m), 3.75-3.36 (6H, m), 2.00-1.4 (10H, m). LCMS (ES+) RT 3.90 minutes, 564 (M+H)+.
- Intermediate 48
- The title compound was prepared from Intermediate 43 (1.5 g, 2.8 mmol) and 2,4-difluoroaniline (0.35 mL, 3.3 mmol) following the method of Intermediate 45 to give the product as a solid (1.14 g, 69%). δH (CDCl3) 9.33 (1H, bs), 7.39-7.30 (2H, m), 7.19-7.14 (3H, m), 6.96 (1H, dd, J 14.6, 9.1 Hz), 6.84 (1H, t, J 2.6 Hz), 6.73 (1H, t, J 8.2 Hz), 6.35 (1H, d, J 9.8 Hz), 4.48-4.38 (2H, m), 3.75-3.30 (6H, m), 2.39 (3H, s), 1.97-1.50 (4H, m), 1.49-1.25 (6H, m).
- Intermediate 49
- The title compound was prepared from Intermediate 43 (1.5 g, 2.8 mmol) and 4-fluoro-3-methylaniline (0.42 mL, 3.3 mmol) following the method of Intermediate 45 to give the product as a solid (879 mg). δH (CDCl3) 9.41 (1H, bs), 7.48-7.38 (2H, m), 7.28-7.13 (4H, m), 6.84-6.74 (3H, m), 6.30 (1H, d, J 9.8 Hz), 4.46-4.36 (2H, m), 3.71-3.25 (6H, m), 2.37 (3H, s), 2.15 (3H, s), 1.96-1.54 (6H, m), 1.45-1.40 (3H, m). LCMS (ES+) RT 4.21 minutes, 576 (M+H)+.
- Intermediate 50
- The title compound was prepared from Intermediate 43 (1.5 g, 2.8 mmol) and m-toluidine (0.37 mL, 3.3 mmol) following the method of Intermediate 45 to give the product as a solid (1.0 g, 63%). δH (CDCl3) 9.29 (1H, m), 7.30-7.19 (5H, m), 7.09 (1H, t, J 8.3 Hz), 6.78-6.76 (3H, m), 6.32 (1H, d, J 9.7 Hz), 4.48-4.36 (2H, m), 3.76-3.32 (6H, m), 2.39 (3H, s), 2.23 (3H, s), 1.97-1.58 (6H, m), 1.54-1.42 (4H, m).
- Intermediate 51
- The title compound was prepared from Intermediate 44 (0.48 g, 0.896 mmol) and 2,4-difluoroaniline (0.11 mL, 1.08 mmol) following the method of Intermediate 45 to give the product as a yellow solid (206 mg, 39%). LCMS RT 3.87 minutes, 606 (M+Na)+.
- Intermediate 52
- The title compound was prepared from Intermediate 44 (0.48 g, 0.896 mmol) and 3-methyl-4-fluoroaniline (0.135 g, 1.08 mmol) following the method of Intermediate 45 to give the product as a solid (90 mg). δH (CDCl3) LCMS RT 3.94 minutes, 581 (M+H)+.
- Intermediate 53
- Acetonitrile (10 mL) was added to a solution of sodium bis(trimethylsilyl)amide (100 mL, 1.0M in THF, 100 mmol) in THF (50 mL) at −78° C. to give a thick white precipitate. 2-Chlorophenyl isothiocyanate (7.72 g, 45.45 mmol) was added to give a brown solution. The mixture was allowed to warm to r.t. over 1 h then diluted with EtOH (50 mL). N,N-Dimethyluracil (6.4 g, 45 mmol) was added and the mixture heated at reflux for 24 h. Volatiles were removed in vacuo and the residue dissolved in acetonitrile (100 mL). Chloroacetonitrile (2.85 mL, 45 mmol) was added and the mixture heated at 50° C. for 1 h, a second charge of chloroacetonitrile (2.85 mL, 45 mmol) was added and heating continued for 1.5 h. Some of the acetonitrile (˜50 mL) was removed in vacuo and water was added to precipitate the product. The brown solid was filtered off, washed with water (50 mL) and Et2O (50 mL) and dried to give the title compound as a brown solid (14.3 g, quant.). δH (DMSO-d6) 8.10 (1H, d, J 9.7 Hz), 7.75-7.73 (1H, m), 7.65-7.54 (3H, m), 7.14 (2H, br s, NH2), 6.54 (1H, d, J 9.7 Hz). LCMS (ES+) RT 2.97 minutes, 302 (M+H)+.
- Intermediate 54
- Intermediate 53 (1.17 g, 3.88 mmol) was suspended in acetonitrile (20 mL). Copper(II) bromide (953 mg, 4.27 mmol) was added followed by tert-butyl nitrite (0.64 mL, 5.43 mmol). The mixture was stirred at r.t. for 3 h then partitioned between 2M HCl aq (100 mL) and EtOAc (100 mL). The organic layer was washed with 2M HCl aq (50 mL), 2M NaOH aq (50 mL) and water (25 mL), dried (Na2SO4) and concentrated in vacuo. Purification by column chromatography (silica, 0 to 5% EtOAc in DCM) gave the title compound as a pale brown solid (980 mg, 67%). δH (CDCl3) 7.70 (1H, d, J 9.7 Hz), 7.61 (1H, dd, J 1.7, 7.7 Hz), 7.52-7.44 (2H, m), 7.34 (1H, dd, J 1.7, 7.7 Hz), 6.70 (1H, d, J 9.7 Hz). LCMS (ES+) RT 3.56 minutes, 365 (M+H)+.
- Intermediate 55
- A mixture of Intermediate 54 (1.86 g, 5.0 mmol) in methanol (50 mL) and 2M NaOH aq (30 mL) was heated at reflux for 1.5 h. Volatiles were removed in vacuo and the residue treated with 2M HCl aq (75 mL). The mixture was stirred at r.t. overnight to give a fine off-white precipitate. The solid was filtered off and dried to give the title compound as an off-white solid (1.80 g, 92%). δH (DMSO-d6) 13.53 (1H, br s), 7.75 (1H, d, J 9.7 Hz), 7.64-7.62 (1H, m), 7.56-7.54 (1H, m), 7.51-7.42 (2H, m), 6.52 (1H, d, J 9.7 Hz). LCMS (ES+) RT 3.13 minutes, 384 (35Cl79Br) (M+H)+.
- Intermediate 56
- Thionyl chloride (0.66 mL, 9.1 mmol) was added to a suspension of Intermediate 55 (1.75 g, 4.55 mmol) in chloroform (50 mL). The mixture was heated at 50° C. for 1 h. A second charge of thionyl chloride (0.66 mL, 9.1 mmol) was added and the mixture heated at 50° C. for a further 1 h then stirred at r.t. overnight and finally heated at reflux for a further 1 h to give a solution. Volatiles were removed in vacuo and the residue dissolved in DCM (30 mL). Triethylamine (0.25 mL, 9.1 mmol) and (R)-2-pyrrolidinemethanol (0.540 mL, 5.46 mmol) were added and the solution stirred at r.t. for 3 h. DCM (50 mL) was added and the mixture washed with 2M HCl aq (100 mL) and 2M NaOH aq (100 mL). The organic phase was dried (Na2SO4) and concentrated in vacuo to give the title compound as a pale brown foam (2.15 g, quant.). δH (CDCl3) 7.70 (1H, d, J 9.6 Hz), 7.60-7.55 (1H, m), 7.48-7.32 (3H, m), 6.66 (1H, d, J 9.6 Hz), 4.28-4.16 (1H, br s), 3.70-3.48 (5H, m), 2.13-2.09 (1H, m), 1.92-1.81 (1H, m), 1.79-1.59 (2H, m). LCMS (ES+) RT 2.91 minutes, 467 (M+H)+.
- Intermediate 57
- 3,4-Dihydro-2H-pyran (2.0 mL, 22.4 mmol) and p-toluenesulfonic acid monohydrate (45 mg, 5 mol %) were added to a solution of Intermediate 56 (2.10 g, 4.48 mmol) in DCM (25 mL). The mixture was stirred at r.t. for 48 h then diluted with DCM (50 mL) and washed with a mixture of Na2CO3 aq (50 mL) and brine (50 mL). The organic phase was dried (Na2SO4) and concentrated in vacuo. Purification by column chromatography (silica, 70% EtOAc in hexane) gave the title compound as a yellow solid (2.08 g, 84%). δH (CDCl3) 7.69 (1H, m), 7.60-7.55 (1H, m), 7.50-7.32 (3H, m), 6.65 (1H, m), 4.50 (1H, br m), 4.29 (1H, br m), 3.70-3.31 (6H, m), 2.06-1.80 (4H, m), 1.69-1.40 (6H, m). LCMS (ES+) RT 3.61 minutes, 551 (M+H)+.
- Intermediate 58
- From Intermediate 57 and 4-fluoro-3-methylaniline by the method of Intermediate 45. Yellow solid. δH (CDCl3) 9.57 (1H, br s), 7.67-7.63 (1H, m), 7.54-7.40 (3H, m), 7.25 (1H, dd, J 1.0, 9.8 Hz), 6.95-6.85 (3H, m), 6.37 (1H, dd, J 1.0, 9.8 Hz), 4.56-4.50 (1H, m), 4.48-4.43 (1H, m), 3.84-3.40 (6H, m), 2.24 (3H, s), 2.02-1.45 (10H, m). LCMS (ES+) RT 4.05 minutes, 596 (M+H)+.
- Intermediate 59
- From Intermediate 57 and 2,4-difluoroaniline by the method of Intermediate 45. Off-white solid. δH (CDCl3) 9.45-9.40 (1H, m), 7.64-7.61 (1H, m), 7.52-7.39 (3H, m), 7.26 (1H, d, J 9.8 Hz), 7.07-7.01 (1H, m), 6.92-6.87 (1H, m), 6.82-6.77 (1H, m), 6.40 (1H, d, J 9.8 Hz), 4.53-4.41 (2H, m), 3.81-3.37 (6H, m), 2.00-1.85 (3H, m), 1.82-1.67 (1H, m), 1.65-1.32 (6H, m). LCMS (ES+) RT 4.017 minutes, 622.1 (M+Na)+.
- Intermediate 60
- To a solution of Intermediate 28 (˜4.20 g) in 1,4-dioxane (10 mL) was added 2M HCl(aq) (10 mL) and the reaction mixture heated at 70° C. for 1 h. The reaction was diluted with water (30 mL), extracted with EtOAc (3×30 mL) and the EtOAc extracts dried (MgSO4) and concentrated in vacuo. The crude residue was purified by chromatography on silica (0-5% EtOAc in DCM) to give the title compound as a pale yellow solid (2.13 g). δH (CDCl3) 7.94 (1H, d, J 9.4 Hz), 7.64-7.53 (3H, m), 7.46 (2H, m), 7.45 (1H, m), 7.20 (1H, m), 6.99 (1H, m), 6.48 (1H, d, J 9.4 Hz), 5.74 (1H, s). LCMS (ES+) RT 3.54 minutes, 354.9 (M+H)+.
- Intermediate 61
- Sodium bis(trimethylsilyl)amide (6.0 mL, 1.0M in THF, 6 mmol) was added to a solution of Intermediate 60 (2.0 g, 5.65 mmol) in THF (50 mL) at 0° C. After 30 min, di-tert-butyl dicarbonate (1.36 g, 6.22 mmol) was added and the mixture stirred at r.t. for 1 h. The reaction mixture was partitioned between EtOAc and brine. The aqueous phase was extracted with EtOAc (×3), the combined organic extracts washed with brine, dried (MgSO4) and concentrated in vacuo. Purification by column chromatography (silica, 10% EtOAc in DCM) gave the title compound (1.2 g, 47%). δH (CDCl3) 7.45 (1H, d, J 9.5 Hz), 7.43-7.30 (3H, m), 7.22-7.19 (2H, m), 7.08-7.03 (1H, m), 6.76-6.65 (2H, m), 6.49-6.45 (2H, m), 1.26 (9H, s). LCMS (ES+) RT 3.79 minutes, 455 (M+H)+.
- Intermediate 62
- n-Butyllithium (0.54 mL of a 2.5M solution in hexanes, 1.35 mmol) was added to a solution of Intermediate 61 (600 mg, 1.32 mmol) in THF (30 mL) at −78° C. After 20 min, sulfur dioxide gas was bubbled through the solution for 5 min.
- The reaction mixture was allowed to warm to r.t. and solvents were removed in vacuo. The residue was dissolved in DCM (40 mL) and N-chlorosuccinimide (210 mg, 1.45 mmol) was added. After 90 min at r.t. a solution of (R)-2-pyrrolidinemethanol (146 mg, 1.45 mmol) in DCM (5 mL) was added and the mixture stirred for a further 30 min. The mixture was diluted with DCM and washed with brine. The organic phase was dried (MgSO4) and concentrated in vacuo. Purification by column chromatography (silica, 5% to 15% EtOAc in DCM) gave the title compound (340 mg, 42%). δH (CDCl3) 7.40-7.34 (4H, m), 7.18-7.10 (3H, m), 6.74-6.67 (1H, m), 6.65-6.58 (1H, m), 6.49 (1H, d, J 9.7 Hz), 3.95 (1H, br m), 3.92-3.24 (4H br m), 1.77-1.58 (5H, br m), 1.27 (9H, s). LCMS (ES+) RT 3.55 minutes, 618 (M+H)+.
- Intermediate 63
- The title compound was prepared from Intermediate 15 (1.5 g, 3.52 mmol) and sodium hydroxide (150 mg) following the procedure of Intermediate 30 to give the title compound as a solid (1.47 g). δH (DMSO-d6) 9.97 (1H, bs), 9.56 (1H, d, J 9.6 Hz), 7.23-7.01 (2H, m), 7.26 (1H, t, J 7.0 Hz), 7.34 (1H, d, J 9.5 Hz), 7.47-7.13 (3H, m), 7.72-7.64 (3H, m). LCMS (ES+) RT 3.42 minutes, 399 (M+H)+.
- Intermediate 64
- To a solution of Intermediate 35 (300 mg, 0.53 mmol) in DCM (5 mL) was added tert-butyl pyrrolidin-3-ylcarbamate (300 mg, 1.6 mmol) and the reaction mixture stirred at r.t. for 18 h. The reaction mixture was concentrated in vacuo and the crude product purified by column chromatography (silica, 60% ethyl acetate in isohexane) to give the title compound as a yellow gum (277 mg). NMR δH (CDCl3) 7.53 (3H, m), 7.19 (2H, m), 7.17 (1H, d, J 9.5 Hz), 6.98 (1H, m), 6.85 (1H, m), 6.73 (1H, m), 6.38 (1H, d, J 9.7 Hz), 4.50 (1H, bm), 3.76 (1H, m), 3.61 (2H, m), 3.58 (1H, m), 2.10 (1H, m), 1.80 (1H, m), 1.35 (9H, s). LCMS (ES+) RT 3.50 minutes, 567 (M+H)+.
- Intermediate 65
- To a solution of Intermediate 35 (1 g, 1.77 mmol) in DCM (30 mL) was added tert-butyl (S)-pyrrolidin-3-ylcarbamate (363 mg, 1.95 mmol) and the reaction mixture stirred at r.t. for 18 h. The reaction mixture was concentrated in vacuo and the crude product purified by column chromatography (silica, ethyl acetate) to give the title compound as a white solid (700 mg). LCMS (ES+) RT 3.56 minutes, 567 (M+H)+.
- Intermediate 66
- To a solution of Intermediate 34 (1.0 g, 1.79 mmol) in DCM (30 mL) was added tert-butyl (S)-pyrrolidin-3-ylcarbamate (372 mg, 2.0 mmol) and the reaction mixture stirred at r.t. for 18 h. The reaction mixture was concentrated in vacuo and the crude product purified by column chromatography (silica, 20% EtOAc in DCM) to give the title compound as an off white solid (1.2 g). NMR δH (CDCl3) 9.61 (1H, bs), 7.65-7.55 (3H, m), 7.44-7.41 (2H, m), 7.25 (1H, d, J 9.7 Hz), 6.99-6.85 (3H, m), 6.40 (1H, d, J 9.7 Hz), 4.62 (1H, m), 4.23 (1H, m), 3.86-3.81 (1H, m), 3.70-3.66 (2H, m), 3.47 (1H, dd, J 10.3, 4.2 Hz), 2.27 (3H, d, J 1.9 Hz), 2.18-2.12 (1H, m), 1.91-1.85 (1H, m), 1.44 (9H, s). LCMS (ES+) RT 3.64 minutes, 563 (M+H)+.
- Intermediate 67
- A solution of LiOH monohydrate (390 mg, 9.27 mmol) in water (50 mL) was added to a suspension of Intermediate 17 (3.5 g, 8.42 mmol) in THF (50 mL) and EtOH (100 mL) and the mixture heated to reflux for 5 h. Solvent was removed in vacuo and the residue co-evaporated with toluene (×3) to give the intermediate lithium 3-[(2-cyanophenyl)amino]-6-oxo-7-phenyl-6,7-dihydrothieno[2,3-b]pyridine-2-carboxylate as a brown solid. This solid was dissolved in DMF (100 mL) and EDC (2.41 g, 12.6 mmol) added. The reaction was stirred for 20 minutes at r.t. before adding pentafluorophenol (2.89 g, 15.7 mmol) and then stirred for a further 18 h. DMF was removed in vacuo and the residue partitioned between DCM and water. The organic layer was separated, dried (MgSO4) and concentrated in vacuo. The crude product was purified by column chromatography (silica, 30-100% EtOAc in isohexane) to give the title compound as a solid (1.35 g). LCMS (ES+) RT 4.06 minutes, 554 (M+H)+.
- Intermediate 68
- Thionyl chloride (5.2 mL, 71 mmol) was added dropwise to a suspension of Intermediate 38 (5.2 g, 14 mmol) in toluene (150 mL). The reaction was then heated at reflux for 3 h before allowing the reaction to cool to room temperature. The solvent and residual thionyl chloride were removed in vacuo and the resultant solid co-evaporated with toluene (×3). This gave the title compound as an orange solid (4.9 g) and was used without further purification. NMR δH (CDCl3) 7.77 (1H, d, J 9.7 Hz), 7.29 (4H, m), 6.68 (2H, d, J 9.7 Hz).
- Intermediate 69
- To a solution of Intermediate 68 (2.5 g, 6.5 mmol) and diisopropylethylamine (1.7 mL, 9.7 mmol) in DCM (100 mL) was added (R)-3-hydroxypyrrolidine (850 mg, 9.7 mmol) and the reaction stirred at r.t. for 18 h. The reaction mixture was washed with water and brine, the DCM layer separated, dried (MgSO4) and then concentrated in vacuo to give the title compound as an orange solid (2.65 g). LCMS RT 2.67 minutes, 439 (M+H)+.
- Intermediate 70
- To a solution of Intermediate 68 (2.5 g, 6.5 mmol) and diisopropylethylamine (1.7 mL, 9.7 mmol) in DCM (10 mL) was added (S)-3-hydroxypyrrolidine (850 mg, 9.7 mmol) and the reaction stirred at r.t. for 18 h. The reaction mixture was washed with water and brine, the DCM layer separated, dried (MgSO4) and then concentrated in vacuo to give the title compound as an orange solid (2.84 g). LCMS RT 2.67 minutes, 439 (M+H)+.
- Intermediate 71
- To a solution of Intermediate 69 (2.65 g, 6.0 mmol) in DCM (80 mL) was added p-toluenesulphonic acid (10 mg, 0.06 mmol) and 3,4-dihydro-2H-pyran (2.8 mL, 30 mmol) and the reaction stirred at r.t. for 3 h. The reaction mixture was washed with sat. NaHCO3(aq) (×2), then brine, dried (MgSO4) and concentrated in vacuo. The crude product was purified by column chromatography (silica, 80% EtOAc in isohexane) to give the title compound as a white solid (2.40 g). LCMS RT 3.28 minutes, 523 (M+H)+.
- Intermediate 72
- To a solution of Intermediate 70 (2.65 g, 6.0 mmol) in DCM (80 mL) was added p-toluenesulphonic acid (10 mg, 0.06 mmol) and 3,4-dihydro-2H-pyran (2.8 mL, 30 mmol) and the reaction stirred at r.t. for 3 h. The reaction mixture was washed with sat. NaHCO3(aq) (×2), then brine, dried (MgSO4) and concentrated in vacuo. The crude product was purified by column chromatography (silica, 80% EtOAc in isohexane) to give the title compound as a white solid (2.74 g). LCMS RT 3.28 minutes, 523 (M+H)+.
- Intermediate 73
- To a de-gassed solution of Intermediate 71 (1.2 g, 2.30 mmol), tris(dibenzylideneacetone)dipalladium(0) (210 mg, 0.23 mmol) and (+/−)-BINAP (290 mg, 0.46 mmol) in toluene (15 mL) was added 2,4-difluoroaniline (281 μL, 2.76 mmol) and caesium carbonate (1.0 g, 3.22 mmol). The reaction was heated at 110° C. under nitrogen for two days. The reaction mixture was diluted with EtOAc (80 mL), washed with water, brine (×2), dried (MgSO4) and concentrated in vacuo. The crude product was purified by column chromatography (silica, 50% EtOAc in isohexane) to give the title compound as a brown solid (876 mg). LCMS RT 3.76 minutes, 570 (M+H)+.
- Intermediate 74
- To a de-gassed solution of Intermediate 72 (1.37 g, 2.63 mmol), tris(dibenzylideneacetone)dipalladium(0) (120 mg, 0.13 mmol) and (+/−)-BINAP (160 mg, 0.26 mmol) in toluene (15 mL) was added 2,4-difluoroaniline (321 μL, 3.16 mmol) and caesium carbonate (1.20 g, 3.68 mmol). The reaction was heated at 110° C. under nitrogen for 18 h. Additional equivalents of Pd2(dba)3 (60 mg, 0.065 mmol) and (+/−)-BINAP (80 mg, 0.13 mmol) were added and the reaction heated at reflux for a further 2 days. The reaction mixture was diluted with EtOAc (80 mL), washed with water, brine (×2), dried (MgSO4) and concentrated in vacuo. The crude product was purified by column chromatography (silica, 50% EtOAc in isohexane) to give the title compound as a brown solid (767 mg). LCMS RT 3.74 minutes, 570 (M+H)+.
- Intermediate 75
- To a de-gassed solution of Intermediate 72 (1.37 g, 2.63 mmol), tris(dibenzylideneacetone)dipalladium(0) (120 mg, 0.13 mmol) and (+/−-BINAP (160 mg, 0.26 mmol) in toluene (15 mL) was added 4-fluoro-3-methylaniline (400 mg, 3.16 mmol) and caesium carbonate (1.20 g, 3.68 mmol). The reaction was heated at 110° C. under nitrogen for 18 h. Additional equivalents of Pd2(dba)3 (60 mg, 0.065 mmol) and (+/−)-BINAP (80 mg, 0.13 mmol) were added and the reaction heated at reflux for a further 2 days. The reaction mixture was diluted with EtOAc (80 mL), washed with water, brine (×2), dried (MgSO4) and concentrated in vacuo. The crude product was purified by column chromatography (silica, 50% EtOAc in isohexane) to give the title compound as a brown solid (980 mg). LCMS RT 3.84 minutes, 566 (M+H)+.
- Intermediate 76
- The title compound was prepared from Intermediate 55 and (S)-3-hydroxypyrrolidine following the method of Intermediate 56.
- Intermediate 77
- The title compound was prepared from Intermediate 76 and 3,4-dihydro-2H-pyran following the method of Intermediate 57. NMR δH (CDCl3) 7.77 (1H, d, J 9.6 Hz), 7.66-7.61 (1H, m), 7.54-7.41 (3H, m), 6.73 (1H, d, J 9.6 Hz), 4.69-4.53 (1H, m), 4.45-4.43 (1H, m), 3.86-3.49 (6H, m), 2.17-2.14 (2H, m), 1.87-1.69 (2H, m), 1.55-1.40 (4H, m). LCMS (ES+) RT 3.45 minutes, 539 (M+H)+.
- Intermediate 78
- The title compound was prepared from Intermediate 77 (883 mg, 1.64 mmol) and 4-fluoro-3-methylaniline (267 mg, 2.13 mmol) following the method of Intermediate 75. The crude product was purified by column chromatography (silica, 10% EtOAc in DCM) to give the title compound as a yellow solid (623 mg). NMR δH (CDCl3) 9.70 (1H, s), 7.68-7.64 (1H, m), 7.55-7.41 (3H, m), 7.27-7.24 (1H, m), 6.96-6.85 (3H, m), 6.37 (1H, d, J 9.8 Hz), 4.65-4.63 (1H, m), 4.42-4.40 (1H, m), 3.84-3.64 (5H, m), 3.51-3.47 (1H, m), 2.24 (3H, s), 2.16-2.01 (1H, m), 1.99-1.92 (1H, m), 1.80-1.70 (1H, m), 1.68-1.67 (1H, m), 1.56-1.49 (4H, m). LCMS (ES+) RT 3.94 minutes, 582 (M+H)+.
- Intermediate 79
- The title compound was prepared from Intermediate 77 (883 mg, 1.64 mmol) and m-toluidine (0.28 mL, 2.62 mmol) following the method of Intermediate 75. The crude product was purified by column chromatography (silica, 10% EtOAc in DCM) to give the title compound as a pale yellow solid (509 mg). NMR δH (CDCl3) 9.65 (1H, m), 7.68-7.65 (3H, m), 7.39 (1H, d, J 9.7 Hz), 7.11 (1H, t, J 7.5 Hz), 6.90-6.84 (3H, m), 6.40 (1H, d, J 9.8 Hz), 4.63-4.60 (1H, m), 4.40-4.38 (1H, m), 3.81-3.67 (5H, m), 3.65-3.63 (1H, m), 2.31 (3H, s), 2.17-1.57 (5H, m), 1.53 (3H, s). LCMS (ES+) RT 3.91 minutes, 564 (M+H)+.
- Intermediate 80
- The title compound was prepared from Intermediate 77 (883 mg, 1.64 mmol) and 2,4-difluoroaniline (0.28 mL, 2.75 mmol) following the method of Intermediate 75. The crude product was purified by column chromatography (silica, 10% EtOAc in DCM) to give the title compound as a brown solid (750 mg). NMR δH (CDCl3) 9.66 (1H, d, J 4.4 Hz), 7.68-7.64 (1H, m), 7.56-7.41 (3H, m), 7.27 (1H, d, J 8.8 Hz), 7.07-7.04 (1H, m), 6.94-6.89 (1H, m), 6.84-6.80 (1H, m), 6.42 (1H, d, J 9.7 Hz), 4.65-4.63 (1H, m), 4.40-4.38 (1H, m), 3.86-3.61 (5H, m), 3.51-3.44 (1H, m), 2.07-1.89 (2H, m), 1.79-1.77 (1H, m), 1.71-1.68 (1H, m), 1.59-1.49 (4H, m). LCMS (ES+) RT 3.83 minutes, 586 (M+H)+.
- Intermediate 81
- The title compound was prepared from Intermediate 37 and (S)-3-hydroxypyrrolidine following the method of Intermediate 56. NMR δH (CDCl3) 7.66 (1H, d, J 9.6 Hz), 7.30 (2H, d, J 8.1 Hz), 7.18 (2H, d, J 8.1 Hz), 6.65 (1H, d, J 9.6 Hz), 4.44 (1H, bm), 3.80-3.25 (4H, m), 2.37 (3H, s), 2.20-1.93 (3H, m). LCMS (ES+) RT 2.65 minutes, 433 (M+H, 79Br)+, 435 (M+H, 81Br)+.
- Intermediate 82
- The title compound was prepared from Intermediate 37 (6.0 g, 18.0 mmol) and (R)-3-hydroxypyrrolidine (2.0 g, 27.0 mmol) following the method of Intermediate 56. The crude product was purified by column chromatography (silica, 20% THF in DCM) to give the title compound as a white solid (5.36 g). δH 7.68 (1H, d, J 9.6 Hz), 7.32 (2H, m), 7.20 (2H, m), 6.66 (1H, d, J 9.6 Hz), 4.49 (1H, bs), 3.78-3.60 (3H, m), 2.39 (3H, s), 1.97 (2H, bs), 1.82 (2H, bs). LCMS (ES+) RT 2.64 minutes, 433 (M+H, 79Br)+, 435 (M+H, 81Br)+.
- Intermediate 83
- Intermediate 36 (17.6 g, 50 mmol) was suspended in DCM (150 mL) to which thionyl chloride (30 mL, 411 mmol) and DMF (0.5 mL) were added. The mixture was heated under reflux for 1 h during which the solid dissolved to form a dark solution. After cooling to ambient temperature, the solution was evaporated to dryness in vacuo (30° C./150 mBar). This step was repeated twice with fresh DCM (2×100 mL). The intermediate acid chloride was thus obtained as a mottled brown solid.
- In a separate flask, 3-hydroxyazetidine hydrochloride (10.9 g, 100 mmol) and diisopropylethylamine (50 mL, 360 mmol) were stirred at 20-25° C. in 1:1 DCM:DMF (400 mL) for 1 h then cooled to 0-5° C. A solution of the acid chloride (19.9 g) in DCM (200 mL) was added to this preparation over 1 h and the resulting orange-brown solution stirred out for another hour. Following evaporation to dryness (5-100 mBar/40° C.), the residue was partitioned between EtOAc (500 mL) and water (150 mL) at 40° C. The organic phase was washed twice with water (2×100 mL) then re-evaporated. The residue was re-suspended in fresh EtOAc (200 mL) at 40° C. and then filtered. The title compound was obtained as a fawn powder after washing with EtOAc (3×30 mL) and drying in vacuo at 50° C. (16.5 g, 81.5% yield, m.p. 199.1° C.). δH (DMSO-d6) 7.87 (1H, d, J 9.8 Hz), 7.65 (3H, m), 7.55 (2H, m), 6.69 (1H, d, J 9.8 Hz), 5.62 (1H, d, J 6.5 Hz), 4.46 (1H, m), 4.30 (2H, m), 3.87 (2H, br m). LCMS (ES+) RT 2.19 minutes, 405 (M+H)+.
- Intermediate 84
- p-Toluenesulfonic acid monohydrate (0.28 g, 1.47 mmol) was added to a suspension of Intermediate 83 (11.9 g, 29 mmol) in DCM (100 mL) containing 3,4-dihydro-2H-pyran (7.5 g, 89 mmol). The mixture was stirred until all the starting material had dissolved to give an orange solution and then left to stand at 20-25° C. overnight. Sat. NaHCO3(aq) (20 mL) was added to quench the reaction and the organic phase washed subsequently with water (25 mL). After drying (Na2SO4) and removal of solvent in vacuo the crude product was obtained as a brown glass (22.8 g). This residue was taken up in EtOAc (100 mL) at 40° C., and then seeded after the resulting solution had cooled to 25° C. Once crystallisation had initiated the temperature was reduced further to 0-5° C. and the slurry stirred out for 1 h. The fawn solid was filtered off, washed with EtOAc (2×25 mL) and dried at 40° C. in vacuo, affording the title compound (14.1 g, 71.2% yield, m.p. 162° C.). δH (CDCl3) 7.78 (1H, d, J 9.8 Hz), 7.67 (3H, m), 7.48 (2H, m), 6.73 (1H, d, J 9.8 Hz), 4.70 (1H, m), 4.68 (1H, m), 4.40 (2H, dd), 4.19 (2H, m), 3.81 (1H, m), 3.50 (1H, m), 1.42-1.90 (6H, br m). LCMS (ES+) RT 3.31 minutes, 489 (M+H)+.
- Intermediate 85
- Intermediate 84 (2.00 g, 4.21 mmol), 4-fluoro-3-methylaniline (0.58 g, 4.64 mmol), rac-BINAP (0.26 g, 0.42 mmol), Pd2(dba)3 (0.19 g, 0.21 mmol) cesium carbonate (2.01 g, 6.17 mmol) and toluene (20 mL) were charged to an oven-dried flask and heated to reflux for 2 h under an atmosphere of nitrogen. After cooling to r.t. water (20 mL) was added and this mixture stirred for 10 min. At this time the solid was isolated via filtration, washed with toluene (2×5 mL) and water (2×5 mL) and dried in vacuo to yield the title compound (1.89 g, 84%). δH (CDCl3) 9.62 (1H, s), 7.53-7.64 (3H, m), 7.38-7.41 (2H, m), 7.16-7.20 (1H, d), 6.87-6.98 (3H, m), 6.36-6.39 (1H, d), 4.51-4.60 (2H, m), 4.32-4.49 (2H, m), 4.04-4.16 (2H, m), 3.78-3.85 (1H, m), 3.47-3.51 (1H, m), 2.25 (3H, s), 1.51-1.81 (6H, m). LCMS (ES+), RT 4.19 minutes, 534 (M+H)+.
- Intermediate 86
- A mixture of Intermediate 35 (800 mg, 1.42 mmol), Et3N (0.5 mL) and tert-butyl piperidin-4-ylcarbamate (354 mg, 1.70 mmol) in DCM (20 mL) was stirred at r.t for 18 h. The reaction was concentrated under vacuum and triturated with Et2O. Purification by chromatography (silica, 2% EtOAc in DCM) gave the title compound as an off-white solid (267 mg, 32%). δH (DMSO-d6) 8.40 (1H, s), 7.87 (1H, d, J 9.6 Hz), 7.7-7.6 (3H, m), 7.57-7.53 (2H, m), 7.33-7.26 (1H, m), 6.98-6.9 (2H, m), 6.86-6.83 (1H, m), 6.57 (1H, d, J 9.6 Hz), 3.85-3.80 (2H, m), 3.40-3.30 (1H, m), 2.55-2.50 (2H, m), 1.65-1.60 (2H, m), 1.38 (9H, s), 1.18-1.14 (2H, m). LCMS (ES+) RT 3.50 minutes, 581 (M+H)+.
- Intermediate 87
- A mixture of Intermediate 35 (483 mg, 0.85 mmol), Et3N (0.5 mL) and tert-butyl azetidin-3-ylcarbamate (175 mg, 1.02 mmol) in DCM (20 mL) was stirred at r.t. for 18 h. The reaction mixture was concentrated under vacuum and triturated with Et2O. The title compound was obtained as a yellow solid (386 mg, 82%). δH (DMSO-d6) 9.32 (1H, s), 7.71-7.62 (3H, m), 7.57-7.50 (2H, m), 7.45-7.38 (1H, m), 7.36 (1H, d, J 9.7 Hz), 7.17-7.10 (1H, m), 7.09-7.00 (1H, m), 6.47 (1H, d, J 9.7 Hz), 4.60-4.30 (3H, m), 3.90-3.80 (2H, m), 3.35-3.30 (1H, m), 1.40 (9H, s). LCMS (ES+) RT 3.58 minutes, 553 (M+H)+.
- Intermediate 88
- From Intermediate 55 (4.7 g, 12.2 mmol) and (R)-3-hydroxypyrrolidine (1.13 g, 13 mmol) by the method of Intermediate 56 to give the title compound as a yellow solid (5.70 g, quant). δH (CDCl3) 7.77 (1H, d, J 9.6 Hz), 7.63-7.60 (1H, m), 7.51-7.37 (3H, m), 6.70 (1H, d, J 9.6 Hz), 4.51 (1H, br m), 3.78-3.53 (4H, m), 2.20-1.70 (2H, m), 1.60 (1H, br s). LCMS (ES+) RT 2.70 minutes, 453 (M+H)+.
- Intermediate 89
- From Intermediate 88 (5.35 g, 11.8 mmol) and 3,4-dihydro-2H-pyran (3.3 mL, 35.4 mmol) by the method of Intermediate 57 to give the title compound as an orange solid (6.70 g, quant). δH (DMSO-d6) 7.91-7.60 (5H, m), 6.70 (1H, d, J 9.6 Hz), 4.85-4.83 (1H, m), 4.78-4.67 (1H, m), 4.34-4.27 (1H, m), 3.93-3.40 (5H, m), 2.10-1.95 (2H, m), 1.85-1.40 (6H, m). LCMS (ES+) RT 3.46 minutes, 537 (M+H)+.
- Intermediate 90
- From Intermediate 89 (6.35 g, 11.8 mmol) and 2,4-difluoroaniline (1.45 mL, 14.1 mmol) by the method of Intermediate 75 to give the title compound as a pale brown solid (3.0 g, 43%). δH (DMSO-d6) 8.99-8.94 (1H, m), 7.83-7.79 (1H, m), 7.74-7.59 (4H, m), 7.39-7.26 (1H, m), 7.06-6.93 (2H, m), 6.51 (1H, d, J 9.7 Hz), 4.62-4.54 (1H, m), 4.23-4.18 (1H, m), 3.73-3.50 (6H, m), 1.95-1.35 (8H, m). LCMS (ES+) RT 3.85 minutes, 586 (M+H)+.
- To a suspension of Intermediate 45 (7.3 g, 12.9 mmol) in ethanol (300 mL) was added 10% HCl(aq) (40 mL) and the reaction stirred at room temperature for 16 h. The reaction mixture was then concentrated in vacuo to give an orange/brown oil. The crude product was purified by column chromatography (silica, EtOAc) followed by a second column (silica, 10% THF in DCM) to give the title compound as a light yellow solid (4.05 g). δH (CDCl3) 9.36 (1H, bs), 7.68-7.36 (3H, m), 7.33-7.18 (2H, m), 7.14-7.06 (1H, m), 7.04-7.00 (1H, m), 6.97-6.73 (2H, m), 6.35 (1H, d, J 9.7 Hz), 4.36-4.28 (1H, m), 3.74-3.47 (4H, m), 2.00-1.68 (3H, m), 1.60-1.50 (1H, m). LCMS (ES+) RT 3.19 minutes, 482 (M+H)+.
- The title compound was prepared from Intermediate 46 (2.0 g, 3.68 mmol) following the method of Example 1 to give the title compound as a pale yellow solid (747 mg). δH (CDCl3) 7.77 (3H, m), 7.71 (2H, m), 7.51 (H, d, J 9.73 Hz), 7.36 (1H, m), 7.07 (3H, m), 6.58 (1H, d, J 9.75 Hz), 4.57 (1H, m), 4.00-3.75 (4H, m), 2.51 (3H, s), 2.25-2.00 (3H, m), 1.81 (1H, m). LCMS (ES+) RT 3.18 minutes, 460 (M+H)+.
- The title compound was prepared from intermediate 47 (0.85 g, 11.5 mmol) following the method of Example 1 to give the title compound as a pale yellow solid (545 mg). δH (CDCl3) 7.60 (3H, m), 7.55 (3H, m), 7.37 (1H, m), 7.03 (2H, m), 6.95 (1H, m), 6.49 (H, d, J 9.7 Hz), 4.38 (1H, m), 3.80 (1H, m) 3.76 (1H, m), 3.62 (2H, m), 2.18 (1H, s), 1.96 (3H, m), 1.66 (1H, m). LCMS (ES+) RT 3.15 minutes, 480 (M+H)+.
- The title compound was prepared from Intermediate 48 (1.14 g, 2.0 mmol) following the method of Example 1 to give the title compound as a pale yellow solid (470 mg, 46%). δH (CDCl3) 7.31-7.29 (2H, m), 7.19-7.13 (3H, m), 6.95-6.84 (1H, m), 6.83-6.80 (1H, m), 6.74 (1H, t, J 7.7 Hz), 6.34 (1H d, J 9.7 Hz), 4.31-4.25 (1H, m), 3.72-3.48 (4H, m), 2.37 (3H, s), 1.96-1.73 (3H, m), 1.62-1.51 (1H, m). LCMS (ES+) RT 3.24 minutes, 496 (M+H)+.
- The title compound was prepared from Intermediate 49 (879 mg, 1.52 mmol) following the method of Example 1 to give the title compound as a pale yellow solid (410 mg, 54%). δH (CDCl3) 9.35 (1H, bs), 7.30 (2H, m), 7.21-7.12 (3H, m), 6.86-6.75 (3H, m), 6.29 (1H, d, J 9.7 Hz), 4.30-4.25 (2H, m), 3.72-3.70 (1H, m), 3.69-3.63 (1H, m), 3.62-3.49 (2H, m), 2.174 (3H, s), 2.170 (3H, s), 1.96-1.74 (3H, m), 1.58-1.50 (1H, m). LCMS (ES+) RT 3.30 minutes, 492 (m+H)+.
- The title compound was prepared from Intermediate 50 (1.0 g, 1.8 mmol) following the method of Example 1 to give the title compound as a yellow solid (492 mg, 56%). δH (CDCl3) 9.20 (1H, bs), 7.31-7.18 (5H, m), 7.09 (1H, t, J 8.0 Hz), 6.80-6.75 (3H, m), 6.30 (1H, d, J 9.6 Hz), 4.29-4.19 (2H, m), 3.71-3.67 (1H, m), 3.65-3.59 (1H, m), 3.52-3.46 (2H, m), 2.37 (3H, s), 2.23 (3H, s), 1.96-1.73 (3H, m), 1.69-1.56 (1H, m). LCMS (ES+) RT 3.27 minutes, 474 (M+H)+.
- The title compound was prepared from Intermediate 51 (206 mg, 0.35 mmol) following the method of Example 1 to give the title compound as an off-white solid (155 mg). δH (DMSO-d6) 8.92 (1H, s), 7.92 (1H, d, J 9.6 Hz), 7.79 (2H, m), 7.66 (2H, t, J 8.6 Hz), 7.51-7.46 (1H, m), 7.20-7.10 (2H, m), 6.68 (1H d, J 9.6 Hz), 4.82 (1H, m), 4.10 (1H, bs), 3.54 (1H, m), 3.44 (1H, m), 3.11 (1H, m), 1.98-1.87 (3H, m), 1.80 (1H, m). LCMS (ES+) RT 3.15 minutes, 500 (M+H)+.
- The title compound was prepared from Intermediate 52 (90 mg, 0.16 mmol) following the method of Example 1 to give the title compound as a pale yellow solid (63 mg). δH (DMSO-d6) 8.80 (1H, s), 7.81 (1H, d, J 9.6 Hz), 7.66 (2H, m), 7.52 (2H, t, J 8.5 Hz), 7.05 (1H, t, J 9.1 Hz), 6.87-6.85 (1H, m), 6.82-6.78 (1H, m), 6.56 (1H, d, J 9.6 Hz), 4.67 (1H, t, J 5.5 Hz), 3.96 (1H, m), 3.36-3.32 (2H, m), 2.87 (1H, m), 2.20 (3H, s), 1.72-1.69 (3H, m), 1.63-1.58 (1H, m). LCMS (ES+) RT 3.22 minutes, 496 (M+H)+.
- 1M HCl aq (2 mL) was added to a solution of Intermediate 58 (500 mg, 0.84 mmol) in EtOH (20 mL) and the mixture stirred at r.t. overnight. Saturated Na2CO3 aq (50 mL) was added and the mixture extracted with EtOAc (50 ml then 10 mL). The combined organics were dried (Na2SO4) and concentrated in vacuo. The residual gum was treated with DCM (5 mL) and then the solvent removed in vacuo to give the title compound as a yellow solid (400 mg, 93%). δH (CDCl3) 9.47 (1H, br d, J 7.7 Hz), 7.60-7.56 (1H, m), 7.49-7.33 (3H, m), 7.18 (1H, dd, J 0.5, 9.8 Hz), 6.89-6.79 (3H, m), 6.30 (1H, dd, J 0.5, 9.8 Hz), 4.33-4.31 (1H, m), 4.29 (1H, br s), 3.74-3.37 (4H, m), 2.19 (3H, d, J 1.5 Hz), 1.99-1.64 (4H, m). LCMS (ES+) RT 3.28 minutes, 512 (M+H)+.
- From Intermediate 59 by the method of Example 9. Brown solid. δH (CDCl3) 9.40 (1H, s), 7.65-7.62 (1H, m), 7.53-7.39 (3H, m), 7.24 (1H, d, J 9.9 Hz), 7.10-7.04 (1H, m), 6.84-6.80 (1H, m), 6.41 (1H, d, J 9.8 Hz), 4.40-4.34 (1H, m), 4.17-4.18 (1H, m), 3.79-3.54 (4H, m), 1.98-1.75 (3H, m), 1.55-1.50 (1H, m). LCMS (ES+) RT 3.247 minutes, 516 (M+H)+.
- To a suspension of Intermediate 63 (1.0 g, 2.4 mmol) in DCM (15 mL) was added EDC (0.73 g, 3.7 mmol, 1.5 equiv.), HOBT (0.33 g, 3.7 mmol, 11.5 equiv.) and the mixture stirred at r.t. for 15 minutes. (R)-2-Pyrrolidinemethanol (0.25 mL, 3.7 mmol) was added and the reaction stirred at r.t. for 18 h. The reaction was diluted with DCM (10 mL), washed with water (10 mL) and brine (10 mL), dried (MgSO4) and concentrated in vacuo. The crude residue was purified by column chromatography (silica, 20% EtOAc in DCM) to give the title compound as an off-white solid (492 mg). δH (DMSO-d6) 9.00 (1H, bs), 7.77-7.68 (7H, m), 7.38 (1H, m), 7.07 (2H, m), 6.64 (1H, d, J 9.6 Hz), 4.78 (1H, t, J 5.9 Hz), 4.22-4.15 (1H, m), 3.55-3.53 (2H, m), 3.46-3.39 (1H, m), 3.26-3.18 (1H, m), 1.99-1.77 (4H, m). LCMS (ES+) RT 3.28 minutes, (Cl37) 482 (M+H)+.
- General Procedure for Preparing Amide Examples by EDC Coupling
- The following Examples were all prepared from the appropriate carboxylic acid intermediate and amine starting materials following the method described for Example 11.
- The title compound was prepared from Intermediate 63 (500 mg, 1.24 mmol) and (S)-2-pyrrolidinemethanol (0.12 mL, 1.86 mmol) following the method of Example 11 to give the title compound as an off-white solid (40 mg). δH (CDCl3) 7.57-7.42 (3H, m), 7.39-7.29 (4H, m), 7.14-7.05 (1H, m), 6.95-6.84 (2H, m), 6.39 (1H, d, J 9.7 Hz), 4.32-4.24 (1H, m), 3.70-3.58 (2H, m), 3.52-3.38 (2H, m), 1.97-1.49 (4H, m). LCMS (ES+) RT 3.27 minutes, (Cl37) 482 (M+H)+.
- The title compound was prepared from Intermediate 29 and (R)-2-pyrrolidinemethanol following the method of Example 11 to give the title compound as a pale yellow solid. δH (CDCl3) 7.56-7.47 (3H, m), 7.36-7.33 (2H, m), 7.27-7.19 (3H, m), 7.02-6.99 (3H, m), 6.34 (1H, d, J 9.7 Hz), 4.34-4.29 (1H, m), 3.73-3.69 (1H, m), 3.65-3.62 (1H, m), 3.57-3.48 (2H, m), 2.06-1.70 (3H, m), 1.60-1.45 (2H, m). LCMS (ES+) RT 3.10 minutes, 446 (M+H)+.
- The title compound was prepared from Intermediate 29 and (R)-2-pyrrolidinemethanol following the method of Example 11 to give the title compound as a pale yellow solid. δH (CDCl3) 9.31 (1H, bs), 7.55-7.46 (3H, m), 7.35-7.32 (2H, m), 7.26-7.18 (3H, m), 7.01-6.98 (3H, m), 6.33 (1H, d, J 9.7 Hz), 4.32-4.29 (1H, m), 4.14 (1H, bs), 3.73-3.64 (2H, m), 3.61-3.50 (2H, m), 1.97-1.71 (3H, m), 1.58-1.50 (1H, m). LCMS (ES+) RT 3.11 minutes, 446 (M+H)+.
- The title compound was prepared from Intermediate 28 (1.0 g, 2.58 mmol) and (S)-2-pyrrolidinemethanol (390 mg, 3.87 mmol) following the method of Example 11 to give the title compound as a pale yellow solid (300 mg). δH (CDCl3) 7.65-7.48 (3H, m), 7.35-7.32 (2H, m), 7.15 (1H, d, J 9.7 Hz), 7.04-7.01 (1H, m), 6.99-6.72 (2H, m), 6.36 (1H, d, J 9.7 Hz), 4.37-4.29 (1H, m), 3.74-3.47 (4H, m), 1.95-1.74 (3H, m), 1.61-1.53 (1H, m). LCMS (ES+) RT 3.18 minutes, 482 (M+H)+.
- The title compound was prepared from Intermediate 29 and (S)-2-(methoxymethyl)pyrrolidine following the method of Example 11 to give the title compound as a pale yellow solid. δH (CDCl3) 9.50 (1H, bs), 7.55-7.46 (3H, m), 7.40-7.30 (2H, m), 7.27 (1H, d, J 9.7 Hz), 7.25-7.18 (2H, m), 6.99-6.95 (3H, m), 6.33 (1H, d, J 9.7 Hz), 4.35-4.30 (1H, m), 3.62-3.56 (1H, m), 3.51-3.43 (2H, m), 3.41-3.30 (1H, m), 3.23 (3H, s), 1.92-1.73 (4H, m). LCMS (ES+) RT 3.49 minutes, 460 (M+H)+.
- The title compound was prepared from Intermediate 29 and (R)-2-(methoxymethyl)pyrrolidine following the method of Example 11 to give the title compound as a pale yellow solid. δH (CDCl3) 9.45 (1H, bs), 7.55-7.46 (3H, m), 7.40-7.30 (2H, m), 7.27 (1H, d, J 9.7 Hz), 7.25-7.18 (2H, m), 6.99-6.95 (3H, m), 6.33 (1H, d, J 9.7 Hz), 4.35-4.30 (1H, m), 3.62-3.56 (1H, m), 3.51-3.43 (2H, m), 3.41-3.30 (1H, m), 3.23 (3H, s), 1.92-1.73 (4H, m). LCMS (ES+) RT 3.49 minutes, 460 (M+H)+.
- The title compound was prepared from Intermediate 30 (800 mg, 1.87 mmol) and (R)-2-pyrrolidinemethanol (0.28 mL, 2.81 mmol) following the method of Example 11 to give the title compound as a pale yellow solid (251 mg). δH (CDCl3) 9.43 (1H, bs), 7.51-7.48 (2H, m), 7.39-7.19 (2H, m), 7.13 (1H, d, J 9.8 Hz), 6.80-6.76 (3H, m), 6.28 (1H, d, J 9.8 Hz), 4.36-4.25 (2H, m), 3.75-3.50 (4H, m), 2.18 (3H, s), 1.98-1.73 (3H, m), 1.60-1.52 (1H, m). LCMS (ES+) RT 3.39 minutes, 512 (M+H)+.
- The title compound was prepared from Intermediate 31 (1.0 g, 2.4 mmol) and (S)-2-pyrrolidinemethanol (0.36 mL, 3.6 mmol) following the method of Example 11 to give the title compound as a pale yellow solid (212 mg). δH (CDCl3) 9.38 (1H, bs), 7.45-7.40 (1H, m), 7.38-7.27 (1H, m), 7.18-7.12 (3H, m), 6.87-6.76 (3H, m), 6.30 (1H, d, J 9.8 Hz), 4.36-4.28 (2H, m), 3.75-3.48 (4H, m), 2.37 (3H, s), 2.18 (3H, s), 1.97-1.82 (3H, m), 1.70-1.59 (1H, m). LCMS (ES+) RT 3.34 minutes, 492 (M+H)+.
- The title compound was prepared from Intermediate 32 (842 mg, 2.15 mmol) and (R)-2-pyrrolidinemethanol (0.32 mL, 3.23 mmol) following the method of Example 11 to give the title compound as a pale yellow solid (179 mg). δH (CDCl3) 9.21 (1H, bs), 7.40-7.35 (1H, m), 7.27-7.24 (2H, m), 7.18-7.07 (3H, m), 6.81-6.76 (3H, m), 6.31 (1H, d, J 9.7 Hz), 4.30-4.22 (2H, m), 3.70-3.46 (4H, m), 2.37 (3H, s), 2.25 (3H, s), 1.98-1.66 (3H, m), 1.58-1.47 (1H, m). LCMS (ES+) RT 3.30 minutes, 474 (M+H)+.
- The title compound was prepared from Intermediate 31 (640 mg, 1.54 mmol) and (R)-2-pyrrolidinemethanol (0.25 mL, 2.3 mmol) following the method of Example 11 to give the title compound as a pale yellow solid (112 mg). δH (CDCl3) 7.49-7.35 (1H, m), 7.26 (1H, d, J 9.7 Hz), 7.24-7.23 (3H, m), 6.98-6.91 (3H, m), 6.88 (1H, d, J 9.8 Hz), 4.39-4.35 (1H, m), 3.83-3.56 (4H, m), 2.45 (3H, s), 2.26 (3H, s), 1.99-1.81 (3H, m), 1.68-1.60 (1H, m). LCMS (ES+) RT 3.34 minutes, 492 (M+H)+.
- The title compound was prepared from Intermediate 33 (340 mg, 0.77 mmol) and (R)-2-pyrrolidinemethanol (0.12 mL, 1.16 mmol) following the method of Example 11 to give the title compound as a yellow solid (71 mg). δH (CDCl3) 7.58-7.51 (3H, m), 7.34-7.21 (2H, m), 7.19-7.17 (1H, m), 7.05-6.98 (2H, m), 6.88-6.82 (1H, m), 6.38 (1H, d, J 9.7 Hz), 4.34-4.30 (1H, m), 3.72-3.48 (4H, m), 1.99-1.53 (4H, m). LCMS (ES+) RT 3.21 minutes, 498 (M+H)+.
- The title compound was prepared from Intermediate 33 (340 mg, 0.77 mmol) and (S)-2-pyrrolidinemethanol (0.12 mL, 1.16 mmol) following the method of Example 11 to give the title compound as a yellow solid (65 mg). δH (CDCl3) 7.66-7.59 (3H, m), 7.44-7.31 (2H, m), 7.28-7.26 (1H, m), 7.14-7.08 (2H, m), 6.98-6.93 (1H, m), 6.47 (1H, d, J 9.8 Hz), 4.43-4.40 (1H, m), 3.81-3.57 (4H, m), 2.06-1.62 (4H, m). LCMS (ES+) RT 3.21 minutes, 498 (M+H)+.
- (R)-2-Pyrrolidinemethanol (0.398 mL, 4.037 mmol) was added to a solution of Intermediate 34 (1.5 g, 2.69 mmol) in DCM (20 mL) and the mixture stirred at r.t. for 24 h. The volatiles were removed in vacuo and the residue was purified by column chromatography (silica, 1-10% THF in DCM) to produce the title compound as an orange solid (0.737 g). δH (DMSO-d6) 8.45 (1H, s), 7.65-7.55 (4H, br m), 7.49-7.46 (2H, m), 6.98-6.93 (1H, m), 6.88-6.86 (1H, m), 6.80-6.76 (1H, m), 6.42 (1H, d, J 9.63 Hz), 4.06 (1H, m), 3.45-3.36 (3H, m), 3.21-3.17 (2H, m), 2.08 (3H, s), 1.85-1.74 (3H, m), 1.68-1.60 (1H, m). LCMS (ES+) 478 (M+H)+. HPLC Chiralpak AS 80:20 Isohexane/EtOH. RT 19.62 minutes.
- (S)-2-Pyrrolidinemethanol (0.198 mL, 2.007 mmol) was added to a solution of Intermediate 34 (0.750 g, 1.338 mmol) in DCM (10 mL) and the mixture stirred at r.t. for 24 h. The volatiles were removed in vacuo and the residue was purified by column chromatography (silica, 1-10% THF in DCM) to produce the title compound as an orange solid (0.369 g). δH (DMSO-d6) 8.46 (1H, s), 7.65-7.55 (4H, br m), 7.49-7.46 (2H, m), 6.98-6.93 (1H, m), 6.88-6.86 (1H, m), 6.80-6.76 (1H, m), 6.42 (1H, d, J 9.63 Hz), 4.05 (1H, m), 3.46-3.35 (3H, m), 3.20-3.16 (2H, m), 2.19 (3H, s), 1.84-1.72 (3H, m), 1.68-1.60 (1H, m). LCMS (ES+) 478 (M+H)+. HPLC Chiralpak AS 80:20 Isohexane/EtOH. RT 15.37 minutes.
- (S)-3-Hydroxypyrrolidine (107 mg, 1.23 mmol) was added to a solution of Intermediate 35 (400 mg, 0.709 mmol) in DCM (8 mL) and the reaction stirred at room temperature for 24 h. The volatiles were removed in vacuo and the crude residue purified by column chromatography (silica, 5-15% THF in DCM) and (silica, 20-80% EtOAc in isohexane) to give the title compound as a pale yellow solid (156 mg). δH (CDCl3) 7.46-7.53 (3H, m), 7.33 (2H, m), 7.19 (1H, d, J 10.2 Hz), 6.95-7.01 (1H, m), 6.82-6.87 (1H, m), 6.72-6.76 (1H, m), 6.35-6.38 (1H, m), 4.22 (1H, m), 3.64-3.69 (2H, m), 3.62 (1H, m), 3.55 (1H, m), 1.89-1.94 (2H, m). LCMS (ES+) RT 2.98 minutes, 468 (M+H)+.
- (R)-3-Hydroxypyrrolidine (107 mg, 1.23 mmol) was added to a solution of Intermediate 35 (232 mg, 0.411 mmol) in DCM (4 mL) and the reaction stirred at room temperature for 24 h. The volatiles were removed in vacuo and the crude residue purified by column chromatography (silica, 5-15% THF in DCM) to give the title compound as a pale yellow solid (91 mg). δH (CDCl3) 7.48 (3H, m), 7.31 (2H, m), 7.15 (1H, d, J 9.7 Hz), 6.95 (1H, m), 6.82 (1H, m), 6.72 (1H, m), 6.34 (1H, d, J 9.7 Hz), 4.41 (1H, m), 3.67-3.59 (3H, m), 3.53 (1H, m), 1.90 (2H, m). LCMS (ES+) RT 2.95 minutes, 468 (M+H)+.
- The title compound was prepared from (S)-3-hydroxypyrrolidine (100 mg, 1.10 mmol) and Intermediate 34 (200 mg, 0.36 mmol) following the method of Example 28 to give the title compound as a pale yellow solid (55 mg). δH (CDCl3) 7.51 (3H, m), 7.34 (2H, m), 7.19 (1H, m), 6.84 (2H, m), 6.80 (1H, m), 6.33 (1H, d, J 9.75 Hz), 4.44 (1H, m), 3.66 (4H, m), 2.18 (3H, s), 1.91 (2H, m). LCMS (ES+) RT 3.02 minutes, 464 (M+H)+.
- The title compound was prepared from (R)-3-hydroxypyrrolidine (100 mg, 1.10 mmol) and Intermediate 34 (200 mg, 0.36 mmol) following the method of Example 28 to give the title compound as a pale yellow solid (73 mg). δH (CDCl3) 7.65 (3H, m), 7.60 (2H, m), 7.29 (1H, m), 6.90 (3H, m), 6.48 (1H, d, J 9.73 Hz), 4.58 (1H,m), 3.80 (3H, m), 3.76 (1H, m), 2.31 (3H, s), 2.07 (2H, m). LCMS (ES+) RT 3.02 minutes, 464 (M+H)+.
- The title compound was prepared from (S,S)-3,4-dihydroxypyrrolidine (110 mg, 1.10 mmol) and Intermediate 35 (200 mg, 0.35 mmol) following the method of Example 28 to give the title compound as a pale yellow solid (144 mg). δH (CDCl3) 9.49 (1H, s), 7.51 (3H, m), 7.34 (2H, m); 7.18 (1H, m), 6.93 (1H, m), 6.84 (1H, m), 6.82 (1H, m), 6.36 (1H, d, J 9.72 Hz), 4.15 (2H, m), 3.83 (2H, m), 3.57 (2H, d, J 12.4 Hz). LCMS (ES+) RT 2.74 minutes, 484 (M+H)+.
- The title compound was prepared from 3-hydroxyazetidine hydrochloride (110 mg, 1.05 mmol) and Intermediate 35 (200 mg, 0.35 mmol) with the addition of diisopropylethylamine (0.195 mL, 1.12 mmol) following the method of Example 28 to give the title compound as a white solid (64 mg). δH (CDCl3) 9.48 (1H, s), 7.53 (3H, m), 7.32 (2H, m), 7.10 (1H, d, J 9.7 Hz), 6.86 (1H, m), 6.83 (1H, m), 6.74 (1H, m), 6.33 (1H, d, J 9.8 Hz), 4.58 (1H, s), 4.34 (2H, m), 3.94 (2H, m), 2.07 (1H, s). LCMS (ES+) RT 3.06 minutes, 454 (M+H)+.
- The title compound was prepared from 2-[(2S)pyrrolidin-2-yl]propan-2-ol (140 mg, 1.05 mmol) and Intermediate 35 (200 mg, 0.35 mmol) following the method of Example 28 to give the title compound as a pale yellow solid (140 mg). δH (CDCl3) 8.95 (1H, s), 7.51 (3H, m), 7.49 (2H, m), 7.19 (1H, m), 6.87 (1H, m), 6.84 (1H, m), 6.76 (1H, m), 6.37 (1H, d, J 9.7 Hz), 4.36 (1H, m), 3.90 (1H, m), 3.34 (1H, m), 1.93 (1H, m), 1.84 (1H, m), 1.67 (2H, m), 1.13 (3H, s), 1.00 (3H, s). LCMS (ES+) RT 3.47 minutes, 510 (M+H)+.
- The title compound was prepared from 2-[(2R)-pyrrolidin-2-yl]propan-2-ol hydrochloride (165 mg, 1.05 mmol) and Intermediate 35 (200 mg, 0.35 mmol) with the addition of diisopropylethylamine (0.20 mL, 1.12 mmol) following the method of Example 28 to give the title compound as an off-white solid (89 mg). δH (CDCl3) 8.96 (1H, s), 7.63 (3H, m), 7.32 (2H, m), 7.23 (1H, m), 7.01 (1H, m), 6.83 (1H, m), 6.74 (1H, m), 6.38 (1H, d, J 9.7 Hz), 5.00 (1H, s), 4.32 (1H, m), 3.90 (1H, m), 3.33 (1H, m), 2.00 (2H, m), 1.92 (2H, m), 1.15 (3H, s), 1.00 (3H, s). LCMS (ES+) RT 3.47 minutes, 510 (M+H)+.
- To a suspension of Intermediate 17 (400 mg, 0.96 mmol) in 2-ethoxyethanol (5 mL) was added (S)-2-pyrrolidinemethanol (0.48 mL, 4.81 mmol) and the reaction heated at 78° C. for 2 days. Solvent was removed in vacuo and the residue purified by column chromatography (silica, 30-80% EtOAc in isohexane) to give the title compound as a solid (123 mg). δH (CDCl3) 9.26 (1H, bs), 7.57-7.48 (4H, m), 7.40-7.36 (3H, m), 7.26 (1H, d, J 9.7 Hz), 7.00-6.95 (2H, m), 6.44 (1H, d, J 9.7 Hz), 4.29-4.33 (1H, m), 3.68-3.61 (2H, m), 3.52-3.46 (2H, m), 1.97-1.83 (2H, m), 1.81-1.73 (1H, m), 1.60-1.53 (1H, m). LCMS (ES+) RT 2.98 minutes, 471 (M+H)+.
- To a suspension of Intermediate 17 (400 mg, 0.96 mmol) in 2-ethoxyethanol (5 mL) was added (R)-2-pyrrolidinemethanol (0.48 mL, 4.81 mmol) and the reaction heated at 78° C. for 2 days. Solvent was removed in vacuo and the residue purified by column chromatography (silica, 30-80% EtOAc in isohexane) to give the title compound as a white solid (105 mg). δH (CDCl3) 9.25 (1H, bs), 7.57-7.48 (4H, m), 7.45-7.36 (3H, m), 7.26 (1H, d, J 9.7 Hz), 7.00-6.95 (2H, m), 6.44 (1H, d, J 9.7 Hz), 4.30 (1H, m), 3.71-3.61 (2H, m), 3.52-3.47 (2H, m), 2.00-1.87 (2H, m), 1.80-1.70 (1H, m), 1.65-1.60 (1H, m). LCMS (ES+) RT 2.94 minutes, 471 (M+H)+.
- A mixture of Intermediate 26 (500 mg, 1.4 mmol) and (R)-2-pyrrolidinemethanol (2 mL, 20 mmol) was heated at 130° C. in a sealed Schlenk tube for 6 h. The reaction was cooled to room temperature and partitioned between EtOAc (50 mL) and water (50 mL). The EtOAc layer was washed with water (2×20 mL), dried (Na2SO4) and concentrated in vacuo. The crude residue was purified by column chromatography (silica, 20-50% EtOAc in DCM) to give the title compound as a yellow solid (405 mg, 70%). δH (CDCl3) 9.31 (1H, bs), 7.23-7.14 (3H, m), 6.99-6.94 (3H, m), 6.24 (1H, d, J 9.7 Hz), 4.40-4.34 (1H, m), 4.18-4.16 (1H, m) 3.98-3.88 (3H, m), 3.76-3.58 (3H, m), 2.04-1.93 (3H, m), 1.90-1.81 (1H, m), 1.67-1.61 (1H, m), 0.62-0.58 (4H, m). LCMS (ES+) RT 3.12 minutes, 424 (M+H)+.
- To a suspension of Intermediate 16 (224 mg) in 2-ethoxyethanol (2 mL) was added (R)-2-pyrrolidinemethanol (1.0 mL) and the reaction heated at 110° C. for 18 h in a sealed tube. Solvent was removed in vacuo and the residue purified by column chromatography (silica, 70% EtOAc in isohexane) to give the title compound as a white solid (112 mg). δH (DMSO-d6) 9.18 (1H, s), 7.90 (1H, dd, J 9.6, 1.3 Hz), 7.80-7.62 (5H, m), 7.51 (1H, t, J 7.9 Hz), 7.37-7.25 (3H, m), 6.69 (1H, d, J 9.6 Hz), 4.75 (1H, m), 4.00 (1H, m), 3.50-3.28 (3H, m), 2.90 (1H, m), 1.95-1.65 (4H, m). LCMS (ES+) RT 2.99 minutes, 471 (M+H)+.
- A mixture of Intermediate 62 (340 mg), trifluoroacetic acid (5 mL) and DCM (20 mL) was stirred at r.t. overnight. Solvents were removed in vacuo and the residue azeotroped with toluene (×3). The residue was dissolved in DCM, treated with triethylamine (10 mL) and the mixture concentrated in vacuo. Purification by column chromatography (silica, 20% EtOAc in DCM) gave the title compound (160 mg, 23%). δH (CDCl3) 7.58-7.49 (3H, m), 7.36-7.31 (3H, m), 7.02 (1H, d, J 9.9 Hz), 6.99-6.78 (3H, m), 6.38 (1H, d, J 9.9 Hz), 3.73-3.69 (1H, m), 3.65-3.45 (2H, m), 3.35-3.28 (1H, m), 3.25-3.17 (1H, m), 2.15 (1H br m), 1.97-1.60 (4H, m). LCMS (ES+) RT 3.34 minutes, 518 (M+H)+.
- Intermediate 35 (1 g, 1.77 mmol) and (R)-3-aminopyrrolidine dihydrochloride (309 mg, 1.95 mmol) were dissolved in dichloromethane (50 mL) and treated with triethylamine (360 mg, 3.0 mmol). After stirring at room temperature for 18 h the reaction mixture was washed with water, the organic phase separated, dried (sodium sulphate) and concentrated in vacuo. The crude product was purified by column chromatography (silica, 0-100% THF in DCM) to give the title compound as a white solid (300 mg). NMR δH (DMSO) 9.08 (1H, brs), 7.67-7.50 (6H, m), 7.35-7.27 (1H, m), 7.06-6.93 (2H, m), 6.47 (1H, d, J 9.7 Hz), 3.43-3.32 (2H, m), 3.31-3.28 (1H, m), 3.00 (1H, dd, J 4.0, 10.5 Hz), 1.89-1.77 (1H, m), 1.65-1.53 (1H, m), 1.52-1.45 (1H, m). LCMS (ES+) RT 2.25 minutes, 467 (M+H)+.
- The following Examples 42-53 were all prepared from the appropriate pentafluorophenyl ester intermediate and amine starting materials following the method described for Example 41. Where necessary reactions were run in the presence of a tertiary amine base such as triethylamine to neutralise acid salts of the starting materials.
- Prepared from Intermediate 35 (1 g, 1.77 mmol), (S)-2-(aminomethyl)-pyrrolidine (192 mg, 1.95 mmol) and triethylamine (360 mg, 3.0 mmol) by the method of Example 41. Chromatography (silica, 0-100% THF in DCM) gave the title compound as a white solid (296 mg). NMR δH (DMSO) 8.73 (1H, brs), 7.74 (1H, d, J 9.3 Hz), 7.66-7.56 (3H, m), 7.52-7.50 (2H, m), 7.29 (1H, dt, J 2.6, 8.9 Hz), 6.99-6.89 (2H, m), 6.42 (1H, d, J 9.6 Hz), 3.88-3.78 (1H, m), 2.43 (1H, dd, J 3.7, 12.6 Hz), 2.12 (1H, dd, J 7.9, 12.5 Hz), 1.75-1.56 (4H, m), 1.30-1.11 (2H, brm). LCMS (ES+) RT 2.32 minutes, 481 (M+H)+.
- Prepared from Intermediate 35 (1 g, 1.77 mmol), (R)-2-(aminomethyl)-pyrrolidine (350 mg, 1.95 mmol) and triethylamine (2 mL, 14.3 mmol) by the method of Example 41. Chromatography (reverse phase silica, 60% ethanol:40% water) gave the title compound as a white solid (390 mg). NMR δH (CDCl3) 9.38 (1H, s), 7.64-7.54 (3H, m), 7.50-7.31 (2H, m), 7.32-7.24 (1H, m), 7.11-7.03 (1H, m), 6.97-6.90 (1H, m), 6.87-6.81 (1H, m), 6.44 (1H, d, J 9.7 Hz), 4.33-4.27 (1H, m), 3.77-3.67 (1H, m), 3.61-3.54 (1H, m), 2.95 (1H, dd, J 5.1, 12.9 Hz), 2.83 (1H, dd, J 6.1, 12.9 Hz), 2.08-1.74 (4H, m). LCMS (ES+) RT 2.32 minutes, 481 (M+H)+.
- Prepared from Intermediate 35 (0.75 g, 1.33 mmol) and (R)-3-(dimethylamino)pyrrolidine (166 mg, 1.46 mmol) by the method of Example 41. Chromatography (reverse phase silica, 60% ethanol:40% water) gave the title compound as a white solid (440 mg). NMR δH (DMSO) 8.82 (1H, s), 7.67-7.59 (4H, m), 7.52-7.49 (2H, m), 7.35-7.27 (1H, m), 7.03-6.91 (2H, m), 6.48 (1H, d, J 9.7 Hz), 3.50-3.21 (4H, m), 3.00 (1H, t, J 8.9 Hz), 2.06 (6H, s), 1.96-1.92 (1H, m), 1.59-1.49 (1H, m). LCMS (ES+) RT 2.266 minutes, 495 (M+H)+.
- Prepared from Intermediate 35 (200 mg, 0.36 mmol) and 4-hydroxypiperidine (110 mg, 1.1 mmol) by the method of Example 41 to give the title compound as a white powder (100 mg). NMR δH (CDCl3) 7.93 (1H, s), 7.51 (3H, m), 7.35 (2H, m), 7.24 (1H, d, J 9.7 Hz), 6.81-6.93 (2H, m), 6.75 (1H, m), 6.41 (1H, d, J 9.7 Hz), 3.86 (3H, m), 3.22 (2H, m), 1.77 (2H, m), 1.40 (2H, m). LCMS (ES+) RT 2.90 minutes, 482 (M+H)+.
- Prepared from Intermediate 35 (200 mg, 0.36 mmol), 3-hydroxypiperidine hydrochloride (98 mg, 0.70 mmol) and diisopropylethylamine (101 mg, 0.78 mmol) by the method of Example 41. Chromatography (silica, 15% THF in DCM) gave the title compound as a white solid (137 mg). NMR δH (CDCl3) 7.46-7.55 (3H, m), 7.33-7.35 (2H, m), 7.23 (1H, d, J 9.7 Hz), 6.82-6.93 (2H, m), 6.70-6.75 (1H, m), 6.41 (1H, d, J 9.7 Hz), 3.72-3.77 (1H, m), 3.56-3.60 (1H, m), 3.38-3.49 (3H, m), 1.70-1.80 (2H, m), 1.53-1.59 (1H, m), 1.38-1.42 (1H, m). LCMS (ES+) RT 3.02 minutes, 482 (M+H)+.
- Prepared from Intermediate 34 (1.0 g, 1.79 mmol), (R)-3-aminopyrrolidine dihydrochloride (311 mg, 1.96 mmol) and triethylamine (1 mL, 7.2 mmol) by the method of Example 41. Chromatography (silica, 10% isopropanol in DCM) gave the title compound as a yellow solid (620 mg). NMR δH (CDCl3) 9.54 (1H, bs), 7.56-7.44 (3H, m), 7.34-7.31 (2H, m), 7.19-7.14 (1H, m), 6.88-6.75 (3H, m), 6.31 (1H, d, J 10.2 Hz), 3.73-3.65 (2H, m), 3.59-3.52 (2H, m), 3.29 (1H, dd, J 11.0, 4.5 Hz), 2.37-2.06 (2H, bm), 2.17 (3H, d, J 2.3 Hz), 2.04-1.95 (1H, m), 1.70-1.62 (1H, m). LCMS (ES+) RT 2.33 minutes, 463 (M+H)+.
- Prepared from Intermediate 34 (1.0 g, 1.79 mmol), (S)-2-(aminomethyl)-pyrrolidine (200 mg) and triethylamine (1 mL) by the method of Example 41. Chromatography (reverse phase silica, 60% MeCN in water) gave the title compound as a white solid (260 mg). NMR δH (CDCl3) 9.57 (1H, bs), 7.64-7.55 (3H, m), 7.43-7.31 (2H, m), 7.28-7.24 (1H, m), 6.98-6.84 (3H, m), 6.40 (1H, d, J 9.7 Hz), 4.30-4.23 (1H, m), 3.75-3.69 (1H, m), 3.61-3.54 (1H, m), 2.94 (1H, dd J 11.8, 4.4 Hz), 2.75 (1H, dd, J 12.8, 7.0 Hz), 2.27 (3H, d, J 1.8 Hz), 2.04-1.74 (4H, m). LCMS (ES+) RT 2.36 minutes, 477 (M+H)+.
- Prepared from Intermediate 34 (1.0 g, 1.79 mmol), (R)-3-(dimethylamino)-pyrrolidine (245 mg, 2.15 mmol) and triethylamine (1 mL) by the method of Example 41. Chromatography (silica, 50-100% MeCN in DCM) gave the title compound as a pale yellow solid (610 mg). NMR δH (CDCl3) 9.50 (1H, bs), 7.55-7.45 (3H, m), 7.34-7.32 (2H, m), 7.17 (1H, d, J 9.8 Hz), 6.89-6.75 (3H, m), 6.31 (1H, d, J 9.8 Hz), 3.81-3.68 (2H, m), 3.52-3.42 (1H, m), 3.31-3.24 (1H, m), 2.67-2.57 (1H, m), 2.17 (9H, s), 2.06-1.93 (1H, m), 1.80-1.70 (1H, m). LCMS (ES+) RT 2.34 minutes, 491 (M+H)+.
- Prepared from Intermediate 35 (196 mg, 0.35 mmol) and (3R,4R)-3,4-dihydroxypyrrolidine (107 mg, 1.04 mmol) by the method of Example 41. Column chromatography (silica, 0-8% MeOH in DCM) gave the title compound as a yellow solid (111 mg). NMR δH (CDCl3) 7.33-7.41 (3H, m), 7.20 (2H, bm), 7.02 (1H, m), 6.82-6.88 (1H, m), 6.68-6.74 (1H, m), 6.58-6.63 (1H, m), 6.23 (1H, d, J 9.7 Hz), 4.02 (2H, m), 3.69 (2H, m), 3.43 (2H, d, J 12.5 Hz). LCMS (ES+) RT 2.79 minutes, 484 (M+H)+.
- Prepared from Intermediate 35 (250 mg, 0.44 mmol), cis-3,4-dihydroxy-pyrrolidine hydrochloride (130 mg, 0.94 mmol) and diisopropylethylamine (127 mg, 0.98 mmol) by the method of Example 41. Column chromatography (silica, 5-15% THF in DCM) gave the title compound as a yellow solid (98 mg). NMR δH (CDCl3) 7.48-7.56 (3H, m), 7.31-7.34 (2H, m), 7.15 (1H, m), 6.96-7.02 (1H, m), 6.82-6.88 (1H, m), 6.72-6.78 (1H, m), 6.36 (1H, d, J 9.7 Hz), 4.20-4.22 (2H, m), 3.77 (2H, m), 3.53 (2H, m). LCMS (ES+) RT 2.84 minutes, 484 (M+H)+.
- Prepared from Intermediate 67 (340 mg, 0.61 mmol) and (S)-3-hydroxy-pyrrolidine (227 mg, 2.60 mmol) by the method of Example 41. Column chromatography (silica, 30-100% EtOAc in isohexane) gave the title compound as a white solid (210 mg). NMR δH (DMSO) 9.68 (1H, s), 7.86 (1H, m), 7.72-7.81 (4H, m), 7.63-7.71 (3H, m), 7.19 (1H, m), 7.12 (1H, d), 6.64 (1H, d, J 9.7 Hz), 5.07 (1H, bs), 4.34 (1H, bs), 3.59 (3H, m), 3.39 (1H, m), 1.88-1.97 (2H, m). LCMS (ES+) RT 2.81 minutes, 457 (M+H)+.
- Prepared from Intermediate 67 (340 mg, 0.61 mmol) and (R)-3-hydroxy-pyrrolidine (227 mg, 2.60 mmol) by the method of Example 41. Column chromatography (silica, 30-100% EtOAc in isohexane) gave the title compound as a white solid (225 mg). NMR δH (DMSO) 9.59 (1H, s), 7.70 (1H, m), 7.62-7.73 (4H, m), 7.54-7.60 (3H, m), 7.10 (1H, m), 7.03 (1H, m), 6.56 (1H, d, J 9.7 Hz), 4.98 (1H, bs), 4.25 (1H, bs) 3.51 (3H, m), 3.30 (1H, m), 1.79-1.88 (2H, m). LCMS (ES+) RT 2.81 minutes, 457 (M+H)+.
- Intermediate 64 (270 mg, 0.48 mmol) was dissolved in 4M HCl in dioxane (30 mL) and stirred at r.t. for 18 h. The reaction mixture was concentrated in vacuo and the residue dissolved in DCM and washed with sat. NaHCO3(aq) (×2). The organic layer was separated, dried (MgSO4) and the crude product purified by column chromatography (silica, 2-6% MeOH in DCM) to give the title compound as a white solid (89 mg). NMR δH (DMSO) 9.01 (1H, s), 7.42-7.59 (6H, m), 7.25 (1H, m), 6.98 (2H, m), 6.40 (1H, d, J 9.7 Hz), 5.50 (1H, bm), 3.45 (3H, m), 3.20 (1H, m), 1.86 (1H, m), 1.65 (1H, m). LCMS (ES+) RT 2.23 minutes, 467 (M+H)+.
- Intermediate 65 (0.7 g, 1.24 mmol) was dissolved in dichloromethane (10 mL), treated with trifluoroacetic acid (5 mL) and stirred at room temperature for 2 h. The reaction mixture was concentrated in vacuo and the residual trifluoroacetic acid removed by azeotrope with heptane. The resulting yellow oil was redissolved in dichloromethane, washed with sodium hydrogen-carbonate solution, dried over sodium sulphate and concentrated in vacuo. Chromatography (reverse phase silica, 60% ethanol:40% water) gave the title compound as a white solid (336 mg). NMR δH (DMSO) 9.08 (1H, s), 7.66-7.50 (6H, m), 7.35-7.27 (1H, m), 7.08-6.94 (2H, m), 6.47 (1H, d, J 9.7 Hz), 3.43-3.35 (2H, m), 3.02-2.98 (1H, m), 1.83-1.76 (1H, m), 1.68-1.48 (3H, m). LCMS (ES+) RT 2.239 minutes, 467 (M+H)+.
- Intermediate 66 (1.2 g, 1.79 mmol) was dissolved in dioxane (20 mL), treated with c.HCl (5 mL) and stirred at room temperature for 20 minutes. The reaction mixture was diluted with DCM (100 mL) and neutralised with sat. NaHCO3(aq). The aqueous was extracted with several portions of DCM and the combined extracts dried (MgSO4) and concentrated in vacuo. The crude product was purified by column chromatography (silica, 50-100% MeCN in DCM and then 15% isopropanol in DCM) to give the title compound as a pale yellow solid (520 mg). NMR δH (CDCl3) 9.57 (1H, bs), 7.56-7.46 (3H, m), 7.35-7.32 (2H, m), 7.19-7.15 (1H, m), 6.89-675 (3H, m), 6.31 (1H, d, J 9.7 Hz), 3.74-3.66 (2H, m), 3.61-3.53 (2H, m), 3.24 (1H, dd, J 10.9, 4.6 Hz), 2.17 (3H, d, J 1.6 Hz), 2.03-1.97 (1H, m), 1.89-1.67 (1H, m). LCMS (ES+) RT 2.32 minutes, 463 (M+H)+.
- To a solution of Intermediate 73 (876 mg, 1.54 mmol) in EtOH (45 mL) was added 10% HCl(aq) (5 mL) and the reaction stirred at r.t. for 18 h. The reaction was diluted with EtOAc (100 mL), washed with sat. NaHCO3(aq) (×2) and then brine. The organic layer was separated, dried (MgSO4) and concentrated in vacuo. The crude product was purified by column chromatography (silica, 80% EtOAc in isohexane, loading the product in DCM) to give the title compound as a yellow solid (270 mg). NMR δH (CDCl3) 7.36 (2H, m), 7.19 (3H, m), 6.99 (1H, m), 6.76 (1H, m), 6.72 (1H, m), 6.33 (1H, d, J 9.7 Hz), 4.45 (1H, m), 3.62 (4H, m), 1.85 (2H, m). LCMS (ES+) RT 3.04 minutes, 486 (M+H)+.
- To a solution of Intermediate 74 (767 mg, 1.35 mmol) in EtOH (45 mL) was added 10% HCl(aq) (5 mL) and the reaction stirred at r.t. for 18 h. The reaction was diluted with EtOAc (100 mL), washed with sat. NaHCO3(aq) (×2) and then brine. The organic layer was separated, dried (MgSO4) and concentrated in vacuo. The crude product was purified by column chromatography (silica, 80% EtOAc in isohexane, loading the product in DCM) to give the title compound as a yellow solid (304 mg). NMR δH (CDCl3) 7.27 (2H, m), 7.20 (3H, m), 6.99 (1H, m), 6.85 (1H, m), 6.74 (1H, m), 6.36 (1H, d, J 9.7 Hz), 4.46 (1H, m), 3.75-3.50 (4H, m), 1.97 (2H, m). LCMS (ES+) RT 3.05 minutes, 486 (M+H)+.
- To a solution of Intermediate 75 (980 mg, 1.35 mmol) in EtOH (45 mL) was added 10% HCl(aq) (5 mL) and the reaction stirred at r.t. for 18 h. The reaction was diluted with EtOAc (100 mL), washed with sat. NaHCO3(aq) (×2) and then brine. The organic layer was separated, dried (MgSO4) and concentrated in vacuo. The crude product was purified by column chromatography (silica, 50-100% EtOAc in isohexane) to give the title compound as a pale yellow solid (654 mg). NMR δH (CDCl3) 7.27 (2H, m), 7.14 (3H, m), 6.84-6.72 (3H, m), 6.26 (1H, d, J 9.7 Hz), 4.39 (1H, m), 3.62 (4H, m), 2.12 (3H, s), 1.88 (2H, m). LCMS (ES+) RT 3.12 minutes, 482 (M+H)+.
- The title compound was prepared from Intermediate 78 (623 mg, 1.07 mmol) following the procedure used for Example 58 to give a light yellow solid (253 mg). NMR δH (CDCl3) 9.60 (1H, s), 7.64-7.57 (1H, m), 7.52-7.37 (3H, m), 7.25 (1H, d, J 9.8 Hz), 6.98-6.70 (3H, m), 6.34 (1H, d, J 9.8 Hz), 4.34 (1H, bs), 3.72-3.50 (4H, m), 3.08 (1H, bs), 2.22 (3H, s), 1.86 (2H, m). LCMS (ES+) RT 3.17 minutes, 498 (M+H)+.
- The title compound was prepared from Intermediate 79 (509 mg, 0.90 mmol) following the procedure used for Example 58. The crude product was purified by column chromatography (silica, 20% EtOAc in DCM) to give the title compound as a light yellow solid (253 mg). NMR δH (CDCl3) 9.62 (1H, bs), 7.72-7.60 (1H, m), 7.58-7.25 (4H, m), 7.23-7.20 (1H, m), 7.02-6.86 (3H, m), 7.46 (1H, d, J 7.3 Hz), 4.35 (1H, bs), 3.74-3.50 (4H, m), 3.13 (1H, bs), 2.40 (3H, s), 1.96 (2H, bs). LCMS (ES+) RT 3.12 minutes, 480 (M+H)+.
- The title compound was prepared from Intermediate 80 (750 mg, 1.28 mmol) following the procedure used for Example 58 to give a light yellow solid (367 mg). NMR δH (CDCl3) 9.56 (1H, s), 7.69-7.58 (1H, m), 7.43-7.38 (3H, m), 7.26 (1H, d, J 9.7 Hz), 7.07-6.97 (1H, m), 6.95-6.87 (1H, m), 6.80-6.78 (1H, m), 6.40 (1H, d, J 9.7 Hz), 4.35 (1H, s), 3.77-3.52 (4H, m), 3.00 (1H, bs), 1.90 (2H, s). LCMS (ES+) RT 3.10 minutes, 502 (M+H)+.
- To a solution of Intermediate 81 (1.0 g, 2.31 mmol), tris(dibenzylideneacetone)dipalladium(0) (212 mg, 0.23 mmol, 10 mol %) and (+/−)-BINAP (288 mg, 0.46 mmol, 20 mol %) in toluene (50 mL) and under nitrogen was added 2,4-difluoroaniline (300 μL, 2.77 mmol) and caesium carbonate (1.05 g, 3.23 mmol, 1.4 equiv.). The reaction was heated at 100° C. under nitrogen for 4 days. The reaction mixture was diluted with EtOAc (80 mL), washed with water, brine (×2), dried (MgSO4) and concentrated in vacuo. The crude product was purified by column chromatography (silica, 20% EtOAc in isohexane) to give the title compound as a white solid (123 mg). NMR δH (CDCl3) 9.49 (1H, s), 7.33-7.30 (2H, m), 7.22-7.18 (2H, m), 7.16 (1H, d, J 9.7 Hz), 6.97 (1H, dd, J 9.0, 5.7 Hz), 6.86-6.81 (1H, m), 6.75-6.72 (1H, m), 6.35 (1H, d, J 9.7 Hz), 4.42 (1H, bs), 3.70-3.62 (3H, m), 3.56-3.53 (1H, m), 2.39 (3H, s), 1.97-1.85 (3H, m). LCMS (ES+) RT 3.13 minutes, 482 (M+H)+.
- The title compound was prepared from Intermediate 81 (1.0 g, 2.3 mmol) and 4-fluoro-3-methylaniline (347 mg) following the method of Example 63. The crude product was purified by column chromatography (silica, 20% EtOAc in DCM) to give the title compound as a white solid (60 mg). NMR δH (CDCl3) 9.56 (1H, bs), 7.33-7.30 (2H, m), 7.22-7.13 (3H, m), 6.89-6.78 (3H, m), 6.31 (1H, d, J 9.7 Hz), 4.44 (1H, m), 3.71-3.67 (3H, m), 3.63-3.57 (1H, m), 2.39 (3H, s), 2.17 (3H, d, J 1.8 Hz), 1.96-1.90 (2H, m), 1.59 (1H, bs). LCMS (ES+) RT 3.20 minutes, 478 (M+H)+.
- The title compound was prepared from Intermediate 82 and 2,4-difluoroaniline following the method of Example 63 to give a white solid. NMR δH (CDCl3) 7.44-7.21 (2H, m), 7.19-7.16 (3H, m), 6.99-6.97 (1H, m), 6.96-6.94 (1H, m), 6.92-6.87 (1H, m), 6.98 (1H, d, J 9.8 Hz), 4.44 (1H, bs), 3.71-3.63 (3H, m), 3.57-3.54 (1H, m), 2.39 (3H, s), 1.99-1.96 (2H, m). LCMS (ES+) RT 3.14 minutes, 482 (M+H)+.
- The title compound was prepared from Intermediate 82 (1.0 g, 2.3 mmol) and 4-fluoro-3-methylaniline (0.34 mL, 2.7 mmol) following the method of Example 63. The crude product was purified by column chromatography (silica, 70% EtOAc in isohexane) to give the title compound as a white solid (80 mg). NMR δH (CDCl3) 7.32-7.30 (2H, m), 7.27-7.15 (3H, m), 6.88-6.77 (3H, m), 6.35 (1H, d, J 9.8 Hz), 4.42 (1H, bs), 3.73-3.62 (4H, m), 2.39 (3H, s), 2.17 (3H, s), 1.98-1.89 (2H, m). LCMS (ES+) RT 3.17 minutes, 478 (M+H)+.
- Intermediate 85 (1.89 g, 3.55 mmol) was suspended in EtOH (76 mL) and 10% HCl (10 mL) and stirred at 40° C. for 36 h. The mixture was concentrated under reduced pressure and the residue redissolved in DCM/MeOH. Decolourising charcoal (0.09 g) was added and the suspension stirred for 30 min, filtered and reconcentrated to give crude product (1.58 g, 99%). This crude material was suspended in EtOH (8 mL) and stirred at r.t. for 4 h. The solid was isolated by filtration, washed with EtOH (3×2 mL) and dried in vacuo to yield the pure title compound (1.49 g, 94%). δH (CDCl3) 9.60 (1H, s), 7.52-7.63 (3H, m), 7.38-7.41 (2H, m), 7.16-7.19 (1H, d), 6.86-6.98 (3H, m), 6.35-6.39 (1H, d), 4.36-4.42 (2H, m), 3.97-4.03 (2H, m), 2.33-2.43 (1H, m), 2.25 (3H, s). LCMS (ES+) RT 3.09 min, (M+H)+ 450.
- Intermediate 86 (326 mg, 0.46 mmol) was dissolved in a solution of HCl in 1,4-dioxane (4.0N) and stirred under N2 at r.t for 18 h. The crude product was concentrated in vacuo and triturated with Et2O. Purification by chromatography (silica, 5% MeOH in DCM) gave the title compound as a light brown solid (175 mg, 80%). δH (DMSO-d6) 8.41 (1H, s), 7.86 (1H, d, J 9.6 Hz), 7.68-7.59 (5H, m), 7.31-7.26 (1H, m), 7.00-6.91 (2H, m), 6.89-6.53 (3H, m), 3.90-3.87 (2H, m), 3.10-2.95 (1H, m), 2.70-2.66 (2H, m), 1.75-1.72 (2H, m), 1.20-1.11 (2H, m). LCMS (ES+) RT 2.17 minutes, 481 (M+H)+.
- From Intermediate 87 (386 mg, 0.70 mmol) by the method of Example 68 to give the title compound as an off-white solid (303 mg, 95%). δH (DMSO-d6) 9.29 (1H, s), 8.20-7.80 (2H, br s), 7.70-7.63 (3H, m), 7.57-7.53 (2H, m), 7.46-7.40 (1H, m), 7.32 (1H, d, J 9.7 Hz), 7.22-7.16 (1H, m), 7.12-7.05 (1H, m), 6.48 (1H, d, J 9.7 Hz), 4.33-4.25 (2H, m), 4.05-3.90 (3H, m). LCMS (ES+) RT 2.23 minutes, 453 (M+H)+.
- Example 68 (111 mg, 0.23 mmol), paraformaldehyde (70 mg, 0.56 mmol) and sodium cyanoborohydride (36 mg, 0.54 mmol) in MeOH (10 mL) were stirred at r.t. for 18 h. The reaction mixture was acidified using aq HCl (2N) and stirred for 20 min. The acidic mixture was neutralised with 10% aq. NaOH and extracted with DCM. The DCM extract was dried (Na2SO4) and concentrated in vacuo. The crude product was purified by chromatography (silica, 2% MeOH in DCM) to give the title compound as an off-white solid (30 mg, 25%). δH (CDCl3) 8.00 (1H, s), 7.63-7.52 (3H, m), 7.42-7.40 (2H, m), 7.32 (1H, d, J 9.7 Hz), 7.00-6.90 (2H, m), 6.82-6.75 (1H, m), 6.48 (1H, d, J 9.7 Hz), 4.42-4.35 (2H, m), 2.95-2.80 (2H, m), 2.35-2.25 (1H, m), 1.90-1.75 (2H, m), 1.54 (6H, s), 1.40-1.30 (2H, m). LCMS (ES+) RT 2.20 minutes, 509 (M+H)+.
- From Example 69 (168 mg, 0.37 mmol), paraformaldehyde (103 mg, 0.82 mmol) and sodium cyanoborohydride (52 mg, 0.82 mmol) by the method of Example 70 to give the title compound as an off-white solid (130 mg, 70%). δH (DMSO-d6) 11.23 (1H, s), 7.71-7.62 (3H, m), 7.56-7.54 (2H, m), 7.44-7.39 (2H, m), 7.18-7.12 (1H, m), 7.08-7.04 (1H, m), 6.48 (1H, d, J 9.7 Hz), 4.15-3.95 (2H, m), 3.85-3.75 (2H, m), 3.10-3.00 (1H, m), 2.07 (6H, s). LCMS (ES+) RT 2.26 minutes, 481 (M+H)+.
- Intermediate 35 (1.0 g, 1.77 mmol) and (S)-3-dimethylaminopyrrolidine (222 mg, 1.95 mmol) were dissolved in DCM and stirred at r.t. for 18 h. The solution was washed with aq NaHCO3 solution, dried (Na2SO4) and concentrated in vacuo. Chromatography (60:40 ethanol:water on reverse phase silica) gave the title compound (387 mg, 44%). δH (DMSO-d6) 8.82 (1H, br s), 7.67-7.59 (4H, m), 7.51 (2H, dd, J 1.78, 8.15 Hz), 7.36-7.28 (1H, m), 7.00-6.91 (2H, m), 6.48 (1H, d, J 9.6 Hz), 3.50-3.24 (3H, m), 2.98 (1H, t, J 9.7 Hz), 2.50-2.44 (1H, m), 2.03 (6H, s), 1.97-1.91 (1H, m), 1.50 (1H, t, J 9.7 Hz). LCMS (ES+) RT 2.214 minutes, 495 (M+H)+.
- From Intermediate 34 (1 g, 1.77 mmol) and (S)-3-dimethylaminopyrrolidine (222 mg, 1.94 mmol) by the method of Example 72. δH (DMSO-d6) 8.78 (1H, s), 7.67-7.56 (4H, m), 7.51 (2H, dd, J 8.2, 1.9 Hz), 7.00 (1H, t, J 9.11 Hz), 6.83-6.80 (1H, m), 6.75-6.70 (1H, m), 6.49 (1H, d, J 9.6 Hz), 3.44-3.20 (3H, m), 2.97 (1H, t, J 9.9 Hz), 2.42-2.35 (1H, m), 2.15 (3H, s), 1.99 (6H, s), 1.91-1.87 (1H, m), 1.47-1.40 (1H, m). LCMS (ES+) RT 2.282 minutes, 491 (M+H)+.
- From Intermediate 90 (3.0 g, 5.1 mmol) by the method of Example 62 to give the title compound as a pale yellow solid (1.61 g, 63%). δH (CDCl3) 7.60-7.57 (1H, m), 7.48-7.33 (3H, m), 7.19 (2H, m), 7.00 (1H, dt, J 9.0, 5.7 Hz), 6.87-6.82 (1H, m), 6.77-6.73 (1H, m), 6.35 (1H, d, J 9.8 Hz), 4.43-4.40 (1H, m), 3.69-3.52 (4H, m), 1.97-1.91 (3H, m). LCMS (ES+) RT 3.10 minutes, 502 (M+H)+.
- Preparation of Activated Human p38α for Inhibitor Assays
- Purification of Human p38α
- Human p38α, incorporating an N-terminal (His)6 tag, was expressed in baculovirus-infected High-Five™ cells (Invitrogen) according to the manufacturer's instructions. The cells were harvested 72 h post-infection and lysed in phosphate buffered saline (PBS) containing 1% (w/v) β-octylglucoside and Complete, EDTA-free™ protease inhibitors (Roche Molecular Biochemicals). The lysate was centrifuged at 35000×g for 30 min at 4° C. and the supernatant applied to a NiNTA™ column (Qiagen). Bound protein was eluted by 150 mM imidazole in PBS (after a wash with 15 mM imidazole in PBS) and directly applied to a HiTrap Q≯ column (AP Biotech). Bound protein was eluted using a 20 column volume, 0 to 1M NaCl gradient. Fractions containing (His)6-p38 were aliquotted and stored at −70° C. prior to their activation.
- Preparation of GST-MKK6EE-Containing Lysates
- E. coli (BL21 pLysS) expressing the constitutively activated form of human MKK6 fused with an N-terminal glutathione-S-transferase tag (GST-MKK6EE) were harvested by centrifugation and frozen at −70° C. Cells were lysed by resuspension in 1/10th the culture volume of PBS containing Complete, EDTA-free™ protease inhibitors followed by sonication on ice for 4×15 sec. Cell debris was removed by centrifugation at 35,000×g and the resultant supernatant stored in aliquots at −70° C.
- Activation of (His)6-p38
- 0.45 mL of purified (His)6-p38 was incubated with 50 μL of the GST-MKK6EE-containing lysate for 30 min at 23° C. in the presence of 1 mM β-glycerophosphate, 10 mM MgCl2 and 9 mM ATP. The extent of activation was monitored by mass spectrometric detection of the doubly-phosphorylated form of (His)6-p38, which routinely comprised greater than 90% of the final (His)6-p38 preparation. The activated (His)6-p38 was then diluted ×10 in PBS and repurified using the method described above. The concentration of purified, activated (His)6-p38 was measured by UV absorbance at 280 nm using A280, 0.1%=1.2 and the preparation stored in aliquots at −70° C. prior to its use in inhibitor assays.
- p38 Inhibition Assays
- Inhibition of Phosphorylation of Biotinylated Myelin Basic Protein (MBP)
- The inhibition of p38 catalysed phosphorylation of biotinylated MBP is measured using a DELFIA based format. The assay was performed in a buffer comprising 20 mM HEPES (pH 7.4), 5 mM MgCl2 and 3 mM DTT. For a typical IC50 determination, biotinylated MBP (2.5 μM) was incubated at room temperature in a streptavidin-coated microtitre plate together with activated gst-p38 (10 nM) and ATP (1 μM) in the presence of a range of inhibitor concentrations (final concentration of DMSO is 2 percent). After fifteen minutes the reaction was terminated by the addition of EDTA (75 mM). The microtitre plate was then washed with Tris buffered saline (TBS), prior to the addition of 100 μl of anti-phospho MBP antibody (mouse) together with europium-labeled anti-mouse IgG antibody. After one hour at room temperature the plate was again washed in TBS followed by the addition of Enhancement solution (PerkinElmer Wallac). Fluorescence measurements were performed after a further fifteen minutes at room temperature.
- IC50 values are determined from the plot of log10 inhibitor concentration (x-axis) versus percentage inhibition of the fluorescence generated by a control sample in the absence of inhibitor (y-axis).
- Purification of Human Peripheral Blood Mononuclear Cells
- Peripheral blood mononuclear cells (PBMC) were isolated from normal healthy volunteers. Whole blood was taken by venous puncture using heparinised vacutainers (Becton Dickinson), diluted 1 in 4 in RPMI 1640 (Gibco, UK) and centrifuged at 400 g for 35 min over a Ficoll-paque gradient (Amersham-Pharmacia Biotech, UK). Cells at the interface were removed and washed once followed by a low speed spin (250 g) to remove platelets. Cells were then resuspended in DMEM containing 10% FCS, penicillin 100 units ml−1, streptomycin 50 μg ml−1 and glutamine 2 mM (Gibco, UK).
- Inhibitor Dilutions
- Inhibitor stocks (20 mM) were kept as a frozen solution (−20° C.) in DMSO. Serial dilutions of inhibitors were performed in DMSO as 250-times concentrated stocks. Inhibitors were diluted 1 in 250 into tissue culture media, prewarmed to 37° C. and transferred to plates containing PBMC. PBMC and inhibitors were incubated together for 30 min prior to addition of LPS. Inhibitors used in whole blood assays were prepared according to a different regime. Using the same stock solution serial dilutions of inhibitors were performed in DMSO. Inhibitors were then diluted 1 in 500 straight into whole blood in a volume of 1 μl. Inhibitor was incubated with whole blood for 30 min prior to the addition of LPS.
- LPS Stimulation of PBMC
- PBMC were resuspended at a density of 2×105 cells/well in flat bottomed 96-well tissue culture treated plates. After the addition of inhibitor cells were stimulated with an optimal dose of LPS (E coli strain B5:055, Sigma, at a final concentration of 1 μg ml−1) and incubated at 37° C. in 5% CO2/95% air for 18 hours. TNF-α levels were measured from cell free supernatants by sandwich ELISA (BioSource #CHC1751).
- LPS Stimulation of Whole Blood
- Whole blood was taken by venous puncture using heparinised vacutainers (Becton Dickinson), and 500 μl of blood aliquoted into each well of a 24-well tissue culture treated plate. After the addition of inhibitor cells were stimulated with an optimal dose of LPS (E coli strain B5:055, Sigma, at a final concentration of 1 μg ml−1) and incubated at 37° C. without CO2 for 18 hours. TNF-α levels were measured from cell free supernatants by sandwich ELISA (BioSource #CHC1751).
- Rat LPS Induced TNF Release
- Male Lewis rats (180-200 g) are anaesthetised with Isofluor and injected i.v. with LPS* in a volume of 0.5 ml sterile saline. After 90 minutes blood is collected into EDTA tubes for preparation of plasma samples. Plasma is stored at −70° C. prior to assay for TNF-α by commercial ELISA.
- Rat CIA
- Female Lewis rats (180-200 g) are anaesthetised with Isofluor and immunised i.d. at the base of the tail with 2×100 μl of emulsion containing 4 mg/ml bovine collagen II in 0.01M acetic acid and Freund's Incomplete Adjuvant at a ratio of 1:1. A polyarthritis develops with onset from about 13 days post sensitisation. The disease is mainly confined to the ankles and is quantified by plethysmometry. Results are expressed as change in paw volume over time.
- In the p38 inhibitor assays described above compounds of the invention have IC50 values of around 1 μM and below. The compounds of the invention are clearly potent inhibitors of p38 kinase, especially p38α kinase.
Claims (26)
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0314492.0 | 2003-06-20 | ||
GB0314492A GB0314492D0 (en) | 2003-06-20 | 2003-06-20 | Chemical compounds |
GB0329485.7 | 2003-12-19 | ||
GB0329485A GB0329485D0 (en) | 2003-12-19 | 2003-12-19 | Chemical compounds |
PCT/GB2004/002621 WO2004113347A1 (en) | 2003-06-20 | 2004-06-18 | Thienopyridone derivatives as kinase inhibitors |
Publications (2)
Publication Number | Publication Date |
---|---|
US20070099894A1 true US20070099894A1 (en) | 2007-05-03 |
US7521460B2 US7521460B2 (en) | 2009-04-21 |
Family
ID=33542685
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/561,052 Expired - Fee Related US7521460B2 (en) | 2003-06-20 | 2004-06-18 | Thienopyridone derivatives as kinase inhibitors |
Country Status (12)
Country | Link |
---|---|
US (1) | US7521460B2 (en) |
EP (1) | EP1641804A1 (en) |
JP (1) | JP2007516161A (en) |
KR (1) | KR20060021905A (en) |
AU (1) | AU2004249495A1 (en) |
BR (1) | BRPI0410653A (en) |
CA (1) | CA2528602A1 (en) |
EA (1) | EA010297B1 (en) |
IL (1) | IL172132A0 (en) |
MX (1) | MXPA05013227A (en) |
NO (1) | NO20060279L (en) |
WO (1) | WO2004113347A1 (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060025428A1 (en) * | 2002-08-13 | 2006-02-02 | Brookings Daniel C | Bicyclic heteroaromatic compounds as kinase inhibitors |
US20060247269A1 (en) * | 2003-06-20 | 2006-11-02 | Brookings Daniel C | Thienopyridone derivatives as kinase inhibitors |
US20070078131A1 (en) * | 2003-10-24 | 2007-04-05 | Celltech R&D Limited | Thieno-pyridinone derivatives as kinase inhibitors |
Families Citing this family (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0214268D0 (en) * | 2002-06-20 | 2002-07-31 | Celltech R&D Ltd | Chemical compounds |
EA015252B1 (en) | 2005-05-10 | 2011-06-30 | Интермьюн, Инк. | Method of modulating stress-activated protein kinase system |
ATE504565T1 (en) | 2005-10-07 | 2011-04-15 | Exelixis Inc | AZETIDINES AS MEK INHIBITORS IN THE TREATMENT OF PROLIFERATIVE DISEASES |
EP1960405A2 (en) * | 2005-11-23 | 2008-08-27 | Intermune, Inc. | Method of modulating stress-activated protein kinase system |
GB0601962D0 (en) | 2006-01-31 | 2006-03-15 | Ucb Sa | Therapeutic agents |
JP5302883B2 (en) | 2006-04-07 | 2013-10-02 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Thienopyrimidine having MNK1 / MNK2 inhibitory activity for pharmaceutical composition |
EP1889847A1 (en) | 2006-07-10 | 2008-02-20 | DeveloGen Aktiengesellschaft | Pyrrolopyrimidines for pharmaceutical compositions |
WO2008064829A2 (en) * | 2006-11-30 | 2008-06-05 | Ucb Pharma, S.A. | Novel aminothienopyridinone derivatives processes for preparing them and pharmaceutical compositions thereof |
PL2101759T3 (en) * | 2006-12-14 | 2019-05-31 | Exelixis Inc | Methods of using mek inhibitors |
WO2008124085A2 (en) * | 2007-04-03 | 2008-10-16 | Exelixis, Inc. | Methods of using combinations of mek and jak-2 inhibitors |
GB0714384D0 (en) | 2007-07-23 | 2007-09-05 | Ucb Pharma Sa | theraputic agents |
WO2009093008A1 (en) | 2008-01-21 | 2009-07-30 | Ucb Pharma S.A. | Thieno-pyridine derivatives as mek inhibitors |
CN102099036B (en) | 2008-06-03 | 2015-05-27 | 英特芒尼公司 | Compounds and methods for treating inflammatory and fibrotic disorders |
GB0811304D0 (en) | 2008-06-19 | 2008-07-30 | Ucb Pharma Sa | Therapeutic agents |
EP2331551B1 (en) | 2008-08-26 | 2016-06-29 | Evotec International GmbH | Thienopyrimidines for pharmaceutical compositions |
BR112012021364A2 (en) | 2010-02-26 | 2016-10-25 | Boehringer Ingelheim Int | "thienopyrimidines-containing cycloalkyl compounds and pharmaceutical compositions". |
UY33241A (en) | 2010-02-26 | 2011-09-30 | Boehringer Ingelheim Int | ? Tienopyrimidines containing heterocycloalkyl for pharmaceutical compositions ?. |
WO2011104340A1 (en) | 2010-02-26 | 2011-09-01 | Boehringer Ingelheim International Gmbh | Thienopyrimidines containing a substituted alkyl group for pharmaceutical compositions |
EP2598660B1 (en) | 2010-07-26 | 2017-03-15 | Biomatrica, INC. | Compositions for stabilizing dna, rna and proteins in blood and other biological samples during shipping and storage at ambient temperatures |
CA2806734A1 (en) | 2010-07-26 | 2012-02-09 | Biomatrica, Inc. | Compositions for stabilizing dna, rna and proteins in saliva and other biological samples during shipping and storage at ambient temperatures |
AR092742A1 (en) | 2012-10-02 | 2015-04-29 | Intermune Inc | ANTIFIBROTIC PYRIDINONES |
BR112015008113B1 (en) | 2012-10-12 | 2022-05-24 | Exelixis, Inc. | New process to prepare compounds for use in cancer treatment |
WO2014081800A1 (en) * | 2012-11-21 | 2014-05-30 | Zoetis Llc | Synthesis of spirocyclic isoxazoline derivatives |
US9725703B2 (en) | 2012-12-20 | 2017-08-08 | Biomatrica, Inc. | Formulations and methods for stabilizing PCR reagents |
EP3007556B1 (en) | 2013-06-13 | 2020-05-20 | Biomatrica, INC. | Cell stabilization |
CN110452216B (en) | 2014-04-02 | 2022-08-26 | 英特穆恩公司 | Anti-fibrotic pyridinones |
EP3154338B1 (en) | 2014-06-10 | 2020-01-29 | Biomatrica, INC. | Stabilization of thrombocytes at ambient temperatures |
CN108700498B (en) | 2015-12-08 | 2021-07-13 | 生物马特里卡公司 | Reducing erythrocyte sedimentation rate |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6180792B1 (en) * | 1994-04-19 | 2001-01-30 | Takeda Chemical Industries, Ltd. | Condensed-ring thiophene derivatives and thienopyrimide derivatives, their production and use |
US20060004025A1 (en) * | 2002-06-20 | 2006-01-05 | Brookings Daniel C | Arylamine substututed bicyclic heteroaromatic compounds as p38 kinase inhibitors |
US20060025428A1 (en) * | 2002-08-13 | 2006-02-02 | Brookings Daniel C | Bicyclic heteroaromatic compounds as kinase inhibitors |
US20060247269A1 (en) * | 2003-06-20 | 2006-11-02 | Brookings Daniel C | Thienopyridone derivatives as kinase inhibitors |
US20070078131A1 (en) * | 2003-10-24 | 2007-04-05 | Celltech R&D Limited | Thieno-pyridinone derivatives as kinase inhibitors |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999064400A1 (en) * | 1998-06-12 | 1999-12-16 | Vertex Pharmaceuticals Incorporated | INHIBITORS OF p38 |
GB0124848D0 (en) * | 2001-10-16 | 2001-12-05 | Celltech R&D Ltd | Chemical compounds |
-
2004
- 2004-06-18 AU AU2004249495A patent/AU2004249495A1/en not_active Abandoned
- 2004-06-18 WO PCT/GB2004/002621 patent/WO2004113347A1/en active Application Filing
- 2004-06-18 KR KR1020057024352A patent/KR20060021905A/en not_active Application Discontinuation
- 2004-06-18 EA EA200600064A patent/EA010297B1/en not_active IP Right Cessation
- 2004-06-18 BR BRPI0410653-9A patent/BRPI0410653A/en not_active IP Right Cessation
- 2004-06-18 EP EP04742976A patent/EP1641804A1/en not_active Withdrawn
- 2004-06-18 CA CA002528602A patent/CA2528602A1/en not_active Abandoned
- 2004-06-18 JP JP2006516443A patent/JP2007516161A/en not_active Abandoned
- 2004-06-18 US US10/561,052 patent/US7521460B2/en not_active Expired - Fee Related
- 2004-06-18 MX MXPA05013227A patent/MXPA05013227A/en unknown
-
2005
- 2005-11-23 IL IL172132A patent/IL172132A0/en unknown
-
2006
- 2006-01-19 NO NO20060279A patent/NO20060279L/en not_active Application Discontinuation
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6180792B1 (en) * | 1994-04-19 | 2001-01-30 | Takeda Chemical Industries, Ltd. | Condensed-ring thiophene derivatives and thienopyrimide derivatives, their production and use |
US20060004025A1 (en) * | 2002-06-20 | 2006-01-05 | Brookings Daniel C | Arylamine substututed bicyclic heteroaromatic compounds as p38 kinase inhibitors |
US20060025428A1 (en) * | 2002-08-13 | 2006-02-02 | Brookings Daniel C | Bicyclic heteroaromatic compounds as kinase inhibitors |
US20060247269A1 (en) * | 2003-06-20 | 2006-11-02 | Brookings Daniel C | Thienopyridone derivatives as kinase inhibitors |
US20070078131A1 (en) * | 2003-10-24 | 2007-04-05 | Celltech R&D Limited | Thieno-pyridinone derivatives as kinase inhibitors |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060025428A1 (en) * | 2002-08-13 | 2006-02-02 | Brookings Daniel C | Bicyclic heteroaromatic compounds as kinase inhibitors |
US7592455B2 (en) | 2002-08-13 | 2009-09-22 | Ucb Pharma S.A. | Bicyclic heteroaromatic compounds as kinase inhibitors |
US20060247269A1 (en) * | 2003-06-20 | 2006-11-02 | Brookings Daniel C | Thienopyridone derivatives as kinase inhibitors |
US20070078131A1 (en) * | 2003-10-24 | 2007-04-05 | Celltech R&D Limited | Thieno-pyridinone derivatives as kinase inhibitors |
US7795256B2 (en) | 2003-10-24 | 2010-09-14 | Ucb Pharma S.A. | Thieno-pyridinone derivatives as kinase inhibitors |
Also Published As
Publication number | Publication date |
---|---|
CA2528602A1 (en) | 2004-12-29 |
EA010297B1 (en) | 2008-08-29 |
NO20060279L (en) | 2006-03-20 |
EA200600064A1 (en) | 2006-08-25 |
EP1641804A1 (en) | 2006-04-05 |
WO2004113347A1 (en) | 2004-12-29 |
AU2004249495A1 (en) | 2004-12-29 |
MXPA05013227A (en) | 2006-03-09 |
JP2007516161A (en) | 2007-06-21 |
KR20060021905A (en) | 2006-03-08 |
US7521460B2 (en) | 2009-04-21 |
BRPI0410653A (en) | 2006-07-04 |
IL172132A0 (en) | 2006-04-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7521460B2 (en) | Thienopyridone derivatives as kinase inhibitors | |
US20110034495A1 (en) | Method of Modulating Stress-Activated Protein Kinase System | |
US7176215B2 (en) | Bicyclic oxopyridine and oxopyrimidine derivatives | |
US7763729B2 (en) | Bicyclic heteroaromatic derivatives | |
US7592455B2 (en) | Bicyclic heteroaromatic compounds as kinase inhibitors | |
AU2002336172A1 (en) | Bicyclic oxopyridine and oxopyrimidine derivatives | |
US20060247269A1 (en) | Thienopyridone derivatives as kinase inhibitors | |
US7456286B2 (en) | Bicyclic heteroaromatic compounds as kinase inhibitors |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: CELLTECH R&D LIMITED, UNITED KINGDOM Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:BROOKINGS, DANIEL CHRISTOPHER;DAVIS, JEREMY MARTIN;LANGHAM, BARRY JOHN;REEL/FRAME:018380/0001;SIGNING DATES FROM 20060612 TO 20060703 |
|
AS | Assignment |
Owner name: UCB PHARMA S.A., BELGIUM Free format text: CON;ASSIGNOR:CELLTECH R&D LIMITED;REEL/FRAME:021478/0274 Effective date: 20080529 Owner name: UCB PHARMA S.A.,BELGIUM Free format text: CON;ASSIGNOR:CELLTECH R&D LIMITED;REEL/FRAME:021478/0274 Effective date: 20080529 |
|
REMI | Maintenance fee reminder mailed | ||
LAPS | Lapse for failure to pay maintenance fees | ||
STCH | Information on status: patent discontinuation |
Free format text: PATENT EXPIRED DUE TO NONPAYMENT OF MAINTENANCE FEES UNDER 37 CFR 1.362 |
|
FP | Lapsed due to failure to pay maintenance fee |
Effective date: 20130421 |